

Intermittent iron supplementation for improving nutrition and development in children under 12 years of age (Review)

De-Regil LM, Jefferds MED, Sylvetsky AC, Dowswell T

De-Regil LM, Jefferds MED, Sylvetsky AC, Dowswell T. Intermittent iron supplementation for improving nutrition and development in children under 12 years of age. *Cochrane Database of Systematic Reviews* 2011, Issue 12. Art. No.: CD009085. DOI: 10.1002/14651858.CD009085.pub2.

www.cochranelibrary.com

Intermittent iron supplementation for improving nutrition and development in children under 12 years of age (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

WILEY

TABLE OF CONTENTS

HEADER	1
ABSTRACT	1
PLAIN LANGUAGE SUMMARY	2
SUMMARY OF FINDINGS FOR THE MAIN COMPARISON	4
BACKGROUND	6
Figure 1	7
OBJECTIVES	8
METHODS	8
RESULTS	13
Figure 2	13
	14
Figure 3	
	17
ADDITIONAL SUMMARY OF FINDINGS	23
DISCUSSION	26
AUTHORS' CONCLUSIONS	27
ACKNOWLEDGEMENTS	28
REFERENCES	29
CHARACTERISTICS OF STUDIES	35
DATA AND ANALYSES	92
Analysis 1.1. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years,	
Outcome 1 Anaemia (ALL)	105
Analysis 1.2. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years,	
Outcome 2 Anaemia (by dose of elemental iron in the intermittent group).	106
Analysis 1.3. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years,	100
Outcome 3 Anaemia (by duration of the intervention).	107
	10/
Analysis 1.4. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years,	100
Outcome 4 Anaemia (by type of compound).	108
Analysis 1.5. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years,	
Outcome 5 Anaemia (by anaemia status at baseline)	109
Analysis 1.6. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years,	
Outcome 6 Anaemia (by intermittent regimen)	111
Analysis 1.7. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years,	
Outcome 7 Anaemia (by sex)	112
Analysis 1.8. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years,	
Outcome 8 Anaemia (by nutrient).	113
Analysis 1.9. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years,	
Outcome 9 Haemoglobin (ALL).	114
Analysis 1.10. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years,	
Outcome 10 Haemoglobin (by by dose of elemental iron in the intermittent group).	116
Analysis 1.11. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years,	110
	117
Outcome 11 Haemoglobin (by duration of the intervention).	117
Analysis 1.12. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years,	
Outcome 12 Haemoglobin (by type of compound)	119
Analysis 1.13. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years,	
Outcome 13 Haemoglobin (by anaemia status at baseline)	120
Analysis 1.14. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years,	
Outcome 14 Haemoglobin (by intermittent regimen)	122
Analysis 1.15. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years,	
Outcome 15 Haemoglobin (by sex).	123
Analysis 1.16. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years,	
Outcome 16 Haemoglobin (by nutrient).	125
Intermittent iron supplementation for improving nutrition and development in children under 12 years of age (Review)	
intermittent iron supplementation for improving nutrition and development in children under 12 years of age (Review)	i

Analysis 1.17. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years, Outcome 17 Iron deficiency (ALL).	127
Analysis 1.18. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years,	12/
Outcome 18 Ferritin (ALL).	128
Analysis 1.19. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years,	
Outcome 19 Ferritin (by dose of elemental iron in the intermittent group).	129
Analysis 1.20. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years,	120
Outcome 20 Ferritin (by duration of the supplementation)	130
Outcome 21 Ferritin (by type of compound).	131
Analysis 1.22. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years,	101
Outcome 22 Ferritin (by anaemia status at baseline).	132
Analysis 1.23. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years,	
Outcome 23 Ferritin (by supplementation regimen).	133
Analysis 1.24. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years,	
Outcome 24 Ferritin (by sex).	134
Analysis 1.25. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years,	125
Outcome 25 Ferritin (by nutrient)	135
Outcome 26 All cause morbidity (ALL).	136
Analysis 1.27. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years,	150
Outcome 27 Any side effects (ALL).	136
Analysis 1.28. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years,	
Outcome 28 Nausea	137
Analysis 1.29. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years,	
Outcome 29 Adherence (ALL).	138
Analysis 1.30. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years,	120
Outcome 30 Mental development scale (ALL)	138
Outcome 31 Orientation engagement (ALL).	139
Analysis 1.32. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years,	157
Outcome 32 Emotional regulation (ALL).	140
Analysis 1.33. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years,	
Outcome 33 Motor quality (ALL).	140
Analysis 1.34. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years,	
Outcome 34 Psychomotor development index (ALL).	141
Analysis 1.35. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years, Outcome 35 IQ (ALL).	141
Analysis 1.36. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years,	141
Outcome 36 Thai language (ALL).	142
Analysis 1.37. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years,	
Outcome 37 Mathematics (ALL).	142
Analysis 1.38. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years,	
Outcome 38 WAZ	143
Analysis 1.39. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years,	
Outcome 39 HAZ.	144
Analysis 2.1. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years, Outcome 1 Anaemia (ALL).	1/5
Analysis 2.2. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years,	145
Outcome 2 Anaemia (by dose of elemental iron in the intermittent group).	146
Analysis 2.3. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years,	
Outcome 3 Anaemia (by duration of the supplementation).	147

Analysis 2.4. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years,	
Outcome 4 Anaemia (by type of compound).	148
Analysis 2.5. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years,	
Outcome 5 Anaemia (by anaemia status at baseline)	149
Analysis 2.6. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years,	
Outcome 6 Anaemia (by supplementation regimen).	150
Analysis 2.7. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years,	
Outcome 7 Anaemia (by sex).	151
Analysis 2.8. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years,	
Outcome 8 Anaemia (by nutrient)	152
Analysis 2.9. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years,	
Outcome 9 Haemoglobin (ALL).	153
Analysis 2.10. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years,	
Outcome 10 Haemoglobin (by dose of elemental iron in the intermittent group).	154
Analysis 2.11. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years,	
Outcome 11 Haemoglobin (by duration of the supplementation)	155
Analysis 2.12. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years,	
Outcome 12 Haemoglobin (by type of compound)	157
Analysis 2.13. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years,	
Outcome 13 Haemoglobin (by anaemia status at baseline).	158
Analysis 2.14. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years,	
Outcome 14 Haemoglobin (by supplementation regimen).	160
Analysis 2.15. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years,	
Outcome 15 Haemoglobin (by sex).	161
Analysis 2.16. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years,	
Outcome 16 Haemoglobin (by nutrient).	163
Analysis 2.17. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years,	
Outcome 17 Iron deficiency (ALL).	164
Analysis 2.18. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years,	
Outcome 18 Ferritin (ALL).	165
Analysis 2.19. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years,	
Outcome 19 Ferritin (by dose of elemental iron in the intermittent group).	166
Analysis 2.20. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years,	
Outcome 20 Ferritin (by duration of the supplementation).	167
Analysis 2.21. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years,	
Outcome 21 Ferritin (by type of compound).	168
Analysis 2.22. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years,	
Outcome 22 Ferritin (by anaemia status at baseline).	169
Analysis 2.23. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years,	
Outcome 23 Ferritin (by supplementation regimen).	170
Analysis 2.24. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years,	
Outcome 24 Ferritin (by sex).	171
Analysis 2.25. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years,	
Outcome 25 Ferritin (by nutrient).	172
Analysis 2.26. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years,	
Outcome 26 Increase in steps climbed (ALL).	173
Analysis 2.27. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years,	
Outcome 27 All cause morbidity (ALL). \ldots \ldots \ldots \ldots \ldots \ldots \ldots	173
Analysis 2.28. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years,	
Outcome 28 Diarrhoea (ALL).	174
Analysis 2.29. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years,	
Outcome 29 Any side effects (ALL).	175

Analysis 2.30. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years, Outcome 30 Adherence (ALL).	176
Analysis 2.31. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years, Outcome 31 IQ (ALL).	177
Analysis 2.32. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years,	177
Outcome 32 Thai language (ALL).	177
Analysis 2.33. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years,	
Outcome 33 Mathematics (ALL)	178
Analysis 2.34. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years,	
Outcome 34 HAZ	178
Analysis 3.1. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months,	
Outcome 1 Anaemia (ALL)	179
Analysis 3.2. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months,	
Outcome 2 Anaemia (by dose of elemental iron in the intermittent group).	180
Analysis 3.3. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months,	
Outcome 3 Anaemia (by duration of the supplementation)	181
Analysis 3.4. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months,	
Outcome 4 Anaemia (by type of compound).	182
Analysis 3.5. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months,	
Outcome 5 Anaemia (by anaemia status at baseline).	183
Analysis 3.6. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months,	
Outcome 6 Anaemia (by intermittent regimen).	184
Analysis 3.7. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months,	
Outcome 7 Anaemia (by sex). .<	185
Analysis 3.8. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months,	10)
Outcome 8 Anaemia (by nutrient).	186
Analysis 3.9. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months,	100
Outcome 9 Haemoglobin (ALL).	187
Analysis 3.10. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months,	
Outcome 10 Haemoglobin (by dose of elemental iron in the intermittent group).	188
Analysis 3.11. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months,	
Outcome 11 Haemoglobin (by duration of the supplementation).	189
Analysis 3.12. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months,	
Outcome 12 Haemoglobin (by type of iron compound).	190
Analysis 3.13. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months,	
Outcome 13 Haemoglobin (by anaemia status at baseline).	191
Analysis 3.14. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months,	
Outcome 14 Haemoglobin (by supplementation regimen).	192
Analysis 3.15. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months,	
Outcome 15 Haemoglobin (by sex).	193
Analysis 3.16. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months,	
Outcome 16 Haemoglobin (by nutrient).	194
Analysis 3.17. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months,	
Outcome 17 Iron deficiency (ALL).	195
Analysis 3.18. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months,	
Outcome 18 Ferritin (ALL)	196
Analysis 3.19. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months,	
Outcome 19 Ferritin (by dose of iron in the intermittent group).	197
Analysis 3.20. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months,	
Outcome 20 Ferritin (by duration of the supplementation)	198
Analysis 3.21. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months,	
Outcome 21 Ferritin (by type of iron compound).	199

Analysis 3.22. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months, $22 E_{1} + \frac{1}{2} = 1$	200
	200
Analysis 3.23. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months, Outcome 23 Ferritin (by supplementation regimen).	201
Analysis 3.24. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months,	
Outcome 24 Ferritin (by sex).	202
Analysis 3.25. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months,	
Outcome 25 Ferritin (by nutrient).	203
Analysis 3.26. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months,	200
Outcome 26 All cause morbidity (ALL).	204
Analysis 3.27. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months,	204
	20%
Outcome 27 Any side effects (ALL)	204
	205
Outcome 28 Adherence (ALL)	205
Analysis 3.29. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months,	
Outcome 29 Mental development scale (ALL).	206
Analysis 3.30. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months,	
Outcome 30 Orientation engagement (ALL)	206
Analysis 3.31. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months,	
Outcome 31 Emotional regulation (ALL)	207
Analysis 3.32. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months,	
Outcome 32 Motor quality (ALL)	207
Analysis 3.33. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months,	
Outcome 33 Psychomotor development index (ALL)	208
Analysis 3.34. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months,	
Outcome 34 HAZ	208
Analysis 4.1. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months,	
Outcome 1 Anaemia (ALL).	209
Analysis 4.2. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months,	
Outcome 2 Haemoglobin (ALL).	210
Analysis 4.3. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months,	
Outcome 3 Haemoglobin (by dose of elemental iron in the intermittent group).	211
Analysis 4.4. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months,	
Outcome 4 Haemoglobin (by duration of supplementation).	212
Analysis 4.5. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months,	212
	213
Analysis 4.6. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months,	215
	214
Outcome 6 Haemoglobin (by anaemia status at baseline)	214
	216
Outcome 7 Haemoglobin (by supplementation regimen).	216
Analysis 4.8. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months,	~
Outcome 8 Haemoglobin (by sex).	217
Analysis 4.9. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months,	
Outcome 9 Haemoglobin (by nutrient)	218
Analysis 4.10. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months,	
	220
Analysis 4.11. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months,	
	221
Analysis 4.12. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months,	
0 1	222
Analysis 4.13. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months,	
Outcome 13 Ferritin (by duration of supplementation).	223

Analysis 4.14. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months,	
Outcome 14 Ferritin (by type of compound)	224
Analysis 4.15. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months,	
Outcome 15 Ferritin (by anaemia status at baseline).	225
Analysis 4.16. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months,	
Outcome 16 Ferritin (by supplementation regimen).	226
Analysis 4.17. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months,	
Outcome 17 Ferritin (by sex).	227
Analysis 4.18. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months,	
Outcome 18 Ferritin (by nutrient).	228
Analysis 4.19. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months,	
Outcome 19 All cause morbidity (ALL).	229
Analysis 4.20. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months,	
Outcome 20 Diarrhoea (ALL)	229
Analysis 4.21. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months,	
Outcome 21 Any side effects (ALL)	230
Analysis 4.22. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months,	
Outcome 22 Adherence (ALL)	231
Analysis 4.23. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months,	
Outcome 23 HAZ	232
Analysis 4.24. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months,	
Outcome 24 WAZ	232
Analysis 5.1. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years,	
Outcome 1 Anaemia (ALL).	233
Analysis 5.2. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years,	
Outcome 2 Anaemia (by dose).	234
Analysis 5.3. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years,	
Outcome 3 Anaemia (by duration).	235
Analysis 5.4. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years,	
Outcome 4 Anaemia (by type of compound).	236
Analysis 5.5. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years,	
Outcome 5 Anaemia (by anaemia status at baseline).	237
Analysis 5.6. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years,	
Outcome 6 Anaemia (by intermittent regimen).	238
Analysis 5.7. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years,	
Outcome 7 Anaemia (by sex).	239
Analysis 5.8. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years,	
Outcome 8 Anaemia (by nutrient).	240
Analysis 5.9. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years,	
Outcome 9 Haemoglobin (ALL).	241
Analysis 5.10. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years,	
Outcome 10 Haemoglobin (by dose of elemental iron in the intermittent group).	242
Analysis 5.11. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years,	
Outcome 11 Haemoglobin (by duration of the supplementation).	243
Analysis 5.12. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years,	210
Outcome 12 Haemoglobin (by type of iron compound).	244
Analysis 5.13. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years,	211
Outcome 13 Haemoglobin (by anaemia status at baseline).	245
Analysis 5.14. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years,	21)
Outcome 14 Haemoglobin (by supplementation regimen).	246
Analysis 5.15. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years,	240
Outcome 15 Haemoglobin (by sex).	247
	27/

Analysis 5.16. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years, Outcome 16 Haemoglobin (by nutrient).	248
Analysis 5.17. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years, Outcome 17 Ferritin (ALL).	249
Analysis 5.18. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years, Outcome 18 All cause morbidity (ALL).	249
Analysis 5.19. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years, Outcome 19 Any side effects (ALL).	250
Analysis 5.20. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years, Outcome 20 Nausea.	250
Analysis 5.21. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years, Outcome 21 IQ (ALL).	251
Analysis 5.22. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years, Outcome 22 Thai language (ALL).	252
Analysis 5.23. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years, Outcome 23 Mathematics (ALL).	252
Analysis 5.24. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years, Outcome 24 Increase in steps climbed (ALL).	253
Analysis 5.25. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years, Outcome 25 WAZ.	253
Analysis 5.26. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years, Outcome 26 HAZ.	254
Analysis 6.1. Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years, Outcome 1 Anaemia (ALL).	254
Analysis 6.2. Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years, Outcome 2 Haemoglobin (ALL).	255
Analysis 6.3. Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years, Outcome 3 Haemoglobin (by dose of elemental iron).	256
Analysis 6.4. Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years, Outcome 4 Haemoglobin (by duration of the supplementation).	257
Analysis 6.5. Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years, Outcome 5 Haemoglobin (by type of compound).	258
Analysis 6.6. Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years, Outcome 6 Haemoglobin (by baseline prevalence of anaemia).	259
Analysis 6.7. Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years, Outcome 7 Haemoglobin (by supplementation regimen).	260
Analysis 6.8. Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years, Outcome 8 Haemoglobin (by sex).	260
Analysis 6.9. Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years, Outcome 9 Haemoglobin (by nutrient).	261
Analysis 6.10. Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years, Outcome 10 Ferritin (ALL).	262
Analysis 6.11. Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years, Outcome 11 All cause morbidity (ALL).	
Analysis 6.12. Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years,	263
Outcome 12 Diarrhoea (ALL)	264
Outcome 13 Adherence (ALL)	265
Outcome 14 IQ (ALL). .	265 266
	200

Analysis 6.16. Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years,	
	267
Analysis 6.17. Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years,	
Outcome 17 Increase in steps climbed (ALL)	267
Analysis 6.18. Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years,	
Outcome 18 HAZ	268
Analysis 6.19. Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years,	
	268
Analysis 6.20. Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years,	
Outcome 20 WAZ	269
ADDITIONAL TABLES	269
APPENDICES	270
CONTRIBUTIONS OF AUTHORS	274
	274
	275
DIFFERENCES BETWEEN PROTOCOL AND REVIEW	275
INDEX TERMS	275

[Intervention Review]

Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Luz Maria De-Regil¹, Maria Elena D Jefferds², Allison C Sylvetsky³, Therese Dowswell⁴

¹Micronutrient Initiative, Ottawa, Canada. ²International Micronutrient Malnutrition Prevention and Control Program, Nutrition Branch, Division of Nutrition, Physical Activity and Obesity, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. ³Graduate Division of Biological and Biomedical Sciences, Emory University, Atlanta, Georgia, USA. ⁴Cochrane Pregnancy and Childbirth Group, Department of Women's and Children's Health, The University of Liverpool, Liverpool, UK

Contact address: Luz Maria De-Regil, Micronutrient Initiative, 180 Elgin Street, Suite 1000, Ottawa, ON, K2P 2K3, Canada. lderegil@micronutrient.org.

Editorial group: Cochrane Developmental, Psychosocial and Learning Problems Group. **Publication status and date:** Edited (no change to conclusions), published in Issue 3, 2014.

Citation: De-Regil LM, Jefferds MED, Sylvetsky AC, Dowswell T. Intermittent iron supplementation for improving nutrition and development in children under 12 years of age. *Cochrane Database of Systematic Reviews* 2011, Issue 12. Art. No.: CD009085. DOI: 10.1002/14651858.CD009085.pub2.

Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Approximately 600 million children of preschool and school age are anaemic worldwide. It is estimated that half of the cases are due to iron deficiency. Consequences of iron deficiency anaemia during childhood include growth retardation, reduced school achievement, impaired motor and cognitive development, and increased morbidity and mortality. The provision of daily iron supplements is a widely used strategy for improving iron status in children but its effectiveness has been limited due to its side effects, which can include nausea, constipation or staining of the teeth. As a consequence, intermittent iron supplementation (one, two or three times a week on non-consecutive days) has been proposed as an effective and safer alternative to daily supplementation.

Objectives

To assess the effects of intermittent iron supplementation, alone or in combination with other vitamins and minerals, on nutritional and developmental outcomes in children from birth to 12 years of age compared with a placebo, no intervention or daily supplementation.

Search methods

We searched the following databases on 24 May 2011: CENTRAL (2011, Issue 2), MEDLINE (1948 to May week 2, 2011), EMBASE (1980 to 2011 Week 20), CINAHL (1937 to current), POPLINE (all available years) and WHO International Clinical Trials Registry Platform (ICTRP). On 29 June 2011 we searched all available years in the following databases: SCIELO, LILACS, IBECS and IMBIOMED. We also contacted relevant organisations (on 3 July 2011) to identify ongoing and unpublished studies.

Selection criteria

Randomised and quasi-randomised trials with either individual or cluster randomisation. Participants were children under the age of 12 years at the time of intervention with no specific health problems. The intervention assessed was intermittent iron supplementation compared with a placebo, no intervention or daily supplementation.

Data collection and analysis

Two authors independently assessed the eligibility of studies against the inclusion criteria, extracted data from included studies and assessed the risk of bias of the included studies.

Main results

We included 33 trials, involving 13,114 children (-49% females) from 20 countries in Latin America, Africa and Asia. The methodological quality of the trials was mixed.

Nineteen trials evaluated intermittent iron supplementation versus no intervention or a placebo and 21 studies evaluated intermittent versus daily iron supplementation. Some of these trials contributed data to both comparisons. Iron alone was provided in most of the trials.

Fifteen studies included children younger than 60 months; 11 trials included children 60 months and older, and seven studies included children in both age categories. One trial included exclusively females. Seven trials included only anaemic children; three studies assessed only non-anaemic children, and in the rest the baseline prevalence of anaemia ranged from 15% to 90%.

In comparison with receiving no intervention or a placebo, children receiving iron supplements intermittently have a lower risk of anaemia (average risk ratio (RR) 0.51, 95% confidence interval (CI) 0.37 to 0.72, ten studies) and iron deficiency (RR 0.24, 95% CI 0.06 to 0.91, three studies) and have higher haemoglobin (mean difference (MD) 5.20 g/L, 95% CI 2.51 to 7.88, 19 studies) and ferritin concentrations (MD 14.17 µg/L, 95% CI 3.53 to 24.81, five studies).

Intermittent supplementation was as effective as daily supplementation in improving haemoglobin (MD -0.60 g/L, 95% CI -1.54 to 0.35, 19 studies) and ferritin concentrations (MD -4.19 μ g/L, 95% CI -9.42 to 1.05, 10 studies), but increased the risk of anaemia in comparison with daily iron supplementation (RR 1.23, 95% CI 1.04 to1.47, six studies). Data on adherence were scarce and it tended to be higher among those children receiving intermittent supplementation, although this result was not statistically significant.

We did not identify any differential effect of the type of intermittent supplementation regimen (one, two or three times a week), the total weekly dose of elemental iron, the nutrient composition, whether recipients were male or female or the length of the intervention.

Authors' conclusions

Intermittent iron supplementation is efficacious to improve haemoglobin concentrations and reduce the risk of having anaemia or iron deficiency in children younger than 12 years of age when compared with a placebo or no intervention, but it is less effective than daily supplementation to prevent or control anaemia. Intermittent supplementation may be a viable public health intervention in settings where daily supplementation has failed or has not been implemented. Information on mortality, morbidity, developmental outcomes and side effects, however, is still lacking.

PLAIN LANGUAGE SUMMARY

One, two or three times a week iron supplements for improving health and development among children under 12 years of age

Approximately 600 million preschool and school-age children are anaemic worldwide. It is estimated that half of these cases are due to a lack of iron. Iron deficiency anaemia during childhood may slow down growth, reduce motor and brain development, and increase illness and death. If anaemia is not treated promptly, these problems may persist later in life. Taking supplements containing iron (sometimes combined with folic acid and other vitamins and minerals) on a daily basis has shown to improve children's health but its use has been limited because supplements may produce side effects such as nausea, constipation or staining of the teeth. It has been suggested that giving iron one, two or three times a week (known as 'intermittent' supplementation) may reduce these side effects and be easier to remember, and thus encourage children to continue taking the iron supplements.

We analysed 33 trials involving 13,314 children (49% females) from 20 countries in Latin America, Africa and Asia, to assess the effects of intermittent iron supplementation, alone or in combination with other vitamins and minerals, on nutritional and developmental outcomes in children from birth to 12 years of age compared with a placebo, no intervention.or daily supplementation.

The studies were of mixed quality. Overall, the results of this review show that giving children supplements with iron alone or in combination with other vitamins and minerals one, two or three times a week approximately halves their risk of having anaemia in comparison with receiving no iron supplements or a placebo. Giving children supplements on a intermittent basis was as effective as daily supplementation for improving haemoglobin and ferritin concentrations, although, children receiving iron supplements intermittently were at higher risk of having anaemia.

We aimed to examine the effects of intermittent supplementation on illness, death, and school and physical performance, as well as on other side effects, but there was insufficient information to draw firm conclusions.

Intermittent iron supplementation for improving nutrition and development in children under 12 years of age (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

In summary, intermittent iron supplementation is efficacious to improve haemoglobin concentrations and reduce the risk of having anaemia or iron deficiency in children younger than 12 years of age when compared with a placebo or no intervention, but it is less effective than daily supplementation to prevent or control anaemia. Intermittent supplementation may be a viable public health intervention in settings where daily supplementation has failed or has not been implemented. Information on mortality, morbidity, developmental outcomes and side effects, however, is still lacking.

SUMMARY OF FINDINGS FOR THE MAIN COMPARISON [Explanation]

Patient or population: children under 12 years of age

Settings: community settings

Intervention: intermittent supplementation with iron alone or with other nutrients

Comparison: placebo or no intervention

Outcomes	Relative effect (95% Cl)	No of Participants (studies)	Quality of the evidence (GRADE)
Anaemia (haemoglobin below a cut-off defined by trialists, taking into account the age and altitude)		1824 (10 studies)	⊕⊕⊕⊜ moderate ¹
Haemoglobin (g/L)	MD 5.20 (2.51-7.88)	3032 (19 studies)	⊕⊕⊖⊖ Iow ^{2,3}
Iron deficiency (using ferritin concentra- tions)	RR 0.24 (0.06-0.91)	431 (3 studies)	very low ^{2,3,4}
Iron status (ferritin (μ g/L)	MD 14.17 (3.53-24.81)	550 (5 studies)	⊕⊕⊖⊖ Iow ^{2,3}
Iron deficiency anaemia	Not estimable	0 (0 studies)	None of the trials reported on this outcome
All-cause mortality	Not estimable	0 (0 studies)	None of the trials reported on this outcome

CI, confidence interval; RR, risk ratio; MD, mean difference

*GRADE Working Group grades of evidence:

High quality: We are very confident that the true effect lies close to that of the estimate of the effect.

Moderate quality: We have moderate confidence in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low quality: Our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect.

Very low quality: We have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of the effect

Intermittent iron supplementation for improving nutrition and development in children under 12 years of age (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

⊾

¹There was high statistical heterogeneity. Given the large and consistent effect (RR 0.51; 95% CI 0.37-0.72) we have refrained from downgrading even though three of the nine studies are at high risk of bias

² High statistical heterogeneity but results were consistent.

³ Some studies lacked blinding and clear methods of allocation
 ⁴ Wide confidence intervals.

Note: For cluster-randomised trials the analyses only include the estimated effective sample size, after adjusting the data to account for the clustering effect

BACKGROUND

Description of the condition

Iron is an essential nutrient for all body tissues and is present in the brain of the developing fetus, where it is needed for proper formation of neural tissue (Iannoti 2006) and development of brain cells (Beard 2008). Iron deficiency, a common form of nutritional deficiency, results from long-term imbalance caused by an inadequate dietary iron intake; poor iron absorption or utilisation; increased iron requirements for growth during childhood, adolescence or pregnancy; or chronic blood losses (Moy 2006). In the later stages of iron depletion, the haemoglobin concentration decreases, resulting in a condition known as iron deficiency anaemia.

Anaemia is characterised by a reduction in the oxygen-carrying capacity of blood such that the body's needs can no longer be met. In addition to iron deficiency, other vitamin and mineral deficiencies (for example, folate, vitamin B₁₂ and vitamin A), chronic inflammation, parasitic infections and inherited disorders of haemoglobin structure can result in all-cause anaemia (WHO 2001). Among females, anaemia is often exacerbated after beginning menstruation, especially if it occurs at an early age and the young females do not consume sufficient iron to offset menstrual losses (WHO 2001). Haemoglobin concentrations are used to diagnose anaemia, while serum ferritin, an iron storage protein, and serum transferrin, an iron transport protein, are commonly used as indicators of iron status in populations (WHO 2011a; WHO 2011b). Children, particularly those younger than five years, are vulnerable to iron deficiency anaemia because of their increased needs as a result of rapid growth. It is estimated that approximately 600 million preschool and school-aged children are anaemic worldwide, and it is calculated that at least half of the cases are due to iron deficiency (WHO/CDC 2008). In general, low-income countries have a higher prevalence of anaemia (WHO/CDC 2008). This association is also true in high-income countries where people of low socioeconomic status are especially susceptible to iron and other vitamin and mineral deficiencies (Cole 2010).

Consequences of iron deficiency anaemia during childhood include growth retardation, reduced school achievement, impaired motor and cognitive development, and increased morbidity from a variety of causes including diarrhoea and acute respiratory infections (WHO 2001). Specifically, iron deficiency can lead to deficits in memory and behavioural regulation as iron is required to make neurotransmitters such as dopamine, epinephrine and serotonin (Iannoti 2006; Moy 2006; Beard 2008), while impaired myelination contributes to deficits in motor function. Long-term effects of early iron deficiency include decreased work capacity and impaired cognitive and behavioural development (Lozoff 2000; Lozoff 2007). Some of these impairments are thought to be irreversible if they occur at an early age and the consequences may continue even after treatment, reinforcing the importance of prevention (Siddiqui 2004; Iannoti 2006; Lozoff 2007).

Description of the intervention

Mass fortification of food staples with iron; dietary diversification to increase iron intake, absorption and utilisation; and iron supplementation have been used to prevent or treat iron deficiency anaemia. Mass fortification of staple foods with iron is usually not aimed at meeting the needs of young children, with the exception of targeted complementary infant feeding programmes (WHO 2009a). Dietary diversification to improve iron status in populations at risk is also difficult because of limited food access among the most vulnerable populations, the limited quantity of food that children can consume, and the fact that the strategy requires multiple behavioural changes among children and their families. To date, there are few effective dietary diversification intervention programmes at scale (Davidsson 2003). Finally, iron supplementation, which is the provision of doses of iron alone or in combination with other micronutrients in the form of tablets, syrups or capsules, is the most widespread strategy for improving iron status in children worldwide.

The World Health Organization (WHO) recommends a supplemental provision of 2 mg of elemental iron per kilogram body weight per day for three months in children less than six years of age who were born at term. Children of school age and older should receive 30 mg of elemental iron and 250 μ g (0.25 mg) of folic acid daily, particularly in populations where anaemia prevalence is greater than 40% (WHO 2001). Though the current recommendations include iron alone or with folic acid, it has been suggested that administration of additional vitamins and minerals may prevent or reverse anaemia derived from one or more nutritional deficiencies (Bhutta 2009). Daily iron supplementation has proven to be effective in increasing haemoglobin concentrations in children, especially in those who are anaemic (Gera 2007). In spite of this, in real world settings the long regimen duration, the low coverage rates and insufficient tablet distribution, and side effects associated with daily iron supplementation (for example, gastrointestinal discomfort, constipation and staining of teeth with drops or syrups) limit adherence, especially in young children (ACC/SCN 1991; Stoltzfus 2011). In older children these effects may partially be controlled with the use of slow-release iron tablets in which iron has similar bioavailability to regular iron compounds (for example, ferrous sulphate or ferrous fumarate) (Simmons 1993; Bothwell 2000), although their higher cost may be a limiting factor for wider use.

How the intervention might work


Oral iron supplementation on an intermittent basis (that is once, twice or three times a week on non-consecutive days) has been suggested as a more efficient preventive intervention in public health programmes than the more common daily iron supplementation scheme. The basis for this iron intermittent supplementation regimen is that the absorption is maximised by provision of iron in

synchrony with the turnover of the mucosal cells (that is, intestinal cells are 'fresh' to take up iron) (Wright 1990; Berger 1997; Viteri 1997; Beaton 1999; Tavil 2003). In addition, other minerals such as zinc and copper may be more readily absorbed because they are not regularly competing with iron for absorption channels, leading to an improved micronutrient status (Baqui 2005). It has been reported that intermittent supplementation may be safer than daily supplementation because intestinal cells are less exposed to an iron-rich environment, which may cause cell damage (Casanueva 2003; Viteri 2005). Also, it has been suggested that additional iron may exacerbate malaria infection and so this reduced exposure to iron overall is particularly relevant in malaria settings as less iron is available for the parasite's growth (Ekvall 2000; NIH 2011). Though side effects may still occur with intermittent regimens, they are experienced less frequently and may be perceived as more acceptable as a result, increasing adherence to

supplementation programmes (Thu 1999; Viteri 2005).

Despite the biological plausibility of this intervention to reduce anaemia, its success as a public health intervention will likely be determined by several factors such as the available resources; the existence of the appropriate policies and legislation; the production and supply of the supplements; the development of delivery systems; the development and implementation of external and internal quality control systems, and the development and implementation of strategies for information, education and communication for behaviour change among consumers. Figure 1 presents a generic logic model for micronutrient interventions that depicts the programme theory and the plausible relationships between inputs and expected changes in health and outcomes that can be adapted to the context of each setting (De-Regil 2011; WHO/CDC 2011).

Figure 1. WHO/CDC logic model for micronutrients interventions in public health (with permission from WHO)



Why it is important to do this review

mittent iron supplementation regimens in children. It has been reported that the provision of an iron supplement once a week is

There are currently no international recommendations on inter-

comparable to daily supplementation in improving anaemia status (Siddiqui 2004). Other authors suggest that this effect may be enhanced when iron is given twice a week (Schultink 1995; Tavil 2003; Olsen 2006).

Weekly iron and folic acid supplementation has recently been recommended by the WHO to prevent anaemia in women of reproductive age (WHO 2009b). This intervention is currently implemented at scale in many countries around the world as part of public health programmes. It could potentially be targeted to other age groups, such as young children and school-aged children, since the supplement can be provided at home and in schools or other institutional settings. However, to date, there has been no systematic assessment of the safety and effectiveness of weekly or any other intermittent iron supplementation regimen among children to inform policy makers.

This review complements the findings of two related Cochrane systematic reviews exploring the effects of intermittent regimens among menstruating women (Fernández-Gaxiola 2011) and pregnant women (Peña-Rosas 2009).

OBJECTIVES

To assess the effects of intermittent iron supplementation, alone or in combination with other vitamins and minerals, on nutritional and developmental outcomes in children less than 12 years of age compared with daily supplementation, a placebo or no supplementation.

METHODS

Criteria for considering studies for this review

Types of studies

We included randomised and quasi-randomised studies with randomisation at either an individual or cluster level. We defined quasi-randomised trials as trials which use systematic methods to allocate participants to treatment groups, such as alternation, assignment based on date of birth or case record number (Higgins 2011). We did not include cross-over trials nor other types of evidence (for example, cohort or case-control studies) in the metaanalysis but we have considered such evidence in the discussion where relevant.

Types of participants

Children under the age of 12 years at the time of the trials. We did not include studies specifically targeting premature or low birth weight infants, or children with severe infectious diseases, such as HIV, as they may metabolise iron differently and have different health and disease indicators. These topics are subject to separate Cochrane reviews (Adetifa 2009; Mills 2009).

Types of interventions

Oral supplements of iron, alone or with other vitamins and minerals, given on an intermittent basis and compared with a placebo or no supplementation, or compared with the same supplements provided daily.

Oral iron supplementation refers to the delivery of iron compounds directly to the oral cavity, either as a tablet, capsule, dispersible tablet or liquid. For the purpose of this review, intermittent supplementation is defined as the provision of iron supplements one, two or three times a week on non-consecutive days. We performed the following comparisons:

1. any intermittent iron supplementation versus no supplementation or placebo (0 to < 12 years of age);

any intermittent iron supplementation versus any daily iron

supplementation (0 to < 12 years of age);

3. any intermittent iron supplementation versus no supplementation or placebo (0 to 59 months of age);

4. any intermittent iron supplementation versus any daily iron supplementation (0 to 59 months of age);

5. any intermittent iron supplementation versus no supplementation or placebo (5 to < 12 years of age);

6. any intermittent iron supplementation versus any daily iron supplementation (5 to < 12 years of age).

Any intermittent or daily supplementation with iron includes the provision of iron alone, iron plus folic acid or iron plus other vitamins and minerals.

We have included studies that examined interventions where iron supplementation was combined with co-interventions such as deworming, education or other approaches only if the co-interventions were the same in both the intervention and comparison groups.

We excluded studies examining tube feeding, parenteral nutrition or supplementary food-based interventions such as mass fortification of staple or complementary foods, home fortification with micronutrient powders, lipid-based supplements or Foodlets tablets, or biofortification.

Types of outcome measures

Primary outcomes

1. Anaemia (haemoglobin below a cut-off defined by trialists, taking into account the age and altitude)*

- 2. Haemoglobin (g/L)*
- 3. Iron deficiency (as measured by trialists by using indicators of iron status, such as ferritin or transferrin)*
 - 4. Iron status (ferritin in μ g/L)*

5. Iron deficiency anaemia (defined by the presence of anaemia plus iron deficiency, diagnosed with an indicator of iron status selected by trialists)*

6. All-cause mortality (number of deaths during the trial)*
* Outcomes that were included in the 'Summary of Findings' tables.

Secondary outcomes

1. All-cause morbidity (number of children with at least one reported illness during the trial)

2. Acute respiratory infection (as measured by trialists)

3. Diarrhoea (as measured by trialists)

4. Any other adverse side effects (as measured by trialists, such as stained teeth, headache, stomach ache, discomfort, constipation)

5. Adherence (percentage of children who consumed more than 70% of the expected doses)

6. Folate status (as measured by trialists)

7. Mental development and motor skill development (children 0 to 59 months) (as assessed by trialists, including Bayley Mental Development Index (MDI), Bayley Psychomotor Development Index (PDI), Stanford-Binet Test, DENVER II Developmental Screening Test)

8. School performance (children 60 months and older) (as measured by trialists)

9. Physical capacity (children 60 months and older) (as measured by trialists)

10. Height-for-age Z-scores and weight-for-age Z-scores

We planned to group the outcome time points as follows: immediately after the end of the intervention, one to six months after the end of intervention, and seven to 12 months after the end of the intervention. However, we limited our analyses to the end of the intervention as only two trials reported on continued followup after the end of the intervention. We have described this in Characteristics of included studies and plan to extract this information in future updates, if available.

Search methods for identification of studies

Electronic searches

We searched the following electronic databases:

Cochrane Central Register of Controlled Trials (CENTRAL) (2011, Issue 2), part of *The Cochrane Library* (searched 24 May 2011);

MEDLINE,1948 to May week 2, 2011 (searched 24 May 2011); EMBASE, 1980 to 2011 Week 20 (searched 24 May 2011); CINAHL, 1937 to current (searched 24 May 2011); ICTRP (searched 24 May 2011); POPLINE (searched 24 May 2011); SCIELO (searched 29 June 2011); LILACS (searched 29 June 2011); IBECS (searched 29 June 2011); IMBIOMED (searched 29 June 2011).

The search strategies are in Appendix 1.

We did not apply any language restrictions. For those articles written in a language other than English, we extracted the information or commissioned their translation into English.

Searching other resources

For assistance in identifying ongoing or unpublished studies, we contacted authors and known experts to identify any additional or unpublished data. We also contacted the Departments of Nutrition for Health and Development and regional offices of the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), the nutrition section of the United Nations Children's Fund (UNICEF), the World Food Programme (WFP), the Micronutrient Initiative (MI) and Sight and Life Foundation (3 July 2011).

We searched the International Clinical Trials Registry Platform (ICTRP) (searched 24 May 2011) for any ongoing or planned trials.

Data collection and analysis

Selection of studies

LMD screened all titles and abstracts for potential eligibility, while MEJ, TD and AS each assessed one-third of the abstracts. LMD contacted relevant institutions and searched for ongoing trials. All the authors independently assessed half of the full-text articles for inclusion according to the above mentioned criteria; each paper was therefore assessed by two review authors. We resolved any disagreement through discussion.

If studies were published only as abstracts, or the study reports contained little information on methods, we contacted the authors to obtain further details of study design and results.

Data extraction and management

For eligible studies, two authors independently extracted data using a form designed for this review. LMD extracted data from all the studies and the remaining authors each extracted a third. LMD entered data into the Review Manager 5 software (RevMan 2011). The same review author who extracted one-third of the data in duplicate carried out checks for accuracy. We resolved any discrepancies through discussion and documented each stage of the process.

We completed the data collection form electronically and recorded information as follows.

(1) Trial methods

- Study design
- Unit and method of allocation
- Unit of analysis
- Masking of participants and outcome assessors

• Exclusion of participants after randomisation and

- proportion of losses at follow-up
 - Study power

(2) Participants

- Location of the study
- Sample size
- Age
- Sex

• Socioeconomic status (as defined by trialists and where such information was available)

• Baseline status of anaemia

• Inclusion and exclusion criteria as described in the Criteria for considering studies for this review

(3) Intervention

- Dose
- Type of iron compound
- Supplementation regimen
- Duration of the intervention
- Co-intervention

(4) Comparison group

• Type of comparison (no intervention, placebo or daily supplementation with the same nutrients)

(5) Outcomes

• Primary and secondary outcomes outlined in the Types of outcome measures section

We recorded both prespecified and non-prespecified outcomes, although we did not use the latter to underpin the conclusions of the review.

When information regarding any of the studies was unclear, we contacted authors of the original reports to provide further details. If there was insufficient information for us to be able to assess risk of bias, studies were put into the awaiting assessment section of the review until further information is published or made available to us.

Assessment of risk of bias in included studies

One author (LMD) assessed the risk of bias for all the included studies and the remaining authors each assessed one-third of the studies so that all the trials were assessed by two authors independently, using the criteria outlined in the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011). We resolved any disagreement by discussion or by involving a third assessor. We reported this assessment in the 'Description of studies' and risk of bias tables. We explicitly mention when authors provided input on their trials.

(1) Sequence generation (checking for possible selection bias)

We have described for each included study the method used to generate the allocation sequence.

We assessed the method as:

• low risk of bias (any truly random process, for example, random number table; computer random number generator);

• high risk of bias (any non-random process, for example, odd or even date of birth; hospital or clinic record number);

• unclear risk of bias.

(2) Allocation concealment (checking for possible selection bias)

We have described for each included study the method used to conceal the allocation sequence and have assessed whether intervention allocation could have been foreseen in advance of or during recruitment, or changed after assignment.

We assessed the methods as:

• low risk of bias (for example, telephone or central randomisation; consecutively numbered sealed opaque envelopes);

 high risk of bias (open random allocation; unsealed or nonopaque envelopes);

• unclear risk of bias.

(3) Blinding (checking for possible performance and detection bias)

We have described for each included study the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. For interventions involving the provision of iron supplements it may be possible to blind children, clinical staff and outcome assessors to group allocation by providing placebo preparations.

We assessed blinding separately for different classes of outcomes and have noted where there has been an attempt at partial blinding. We assessed the risk of performance bias associated with blinding as:

• low, high or unclear risk of bias for participants;

• low, high or unclear risk of bias for personnel.

We assessed the risk of detection bias associated with blinding as:

• low, high or unclear risk of bias for outcome assessors.

Whilst assessed separately, we combined the results into a single evaluation of risk of bias associated with blinding (Higgins 2011).

(4) Incomplete outcome data (checking for possible attrition bias through withdrawals, dropouts, protocol deviations)

We have described for each included study, and for each outcome or class of outcomes, the completeness of data including attrition and exclusions from the analysis. We have stated whether attrition and exclusions were reported, the numbers included in the analysis at each stage (compared with the total number of randomised participants), reasons for attrition or exclusion, where reported, and whether missing data were balanced across groups. We assessed methods as:

• low risk of bias (less than 20% of cases lost to follow-up and balanced in numbers across intervention groups);

 high risk of bias (20% or more cases lost to follow-up or outcome data imbalanced in numbers across intervention groups);

• unclear risk of bias .

(5) Selective reporting bias

We have described for each included study how we investigated the possibility of selective outcome reporting bias and what we found.

We assessed the methods as:

• low risk of bias (where it was clear that all of the study's prespecified outcomes and all expected outcomes of interest to the review have been reported);

• high risk of bias (where not all the study's prespecified outcomes have been reported; one or more reported primary outcomes were not prespecified; outcomes of interest were reported incompletely and so cannot be used; study fails to include results of a key outcome that would have been expected to have been reported);

• unclear risk of bias.

(6) Other sources of bias

We have described for each included study any important concerns we have about other possible sources of bias.

We assessed whether each study was free of other problems that could put it at risk of bias:

- high risk of other bias;
- low risk of other bias;
- unclear risk of other bias.

(7) Overall risk of bias

We summarised the risk of bias at two levels: within studies (across domains) and across studies.

For the first, we made explicit judgements about whether studies were at high risk of bias, according to the criteria given in the *Cochrane Handbook for Systematic Reviews of Intervention* (Higgins 2011). With reference to (1) to (6) above, we assessed the likely magnitude and direction of the bias and whether we considered it was likely to impact on the findings. Attrition, lack of blinding and losses to follow-up may be particular problems in studies looking at different regimens of iron supplementation and where children are followed up over time. We explored the impact of the level of bias by undertaking sensitivity analyses, see Sensitivity analysis below.

For the assessment across studies, the main findings of the review are set out in 'Summary of findings for the main comparison and Summary of findings 2 (SoF) prepared using GRADE profiler software (GRADEpro 2008). The primary outcomes for each comparison have been listed with estimates of relative effects along with the number of participants and studies contributing data for those outcomes. For each individual outcome, the quality of the evidence has been assessed independently by two review authors using the GRADE approach (Balshem 2010), which involves consideration of within-study risk of bias (methodological quality), directness of evidence, heterogeneity, precision of effect estimates and risk of publication bias; this results in one out of four levels of quality (high, moderate, low or very low). This assessment was limited only to the trials included in this review and as we did not consider there was a serious risk of indirectness or publication bias we did not downgrade in these domains.

Measures of treatment effect

Dichotomous data

For dichotomous data, we have presented results as average risk ratios (RR) with 95% confidence intervals (CI).

Continuous data

We present the results as mean difference (MD) with 95% confidence intervals at the end of the intervention. If trials did not provide this information but reported the mean change, we included these data as suggested by Higgins 2011. There was no need to use the standardised mean difference to combine trials as these outcomes were measured with the same methods.

Unit of analysis issues

Cluster-randomised trials

We included cluster-randomised trials in the analyses along with individually-randomised trials. Cluster-randomised trials are labelled with a (C). We obtained the intra-cluster correlation coefficient (ICC) from Hall 2002 (C) (ICC 0.0698; average cluster size (ACS): 18.55; design effect (DE) 2.22), Desai 2004 (C) (ICC 0.069; ACS: 1.5; DE 1.035) and Roschnik 2004 (C) (ICC 0.1123; ACS: 33.82; DE 4.35). We calculated the ACS from the reports and imputed the ICC from Roschnik 2004 (C) to Roschnik 2003 (C) as the study designs were very similar (ACS: 29); and from Hall 2002 (C) to Liu 1995 (C) (ACS: 27.3), Sinisterra 1997 (C) (ACS: 199.5), Yang 2004 (C) (ACS: 32), Sen 2009 (C) (ACS: 60) and Arcanjo 2011 (C) (ACS: 17.7) and then calculated each trial's effective sample size. In the case of Yang 2004 (C), the number of classes was not clear so we assumed an average cluster size of 32 based on other reports (Okebe 2011). On the other hand, Awasthi 2005 (C) reported that the sample size was calculated including a design effect of 2.0. We used this value to calculate its effective sample size and also to conduct a sensitivity analysis to examine the potential effect of clustering on the CIs of the summary estimates. As the CIs did not change significantly (5% or more), we do not report the results of the sensitivity analysis. Desai 2004 (C) and Engstrom 2008 (C) were not adjusted as the trial authors reported that the analyses accounted for the effect of clustering.

Studies with more than two treatment groups

For studies with more than two intervention groups (multi-arm studies), we included the directly relevant arms only. When we identified studies with various relevant arms, we combined the groups into a single pair-wise comparison (Higgins 2011) and included the disaggregated data in the corresponding subgroup category. When the control group was shared by two or more study arms, we divided the control group (events and total population) over the number of relevant subgroup categories to avoid double counting the participants. The details are described in the Characteristics of included studies tables.

Cross-over trials

We did not include cross-over trials.

Dealing with missing data

For included studies, we have noted levels of attrition in the Characteristics of included studies tables. We explored the impact of including studies with high levels of missing data in the overall assessment of treatment effect by carrying out sensitivity analysis (these same trials were assessed as being at high risk of bias, see Sensitivity analysis below).

We carried out analyses, as far as possible, on an intention-totreat basis (ITT), that is, by attempting to include all participants randomised to each group in the analyses. If this was not possible, we performed an available case analysis in which data were analysed for every participant for whom the outcome was obtained.

Assessment of heterogeneity

We visually examined the forest plots from meta-analyses to look for any obvious heterogeneity among studies in terms of the size or direction of treatment effect. We used the I² statistic, Tau² and Chi² test to quantify the level of heterogeneity among the trials in each analysis. If we identified moderate or substantial heterogeneity, we explored it by prespecified Subgroup analysis and investigation of heterogeneity.

Assessment of reporting biases

Where we suspected reporting bias (see 'Selective reporting bias' above), we attempted to contact study authors asking them to provide missing outcome data. Where this was not possible, and the missing data were thought to introduce serious bias, we explored the impact of including such studies in the overall assessment of results by a sensitivity analysis.

We generated funnel plots (estimated differences in treatment effects against their standard error) only for haemoglobin in comparisons one and two, and ferritin in comparison two, as sufficient studies contributed data to these outcomes. Asymmetry could be due to publication bias but it can also be due to a real relationship between trial size and effect size, such as when larger trials have lower adherence and adherence is positively related to effect size.

Data synthesis

We carried out statistical analysis using the Review Manager 5 software (RevMan 2011). In this review we prespecified that we would use random-effects model analyses in view of anticipated heterogeneity in the interventions, populations and methods used in different trials.

Subgroup analysis and investigation of heterogeneity

Where data were available, we carried out the following subgroup analysis:

1. by dose of elemental iron per week in the intermittent group: 25 mg or less; greater than 25 mg to 75 mg; greater than 75 mg;

2. by duration of the supplementation: 0 to three months or less; more than three months;

3. by type of compound: ferrous sulphate; ferrous fumarate; other;

4. by anaemia status at baseline (haemoglobin < 110 g/L or < 115 g/L for children 6 to 59 months or 5 to 11 years old, respectively, adjusted by altitude where appropriate): anaemic; non-anaemic; mixed or not reported;

5. by intermittent supplementation regimen: one supplement a week; other intermittent regimen;

6. by sex: males; females; mixed or not reported; and

7. by micronutrient composition: iron alone; iron + folic acid;iron + other micronutrient; iron + multiple micronutrients.We used the primary outcomes in subgroup analysis.

Pragmatically, we decided not to conduct subgroup analyses for those outcomes with three trials or fewer. We examined differences between subgroups by visual inspection of the subgroups' confidence intervals; non-overlapping confidence intervals suggesting a statistically significant difference in treatment effect between the subgroups. We also used the Borenstein 2008 approach to formally investigate the differences between two or more subgroups. Analyses were conducted in Revman version 5.1.1 (RevMan 2011).

Sensitivity analysis


We carried out sensitivity analysis to examine the effects of removing studies at high risk of bias (studies with poor or unclear randomisation and allocation concealment, and either blinding or high or imbalanced losses to follow-up) from the analysis. We also examined the effect of different intra-cluster correlation coefficients imputed to cluster-randomised trials on the summary estimates of primary outcomes.

RESULTS

Description of studies

Results of the search

The search strategy identified 7784 references for possible inclusion, 2453 of which were duplicate references. We assessed 81 published articles in full text, three unpublished reports, one review that contained published and unpublished data, and one abstract that has not been published in full. Nine studies were published in languages other than English: Chinese (Yang 2004 (C)), Farsi (Kargarnovin 2010), French (Nguyen 2002) and Spanish (Sinisterra 1997 (C); Rivera 1998; Sotelo-Cruz 2002; Evangelista-Salazar 2004; UNICEF 2006; Avila-Jimenez 2011). Figure 2 depicts the process for assessing and selecting the studies. We included 33 trials (42 references); excluded 40 (41 references); three trials are awaiting assessment (Husseini 1999; Reid 2001; Kargarnovin 2010), and we identified one ongoing study (Zeeba Zaka-ur-Rab 2010).



Intermittent iron supplementation for improving nutrition and development in children under 12 years of age (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Included studies

We included 33 trials with 13,114 children; those studies which included more than two intervention arms may have been included in more than one comparison. All included trials contributed data to the review but some studies randomised participants to intervention arms that were not relevant to the comparisons we assessed. For these studies we did not include data from all groups in the analyses. We have indicated in the Characteristics of included studies tables if any randomised arms were not included.

Three of the trials had two arms providing different regimens of intermittent supplementation (Liu 1995 (C); Faqih 2006; Sen 2009 (C)). In these cases we combined the study arms for the overall comparison and included the disaggregated information in the subgroup analyses. Levels of supervision varied among trials but most of them were unsupervised. In addition, very few studies addressed the use of co-interventions such as health education to improve adherence or deworming prior to supplementation.

The sample size ranged between 60 and 1785 participants but overall tended to be small: 75% of the studies included fewer than 500 children. However, for cluster-randomised trials the analyses only included the estimated effective sample size, after adjusting the data to account for the clustering effect.

Settings

The studies included in the review were carried out over the last 16 years in low- and middle-income countries in Asia, Africa and Latin America: Bangladesh (Baqui 2003), Bolivia (Berger 1997; Aguayo 2000), Brazil (Da Silva 2008; Engstrom 2008 (C); Arcanjo 2011 (C)), China (Liu 1995 (C); Yang 2004 (C)), India (Awasthi 2005 (C); Sen 2009 (C)), Indonesia (Schultink 1995; Palupi 1997; Soemantri 1997), Iran (Khademloo 2009), Jordan (Faqih 2006), Kenya (Olsen 2000; Verhoef 2002; Desai 2004 (C)), Malawi (Young 2001; Roschnik 2003 (C)), Mali (Hall 2002 (C)), Mexico (Evangelista-Salazar 2004), Pakistan (Siddiqui 2004), Panama (Sinisterra 1997 (C)), Phillipines (Roschnik 2004 (C)), South Africa (Taylor 2001), Tanzania (Ekvall 2000), Thailand (Sungthong 2002), Turkey (Ermis 2002; Tavil 2003; Yurdakok 2004) and Vietnam (Thu 1999; Nguyen 2002).

Participants

Participant ages ranged from newborn to 19 years old. While we did not include studies specifically recruiting postmenarchal females, as these are the subject of a separate review (Fernández-Gaxiola 2011), three included studies recruited adolescents and separate data were not available for younger children (Olsen 2000; Taylor 2001; Hall 2002 (C)). Based on the age range reported in these studies, at least half of their participants fulfilled our inclusion criteria and thus we decided to retain them in the review. If the disaggregated data by age is made available to us, we will include it in future updates of the review.

In the analyses (comparisons three to six), we have set out our findings separately for studies recruiting children in these younger and older age groups. Fifteen studies included children from birth to 59 months of age only (Schultink 1995; Palupi 1997; Thu 1999; Ekvall 2000; Young 2001; Ermis 2002; Nguyen 2002; Verhoef 2002; Baqui 2003; Tavil 2003; Evangelista-Salazar 2004; Desai 2004 (C); Yurdakok 2004; Engstrom 2008 (C); Khademloo 2009) and 11 trials included only older children 60 months of age and older (Sinisterra 1997 (C); Soemantri 1997; Aguayo 2000; Taylor 2001; Sungthong 2002; Roschnik 2003 (C); Roschnik 2004 (C); Siddiqui 2004; Da Silva 2008; Sen 2009 (C); Arcanjo 2011 (C)). Seven studies included children in both age categories (Liu 1995 (C); Berger 1997; Olsen 2000; Hall 2002 (C); Yang 2004 (C); Awasthi 2005 (C); Faqih 2006). In those cases we took into account the reported average age in allocating the trial. For example, Faqih 2006 recruited children aged two to six years of age and was included in comparisons two and four (younger children), while Olsen 2000 assessed children aged four to 19 years and was included in comparisons one and five (older children).

On average, 49% of the participants were females, with a range from 37% (Tavil 2003) to 100% (Sen 2009 (C)). Seven trials included only anaemic children (Schultink 1995; Berger 1997; Verhoef 2002; Tavil 2003; Desai 2004 (C); Faqih 2006; Siddiqui 2004); three only non-anaemic (Aguayo 2000; Yang 2004 (C); Yurdakok 2004); and the rest of the trials had a baseline prevalence of anaemia ranging between 15% and 90%.

Participants socioeconomic status was not explicit in most of the studies although references to underprivileged populations were frequent.

Intermittent regimens, dose and type of iron compounds

Nine trials included arms where children were supplemented with iron twice a week (Liu 1995 (C); Schultink 1995; Olsen 2000; Verhoef 2002; Tavil 2003; Desai 2004 (C); Awasthi 2005 (C); Faqih 2006; Sen 2009 (C)) and in two studies children were provided with iron every other day (three times a week) (Ekvall 2000; Ermis 2002). The rest of the studies provided iron supplements once weekly.

The total weekly iron dose given to the children ranged from 7.5 to 200 mg of elemental iron per week. Evangelista-Salazar 2004 provided 7.5 mg; Nguyen 2002 gave 15 mg; two trials provided 20 mg elemental iron (Thu 1999; Baqui 2003); in two trials children received a total weekly dose of 25 mg elemental iron (Da Silva 2008; Engstrom 2008 (C)); three trials gave 30 mg (Palupi 1997; Ekvall

2000; Yang 2004 (C)); one trial (Awasthi 2005 (C)) supplemented participants with 40 mg per week and another trial with 50 mg of iron per week (Arcanjo 2011 (C)). In five trials children received 60 mg of elemental iron per week (Schultink 1995; Sinisterra 1997 (C); Young 2001; Sungthong 2002; Siddiqui 2004); in three trials children received in total a weekly dose of 65 mg (Taylor 2001; Hall 2002 (C); Roschnik 2003 (C)); in one study the dose was 108 mg (Roschnik 2004 (C)); in another study the dose was 120 mg (Olsen 2000); and in Sen 2009 (C) the total weekly dose was 200 mg of elemental iron.

Some studies reported the provision of 1 mg to 8 mg of elemental iron per kg per day (Liu 1995 (C); Berger 1997; Soemantri 1997; Aguayo 2000; Ermis 2002; Verhoef 2002; Tavil 2003; Desai 2004 (C); Yurdakok 2004; Faqih 2006). In these cases we calculated the weekly dose by using the median or average age reported in the trial and the corresponding weight according to the WHO growth charts, percentile 50.

In almost all the studies, ferrous sulphate was the source of supplemental iron. Other iron compounds tested were ferrous polymaltose (Olsen 2000); ferrous dextran (Sen 2009 (C)) and ferrous fumarate (Taylor 2001; Verhoef 2002).

Most of the studies supplemented only with iron; one study gave iron in combination with 30 mg of vitamin C (Evangelista-Salazar 2004) and five studies gave iron in combination with folic acid. In these trials the weekly dose of folic acid also varied: one trial gave 100 µg (0.1 mg) of folic acid per week (Taylor 2001; Awasthi 2005 (C)), in two the dose was 250 µg (0.25 mg) (Hall 2002 (C); Roschnik 2003 (C)), while in Sen 2009 (C) the dose was 500 µg (0.5 mg) folic acid per week . Four studies provided supplements containing multiple micronutrients (Thu 1999; Young 2001; Baqui 2003; Yang 2004 (C)).

Excluded studies

We excluded 40 trials (41 references) from the review. In 12 trials the evaluated population was out of the scope of this review (Beasley 2000; Kianfar 2000; Sharma 2000; Zavaleta 2000; Ahmed 2001; Februhartanty 2002; Shah 2002; Agarwal 2003; Shobha 2003; Jaleel 2004; Soekarjo 2004; Leenstra 2009). The second main reason for exclusion was that trials were not randomised (Rivera 1998; Jayatissa 1999; Perrin 2002; Sotelo-Cruz 2002; Jackson 2003; Kapur 2003; Kanal 2005; Lima 2006; UNICEF 2006; Vir 2008; Mwanakasale 2009; Azeredo 2010). We excluded eight trials because the supplements were provided as Foodlets a (a crushable tablet that may be mixed with foods) and this intervention is outside the scope of this review (Briars 2003; Hop 2005; López de Romaña 2005; Smuts 2005; Lechtig 2006; López de Romaña 2006; Wijaya-Erhardt 2007; Schümann 2009). Six trials were excluded because intermittent supplementation regimens were not compared with daily regimens or no treatment or placebo (Menendez 1997; Tee 1999; Tomashek 2001; Ahmed 2005; Risonar 2008; Avila-Jimenez 2011). We excluded Hafeez 1998 because the intermittent supplements were given on consecutive days and Lin 2001 because the nutrient tested was vitamin A. We have described these studies in the Characteristics of excluded studies tables.

Risk of bias in included studies

Overall, study methods were not well described in many of the included studies and this meant that assessing risk of bias was difficult (*see* Figure 3 and Figure 4). We attempted to contact the study authors for further clarifications and noted in the Characteristics of included studies when the information was provided by the authors.

Figure 3. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.





Figure 4. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.



Where we assessed methods of randomisation or allocation concealment as being at high risk of bias (or unclear), and trials were either not blinded or had high or imbalanced attrition rates, we assumed that they were at high risk of bias in the sensitivity analysis looking at the impact of study quality. Using these criteria, nine studies were assessed as being at low risk of bias (Thu 1999; Aguayo 2000; Ekvall 2000; Olsen 2000; Hall 2002 (C); Sungthong 2002; Verhoef 2002; Desai 2004 (C); Arcanjo 2011 (C)). The remaining studies were either assessed as being at high risk of bias or the methods were unclear.

Allocation

In 20 of the included trials, it was unclear how the randomisation sequence had been generated. In six studies investigators used random number tables (Thu 1999; Aguayo 2000; Verhoef 2002; Roschnik 2004 (C); Faqih 2006; Arcanjo 2011 (C)); in a further six studies computer-generated randomisation sequences were used (Ekvall 2000; Olsen 2000; Hall 2002 (C); Sungthong 2002; Desai 2004 (C); Da Silva 2008), and in two studies the groups were assigned to the treatments by drawing lots (Sinisterra 1997 (C); Sen 2009 (C)).

Eleven of the included studies used methods of concealing group allocation that we judged were low risk of bias, for example, by providing coded supplements to treatment and control groups that appeared similar to participants and to those carrying out randomisation (Berger 1997; Palupi 1997; Thu 1999; Aguayo 2000; Ekvall 2000; Olsen 2000; Taylor 2001; Nguyen 2002; Sungthong 2002; Verhoef 2002; Baqui 2003). In the remaining trials, methods were either not described or were unclear. Eleven trials were randomised at cluster level (Liu 1995 (C); Sinisterra 1997 (C); Hall 2002 (C); Roschnik 2003 (C); Desai 2004 (C); Roschnik 2004 (C); Yang 2004 (C); Awasthi 2005 (C); Engstrom 2008 (C); Sen 2009 (C); Arcanjo 2011 (C)) and in these cases it was judged that selection bias at individual level was unlikely (low risk of bias).

Blinding

In 14 trials, we considered that there was low risk of bias related to blinding (Schultink 1995; Berger 1997; Palupi 1997; Thu 1999; Aguayo 2000; Ekvall 2000; Nguyen 2002; Olsen 2000; Taylor 2001; Verhoef 2002; Sungthong 2002; Baqui 2003; Yang 2004 (C); Arcanjo 2011 (C)). In the remaining trials, blinding was either not attempted or not mentioned.

Incomplete outcome data

While we assessed that the majority of the included trials (20 out of 33) had acceptable levels of attrition (with loss to follow-up and

missing data being less than 20% and balanced across groups), in the remaining trials the levels of attrition were high or not balanced across groups. In these studies high levels of attrition were likely to represent an important source of bias and thus results are difficult to interpret; this is the case particularly if we consider that reasons for attrition may have been related to outcomes (for example, when children with side effects or those who developed anaemia were excluded from the analysis). In one trial (Baqui 2003) the dropout rate was considerably higher in one of the intervention groups (those receiving multi-micronutrients lost 41% compared to a loss of 8% to 19% in other groups) and there were further missing data for some outcomes. High levels of loss to follow-up also occurred in the studies by Engstrom 2008 (C) (20.2% attrition); Faqih 2006 (53% attrition); Young 2001 (60% attrition); Schultink 1995 (75% attrition); Sen 2009 (C) (68% missing data for some outcomes); Roschnik 2003 (C) (41.2% attrition), and Taylor 2001 (36% attrition). In one study (Da Silva 2008), 16% of participants were lost to follow up and loss was not balanced across groups; the reasons given by the authors included children developing anaemia or side effects, with no clarity about the number of children lost in each group for these reasons. In four trials losses to follow-up were not clear as the denominators were not provided (Tavil 2003; Roschnik 2004 (C); Yang 2004 (C); Khademloo 2009).

Selective reporting

We were not able to fully assess outcome reporting bias as we only had access to published study reports. We assessed publication bias using funnel plots only for haemoglobin (in comparisons one and two) and for ferritin (comparison two), as more than 10 trials contributed data to those outcomes. We did not find clear asymmetry that may suggest publication bias (graphs not shown). In the analyses we have ordered studies by weight so that the effect of small studies is more apparent; we have drawn attention to any results where visual inspection of the forest plot seems to suggest a more pronounced treatment effect in small as compared with larger studies.

Other potential sources of bias

In a study (Awasthi 2005 (C)) some children received supervised intake of the supplement; it was not clear whether this varied depending on intervention group.

There was some baseline imbalance on outcomes or other potential confounders in terms of participant characteristics in some studies (Schultink 1995; Sinisterra 1997 (C); Taylor 2001; Siddiqui 2004; Faqih 2006; Arcanjo 2011 (C)).

A potentially important source of bias was the impact of unit of randomisation; several of the included trials did not randomise at

the individual level but used classes, schools or clinics as clusters for randomisation. The impact of the cluster-design effect was not clearly taken into account in most of the cluster-randomised trials (Liu 1995 (C); Sinisterra 1997 (C); Hall 2002 (C); Roschnik 2003 (C); Roschnik 2004 (C); Yang 2004 (C); Awasthi 2005 (C); Engstrom 2008 (C); Arcanjo 2011 (C)). In the Engstrom 2008 (C) trial, regression analysis was carried out to try to identify possible confounding factors but unit of analysis did not appear to be part of this analysis. We were able to obtain the ICCs for three trials (Desai 2004 (C); Roschnik 2003 (C) and Hall 2002 (C)) and we imputed the last two values to other trials to obtain their effective sample size. The summary estimates obtained from cluster trials did not differ significantly from those obtained from studies randomised at an individual level.

There are three trials awaiting assessment (Husseini 1999; Reid 2001; Kargarnovin 2010). Based on the sample size of Kargarnovin 2010 and the findings reported in the abstract, we do not consider that its temporary exclusion from the analysis will bias the results of this review. Similarly, we did not consider that the omission of the data from Reid 2001 was likely to introduce serious bias due to the small sample size. On the other hand, the effect of excluding Husseini 1999 is uncertain as the only information available is published in Beaton 1999 who obtained it by personal communication. At the end of the intervention haemoglobin concentrations were higher and anaemia prevalence was lower among those children receiving daily supplements in comparison to those children receiving intermittent supplements. As we do not have access to the primary information, it is difficult to assess the quality of the study and to adjust data by the effect of clustering, which limits any assessment of its impact on our summary estimate.

Effects of interventions

See: Summary of findings for the main comparison Intermittent use of iron supplements versus placebo or no intervention in children younger than 12 years of age; Summary of findings 2 Intermittent versus daily use of iron supplements in children younger than 12 years of age

We have included data from 33 trials; overall, these trials involved 13,114 children. This figure represents the number of children recruited to studies, in some studies we have not included data for all arms of the trials in the review comparisons. The analyses include only the estimated effective sample size, after adjusting the data to account for the clustering effect.

We have organised the summary of results by comparing supplementation regimens and by primary and secondary outcomes. Most of the included studies focused on haematological outcomes and few reported on any of the other outcomes pre-specified in the review protocol. See the Data and analyses section for detailed results on primary and secondary outcomes.

Comparison I. Intermittent iron supplementation versus no supplementation or placebo (19 trials)

Nineteen trials evaluated this comparison (Berger 1997; Palupi 1997; Thu 1999; Aguayo 2000; Ekvall 2000; Olsen 2000; Taylor 2001; Ermis 2002; Hall 2002 (C); Verhoef 2002; Sungthong 2002; Baqui 2003; Roschnik 2003 (C); Evangelista-Salazar 2004; Roschnik 2004 (C); Yurdakok 2004; Yang 2004 (C); Sen 2009 (C); Arcanjo 2011 (C)). Seven of the trials met the prespecified criteria mentioned above for being at lower risk of bias (Thu 1999; Aguayo 2000; Ekvall 2000; Olsen 2000; Hall 2002 (C); Verhoef 2002; Sungthong 2002). In sensitivity analyses these trials were retained in the analysis whilst trials at higher risk of bias were temporarily removed to examine whether this had any impact on the overall pattern of results.

Primary outcomes

Anaemia

Ten trials with 1824 children provided data on anaemia following the interventions (Berger 1997; Palupi 1997; Thu 1999; Aguayo 2000; Hall 2002 (C); Verhoef 2002; Roschnik 2003 (C); Evangelista-Salazar 2004; Roschnik 2004 (C); Arcanjo 2011 (C)). Those receiving intermittent iron supplementation were significantly less likely to have anaemia at follow-up compared with children receiving no intervention (average risk ratio (RR) 0.51, 95% confidence interval (CI) 0.37 to 0.72) (Analysis 1.1). There was variation among trials in terms of the size of the treatment effect ($T^2 = 0.18$, $I^2 = 81\%$ and Chi² test for heterogeneity P < 0.00001). The large effect remained significant even after excluding the trials at higher risk of bias (RR 0.60; 95% CI 0.42 to 0.87).

Haemoglobin concentrations (g/L)

Nineteen studies with 3032 participants provided data on mean haemoglobin levels following the intervention (Berger 1997; Palupi 1997; Thu 1999; Aguayo 2000; Ekvall 2000; Olsen 2000; Taylor 2001; Ermis 2002; Hall 2002 (C); Verhoef 2002; Sungthong 2002; Baqui 2003; Roschnik 2003 (C); Evangelista-Salazar 2004; Roschnik 2004 (C); Yang 2004 (C); Yurdakok 2004; Sen 2009 (C); Arcanjo 2011 (C)). Those receiving intermittent iron supplements on average had higher haemoglobin (Hb) levels than those receiving no intervention or a placebo; the difference was statistically significant (mean difference (MD) 5.20, 95% CI 2.51 to 7.88) (Analysis 1.9). There were high levels of heterogeneity among trials ($T^2 = 32.45$, $I^2 = 93\%$ and Chi^2 test for heterogeneity P < 0.00001). The effect remained significant after removing the trials at high risk of bias (RR 5.02, 95% CI 2.01 to 8.03).

Iron deficiency

Three trials with 431 children (Verhoef 2002; Evangelista-Salazar 2004; Yang 2004 (C)) reported on this outcome. Findings suggested that children receiving intermittent supplements were at lower risk of having iron deficiency at the end of the intervention as those receiving nothing or a placebo (RR 0.24, 95% CI 0.06 to 0.91) (Analysis 1.17). There were high levels of heterogeneity among trials ($T^2 = 1.01$, $I^2 = 88\%$ and Chi² test for heterogeneity P < 0.0003).

Iron status measured by ferritin (μ g/L)

Five trials with follow-up data for 550 participants (Ermis 2002; Sungthong 2002; Baqui 2003; Yang 2004 (C); Yurdakok 2004) reported higher mean levels of ferritin among those receiving intermittent supplements compared with those receiving no treatment (MD 14.17, 95% CI 3.53 to 24.81) (Analysis 1.18). Only one trial (Sungthong 2002) was assessed as being at lower risk of bias.

Iron deficiency anaemia

No trials reported on this outcome.

All-cause mortality

No trials reported on mortality.

Secondary outcomes

All-cause morbidity

Information on all-cause morbidity was reported in one trial (Palupi 1997), with data for 194 children. There was no evidence of differences between groups (Analysis 1.26).

Acute respiratory infection

No trials reported on this outcome.

Diarrhoea

No trials provided information on diarrhoea.

Any other adverse effects

One trial (Ermis 2002) reported no statistically significant difference in the total number of side effects reported by those children receiving supplements intermittently and those receiving no intervention or a placebo (Analysis 1.27). One trial (Aguayo 2000) reported on nausea and did not find differences between groups (Analysis 1.28).

Adherence

Baqui 2003 and Ekvall 2000 reported that children receiving intermittent iron supplements had similar levels of adherence to intermittent iron supplementation as those children receiving a placebo or no intervention (RR 1.04, 95% CI 0.98 to 1.09) (Analysis 1.29).

Folate status (as measured by trialists)

No trials reported on this outcome.

Mental development and motor skill development

Baqui 2003 reported on several measures of cognitive and physical development. There was no clear evidence of difference between groups for most of these outcomes (Analysis 1.30; Analysis 1.31; Analysis 1.32; Analysis 1.34).

School performance

One study (Sungthong 2002) examined intelligence quotient (IQ), language development and mathematics performance; there were no clear differences between those receiving intermittent iron and those on no supplementation (Analysis 1.35; Analysis 1.36; Analysis 1.37).

Physical capacity

One trial examined (Baqui 2003) the motor quality of children, which included seven items such as motor control and tone, and expressed the results in percentile scores. Authors found that children receiving intermittent supplementation had higher percentile scores although the clinical significance of this difference was not clear (MD 15.60, 95% CI 7.66 to 23.54) (Analysis 1.33).

Height-for-age and weight-for-age Z-scores

Three trials (Palupi 1997; Thu 1999; Aguayo 2000) reported results for weight-for-age and height-for-age Z-scores for schoolaged children and did not find a statistically significant effect on these outcomes (Analysis 1.38; Analysis 1.39).

Comparison 2. Intermittent iron supplementation versus daily iron supplementation (21 trials)

Twenty-one trials evaluated this comparison (Liu 1995 (C); ,Schultink 1995; Berger 1997; Sinisterra 1997 (C); Soemantri 1997; Thu 1999; Young 2001; Ermis 2002; Nguyen 2002; Sungthong 2002, Tavil 2003; Desai 2004 (C); Siddiqui 2004; Yang 2004 (C); Yurdakok 2004; Awasthi 2005 (C); Faqih 2006; Da Silva 2008; Engstrom 2008 (C); Khademloo 2009; Sen 2009 (C)) and all of them contributed data to the analysis. Three of these trials were assessed as being at lower risk of bias and, where they contributed data, they were retained in the analysis when we conducted sensitivity analyses (Thu 1999; Sungthong 2002; Desai 2004 (C)).

Primary outcomes

Anaemia

Six trials with 980 participants provided data on the number of children with anaemia following the interventions (Schultink 1995; Berger 1997; Sinisterra 1997 (C); Thu 1999; Awasthi 2005 (C); Engstrom 2008 (C)). Children receiving intermittent iron supplementation had a higher risk of being anaemic at the end of the study period compared to those receiving daily iron supplementation (RR 1.23, 95% CI 1.04 to 1.47) (Analysis 2.1). Only one trial was considered at low risk of bias (Thu 1999) and found similar results (RR 1.31, 95% CI 0.31 to 5.57).

Haemoglobin concentrations (g/L)

Nineteen trials with 2851 participants provided data on mean haemoglobin levels following the intervention (Liu 1995 (C); Schultink 1995; Berger 1997; Soemantri 1997; Thu 1999; Young 2001; Ermis 2002; Nguyen 2002; Sungthong 2002; Tavil 2003; Desai 2004 (C); Siddiqui 2004; Yang 2004 (C); Yurdakok 2004; Awasthi 2005 (C); Faqih 2006; Engstrom 2008 (C); Khademloo 2009; Sen 2009 (C)). The groups receiving intermittent iron supplements on average had 0.60 less grams of haemoglobin per litre than those receiving daily supplementation but the difference between groups was not statistically significant (95% CI -1.54 to 0.35) (Analysis 2.9). There were high levels of heterogeneity for this outcome ($T^2 = 2.26$, $I^2 = 56\%$, and Chi² test for heterogeneity P = 0.001). When only those trials at lower risk of bias (Sungthong 2002; Desai 2004 (C)) were retained in the analysis, the difference between groups remained statistically non-significant (MD -0.87, 95% CI -2.77 to 1.02) (data for sensitivity analysis not shown).

Iron deficiency

Only one trial (Yang 2004 (C)) reported on iron deficiency and found that at the end of the intervention the number of children with iron deficiency was higher among those who received iron supplements intermittently compared to daily (RR 4.00, 95% CI 1.23 to 13.05) (Analysis 2.17).

Iron status measured by ferritin (ng/L)

Ten trials with data for 902 participants (Liu 1995 (C); Schultink 1995; Ermis 2002; Sungthong 2002; Tavil 2003; Siddiqui 2004; Yang 2004 (C); Yurdakok 2004; Faqih 2006; Khademloo 2009) reported that ferritin values were not statistically different between those receiving iron intermittently and those receiving daily iron (MD -4.19, 95% CI -9.42 to 1.05) (Analysis 2.18). Only one trial was at low risk of bias (Sungthong 2002) and found no differences between these two interventions. There was high heterogeneity for this outcome with considerable variation in mean values between trials; in addition, one of the studies reported exceptionally low standard errors for mean ferritin values (from which we calculated SDs) (Siddiqui 2004). We carried out a sensitivity analysis temporarily excluding this study from the meta-analysis; removing

this study did not change the interpretation of results (MD - 5.20, 95% CI -10.76 to 0.35).

Iron deficiency anaemia

No trials reported data on iron deficiency anaemia.

All-cause mortality

No trials reported mortality by any cause.

Secondary outcomes

All-cause morbidity

Information on all-cause morbidity was reported in two trials (Desai 2004 (C); Da Silva 2008), with data for 601 children. There was no evidence of a difference between groups (RR 0.96, 95% CI 83 to 1.12) (Analysis 2.27).

Acute respiratory infection

No trials reported on this outcome.

Diarrhoea

Two trials (Yurdakok 2004; Da Silva 2008) had data on diarrhoea and did not find differences between groups (Analysis 2.28).

Any other adverse effects

Four trials (Liu 1995 (C); Ermis 2002; Desai 2004 (C); Yurdakok 2004) reported side effects among 895 children. There was no evidence of differences between intermittent and daily iron supplementation (RR 0.60, 96% CI 0.19 to 1.87) (Analysis 2.29).

Adherence

Five trials involving 1130 participants reported on this outcome (Berger 1997; Desai 2004 (C); Awasthi 2005 (C); Engstrom 2008 (C); Sen 2009 (C)). There was no statistically significant difference in adherence to the interventions between groups although it tended to be higher among those children receiving intermittent iron supplements (RR 1.23, 95% CI 0.98 to 1.54) (Analysis 2.30).

Folate status (as measured by trialists)

No trials reported on this outcome.

Mental development and motor skill development

No trials reported on this outcome.

School performance

One study (Sungthong 2002) examined IQ, Thai language development and mathematics performance; there were no clear differences between groups receiving intermittent iron versus no supplementation (Analysis 2.31; Analysis 2.32; Analysis 2.33).

Physical capacity

One trial that provided weekly and twice-a-week supplementation (Sen 2009 (C)) did not find statistically significant differences in the increment of steps climbed by children receiving either intermittent or daily supplementation (Analysis 2.26).

Height-for-age and weight-for-age Z-scores

Three trials reported results for height-for-age Z-scores for schoolaged children and did not find an effect on this outcome (Analysis 2.34).

Subgroup comparisons

There was considerable variation among trials in terms of the populations examined and the way studies were conducted, which very likely resulted in the high statistical heterogeneity observed in some outcomes. For primary outcomes, we examined subgroups to look for possible differences between studies in terms of the duration of the intervention; children's anaemia status at baseline; higher and lower weekly doses of iron; type of iron compound provided; and supplementation regimen.

For most of the outcomes very few studies contributed data, so we limited the subgroup analysis to anaemia and haemoglobin and ferritin concentrations. In the analyses we have provided overall totals along with subtotals for subgroups, and the statistics for subgroup differences.

Intermittent iron dose per week (25 mg or less; greater than 25 mg to 75 mg; greater than 75 mg)

Most of the trials provided between 25 and 75 mg of iron per week. There was some within subgroup heterogeneity and no consistent and clear differences between subgroup categories (Analysis 1.10; Analysis 1.19; Analysis 2.2; Analysis 2.10; Analysis 2.19). It seemed that the effect of intermittent supplementation on anaemia was lost among those children receiving iron doses greater than 75 mg per week, although only two trials contributed to this subgroup (Analysis 1.2).

Duration of the intervention (0 to three months; more than three months)

An almost even number of trials provided iron supplements for three months or less, or for more than three months. There was no statistical evidence that the response of haematological outcomes to intermittent supplementation differed by duration of the intervention (Analysis 1.3; Analysis 1.11; Analysis 1.20; Analysis 2.3; Analysis 2.11; Analysis 2.20).

Type of compound (ferrous sulphate; ferrous fumarate; other) Most of the trials provided iron in the form of ferrous sulphate, but when other compounds were given there was no clear statistical evidence that they produced different results on haematological outcomes from those observed with ferrous sulphate (Analysis 1.4; Analysis 2.4; Analysis 2.12; Analysis 2.21). In one case haemoglobin responded better to supplementation with fumarate, but only one study contributed to this subgroup category and findings

Anaemia status at baseline (anaemic; non-anaemic; mixed or not reported)

should be cautiously interpreted (Analysis 1.21).

Intermittent supplementation appeared to be as efficacious in trials that included only anaemic children as in those studies that included populations with different degrees of anaemia (Analysis 1.5; Analysis 1.13; Analysis 1.22; Analysis 2.5; Analysis 2.13; Analysis 2.22). One study conducted in anaemic Bolivian children (Berger 1997) reported a very pronounced therapeutic effect on haematological outcomes and this trial contributed to the observed statistical heterogeneity; its results were consistent in terms of direction with the rest of the trials.

Intermittent regimen (one supplement a week; other intermittent regimen)

Most of the trials supplemented children on a weekly basis and in some cases only one study was included in each subgroup, which impeded the interpretation of the analyses (Analysis 1.6; Analysis 1.23). For the rest of the subgroup comparisons, there was no statistical evidence that the results of haematological outcomes differed when the supplements were given once, twice or three times a week (Analysis 1.14; Analysis 2.6; Analysis 2.14; Analysis 2.23).

Sex (males; females; mixed or not reported)

All but one trial included males and females, although it was possible to extract the results by sex only from Hall 2002 (C). There was no statistical evidence that in this population the positive effect of intermittent supplementation on haematological outcomes differed by sex (Analysis 1.7; Analysis 1.15; Analysis 1.24; Analysis 2.7; Analysis 2.15; Analysis 2.24).

Supplement's nutrient composition (iron alone; iron + folic acid; iron+other nutrient; iron + multiple micronutrients)

Most of the trials provided only iron. In the majority of the subgroup analyses there was no evidence that the provision of other nutrients in addition to iron altered the effects of intermittent supplementation on haematological outcomes (Analysis 1.16; Analysis 1.25; Analysis 2.8; Analysis 2.16; Analysis 2.25). However, it seemed that the effect of intermittent supplementation on anaemia was higher among those children receiving iron + vitamin C (Analysis 1.8), although this result should be interpreted cautiously as only one trial assessed the joint effect of these micronutrients.

Comparisons 3 to 6. Analysis by age group: children

younger than 60 months versus 60 months and older

We have summarised the results of comparisons 3 to 6 in Table 1 and Table 2.

The visual examination of the confidence intervals suggests that the haematological effects produced by intermittent supplementation are similar between young (0 to 59 months) and older children (60 months and older), although the statistical power may be an issue in assessing the consistency among results.

ADDITIONAL SUMMARY OF FINDINGS [Explanation]

Patient or population: children under 12 years of age

Settings: community settings

Intervention: intermittent supplementation with iron alone or with other micronutrients

Comparison: daily supplementation with iron alone or with other micronutrients

Outcomes	Relative effect (95% Cl)	No of Participants (studies)	Quality of the evidence (GRADE)
Anaemia (haemoglobin below a cut-off defined by trialists, taking into account the age and altitude)		980 (6 studies)	⊕⊕⊜⊜ low ^{1,2}
Haemoglobin (g/L)	MD-0.60 (-1.54-0.35)	2851 (19 studies)	⊕⊕⊖⊖ low ^{1,3}
Iron deficiency (using ferritin concentra- tions)	RR 4.00 (1.23-13.05)	76 (1 study)	○○○○ very low ⁴
Iron status (ferritin (μg/L)	MD - 4.19 (-9.42- 1.05)	902 (10 studies)	$\oplus \oplus \bigcirc \bigcirc$ low ¹³
Iron deficiency anaemia	Not estimable	0 (0 studies)	None of the trials reported on this outcome
Mortality	Not estimable	0 (0 studies)	None of the trials reported on this outcome

CI, confidence interval; RR, risk ratio; MD, mean difference

*GRADE Working Group grades of evidence:

High quality: We are very confident that the true effect lies close to that of the estimate of the effect.

Moderate quality: We have moderate confidence in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low quality: Our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect.

Very low quality: We have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of the effect

Intermittent iron supplementation for improving nutrition and development in children under 12 years of age (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

24

¹ Some studies lacked blinding and clear methods of allocation

² Wide confidence intervals.

³ High heterogeneity but results were mostly consistent.

⁴ Only one trial with unclear methods to generate the random sequence and conceal the allocation. Wide confidence intervals Note: For cluster-randomised trials the analyses only include the estimated effective sample size, after adjusting the data to account for the clustering effect

DISCUSSION

Summary of main results

Available data indicate that among children less than 12 years of age, intermittent supplementation with iron (alone or in combination with other nutrients) effectively increases haemoglobin and ferritin concentrations and reduces the prevalence of anaemia compared to placebo or no intervention. Overall, this positive response does not differ between once, biweekly or three times weekly supplementation; nor does it depend on child's sex or age or the duration of the intervention.

In comparison to daily iron supplementation, children receiving intermittent iron supplementation are more likely to develop anaemia but their haemoglobin and ferritin concentrations are similar.

Adherence tends to be higher in children receiving intermittent iron supplementation compared with those receiving daily iron supplements, although the results were not statistically significant. Information on morbidity, mortality, adverse side effects, neurocognitive and motor outcomes is scarce and therefore no clear conclusions can be drawn.

Overall completeness and applicability of evidence

A total of 33 randomised trials were included in this review, with data for 13,114 children included in the analysis. Seventy-five per cent of the included trials had a sample size of less than 500 children and the trials often lacked blinding and a clear description of randomisation methods. The trials were published in a wide variety of journals (and the level of quality of the journals might vary) and were mostly written in English. The diversity of publications may also reflect the range of settings in which studies were carried out: Latin America, Africa and Asia.

No studies were conducted in high-income countries and it is uncertain whether the results would be similar in those settings. On the one hand, the prevalences of anaemia and iron deficiency are lower in high income countries and there is an inverse relationship between initial iron status and response to iron supplementation. On the other hand, intermittent supplementation for children in high income countries could, however, be successful because of potentially strong institutional infrastructure and high attendance rates at schools that could support sustained high coverage and use of this intervention.

We decided to include only randomised and quasi-randomised trials in this review. Whilst randomisation reduces the risk of bias, this approach also limited the inclusion of large scale pre-post trials with no comparison groups. Such studies are more likely to be affected by external circumstances, such as famines, and it is possible that the magnitude of the effect of intermittent iron supplementation might be different under programmatic conditions. The baseline anaemia and iron deficiency status varied across studies; most were conducted in settings with a high prevalence of anaemia. The studies included in this review largely examined this intervention for prevention as a public health strategy and not treatment of anaemia and iron deficiency as part of clinical practice. However, seven of the 33 trials included only anaemic children and subgroup analysis suggested that weekly supplementation was efficacious compared with daily supplementation. The efficacy of the intermittent supplementation schemes on haematological outcomes also seemed similar across different age groups, with few inconsistencies.

There were insufficient studies to allow us to evaluate in detail all the outcomes of interest, and by subgroups. Particularly, there were insufficient trials and a lack of comparable measures to examine mortality, morbidity, cognitive and developmental outcomes.

In addition, there was a lack of data to meaningfully examine adherence and adverse effects specifically related to intensity and frequency of dosing. These last two are critical limitations considering that these are primary justifications for the use of weekly over daily supplementation.

Quality of the evidence

1. Quality of the evidence across within studies. Less than one third of the trials were assessed as having a low risk of bias after considering the methods for allocating the treatment, the blinding and the attrition rates, with many studies being at high risk of bias (see Risk of bias in included studies). In most of the included trials, the methods used to randomly assign participants and conceal allocation were not described. Blinding of participants, care providers and outcome assessors was not generally attempted, although in some studies technical staff carrying out laboratory investigations were reported to be unaware of group allocation. The lack of blinding may represent a potentially serious source of bias. Attrition was also a problem in many of these studies.

2. Quality of the evidence across studies. We used the GRADE methodology for this assessment and set out the results for primary outcomes in the Summary of findings for the main comparison and the Summary of findings 2. We considered that indirectness or publication bias was unlikely but the quality of the trials and inconsistency (or the lack of studies) were potentially important factors in the overall assessment of the evidence. When intermittent supplementation was compared with a placebo or no intervention, the overall quality of the available evidence was found to be moderate for anaemia, whereas for haemoglobin and ferritin concentrations it was low and very low for iron deficiency. When compared with daily supplementation, the quality of the available evidence with regard to anaemia, haemoglobin and ferritin concentrations was found to be low and for iron deficiency it was very low.

Potential biases in the review process

There were a number of potential biases in the review process. We attempted to be as inclusive as possible in the search strategy and found publications in different languages in journals from all the continents, although the literature identified was predominantly written in English. We were also able to obtain unpublished information.

We attempted to minimise bias in several ways: two review authors independently assessed eligibility for inclusion and two review authors checked data extraction, assessments of risk of bias and data entry. However, carrying out reviews is not an exact science and may require a number of subjective judgements; it is possible that a different review team may have reached different decisions regarding assessments of eligibility and risk of bias. We would encourage readers to examine the Characteristics of included studies tables to assist in the interpretation of results.

In addition to the individual assessments of the study risk of bias, we included 'Summary of findings' tables to assess the overall quality of the evidence for primary outcomes. We attempted to produce the tables using a transparent process with two review authors independently assessing the evidence for each outcome for each quality domain and discussing any disagreements.

Agreements and disagreements with other studies or reviews

To our knowledge, only one meta-analysis of randomised controlled trials has been conducted on the efficacy of intermittent iron supplementation in the control of iron deficiency anaemia (Beaton 1999). It includes the results of 22 trials completed before 1999 in different age groups. In some cases authors were able to obtain the full data sets but in the rest of the cases summary statistics were collected from abstracts, final reports or directly supplied by investigators. Of the included studies, four were carried out among preschool-aged children (age range five months to five years), 10 among school-aged children and adolescents (age range three years to 21 years) and eight among pregnant women. All of the preschool and school children or adolescent trials compared once or twice a week versus daily supplementation, and most included control groups. All the studies reported results for haemoglobin; two studies in preschool children and three in schoolchildren or adolescents also measured ferritin. All the studies that Beaton 1999 included involving preschool and school-aged children were also included in this review.

The authors found that intermittent supplementation was efficacious compared to no treatment and that it increased haemoglobin and ferritin levels and reduced anaemia. In contrast to the present review, they found that daily supplementation was more efficacious than intermittent supplementation in improving haemoglobin and ferritin levels. The authors concluded that weekly supplementation should be considered for preschool and schoolaged children only in situations where there is strong assurance of supervision and high adherence.

The larger number of trials included in this Cochrane review, conducted in different settings and with different levels of supervision, suggest that intermittent supplementation is an efficacious public health intervention in children younger than 12 years of age that may be implemented in a various contexts. It may be a viable approach to consider, particularly where daily supplementation has failed, is operationally complex or unfeasible or in settings where it has not been implemented yet.

The results of the present review are only applicable to children 12 years and younger. However, other systematic review assessing the benefits and safety of this intervention in menstruating women (Fernández-Gaxiola 2011) concur with our findings. From the programme implementation perspective, a recent narrative review reports that weekly iron and folic acid supplementation has been successfully implemented in Cambodia, Egypt, India, Laos, Philippines and Vietnam, reaching over half a million menstruating women (WHO 2009).

AUTHORS' CONCLUSIONS

Implications for practice

The findings from this review show that intermittent supplementation with iron (alone or in combination with other nutrients) is efficacious in improving haemoglobin concentrations and ferritin levels and reducing anaemia among children younger than 12 years of age in settings with moderate to high prevalence of anaemia. The effects of intermittent supplementation on haemoglobin and ferritin outcomes were similar to those achieved with daily supplementation although children receiving intermittent supplements were at higher risk of anaemia.

Most of the evidence in this review is derived from trials providing weekly doses between 25 and 75 mg of elemental iron, either alone, with folic acid or with other micronutrients. The positive effect of intermittent supplementation was observed in populations of males and females, with different anaemia backgrounds, and seemed not to be affected by the duration of the intervention, although a minimum of three months seems reasonable to trigger the haematological response and build some iron stores. Very few trials reported on the level of supervision or the use of a communication or education strategy to improve the use of supplements. An integrated approach with a strong behaviour change communication component that targets different audiences may be necessary to adequately support adherence and appropriate use for any supplementation regimen. Intermittent supplementation for children might be an option for countries with strong institutional infrastructures for delivery that facilitate wide and sustained coverage, for example, where school attendance is high; although

it is clear that efforts should be made to also reach those children not covered by the school or health systems.

This review attempted to examine several of the primary justifications for choosing intermittent over daily supplementation, including improved adherence, reduced side effects and improved efficiency in absorption. Surprisingly, very few trials reported on these outcomes and they did not show that the children receiving supplements intermittently adhere better to the intervention or have fewer side effects that those receiving daily supplements. Clearly, more research is needed in this area. Other rationales for intermittent supplementation include diminished exposure to an iron-rich environment, which may exacerbate oxidative stress in the gut lumen and intestinal mucosal cells, as well as decreased competition with other minerals such as zinc and copper for absorption channels. Unfortunately, few trials reported on other indicators of vitamin and mineral status and therefore no conclusions can be drawn.

In summary, intermittent supplementation is efficacious at improving haemoglobin and ferritin concentrations and reducing anaemia prevalence, although children receiving daily supplements were less likely to present anaemia compared to those receiving intermittent supplements. These results suggest that in settings where daily supplementation is likely to be unsuccessful or not feasible, intermittent supplementation could be an effective public health strategy to improve iron status and reduce anaemia in children under 12 years of age.

Implications for research

Important research is needed at different levels before we can fully assess the effects and safety of intermittent iron supplementation regimens on anaemia, iron status and development in children less than 12 years of age. Future research should focus on the following.

• Clinical research

1. Examining the efficacy of intermittent iron regimens on neurocognitive and developmental outcomes and growth. In addition, attempts should be made to use comparable measures across studies, when possible.

2. Reporting the side effects in greater detail to acknowledge not only the presence of a side effect but also its intensity and frequency.

3. Expanding the evidence on the provision of multiple micronutrients on an intermittent basis and their effect on iron

status and other indicators of vitamin and mineral status, such as retinol or zinc.

4. Reporting comprehensively the effects of the intermittent supplementation on anaemia, haemoglobin concentrations or ferritin to better understand the clinical significance of haemoglobin changes.

• Programme implementation

1. Establishing the periodicity of this intervention over a year, taking into account both its biological and programmatic feasibility.

2. Improving reporting of adherence and addressing the relevance of direct and continued supervision.

3. Exploring the factors which may influence adherence (such as behaviour change communication (BCC)) and the types of support needed to improve adherence in supplementation interventions. BCC and supporting adherence may be important components of an effective supplementation programme but trials rarely provide detailed information about them. This limits the ability to understand the intensity of these activities needed to achieve the effects found in the trials.

4. Examining the cost effectiveness of intermittent compared with daily supplementation, taking into account more than just the differential cost of pills.

ACKNOWLEDGEMENTS

We would like to thank the trial authors and organisations who contributed additional information for this review and Ms Xiaoting Huo for her help in translating Yang 2004 (C) into English. Thanks are due to Deidre Thomas from the US CDC Public Health Library and Information Center and Margaret Anderson from the Cochrane Developmental, Psychosocial and Learning Problems Group (CDPLPG) for their help in devising the search strategy. We would also like to thank the staff at the editorial office of the CDPLPG for their support in the preparation of this review.

As part of the prepublication editorial process the text has been commented on by three peers (an editor and two referees who are external to the editorial team) and one of CDPLPG's statistical editors. We are grateful for their feedback.

REFERENCES

References to studies included in this review

Aguayo 2000 {published data only}

* Aguayo VM. School-administered weekly iron supplementation - effect on the growth and hemoglobin status of non-anemic Bolivian school-age children. A randomized placebo-controlled trial. *European Journal of Nutrition* 2000;**39**(6):263–9.

Arcanjo 2011 (C) {published data only}

* Arcanjo FPN, Arcanjo CC, Amancio OMS, Braga JAP, Leite AJM. Weekly iron supplementation for the prevention of anemia in pre-school children: a randomized, doubleblind, placebo-controlled trial. Journal of Tropical Pediatrics 2011 Feb 1 [Epub ahead of print].

Awasthi 2005 (C) {published data only}

* Awasthi S, Verma T, Vir S. Effectiveness of biweekly versus daily iron-folic acid administration on anaemia status in preschool children. *Journal of Tropical Pediatrics* 2005;**51** (2):67–71.

Baqui 2003 {published data only}

Baqui AH, Walker CL, Zaman K, El Arifeen S, Chowdhury HR, Wahed MA, et al. Weekly iron supplementation does not block increases in serum zinc due to weekly zinc supplementation in Bangladeshi infants. *Journal of Nutrition* 2005;**135**(9):2187–91.

* Baqui AH, Zaman K, Persson LA, El Arifeen S, Yunus M, Begum N, et al. Simultaneous weekly supplementation of iron and zinc is associated with lower morbidity due to diarrhea and acute lower respiratory infection in Bangladeshi infants. *Journal of Nutrition* 2003;**133**(12):4150–7. Black MM, Baqui AH, Zaman K, Ake Persson L, El Arifeen S, Le K, et al. Iron and zinc supplementation promote motor development and exploratory behavior among Bangladeshi infants. *American Journal of Clinical Nutrition* 2004;**80**(4):903–10.

Fischer Walker CL, Baqui AH, Ahmed S, Zaman K, El Arifeen S, Begum N, et al. Low-dose weekly supplementation of iron and/or zinc does not affect growth among Bangladeshi infants. *European Journal of Clinical Nutrition* 2009;**63**(1):87–92.

Berger 1997 {published data only}

* Berger J, Aguayo VM, Téllez W, Luján C, Traissac P, San Miguel JL. Weekly iron supplementation is as effective as 5 day per week iron supplementation in Bolivian school children living at high altitude. *European Journal of Clinical Nutrition* 1997;**51**(6):381–6.

Da Silva 2008 {published and unpublished data}

da Silva DG, Franceschini Sdo C, Sigulem DM. Growth in non-anemic infants supplemented with different prophylactic iron doses. *Jornal de Pediatria* 2008;**84**(4): 365–72.

Desai 2004 (C) {published data only}

* Desai MR, Dhar R, Rosen DH, Kariuki SK, Shi YP, Kager PA, et al. Daily iron supplementation is more efficacious than twice weekly iron supplementation for the treatment of childhood anemia in western Kenya. *Journal of Nutrition* 2004;**134**(5):1167–74.

Ekvall 2000 {published data only}

* Ekvall H, Premji Z, Bjorkman A. Micronutrient and iron supplementation and effective anti-malarial treatment synergistically improve childhood anaemia. *Tropical Medicine and International Health* 2000;**5**(10):696–705.

Engstrom 2008 (C) {published data only}

Engstrom EM, Castro IR, Portela M, Cardoso LO, Monteiro CA. Effectiveness of daily and weekly iron supplementation in the prevention of anemia in infants. *Revista de Saúde Pública* 2008;**42**(5):786–95.

Ermis 2002 {published data only}

* Ermis B, Demirel F, Demircan N, Gurel A. Effects of three different iron supplementations in term healthy infants after 5 months of life. *Journal of Tropical Pediatrics* 2002;**48**(5): 280–4.

Evangelista-Salazar 2004 {published data only}

* Evangelista-Salazar E. Evaluation of the preventive effect of the intermittent provision of iron and vitamin C on the reduction of the iron and neurodevelopment in infants [Evaluacion del efecto preventivo de la administracion intermitente de hierro y vitamina C sobre la disminucion de la reserva de hierro y el neurodesarrollo en lactantes]. Doctoral Thesis. Universidad de Colima, Mexico 2004. Martínez H, Evangelista Salazar JJ, Avila Jiménez L. Iron supplementation for preventing anaemia in infants [Suplementación con hierro para prevenir anemia en la primera infancia]. In: Luis Durán Arenas, Onofre Muñoz Hernández editor(s). *La traducción del conocimiento. del resultado de la investigación a la aplicación de los servicios de salud*. México, D.F: CAMS, 2006:71–86.

Faqih 2006 {published data only}

* Faqih AM, Kakish SB, Izzat M. Effectiveness of intermittent iron treatment of two- to six-year-old Jordanian children with iron-deficiency anemia. *Food and Nutrition Bulletin* 2006;**27**(3):220–7.

Hall 2002 (C) {published and unpublished data}

* Hall A, Roschnik N, Ouattara F, Toure I, Maiga F, Sacko M, et al. A randomised trial in Mali of the effectiveness of weekly iron supplements given by teachers on the haemoglobin concentrations of schoolchildren. *Public Health Nutrition* 2002;**5**(3):413–8.

Khademloo 2009 {published data only}

* Khademloo M, Karami H, Ajami A, Yasari M. Comparison of the effectiveness of weekly and daily iron supplementation in 6- to 24-months-old babies in urban health centers of Sari, Iran. *Pakistan Journal of Biological Sciences* 2009;**12**(2):195–7.

Liu 1995 (C) {published data only}

* Liu X-N, Kang J, Zhao L, Viteri FE. Intermittent iron supplementation in Chinese pre-schoolchildren is efficient and safe. *Food and Nutrition Bulletin* 1995;**16**(2):139–46. Liu XNA, Liu PY. The effectiveness of weekly iron supplementation regimen in improving the iron status of Chinese children and pregnant women. *Biomedical and Environmental Sciences* 1996;**9**(2-3):341–7.

Nguyen 2002 {published data only}

* Nguyen XN, Berger J, Dao TQ, Nguyen CK, Traissac P, Ha HK. Efficacy of daily and weekly iron supplementation for the control of iron deficiency anaemia in infants in rural Vietnam [Efficacite de la supplementation en fer quotidienne et hebdomadaire pour le controle de l'anemie chez le nourrisson en milieu rural au Vietnam]. *Santé* (*Montrouge, France*) 2002;**12**(1):31–7.

Olsen 2000 {published data only}

Olsen A, Nawiri J, Friis H. The impact of iron supplementation on reinfection with intestinal helminths and Schistosoma mansoni in western Kenya. *Transactions* of the Royal Society of Tropical Medicine Hygene 2000;**94**(5): 493–9.

Olsen A, Nawiri J, Magnussen P, Krarup H, Friis H. Failure of twice-weekly iron supplementation to increase blood haemoglobin and serum ferritin concentrations: results of a randomized controlled trial. *Annals of Tropical Medicine and Parasitology* 2006;**100**(3):251–63.

Palupi 1997 {published data only}

* Palupi L, Schultink W, Achadi E, Gross R. Effective community intervention to improve hemoglobin status in preschoolers receiving once-weekly iron supplementation. *American Journal of Clinical Nutrition* 1997;**65**(4):1057–61.

Roschnik 2003 (C) {unpublished data only}

* Roschnik N, Phiri V, Mukaka M. The impact of weekly school-based iron supplementation. Mangochi District, Malawi (Report). Save the Children, USA February 2003.

Roschnik 2004 (C) {published and unpublished data}

Roschnik N, Parawan A, Baylon MA, Chua T, Hall A. Weekly iron supplements given by teachers sustain the haemoglobin concentration of schoolchildren in the Philippines. *Tropical Medicine and International Health* 2004;**9**(8):904–9.

Schultink 1995 {published data only}

Schultink W, Gross R, Gliwitzki M, Karyadi D, Matulessi P. Effect of daily vs twice weekly iron supplementation in Indonesian preschool children with low iron status. *American Journal of Clinical Nutrition* 1995;**61**(1):111–5.

Sen 2009 (C) {published and unpublished data}

Sen A, Kanani SJ. Impact of iron-folic acid supplementation on cognitive abilities of school girls in Vadodara. *Indian Pediatrics* 2009;**46**(2):137–43.

* Sen A, Kanani SJ. Physical work capacity of young underprivileged school girls impact of daily vs intermittent iron folic acid supplementation: a randomized controlled trial. *Indian Pediatrics* 2009;**46**(10):849–54.

Siddiqui 2004 {published data only}

Siddiqui IA, Jaleel A, Rahman MA. Preventive strategy to control iron deficiency anemia in children and adults. *Journal of the Pakistan Medical Association* 2003;**53**(4): 131–3.

Siddiqui IA, Rahman MA, Jaleel A. Efficacy of daily vs. weekly supplementation of iron in schoolchildren with low iron status. *Journal of Tropical Pediatrics* 2004;**5**:276–8.

Sinisterra 1997 (C) {published data only}

* Sinisterra OT, Valdes VE, Valverde C. Effect of supplementation with iron salts and knowledge, attitudes and practices in relation to anaemia among schoolchildren in the province of Cocle, Ministry of Health, Republic of Panama (report). [Efecto de la suplementacion con sales de hierro y de conocimientos, actitudes y practicas en relacion a la anemia en escolares de la provincia de Cocle, Republica de Panama: reporte]. Vol. **DCE/18**, Panama: INCAP, Ministry of Health, Republic of Panama, 1997.

Soemantri 1997 {published data only}

* Soemantri AG, Hapsari DE, Susanto JC, Rohadi W, Tamam M, Irawan PW, et al. Daily and weekly iron supplementation and physical growth of school age Indonesian children. *Southeast Asian Journal of Tropical Medicine and Public Health* 1997;**28 Suppl 2**:69–74.

Sungthong 2002 {published data only}

* Sungthong R, Mo-Suwan L, Chongsuvivatwong V, Geater AF. Once weekly is superior to daily iron supplementation on height gain but not on hematological improvement among schoolchildren in Thailand. *Journal of Nutrition* 2002;**132**(3):418–22.

Sungthong R, Mo-suwan L, Chongsuvivatwong V, Geater AF. Once-weekly and 5-days a week iron supplementation differentially affect cognitive function but not school performance in Thai children. *Journal of Nutrition* 2004; **134**(9):2349–54.

Tavil 2003 {published data only}

* Tavil B, Sipahi T, Gökçe H, Akar N. Effect of twice weekly versus daily iron treatment in Turkish children with iron deficiency anemia. *Pediatric Hematology and Oncology* 2003;**20**(4):319–26.

Taylor 2001 {published data only}

* Taylor M, Jinabhai CC, Couper I, Kleinschmidt I, Jogessar VB. The effect of different anthelmintic treatment regimens combined with iron supplementation on the nutritional status of schoolchildren in KwaZulu-Natal, South Africa: a randomized controlled trial. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 2001;**95**(2):211–6.

Thu 1999 {published data only}

* Thu BD, Schultink W, Dillon D, Gross R, Leswara ND, Khoi HH. Effect of daily and weekly micronutrient supplementation on micronutrient deficiencies and growth in young Vietnamese children. *American Journal of Clinical Nutrition* 1999;**69**(1):80–6.

Verhoef 2002 {published data only}

Verhoef H, West CE, Kraaijenhagen R, Nzyuko SM, King R, Mbandi MM. Malarial anemia leads to adequately

increased erythropoiesis in asymptomatic Kenyan children. *Blood* 2002;**15**(00(10)):489–94.

* Verhoef H, West CE, Nzyuko SM, de Vogel S, van der Valk R, Wanga MA, et al. Intermittent administration of iron and sulfadoxine-pyrimethamine to control anaemia in Kenyan children: a randomised controlled trial. *Lancet* 2002;**21**(360(9337)):908–14.

Yang 2004 (C) {published data only}

* Yang Q, Yin S, Zhao X, An J. Effect of daily or once weekly iron supplementation on growth and iron status of preschool children. *Wei sheng yan jiu = Journal of Hygiene Research* 2004;**33**(2):205–7.

Young 2001 {published data only}

* Young MW. The effectiveness of weekly iron and vitamin supplementation of Malawian preschool children. *South African Medical Journal = Suid-Afrikaanse tydskrif vir geneeskunde* 2001;**91**(1):49–50.

Yurdakok 2004 {published data only}

* Yurdakök K, Temiz F, Yalçin SS, Gümrük F. Efficacy of daily and weekly iron supplementation on iron status in exclusively breast-fed infants. *Journal of Pediatric Hematology/Oncology* 2004;26(5):284–8.

References to studies excluded from this review

Agarwal 2003 {published data only}

* Agarwal KN, Gomber S, Bisht H, Som M. Anemia prophylaxis in adolescent school girls by weekly or daily iron-folate supplementation. *Indian Pediatrics* 2003;**40**(4): 296–301.

Ahmed 2001 {published data only}

* Ahmed F, Khan MR, Jackson AA. Concomitant supplemental vitamin A enhances the response to weekly supplemental iron and folic acid in anemic teenagers in urban Bangladesh. *American Journal of Clinical Nutrition* 2001;74(1):108–15.

Ahmed 2005 {published data only}

* Ahmed F, Khan MR, Akhtaruzzaman M, Karim R, Marks GC, Banu CP, et al. Efficacy of twice-weekly multiple micronutrient supplementation for improving the hemoglobin and micronutrient status of anemic adolescent schoolgirls in Bangladesh. *American Journal of Clinical Nutrition* 2005;**82**(4):829–35.

Avila-Jimenez 2011 {unpublished data only}

* Ávila Jiménez L, Méndez, Villalpando-Hernández S, Martínez-Salgado H. Preventive iron supplementation and nutritional status of infants measured by anthropometry assigned to IMSS obligatory regimen [Suplementación preventiva con hierro y estado nutricio medido por antropometría de lactantes del régimen obligatorio del IMSS]. Unpublished article sent by Dr Homero Martinez. Ávila-Jiménez L, Méndez I, Villalpando-Hernández S, Martínez-Salgado H. Effect of iron supplementation on growth velocity in infants [Efecto de una suplementación con hierro sobre la velocidad de crecimiento en lactantes]. Unpublished article sent by Dr Homero Martinez.

Azeredo 2010 {published data only}

* Azeredo CM, Cotta RM, Sant'Ana LF, Franceschini Sdo C, Ribeiro Rde C, Lamounier JA, et al. Greater effectiveness of daily iron supplementation scheme in infants [Efectividad superior del esquema diario de suplementación de hierro en lactantes]. *Revista de Saúde Pública* 2010;44(2):230–9.

Beasley 2000 {published data only}

* Beasley NM, Tomkins AM, Hall A, Lorri W, Kihamia CM, Bundy DA. The impact of weekly iron supplementation on the iron status and growth of adolescent girls in Tanzania. *Tropical Medicine and International Health* 2000;**5**(11): 794–9.

Briars 2003 {published data only}

* Adank C, Green TJ, Skeaff CM, Briars B. Weekly highdose folic acid supplementation is effective in lowering serum homocysteine concentrations in women. *Annals of Nutrition and Metabolism* 2003;47(2):55–9.

Februhartanty 2002 {published data only}

* Februhartanty J, Dillon D, Khusun H. Will iron supplementation given during menstruation improve iron status better than weekly supplementation?. *Asia Pacific Journal of Clinical Nutrition* 2002;**11**(1):36–41.

Hafeez 1998 {published data only}

* Hafeez A, Ahmad P. Iron deficiency anaemia: continuous versus intermittent treatment in anaemic children. *Journal of the Pakistan Medical Association* 1998;**48**(9):269–72.

Hop 2005 {published data only}

* Hop LT, Berger J. Multiple micronutrient supplementation improves anemia, micronutrient nutrient status, and growth of Vietnamese infants: double-blind, randomized, placebocontrolled trial. *Journal of Nutrition* 2005;**135**(3):660s–5s.

Jackson 2003 {published data only}

* Jackson RT, Al-Mousa Z, Al-Raqua M, Prakash P. Effect of short-term weekly supplementation on anemia and symptoms in adolescent Kuwaiti girls. *Kuwait Medical Journal* 2003;**35**(4):275–80.

Jaleel 2004 {published data only}

* Jaleel A, UrRahman MA. Daily iron supplementation versus intermittent dose. *Saudi Medical Journal* 2004;**25**(8): 1124–5.

Jayatissa 1999 {published data only}

* Jayatissa R, Piyasena P. Adolescent schoolgirls: daily or weekly iron supplementation. *Food and Nutrition Bulletin* 1999;**20**(4):429–34.

Kanal 2005 {published data only}

* Kanal K, Busch-Hallen J, Cavalli-Sforza T, Crape B, Smitasiri S, Cambodian Weekly Iron-Folic Acid Program Team. Weekly iron-folic acid supplements to prevent anemia among Cambodian women in three settings: process and outcomes of social marketing and community mobilization. *Nutrition Reviews* 2005;**63**(12 Pt 2):S126–33.

Kapur 2003 {published data only}

* Kapur D, Sharma S, Agarwal KN. Effectiveness of nutrition education, iron supplementation or both on iron status in children. *Indian Pediatrics* 2003;**40**(12):1131–44.

Kianfar 2000 {published data only}

Kianfar H, Kimiagar M, Ghaffarpour M. Effect of daily and intermittent iron supplementation on iron status of high school girls. *International Journal for Vitamin and Nutrition Research* 2000;**70**(4):172–7.

Lechtig 2006 {published data only}

* Lechtig A, Gross R, Vivanco OA, Gross U, López de Romaña D. Lessons learned from the scaling-up of a weekly multimicronutrient supplementation program in the integrated food security program (PISA). *Food and Nutrition Bulletin* 2006;**27 Suppl Peru**(4):160–5.

Leenstra 2009 {published data only}

* Leenstra T, Kariuki SK, Kurtis JD, Oloo AJ, Kager PA, Ter Kuile FO. The effect of weekly iron and vitamin A supplementation on hemoglobin levels and iron status in adolescent schoolgirls in western Kenya. *European Journal* of Clinical Nutrition 2009;63(2):173–82.

Lima 2006 {published data only}

* Lima AC, Lima MC, Guerra MQF, Romani SAM, Eickmann SH, Lira PIC. Impact of weekly treatment with ferrous sulfate on hemoglobin level, morbidity and nutritional status of anemic infants. *Jornal de Pediatria* 2006;**82**(6):452–7.

Lin 2001 {published data only}

* Lin X, Tang Y, Long Z. Effects of vitamin A and iron supplementation on the improvement of iron status and immunological function in preschool children. *Chinese Journal of Preventive Medicine - Zhonghua Yu Fang Yi Xue* Za Zhi 2001;**35**(6):374–7.

López de Romaña 2005 {published data only}

López de Romaña G, Cusirramos S, López de Romaña D, Gross R. Efficacy of multiple micronutrient supplementation for improving anemia, micronutrient status, growth, and morbidity of Peruvian infants. *Journal of Nutrition* 2005;**135**(3):646s–52s.

López de Romaña 2006 {published data only}

* López de Romaña D, Verona S, Vivanco OA, Gross R. Protective effect of multimicronutrient supplementation against anemia among children, women, and adolescent girls in lower-income areas of Chiclayo, Peru. *Food and Nutrition Bulletin* 2006;**27 Suppl Peru**(4):S143–50.

Menendez 1997 {published data only}

* Menendez C, Kahigwa E, Hirt R, Vounatsou P, Aponte JJ, Font F, et al. Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants. *Lancet* 1997;**350**(9081):844–50.

Mwanakasale 2009 {published data only}

Mwanakasale V, Siziya S, Mwansa J, Koukounari A, Fenwick A. Impact of iron supplementation on schistosomiasis control in Zambian school children in a highly endemic area. *Malawi Medical Journal* 2009;**21**(1):12–8.

Perrin 2002 {published data only}

* Perrin E, Rothman R, Coyne-Beasley T, Ford C, Bordley WC. Is weekly iron and folic acid supplementation as effective as daily supplementation for decreasing incidence of anemia in adolescent girls?. *Archives of Pediatrics and Adolescent Medicine* 2002;**156**(2):128–30.

Risonar 2008 {published data only}

* Risonar MG, Tengco LW, Rayco-Solon P, Solon FS. The effect of a school-based weekly iron supplementation delivery system among anemic schoolchildren in the Philippines. *European Journal of Clinical Nutrition* 2008;**62** (8):991–6.

Rivera 1998 {published data only}

* Rivera G, De Thomson M. Effect of ferrous salts supplementation on iron status of schoolchildren, Chiriqui, Panama, 1995-1997 [Efecto de la suplementacion con sales ferrosas en el estado nutricional de hierro de escolares, Chiriqui, Panama, 1995-1997]. Panama: Ministry of Health, Republic of Panama, 1998.

Schümann 2009 {published data only}

* Schümann K, Longfils, P, Monchy D, von Xylander S, Weinheimer H, Solomons NW. Efficacy and safety of twice-weekly administration of three RDAs of iron and folic acid with and without complement of 14 essential micronutrients at one or two RDAs: a placebo-controlled intervention trial in anemic Cambodian infants 6 to 24 months of age. *European Journal of Clinical Nutrition* 2009; 63(3):355–68.

Shah 2002 {published data only}

* Shah BK, Gupta P. Weekly vs daily iron and folic acid supplementation in adolescent Nepalese girls. *Archives of Pediatrics and Adolescent Medicine* 2002;**156**(2):131–5.

Sharma 2000 {published data only}

* Sharma A, Prasad K, Rao KV. Identification of an appropriate strategy to control anemia in adolescent girls of poor communities. *Indian Pediatrics* 2000;**37**(3):261–7.

Shobha 2003 {published data only}

* Shobha S, Sharada D. Efficacy of twice weekly iron supplementation in anemic adolescent girls. *Indian Pediatrics* 2003;**40**(12):1186–90.

Smuts 2005 {published data only}

* Smuts CM, Dhansay MA, Faber M, van Stuijvenberg ME, Swanevelder S, Gross R, et al. Efficacy of multiple micronutrient supplementation for improving anemia, micronutrient status, and growth in South African infants. *Journal of Nutrition* 2005;**135**(3):653s–9s.

Soekarjo 2004 {published data only}

* Soekarjo DD, Pee S de, Kusin JA, Schreurs WH. Schultink W, Muhilal, et al. Effectiveness of weekly vitamin A (10, 000 IU) and iron (60 mg) supplementation for adolescent boys and girls through schools in rural and urban East Java, Indonesia. *European Journal of Clinical Nutrition* 2004;**58** (6):927–37.

Sotelo-Cruz 2002 {published data only}

* Sotelo-Cruz N, Gómez-Rivera N, Ferrá-Fragoso S, Pereyda-Galaz DE. Ferrous sulfate weekly dose for iron deficiency in preschool children. *Gaceta Médica de México* 2002;**138**(3):225–30.

Tee 1999 {published data only}

* Tee ES, Kandiah M, Awin N, Chong SM, Satgunasingam N, Kamarudin L, et al. School-administered weekly iron-folate supplements improve hemoglobin and ferritin concentrations in Malaysian adolescent girls. *American Journal of Clinical Nutrition* 1999;**69**(6):1249–56.

Tomashek 2001 {published data only}

* Tomashek KM, Woodruff BA, Gotway CA, Bloland P, Mbaruku G. Randomized intervention study comparing several regimens for the treatment of moderate anemia among refugee children in Kigoma Region, Tanzania. *American Journal Tropical Medicine and Hygiene* 2001;**64**(3-4):164–71.

UNICEF 2006 {published data only}

* Ministry of Health Panama, UNICEF, PAHO. [Situacion de deficiencia de hierro y anemia]. *Status of iron deficiency and anaemia*. Panama: UNICEF, 2006.

Vir 2008 {published data only}

* Vir SC, Singh N, Nigam AK, Jain R. Weekly iron and folic acid supplementation with counselling reduces anemia in adolescent girls: a large-scale effectiveness study in Uttar Pradesh, India. *Food and Nutrition Bulletin* 2008;29(3): 186–94.

Wijaya-Erhardt 2007 {published data only}

* Wijaya-Erhardt M, Erhardt JG, Untoro J, Karyadi E, Wibowo L, Gross R. Effect of daily or weekly multiplemicronutrient and iron foodlike tablets on body iron stores of Indonesian infants aged 6-12 mo: a double-blind, randomized, placebo-controlled trial. *American Journal of Clinical Nutrition* 2007;**86**(6):1680–6.

Zavaleta 2000 {published data only}

* Zavaleta N, Respicio G, Garcia T. Efficacy and acceptability of two iron supplementation schedules in adolescent school girls in Lima, Peru. *Journal of Nutrition* 2000;**130**(2):462s–4s.

References to studies awaiting assessment

Husseini 1999 {unpublished data only}

Husseini T. Bagor, Indonesia Trial. Information included in Beaton 1999.

Kargarnovin 2010 {published data only}

* Kargarnovin Z, Tamkins A, Jalaly M, Salavan K, Pam L. Effects of daily versus weekly iron therapy in infants between 6-24 months for iron deficiency anemia. *Journal of Nursing and Midwifery* 2010;**20**(69):48.

Reid 2001 {published data only}

* Reid ED, Lopez P, Galaviz IA, Isoard F, Rosado JL, Allen LH. Hematological and biochemical responses of rural Mexican preschoolers to iron alone or iron plus micronutrients. FASEB Journal. 2001; Vol. 15:A731.

References to ongoing studies

Zeeba Zaka-ur-Rab 2010 {published data only}

* Dr. Zeeba Zaka-ur-Rab. A clinical trial to compare the effects of daily versus intermittent iron supplementation

on markers of oxidative stress and anti-oxidant status in children with iron deficiency anemia . The Clinical Trials Registry- India (CTRI).

Additional references

ACC/SCN 1991

Administrative Committee on Coordination/Subcommittee on Nutrition (United Nations). *Controlling iron deficiency. ACC/SCN State of the Art Series.* Vol. **Nutrition Policy Discussion Paper No 9**, Geneva: United Nations Administrative Committee on Coordination: Subcommittee on Nutrition, 1991.

Adetifa 2009

Adetifa I, Okomo U. Iron supplementation for reducing morbidity and mortality in children with HIV. *Cochrane Database of Systematic Reviews* 2009, Issue 1. [DOI: 10.1002/14651858.CD006736.pub2

Balshem 2010

Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: Rating the quality of evidence. *Journal of Clinical Epidemiology* 2011; **64**(4):401–6.

Baqui 2005

Baqui AH, Fischer Walker CL, Zaman K, Arifeen SE, Chowdhury HR, Wahed MA, et al. Weekly iron supplementation does not block increases in serum zinc due to weekly zinc supplementation in Bangladeshi infants. *Journal of Nutrition* 2005;**135**(9):2187–91.

Beard 2008

Beard JL. Why iron deficiency is important in infant development. *Journal of Nutrition* 2008;**138**(12):2534–6.

Beaton 1999

Beaton GH, McCabe GP. *Efficacy of intermittent iron* supplementation in the control of iron deficiency anaemia in developing countries. An analysis of experience (final report). Ottawa: The Micronutrient Initiative, 1999.

Bhutta 2009

Bhutta Z, Klemm R, Shahid F, Rizvi A, Rah JH, Christian P. Treatment response to iron and folic alone is the same as with multivitamins and/or anthelminthics in severely anemic 6 to 24-month-old children. *Journal of Nutrition* 2009;**139**(8):1568.

Borenstein 2008

Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. *Introduction to Meta-Analysis (Statistics in Practice)*. Chichester (UK): John Wiley & Sons, 2008.

Bothwell 2000

Bothwell TH. Iron requirements in pregnancy and strategies to meet them. *American Journal of Clinical Nutrition* 2000; **72**(1):257S–64S.

Casanueva 2003

Casanueva E, Viteri FE. Iron and oxidative stress in pregnancy. *Journal of Nutrition* 2003;**133**(5):1700S–8S.

Cole 2010

Cole CR, Grant FK, Swaby-Ellis ED, Smith JL, Jacques A, Northrop-Clewes CA, et al. Zinc and iron deficiency and

their interrelations in low-income African American and Hispanic children in Atlanta. *American Journal of Clinical Nutrition* 2010;**91**(4):1027–34.

Davidsson 2003

Davidsson L. Approaches to improve iron bioavailability from complementary foods. *Journal of Nutrition* 2003;**133** (5):1560S–2S.

De-Regil 2011

De-Regil LM, Pena-Rosas JP, Flores-Ayala R, Jefferds MED. WHO/CDC logic model for micronutrient interventions in public health. *FASEB Journal* March 17, 2011;**25**:108.1.

Fernández-Gaxiola 2011

Fernández-Gaxiola AC, De-Regil LM, Nasser M. Intermittent iron supplementation for reducing anaemia and its associated impairments in women of reproductive age. *Cochrane Database of Systematic Reviews* 2011, Issue 12. [DOI: 10.1002/14651858.CD009218

Gera 2007

Gera T, Sachdev HP, Nestel P, Sachdev SS. Effect of iron supplementation on haemoglobin response in children: systematic review of randomised controlled trials. *Journal* of *Pediatric Gastroenterology and Nutrition* 2007;**44**(4): 468–86.

GRADEpro 2008 [Computer program]

Jan Brozek, Andrew Oxman, Holger Schünemann. GRADEpro Version 3.2 for Windows. Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group, 2008.

Higgins 2011

Higgins JPT, Green S, editors. *Cochrane Handbook for Systematic Reviews of Interventions*. Chichester: John Wiley & Sons, 2011.

Iannoti 2006

Iannotti LL, Tielsch JM, Black MM, Black RE. Iron supplementation in early childhood: health benefits and risks. *American Journal of Clinical Nutrition* 2006;**84**(6): 1261–76.

Lozoff 2000

Lozoff B, Jimenez E, Hagen J, Mollen E, Wolf AW. Poorer behavioral and developmental outcome more than 10 years after treatment for iron deficiency in infancy. *Pediatrics* 2000;**105**(4):e51.

Lozoff 2007

Lozoff B. Iron deficiency and child development. *Food and Nutrition Bulletin* 2007;**28**(4):S560–71.

Mills 2009

Mills RJ, Davies MW, McGuire W. Iron supplementation in enterally fed preterm infants. *Cochrane Database* of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/ 14651858.CD005095

Moy 2006

Moy RJD. Prevalence, consequences, and prevention of childhood nutritional iron deficiency: a child public health perspective. *Clinical and Laboratory Haematology* 2006;**28** (5):291–8.

NIH 2011

NIH Iron and Malaria Technical Working Group. Chapter 2: Mechanisms. In: Raiten D, Namaste S, Brabin B editor (s). Considerations for the Safe and Effective use of Iron Interventions. Bethesda: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), 2011 (in press):16–51.

Okebe 2011

Okebe JU, Yahav D, Shbita R, Paul M. Oral iron supplements for children in malaria-endemic areas. *Cochrane Database of Systematic Reviews* 2011, Issue 10. [DOI: 10.1002/14651858.CD006589.pub3

Olsen 2006

Olsen A, Nawiri J, Magnussen P, Krarup H, Friis H. Failure of twice weekly iron supplementation to increase blood haemoglobin and serum ferritin concentrations: results of a randomized controlled trial. *Annals of Tropical Medicine and Parasitology* 2006;**100**(3):251–63.

Peña-Rosas 2009

Peña-Rosas JP, Viteri FE. Effects and safety of preventive oral iron or iron+folic acid supplementation for women during pregnancy. *Cochrane Database of Systematic Reviews* 2009, Issue 4. [DOI: 10.1002/14651858.CD004736.pub3

RevMan 2011 [Computer program]

The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.

Simmons 1993

Simmons. Evaluation of a gastric delivery system for iron supplementation in pregnancy. *American Journal of Clinical Nutrition* 1993;**58**(5):622–6.

Stoltzfus 2011

Stoltzfus RJ. Iron interventions for women and children in low-income countries. *Journal of Nutrition* 2011;**141**(4): 7568-62S.

Thu 1999

Thu BD, Schultink W, Dillon D, Gross R, Dhevita Leswara N, Khoi HH. Effect of daily and weekly micronutrient supplementation on micronutrient deficiencies and growth in young Vietnamese children. *American Journal of Clinical Nutrition* 1999;**69**(1):80–6.

Viteri 1997

Viteri FE. Iron supplementation for the control of iron deficiency in populations at risk. *Nutrition Reviews* 1997;**55** (6):195–209.

Viteri 2005

Viteri FE, Berger J. Importance of pre-pregnancy and pregnancy iron status: can long-term weekly preventive iron and folic acid supplementation achieve desirable and safe status?. *Nutrition Reviews* 2005;**63**(12 Pt 2):S65–76.

WHO 2001

WHO, UNICEF, UNU. Iron Deficiency Anaemia Assessment, Prevention and Control: A Guide for Programme Managers. 1st Edition. Geneva: World Health Organization, 2001: 1–114.

WHO 2009

World Health Organization. Weekly iron and folic acid supplementation programmes for women of reproductive age: An analysis of best programme practices (WHO Position Statement). Manila: World Health Organization Regional Office for the Western Pacific, 2009.

WHO 2009a

World Health Organization. Infant and young child feeding: model chapter for textbooks for medical students and allied health professionals. Geneva: World Health Organization (http://whqlibdoc.who.int/publications/ 2009/9789241597494[.]eng.pdf). Geneva: World Health Organization, 2009.

WHO 2009b

World Health Organization. Weekly iron folic acid supplementation (WIFS) in women of reproductive age: its role in promoting optimal maternal and child health. Geneva: World Health Organization, 2009.

WHO 2011a

World Health Organization. *Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and Mineral Nutrition Information System.* Geneva: World Health Organization, 2011.

WHO 2011b

WHO. Serum ferritin concentrations for the assessment of iron status and iron deficiency in populations. Vitamin and Mineral Nutrition Information System. Geneva: World Health Organization, 2011.

WHO/CDC 2008

World Health Organization/Centers for Disease Control and Prevention (USA). Worldwide prevalence of anaemia 1993-2005. In: de Benoist B, McLean E, Egli I, Cogswell M editor(s). *WHO Global Database on Anaemia*. Geneva: World Health Organization, 2008.

WHO/CDC 2011

World Health Organization, Centers for Disease Control and Prevention. Logic model for micronutrient interventions in public health. Vitamin and Mineral Nutrition Information System. (WHO/NMH/NHD/ MNM/11.5) (http://www.who.int/vmnis/toolkit/WHO-CDC-english⁻colour.pdf, accessed 7 July 2011).. Geneva: World Health Organization, 2011.

Wright 1990

Wright AJ, Southon S. The effectiveness of various iron supplementation regimens in improving the Fe status of anemic rats. *British Journal of Nutrition* 1990;**63**(3):579-85.

* Indicates the major publication for the study

CHARACTERISTICS OF STUDIES

Characteristics of included studies [ordered by study ID]

Aguayo 2000

Methods	Randomised double-blind placebo-controlled trial. 2-arm design with individual ran- domisation
Participants	73 children (64 children followed up), both sexes (30 females (47%)), aged 6-11.9 years (9 years in average), from outskirts of La Paz, Bolivia (4000 m above sea level). Inclusion criterion: non-anaemic. Socioeconomic status not reported
Interventions	Participants were allocated to one of the following groups: Group 1 ($n = 37$): children received weekly tablets containing iron. The iron dose was calculated to provide children with 3 mg of elemental iron per kg of body weight (approximately 85 mg of iron per week). The supplement consisted of two types of tablets containing either 20 mg or 36 mg of elemental iron (as ferrous sulphate). These tablets were used in combination to adjust the dose to the child's weight; Group 2 ($n = 36$): children received a placebo similar in colour and appearance to the iron supplement Length of the intervention: 18 weeks
Outcomes	Haemoglobin, mean haemoglobin change, anaemia, anthropometric measurements (weight for age Z-score, height for age Z-score and mid-upper arm circumference), and side effects
Notes	A teacher trained by the principal investigator was responsible for delivering the iron tablets in the classrooms. All children completed at least 17 doses. Pills were administered on Wednesday and students who were not in school on Wednesday were administered the supplements on Thursday Z-scores used the National Center for Health Statistics data as a reference Non-malaria area.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Children were randomly assigned to the treatment or the control group using a ta- ble with randomly assorted digits
Allocation concealment (selection bias)	Low risk	A teacher trained by the principal investi- gator was responsible for the delivery of the iron tablets in the classrooms. The teacher was provided with a list of the names of the children and the number and kind of pills (colour coded) each child should take ev- ery week. Neither the teacher nor the assis- tant were aware of the composition of the

Aguayo 2000 (Continued)

		tablets delivered to the children and tablets were similar in appearance
Blinding (performance bias and detection bias) All outcomes	Low risk	Tablets were similar in appearance. Participants:Children were not aware of the treatment. Personnel: Neither the teacher nor his assis- tant were aware of the composition of the tablets delivered to the children Outcome assessors: not described.
Incomplete outcome data (attrition bias) All outcomes	Low risk	A complete set of data was obtained for 33 children in the treatment group (89.2 %) and for 31 children (86.1 %) in the control group
Selective reporting (reporting bias)	Unclear risk	There is insufficient information to permit judgement.
Other bias	Low risk	No significant differences at baseline in the variables studied, and females/males ratio. No differences at baseline between those that completed the study and those who dropped out

Arcanjo 2011 (C)

Methods	Cluster-randomised, placebo-controlled double-blind trial. 2 arm design with randomi- sation at classroom level
Participants	106 preschool children, both sexes (56 females (52.8%), aged 5 years. The study was conducted in a public school located in the City of Sobral, in the northeast of Brazil between September and December 2009. Exclusion criteria: current supplement intake. Baseline prevalence of anaemia: 58.5%. Forty per cent of the families had an income <300 USD
Interventions	Classrooms were allocated to one of the following groups: Group 1 (3 classrooms, 52 children): children received once a week 50 mg of elemental iron (as ferrous sulphate heptahydrate) once a week; Group 2 (3 classrooms, 54 children): children received once a week a placebo (on Wednes- days). The placebo contained 2 ml of natural colour additive, annatto, which is odourless and tasteless, providing a yellow-orange colour similar to that of the elemental iron used in the study Length of the intervention: 14 weeks.
Outcomes	Haemoglobin, hematocrit and anaemia (Hb less than 115 g/L)

Arcanjo 2011 (C) (Continued)

The supplements were administered on Wednesdays. The supplement was administered	
by a teacher using a plastic medical syringe with scale to squirt the composition into the	
child's mouth. The syringes were prepared on an individual basis by medical staff	
We adjusted the results of this study to account for the effect of clustering in data; the	
estimated effective sample size was used in the analyses.	
Malaria endemicity not reported.	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	An allocation code was generated with a ta- ble of random numbers for randomizations of schools and classes
Allocation concealment (selection bias)	Low risk	The study used a placebo. Since randomi- sation occurred at classroom level, it is un- likely a selection bias at individual level
Blinding (performance bias and detection bias) All outcomes	Low risk	Participants: were not aware of different in- terventions. Personnel: the teacher was not aware of the treatment nor involved in data collection Ouctome assessors: the staff involved in data collection was blinded with regard to the intervention and placebo groups
Incomplete outcome data (attrition bias) All outcomes	Low risk	During the study, there were 2 (3.8%) dropouts in group 1, and 5 (9.2%) dropouts in group 2. Intention to treat analysis
Selective reporting (reporting bias)	Unclear risk	There is insufficient information to permit judgement.
Other bias	Unclear risk	The data was not adjusted by the effect of clustering. Anaemia prevalence at baseline was not bal- anced between groups: 48% in group 1 and 69% in group 2 (but similar concentrations of haemoglobin)

Awasthi 2005 (C)

Methods	Cluster-randomised community effectiveness trial. 2 arm design with randomisation at subcentre level
Participants	803 children, both sexes (730 females (45.4%)), aged 3-6 years, living in sub centres of Shahpur Baxolia and Sipa Hidayatpur from Nindura Block, Barabanki district, North India. Exclusion criteria: those without written informed consent, or those likely to move within the next three months. Children identified as severely anaemic were given iron and folic acid in therapeutic doses under close supervision (but does not say they were excluded). Baseline prevalence of anaemia in children was 53.79 %. Socioeconomic status not reported
Interventions	Sub centres were allocated to one of the following groups: Group 1 (n = 403): children in Shahpur Baxolia sub centre received tablets containing 20 mg elemental iron (presumably in form of ferrous sulphate) iron and 100 μ g (0.1 mg) folic acid twice a week, on fixed days (Wednesday and Saturday); Group 2 (n = 400): children in Sipa Hidayatpur sub centre received one tablet daily Length of the intervention: one year.
Outcomes	Haemoglobin, haemoglobin mean change, anaemia, and adherence
Notes	Iron and folic acid was given to the children either by the Anganwadi worker, if they were registered and used the informal education services of the Integrated Child Health Development Services, or by the mother for non-registered children. Mothers could pick up monthly supplies for their children one day a month from an Anganwadi centre A monitoring in-charge was responsible for each intervention type. He visited each Anganwadi centre every 15 days to take an account of the IFA distributed to registered children. The monitor in-charge also visited 20 randomly selected houses of non-registered children and collected information about the IFA tablet intake, including the number of pills consumed Sample size was calculated taking into consideration a design effect of 2. We adjusted the results of this study to account for the effect of clustering in data; the estimated effective sample size was used in the analyses. Malaria endemicity not reported.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	For this study all sub centres were listed alphabetically, serially numbered, and two were selected by random for assessment of the interventional strategies, one per sub- centre. It is unclear whether the allocation to the treatment was at random
Allocation concealment (selection bias)	Low risk	Since the intervention was allocated at sub- centre level, it is unlikely there was a selec- tion bias at the individual level

Awasthi 2005 (C) (Continued)

Blinding (performance bias and detection bias)	High risk	Participants: Not reported. Personnel: Not reported.
All outcomes		Outcome assessors: Not reported.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Loss to follow up 8.34% at one year with no difference between groups (biweekly 8. 1% versus daily 8.5%)
Selective reporting (reporting bias)	Unclear risk	There is insufficient information to permit judgement.
Other bias	High risk	Some children had directly observed in- take and others were given the pills by the mother. About 1/3 of the children are reg- istered to obtain services of the Anganwadi centre (under the ICDS services) and this had a differential effect on supplementa- tion (favouring registered children) Results did not account for the cluster ef- fect.
Baqui 2003		
Methods	Randomised, double-blinded community-based trial. 5-arm design with individual ran- domisation	
Participants	799 Bangladeshi children, both sexes (406 females (50.8%)), enrolled at 5-6 months of age for a 6 month study (12 mo old when completed). Potential families were identified through ongoing health and demographic surveillance system. Participants were eligible if did not receive infant formula, were not severely malnourished (mid-upper arm circumference >110mm), not severely anaemic (haemoglobin >90 g/L), with no obvious neurologic disorders, physical disabilities, or chronic illnesses that might affect feeding, activity, and cognitive development. There were no differences in monthly income, household size or father's education across the arms. Approximately two-thirds of the children were mildly anaemic at recruitment	
Interventions	Infants were randomly allocated to one of the following groups: Group 1 (n = 154): Infants received once a week multiple micronutrients in a dose that doubled the recommended dietary allowance (WHO standards) of thiamine, niacin, folic acid, pantothenic acid, iodine, copper, manganese, selenium, and vitamins C, D, E, B ₆ and B ₁₂ . It contained 20 mg elemental iron (as ferrous sulphate), 20 mg elemental zinc (as zinc acetate), and 1 mg riboflavin Group 2 (n = 161): Infants received once a week 20 mg elemental iron and 1 mg riboflavin Group 3 (n = 161): Infants received once a week 20 mg of elemental zinc and 1 mg riboflavin Group 4 (n = 162): Infants received once a week 20 mg of elemental zinc, 20 mg elemental iron and 1 mg riboflavin	

Baqui 2003 (Continued)

	For the purpose of this review, groups 1, 2 & 4 were merged and compared with group 5 Length of the intervention: 6 months.	
Outcomes	Ferritin, diarrhoea, ALRI, physical growth, mental, motor, behavioral development from 6 to 12 month (measured using Bayley II scales of infant development), adherence. Data on diarrhoea and ALRI was not combined as it is reported in incidence rate/(child-y)	
Notes	Supplements were prepared as capsules, which were mixed with flavoured syrup and fed to infants by community health workers All supplements had similar taste and appearance and all groups also received 100,000 IU of vitamin A at the beginning of the study, in line with national policy in Bangladesh Trial with sub-studies with different sample sizes.	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Participants were randomly allocated to the study groups. Method of sequence genera- tion not described
Allocation concealment (selection bias)	Low risk	Each study infant received the assigned supplement in the same type of capsules and labelled in such a way that the various types of supplements could not be differ- entiated
Blinding (performance bias and detection bias) All outcomes	Low risk	Described as doubled-blinded clinical trial. Each study infant received the assigned supplement in the same type of capsules and labelled in such a way that the various types of supplements could not be differ- entiated
Incomplete outcome data (attrition bias) All outcomes	High risk	Drop out rate much higher (41%) in the MM group than in other groups (8-19%) . Motor/Cognitive outcomes: 125 kids (36%) did not complete 12 mo-assessment, leaving 221 children in final sample. There were no differences among arms or major sociodemographic variables for dropouts. 16.3% did not undergo evaluation with HOME scale 5% did not have haemoglobin data at 12 mo, 1.8% did not have anthropometric data at 12 mo but did for other measures

Baqui 2003 (Continued)

Selective reporting (reporting bias)	High risk	Trial with sub studies with different sample sizes.	
Other bias	Unclear risk	No discussion of adjustment or exclusion for inflammation for iron status analysis	
Berger 1997			
Methods	Double-blind randomised controlled tria	l. 3-arm design with individual randomisation	
Participants	average), attending the schools administer Alegria" located in a socio-economically di of 4000 m above sea level). Inclusion cr	176 children, both sexes (91 females (52%)), aged 3.3-8.3 years (69 months old in average), attending the schools administered by the non-governmental organization "Fe y Alegria" located in a socio-economically disadvantaged district of La Paz, Bolivia (altitude of 4000 m above sea level). Inclusion criterion: anaemia (haemoglobin concentration equal to or lower than 144 g/L). No additional exclusion criteria listed. Socioeconomic status not reported	
Interventions	Participants were allocated to one of the following groups: Group 1 (n = 59): children received every Tuesday 3-4 mg of iron per kg of body weight (approximately 60-80 mg per week); Group 2 (n = 59): children received a daily dose of 3-4 mg of iron per kg of body weight, 5 days per week, Monday to Fri. Daily group received 5 times as much iron as weekly; Group 3 (n = 58): children received a placebo, once a week, every Tuesday. Placebo consisted of same tablets without iron Supplements given to groups 1 and 2 consisted of two types of tablets containing either 20 mg or 36 mg of elemental iron in form of ferrous sulphate. These tablets were used in combination to adjust the dose to the child's weight Length of the intervention: 16 weeks		
Outcomes	Haemoglobin, change in haemoglobin, a herence	Haemoglobin, change in haemoglobin, anaemia, zinc erythrocyte protoporphyrin, ad- herence	
Notes	trained school assistants, under the super-	Tablets were given to children at school, with clean, boiled water, at mid morning, by trained school assistants, under the supervision of a member of the research team. Same tablets were used for weekly, daily, and same tablets without iron were used for placebo Non malaria area.	
Risk of bias			
Bias	Authors' judgement	Support for judgement	

Random sequence generation (selection bias)	Unclear risk	Children were randomly assigned to one of three groups. Method of sequence genera- tion not described
Allocation concealment (selection bias)	Low risk	Method of concealment not described, but the study reported as double blind

Berger 1997 (Continued)

Blinding (performance bias and detection bias) All outcomes	Low risk	Described as double-blind trial. Same tablets were used for weekly, daily, and same tablets without iron were used for placebo Participants: children were not aware of the treatment Personnel: personnel were not aware of the treatment Outcome assessors: not described.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Only one person lost to follow-up in each group, 3 people total. Dropouts were due to migration of the family out of the area of study
Selective reporting (reporting bias)	Unclear risk	There is insufficient information to permit judgement.
Other bias	Low risk	The study appears to be free of other sources of bias.

Da Silva 2008

Methods	Randomised controlled trial. 3-arm design with randomisation at individual level
Participants	135 children (114 followed up, 54 female (47%)), both sexes, aged 5 to 6.9 months, from Vicosa, the Southeast of Brazil. Children were identified from live birth forms and parents were interviewed; parents who were interested in participating were recruited (213 children were screened, 78 infants with anaemia were excluded and treated). Inclusion criteria: non-anaemic infants (Hb equal to or greater than 110 g/L), living in urban area; full term, singleton births; birth weight > 2500 g; mother aged > 19 years old; no neonatal abnormalities or chronic disease; no previous iron supplements; non-exclusive breastfeeding. Maternal years of education ranged between 4 and 11 years (mean approximately 8 years)
Interventions	Participants were allocated to one of the following groups: Group 1 (n = 51): infants received 1 mg of elemental iron/kg/day (as liquid ferrous sulphate); Group 2 (n = 42): infants received 2 mg of elemental iron/kg/day (as liquid ferrous sulphate); Group 3 (n = 42): infants received 25 mg elemental iron once a week (as liquid ferrous sulphate) Length of the intervention: 16 weeks For the purpose of this review only groups 2 and 3 were compared as the overall dose of iron given to the children was similar between them
Outcomes	Height, weight and change scores for height and weight (with Z-scores), morbidity (diarrhoea, fever, cough, nasal congestion, wheezing)

Da Silva 2008 (Continued)

Notes	Supplements were provided free to all groups and participants were advised to take 1 hour before meals
	Z scores used the World Health Organization data as a reference Malaria endemicity not reported.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	A computer-generated random number list (method communicated by the author)
Allocation concealment (selection bias)	High risk	Open random allocation schedule. Chil- dren were enrolled to the study in a row; there was a list showing the sequence in which children would be allocated to the groups (method communicated by the au- thor)
Blinding (performance bias and detection bias) All outcomes	High risk	Participants: Not reported. Personnel: Not reported. Outcome assessors: Not reported.
Incomplete outcome data (attrition bias) All outcomes	High risk	135 children were randomised. 114 com- pleted the intervention (84%). Loss was not balanced across groups: 12/51 lost from group 1, 6/42 from group 2, 3/42 from group 3 Reasons for loss included patient with- drawal (7) supplement intolerance (6) anaemia (2) and other reasons. It was not clear how many withdrew from each group for these reasons It was stated that analysis was based on an intention to treat principle, irrespective of adherence, but those lost to follow up did not appear to be included in the analysis, although denominators were not clear in the data tables
Selective reporting (reporting bias)	Unclear risk	There is insufficient information to permit judgement.
Other bias	Low risk	The study appears to be free of other sources of bias.

Desai 2004 (C)

Methods	Cluster-randomised trial. 2x2 factorial design in which housing compounds were the unit of randomisation
Participants	1049 children, both sexes (519 females (49.5%)), aged 2-59 months (27 months in average), living in 14 villages in Asembo, Bondo district, Nyanza Province, western Kenya. Inclusion criteria: haemoglobin 50-109 g/L (anaemic); asexual parasite count <20,000/mm; no history of intake of iron, sulphadoxine-pyrimethamine or amodiaquine use, or blood transfusion within the last 2 weeks, no known sickle cell disease Baseline prevalence of anaemia in children was 74%. Caretakers had a median of 6 or more years of education across all arms and 48.6% of households had a wealth score above the median
Interventions	Compounds were allocated to one of the following groups at baseline: Group 1 (n = 266): children received two doses of 3-6 mg/kg each, separated by 3-4 days (total dose per week: 6-12 mg/kg; approximately 36-72 mg of iron per week). Supervised; Group 2 (n = 271): children received two doses of 3-6 mg/kg each, separated by 3-4 days (total dose per week: 6-12 mg/kg). Unsupervised; Group 3 (n = 261): children received one daily dose of 3-6 mg/(kg per day). Supervised; Group 4 (n = 251): children received one daily dose of 3-6 mg/(kg per day). Unsupervised Target iron dose was ferrous sulphate syrup 40 g/L, 27.5% elemental iron. Iron doses were based on body weight (<5 kg: 1.25 mL/d, 5-10 kg: 2.5 mL/d, >10 kg: 5.0 mL/d). No folic acid was given Supervised arms (Groups 1 and 3) were used to assess the haematological response while unsupervised groups (2 and 4) provided data on adherence and side effects Length of the intervention: 6 weeks.
Outcomes	Haemoglobin, haemoglobin mean change, hematological recovery, microcytosis, all- cause morbidity, clinical malaria, malaria parasitaemia, adherence
Notes	All parents received the 6-week supply of oral iron and received identical instructions in the local language about use, expected side effects, safety and correct dose of iron supplementation To determine differences in the duration of any treatment effect on Hb levels, children were seen again at 12 wk (1 d) The mean cluster size was 1.5 children per compound, and the reported design effect was 1.035. Standard errors were adjusted for clustering at the compound level Malaria-endemic area. All arms were given single treatment dose of sulfadoxine-pyrimethamine (SP)

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	A computer-generated random number listing was used to sequentially assign eli- gible children to 1 of 4 treatment groups, using the housing compound as the ran- domisation unit

Desai 2004 (C) (Continued)

Allocation concealment (selection bias)	Low risk	Plastic screw top bottles used, labelled with personal identifiers and dosing instruc- tions. Since the intervention was allocated at compounds level, it is unlikely there was a selection bias at the individual level
Blinding (performance bias and detection bias) All outcomes	High risk	Participants:were aware of the treatment as- signed. Personnel: no blinding Outcome assessors: no blinding
Incomplete outcome data (attrition bias) All outcomes	Low risk	8.9% (n = 93) and equally divided among the four arms.
Selective reporting (reporting bias)	Unclear risk	There is insufficient information to permit judgement.
Other bias	Unclear risk	Children lost to follow up had lower (P= 0.01) haemoglobin concentrations at en- rolment than those successfully followed for 6 wk, but were not different for other characteristics. None of the characteristics differed among the groups after excluding children lost to follow up. 6 children (4 compounds) excluded from analyses at 6 wk follow up due to missing haemoglobin values. No discussion on adjustment/exclu- sion for inflammation

Ekvall 2000

Methods	Randomised trial. 2-arm design with individual randomisation
Participants	207 children, both sexes (sex distribution unknown), 5 months-3 years of age, living in Fukayosi village, Bagamoyo district of coastal Tanzania, from June to November 1995, during the seasonal peak of perennial malaria transmission. Exclusion criteria: migration plans, the presence of congenital malformations and Hb concentration, 50 g/ L at baseline, requiring immediate treatment. Baseline prevalence of anaemia in children was 89% (Hb lower than 110 g/L). Socioeconomic status not reported
Interventions	Participants were allocated to one of the following groups: Group 1 ($n = 104$): children received three times a week 1 mL of a micronutrient preparation containing 10 mg iron (as ferrous sulphate), 1500 IU vitamin A, 400 IU vitamin D, 5 IU vitamin E, 35 mg vitamin C, 0.5 mg vitamin B ₁ , 0.6 mg vitamin B ₂ , 8 mg niacin and 0.4 mg vitamin B ₆ ; Group 2 ($n = 103$): children received three times a week 1 mL of a placebo (1 mg of promethazine hydrochloride) Iron compound and weekly dose: 30 mg of elemental iron (as ferrous sulphate) per week

Ekvall 2000 (Continued)

	Length of the intervention: 5 months.
Outcomes	Haemoglobin, mean cell volume as an indicator of iron status, clinical malaria, fever, adherence
Notes	All children were to receive a total of 56 doses over 5 months administered during home visits by six research assistants who were assigned 30-35 children each Malaria holoendemic area. For active case detection of clinical malaria episodes, all children were seen fortnightly by the research team at the village dispensary for axillary temperature measurement. Children with malaria received chloroquine syrup (25 mg/kg over three days), and additional treatment with sulphadoxine pyrimethamine (SP) was given if a child showed clinical signs of treatment failure

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	The children were randomly allocated to the supplement group or the placebo group by a computer-generated number table
Allocation concealment (selection bias)	Low risk	The supplement and placebo had different colours to facilitate correct administration. However, neither the research assistants in- volved in the project nor the mothers of the children knew the treatment code.
Blinding (performance bias and detection bias) All outcomes	Low risk	The supplement and placebo had different colours to facilitate correct administration Participants: mothers did not know the treatment code Personnel: research assistants did not know the treatment code Ouctome assessors: not described
Incomplete outcome data (attrition bias) All outcomes	Low risk	6 children were lost to follow up in each group (6%).
Selective reporting (reporting bias)	Unclear risk	There is insufficient information to permit judgement.
Other bias	Low risk	The study appears to be free of other sources of bias.

Engstrom 2008 (C)

Methods	Cluster-randomised trial. 3 arm design in which health facilities were the unit of ran- domisation
Participants	391 children, both sexes (184 females (47%)), 6 months old. Study carried out through primary healthcare units in Rio de Janeiro, Brazil. 15 health care centres (6 intervention, 9 control). Inclusion criteria: absence of iron supplementation in the month preceding recruitment and negative for sickle cell anaemia Baseline prevalence of anaemia (taken from the control group): 60.4%. Socioeconomic status:approximately 30% of the mothers worked outside the home; most families (> 90%) had access to radio and television, but < 20% had access to a car
Interventions	Health facilities were allocated to one of the following groups: Group 1 (n = 188): children received weekly supplementation with 25 mg of elemental iron (as oral ferrous sulphate) per week in syrup and education on anaemia and diet; Group 2 (n = 188): children received daily supplements containing 12.5 mg elemental iron dailyand education on anaemia and diet; Group 3 (n = 94): children received received no intervention and was recruited retro- spectively Length of the intervention: 24 weeks. For the purposes of this review we only compared groups 1 and 2
Outcomes	Haemoglobin, anaemia (Hb <110 g/L) and adherence.
Notes	Analyses were performed taking into account cluster sampling Non-malaria area.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Healthcare units were randomly selected. Method of sequence generation not de- scribed
Allocation concealment (selection bias)	Low risk	Not reported. Since the intervention was allocated at health care unit level, it is un- likely there was a selection bias at the indi- vidual level
Blinding (performance bias and detection bias) All outcomes	High risk	Participants: Mothers were aware of sup- plements Personnel: Clinic staff were aware of sup- plements Outcome assessors: Unlikely Control group identified retrospectively so they were not aware of trial during treat- ment phase

Engstrom 2008 (C) (Continued)

Incomplete outcome data (attrition bias) All outcomes	High risk	38/188 (20.2%) were lost to follow up the daily group and 41/188 (21.8%) in the weekly group
Selective reporting (reporting bias)	Unclear risk	There is insufficient information to permit judgement.
Other bias	Unclear risk	Baseline characteristics were similar for most variables. Regression analysis was car- ried out to identify possible confounders and where possible confounders accounted for at least 10% of variation they were en- tered into the final model. However for anaemia no confounders were maintained in the final regression analysis

Ermis 2002

Methods	Randomised placebo-controlled trial. 4-arm design with individual randomisation
Participants	113 infants, both sexes (56 females (50%)), 5-month old, receiving routine paediatric care at the Research hospital of Karaelmas University in Zonguldak, Turkey. Inclusion criteria: no gestational problems (hypertension, preeclampsia, infection), no congenital anomalies, no neonatal complications, no emergency caesarian delivery, no jaundice requiring phototherapy, no hospitalisation, no chronic illness, no iron therapy, no formula feeding. Must have been exclusively breasted, birthweight > 3.0 kg and gestational age of > 37 weeks. Exclusion: Hb < 95 g/L, serum ferritin <12 ng/mL, MCV < 74 fl or infection during iron supplementation. Children were eliminated from the study if compliance was lower than 75%. 58.6%-74. Baseline prevalence of anaemia not reported. One percent of the mothers of participants included in the study graduated from high school or university
Interventions	Infants were allocated to one of the following groups: Group 1 (n = 30): infants were given a supplement containing 1 mg iron/kg (as ferrous sulphate) daily; Group 2 (n = 30): infants were given a supplement of 2 mg iron/kg (as ferrous sulphate) daily; Group 3 (n = 30): infants were given a supplement of 2 mg iron/kg (as ferrous sulphate)) every other day (approximately 42 mg of iron per week); Group 4 (n = 23): infants received a placebo. Length of the intervention: 4 months. Groups 1 and 2 were combined and compared with group 3.
Outcomes	Haemoglobin, MCV, ferritin, side effects.
Notes	Supplements were given by mothers just before or just after breastfeeding and at least one hour before or after any other food intake Malaria endemicity not reported.

Risk of bias

•		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Children were randomised to the different groups. Method of sequence generation not described
Allocation concealment (selection bias)	Unclear risk	Not reported.
Blinding (performance bias and detection bias) All outcomes	High risk	Participants: Not reported. Personnel: Not reported. Outcome assessors: Not reported.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Two, three and one cases were elimi- nated because of low compliance(<75%), in group 1, 2 and 3, respectively. The causes of non-compliance were infection during iron usage, refusing iron droplets due to unpleasant taste, or mothers forgetting to use the iron drops
Selective reporting (reporting bias)	Unclear risk	Cases with less than 75% of adherence were excluded.
Other bias	Unclear risk	Cases with less than 75% of adherence were excluded. It is unclear why the control group has 25% less participants

Evangelista-Salazar 2004

Methods	Randomised controlled trial. 4-arm design with individual randomisation
Participants	100 newborns, both sexes (50 females), living in Urban areas in Colima, Mexico. Incluson criteria: healthy, term, single-born babies during their first year of life. Exclusion criteria: low birth weight, unknown date of last menses to calculate term pregnancy, twins, bleeding disorder or other medical conditions that may be associated with anaemia (i.e. , malabsorption). Baseline prevalence of anaemia: unknown. Socioeconomic status not reported but children were born to parents that were receiving a salary
Interventions	Neonates were randomly allocated at one of the following groups: Group 1 (n = 25): infants were given weekly a supplement of 7.5 mg elemental iron (as ferrous sulphate), and 30 mg vitamin C; Group 2 (n = 25): infants were given fortnightly a supplement of 7.5 mg elemental iron (as ferrous sulphate), and 30 mg vitamin C; Group 3 (n = 25): infants were given monthly a supplement of 7.5 mg elemental iron (as ferrous sulphate) and 30 mg vitamin C;

Evangelista-Salazar 2004 (Continued)

	Group 4 (n = 25): received no intervention. Length of the intervention: 12 months. During the first 6 months children received 7.5 mg and after that the dose was double. We only included the first period of evaluation in our analysis For the purposes of this review we only compared groups 1 and 4
Outcomes	Anaemia, iron deficiency, haemoglobin, ferritin. Neurocognitive development (Brazelton score at birth, Bayley mental and motor assessment) and growth. The latter data were not extracted as no measures of dispersion are reported
Notes	Trained personnel visited families to assess illness incidence and adherence Ferritin data for the group receiving intermittent supplementation was 201.2 \pm 51.08 and 120.0 \pm 56.63 ng/mL (or μ g/L). Although the results are consistent in terms of direction, these concentrations are much higher than those observed in the rest of the trials included in this review. The corresponding author was contacted to verify this information and we decided not include this information while we await for the response Malaria-free area.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Children randomly allocated to the study groups. Method of sequence generation not described
Allocation concealment (selection bias)	Unclear risk	Not described.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Participants: unclear Personnel: unclear Outcome assessors: Not reported. Trial reported as single blind but the use of placebos is not described, so it is not clear who was not aware of the intervention
Incomplete outcome data (attrition bias) All outcomes	Low risk	Apparently there were no losses to follow- up.
Selective reporting (reporting bias)	Unclear risk	There is insufficient information to permit judgement.
Other bias	Low risk	The study appears to be free of other sources of bias.

Faqih 2006

Methods	Randomised clinical effectiveness trial. 3-arm design with randomisation at individual level
Participants	134 children, both sexes (38.1% female at follow up), aged 2 to 6 years (in average 43 months), attending Prince Hashim Military Hospital of the Royal Medical Services in Zarqa, Jordan. This clinic is open to children from families affiliated with the army who are not medically insured and have generally low income. Inclusion criteria: Iron deficiency anaemia at baseline (Hb \leq 105 g/L and mean corpuscular volume \leq 75), born at full term with birthweight equal or higher than 2.5 kg and exhibited normal growth with no signs of thalassaemia, chronic illness, congential abnormalities, or chronic and repeated infections. Baseline prevalence of anaemia not reported. Socioeconomic status not reported
Interventions	Children were allocated to one of the following groups: Group 1 (n = 45): children received a daily dose of 5 mg elemental iron per kilogram of body weight; Group 2 (n = 45): children received once a week 5 mg of elemental iron per kg of body weight on Fridays (approximately 45 mg of iron per week); Group 3 (n = 44): children received 5 mg of elemental iron per kilogram of body weight twice a week, Friday and Monday (approximately 90 mg of iron per week) Parents were instructed to give the ferrous sulphate supplement in 2 portions between 30 to 60 minutes before breakfast and dinner. Parents were advised to mix the supplement with water, orange juice or lemonade if the child refused the supplement Length of the intervention: three months. All the groups were analysed in this review. Groups 2 and 3 were combined and only reported separately for the subgroup analysis by regimen
Outcomes	Weight, height, haemoglobin, mean corpuscular value, hematocrit, ferritin
Notes	The dose was administered by either of the parents who were advised to mix the supple- ment with water, orange juice, or lemonade if the child refused to take the supplement on an empty stomach. Families also counselled on nutritional causes of IDA, consequences if not treated, iron rich foods, enhancers and inhibitors. Families also received home check up visits every two weeks In Jordan, malaria, hookworm, and schistosoma do not constitute a problem

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Participants were allocated randomly to one of three groups according to a table of random digits
Allocation concealment (selection bias)	Unclear risk	Not reported.
Blinding (performance bias and detection bias) All outcomes	High risk	Participants: Not reported Personnel: Not reported Outcome assessors: Not reported

Faqih 2006 (Continued)

Incomplete outcome data (attrition bias) All outcomes	High risk	71 of 134 children (53%) did not complete the study. Children lost because 1) refused to take the iron, 2) parents did not admin- ister iron for 3 months, 3) parents did not return to clinic for follow up visits. Final number of participants did not differ across groups
Selective reporting (reporting bias)	High risk	Only 34 children had ferritin values.
Other bias	High risk	Very large age range and small sample size for the outcomes, age is important for risk of anaemia and iron deficiency. Baseline haemoglobin higher in group 2 than in group 1

Hall 2002 (C)

Methods	Cluster-randomised trial. 2-arm design with randomisation at school level (60 schools, 30 per arm)
Participants	Children (1201 randomised, 1113 followed up), both sexes (613 female (51%)), aged 6-19 years (mean of 11.4 years), attending rural informal community schools in the Kolondieba district of Mali. Approximately 20 randomly children (10 boys and 10 females) attending 2nd or 4th grade were selected from each school. Any child with severe anaemia (Hb \leq 80 g/L) were excluded. Baseline prevalence of anaemia: approximately 55%. Socioeconomic status not reported
Interventions	Schools were allocated to one of the following groups: Group 1 (n = 551 at follow up, number randomised not clear): children received 65 mg elemental iron (as 200 mg of ferrous sulphate) and 250 μ g (0.25 mg) of folic acid once a week; Group 2 (n = 562 at follow up, number randomised not clear): No intervention Length of the intervention: 10 weeks
Outcomes	Anaemia, haemoglobin. Results by sex are included in the corresponding subgroup anal- ysis
Notes	All children in every school were treated for parasitic infections at baseline using alben- dazole, and vitamin A to treat night blindness. Supplements were given by the teachers and 83% of children were given all 10 tablets and 91% received at least nine tablets Malaria is endemic in Mali, although the study was done in the dry season when trans- mission is less intense than in the wet season Authors provided the ICC (0.0698) and design effect (2.22) to adjust data by the effect of clustering; the estimated effective sample size was used in the analyses.
Risk of bias	

Hall 2002 (C) (Continued)

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	60 schools were randomly assigned to ei- ther a treatment or a comparison group by using a computer-generated random num- ber list (information communicated by the author)
Allocation concealment (selection bias)	Low risk	Not reported. Since the intervention was allocated at health care unit level, it is un- likely there was a selection bias at the indi- vidual level
Blinding (performance bias and detection bias) All outcomes	High risk	Participants: Not reported Personnel: Not reported Outcome assessors: Not reported
Incomplete outcome data (attrition bias) All outcomes	Low risk	1201 children at baseline, 1113 followed up at 14-16 weeks. (93% followed up). 88 children who did not provide second sam- ples had similar Hb levels at baseline than as those children remaining in the study
Selective reporting (reporting bias)	Unclear risk	There is insufficient information to permit judgement.
Other bias	Low risk	The study appears to be free of other bias.

Khademloo 2009

Methods	Randomised controlled trial. 2-arm design with individual randomisation
Participants	100 Infants, both sexes (sex distribution not reported), aged 6-24 months referred to the public health care centre in Sari, Iran. Urban area. Inclusion and exclusion criteria were not adequately described. Baseline prevalence of anaemia not reported. Socioecomic status: although information on sex and mothers' educational level were collected this information was not reported
Interventions	Children were allocated to one of the following groups: Group 1 (n = 50): infants received fifteen drops containing elemental iron (as ferrous sulphate) given daily Group 2 (n = 50): infants received thirty drops of iron once a week Length of the intervention: 12 weeks
Outcomes	Ferritin, haemoglobin.

Khademloo 2009 (Continued)

Notes	Trial not included in the subgroup analysis by dose
	Malaria endemicity not reported.
	The total dose of iron per week is unknown.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Babies "randomly divided in two equal groups". Method of sequence generation not described
Allocation concealment (selection bias)	Unclear risk	Not reported.
Blinding (performance bias and detection bias) All outcomes	High risk	Participants: Not reported Personnel: Not reported Outcome assessors: Not reported.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Not described. Denominators not pro- vided in the results tables
Selective reporting (reporting bias)	Unclear risk	Groups were described as similar at base- line, but information on methods and re- sults was scarce
Other bias	Low risk	The study appears to be free of other sources of bias.

Liu 1995 (C)

Methods	Randomised clinical trial. 3 arm design with randomisation at classroom level
Participants	246 healthy children, both sexes (131 females (57%)), aged 3 to 6 years, attending Kindergarten in Changxi, China, an autonomous region of China. Kindergarten has 9 large classrooms and two meals and two snacks are provided daily. Exclusion criteria were chronic infectious diseases, cardiopathies, or respiratory diseases, and intake during the previous month of supplements or drugs containing iron or specially prescribed iron-rich and absorption-promoting foods for the month prior to entering the study. Approximately 29 % of the children were anaemic at baseline. Socioeconomic status not reported
Interventions	Classrooms were allocated to one of the following groups: Group 1 (n = 89): children received 5-6 mg of elemental iron per kilogram (as ferrous sulphate) daily; Group 2 (n = 74): children received 5-6 mg of elemental iron per kilogram (as ferrous sulphate) twice a week (approximately 170 -204 mg of iron per week); Group 3 (n=83): children received 5-6 mg of elemental iron per kilogram (as ferrous sulphate) tablet once a week (approximately 75 -120 mg of iron per week);

Liu 1995 (C) (Continued)

	Iron tablets were administered by teachers under direct supervision 1 hour after breakfast, making sure that the child swallowed it Length of the intervention: 3 months Group 2 and 3 were combined and compared with group 1; their individual results are presented in the subgroup analyses by regimen and by anaemia status
Outcomes	Haemoglobin and ferritin.
Notes	We adjusted the results of this study to account for the effect of clustering in data; the estimated effective sample size was used in the analyses. Malaria endemicity not reported.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Children were randomly allocated to the classroom according to their age and then classrooms were randomised to each of the three intervention groups. Method of se- quence generation not described
Allocation concealment (selection bias)	Low risk	Not reported. Since randomisation oc- curred at classroom level, it is unlikely a se- lection bias at individual level
Blinding (performance bias and detection bias) All outcomes	High risk	Participants: Not reported Personnel: Not reported Outcome assessors: Results were tabulated, without knowledge of the children's supple- mentation regimen, by two nurses in charge of the clinic at the kindergarten with the assistance of a nonparticipating physician
Incomplete outcome data (attrition bias) All outcomes	Low risk	238 children completed the study. 5 left the kindergarten during the study and 3 chil- dren from daily group discontinued sup- plementation due to persistent nausea
Selective reporting (reporting bias)	Unclear risk	There is insufficient information to permit judgement.
Other bias	High risk	Data not adjusted by the effect of clustering in data

Nguyen 2002

Methods	Randomised trial. 4 arm design with individual randomisation	
Participants	280 children, both sexes (133 females (47.5%), aged 5 to 12 months, living in one of four communes in the rural district of Bac Ninh, Vietnam. Inclusion criteria: Hb< 70 g/L, no pathologies after a clinical examination and not receiving any iron supplements. Baseline prevalence of anaemia: ~60%.Socioeconomic status: ~95% dedicated to agriculture	
Interventions	Two communes were allocated to one of the following groups: Group 1 (n = 70): children received a placebo (2.5 ml of syrup without iron) every day; Group 2 (n = 70): children received a daily dose of 15 mg elemental iron (2.0 \pm 0.3 mg iron/day/kg body weight) (as ferrous sulphate) Participants from other two communes were randomly allocated to one of the following groups: Group 3 (n = 70): children received a daily dose of 15 mg elemental iron (2.0 \pm 0.3 mg iron/day/kg body weight) (as ferrous sulphate); Group 4 (n = 70): children received a weekly dose of 15 mg elemental iron (as ferrous sulphate) Length of the intervention: 3 months (groups 1 and 2) and 6 months (groups 3 and 4) For the purposes of this review only groups 3 and 4 were compared	
Outcomes	Haemoglobin, anthropometric measurements (height for age, weight, age and weight for height were Z-scores)	
Notes	Article translated from French. The supplements were administered between 8 and 10 am by local auxiliaries, under regular supervision of a member of the research team. 98% and 95% of the infants in group 3 and 4, respectively, received more than 90% of the expected total dose of iron Malaria endemicity not reported.	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Only children from groups 3 and 4 were randomly allocated to either daily or weekly supplementation. Method of se- quence generation not described
Allocation concealment (selection bias)	Low risk	Not described, but the trial included the provision of a placebo and multiple blind- ing
Blinding (performance bias and detection bias) All outcomes	Low risk	Participants: the nature of the treatment was unknown to the family of the infant; all the infants received identical looking syrups (with or without iron) Personnel: community auxiliaries were not aware of the treatments Outcome assessors: Neither the people in

Nguyen 2002 (Continued)

		charge of measurements researcher nor the data analysts were aware of the treatments
Incomplete outcome data (attrition bias) All outcomes	Low risk	10 children did not complete the study, 4 because parents refused to continue, 3 due to address change and 4 because of low compliance (consumed less than 80% of the doses)
Selective reporting (reporting bias)	High risk	Results on growth not reported.
Other bias	Low risk	The study appears to be free of other sources of bias.
Olsen 2000		
Methods	Randomised, placebo-controlled, double-blind study. 2-arm design with individual ran- domisation	
Participants	231 children, both sexes (99 females (43%)), aged 4-15 years (8.6 years in average), liv- ing in Luo villages of Asino, Ohala, and Pith-Kodhiambo in Kisumu district of Nyanza Province in western Kenya, Participants had moderately low blood heemoglobin con-	

Farticipants	251 children, both sexes (99 females (45%)), aged 4-15 years (6.6 years in average), in- ing in Luo villages of Asino, Ohala, and Pith-Kodhiambo in Kisumu district of Nyanza Province in western Kenya. Participants had moderately low blood haemoglobin con- centrations (80-130 g/L for children 4-14 years of age or non-pregnant female >14 years of age and 80-135 g/Lif male and >14 years of age). Exclusion criteria: severe anaemia (Hb <80 g/L) or pregnant. Baseline prevalence of anaemia: 47.5%. Socioeconomic status not reported
Interventions	Participants were allocated to one of the following groups: Group 1 ($n = 121$): children received treatment twice weekly with a 60 mg of elemental iron (total of 120 mg of iron per week, as 200 mg of ferrous dextran); Group 2 ($n = 110$): children received a placebo. Length of the intervention: 12 months.
Outcomes	Haemoglobin, serum ferritin (median and interquartile range, could not be extracted), reinfection rates and intensities of hookworm, Ascaris lumbricoides, Trichuris trichiura, and Schistosoma mansoni, compliance ("reasonable")
Notes	At baseline, any individual infected with any intestinal helminth. S. mansoni, and malaria were treated (only abstract says treated with malaria) After baseline examination, each subject was given a container (labelled with the subject's name, study number and identification sticker) containing 50 tablets. At the end of each 4-month period, the number of tablets taken was registered, based on the number of remaining tablets. In order to encourage intake, field assistants visited every participant at least once a month. Tablet intake for the whole study period was 98.9% of the scheduled value, and 90.1% of the children each appeared to take between 80% and 120% of the scheduled number of tablets Iron supplementation had no effect on either reinfection rates or intensities in children. Multiple

Olsen 2000 (Continued)

logistic regression analyses controlling for baseline infection status confirmed the effect in adults of Malaria endemic area.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Simple randomisation using a programme written in advance.
Allocation concealment (selection bias)	Low risk	The tablets were coded by the manufac- turer and sealed envelopes containing the codes were kept closed until the end of the study
Blinding (performance bias and detection bias) All outcomes	Low risk	Participants: received identical pills and in- structions Personnel: envelopes revealing randomiza- tions code not opened until analysis was complete Outcome assessors: envelopes revealing randomizations code not opened until analysis was complete
Incomplete outcome data (attrition bias) All outcomes	Low risk	Of 231 randomised, one became pregnant and 30 lost to follow up. Lost equally dis- tributed across both arms
Selective reporting (reporting bias)	Unclear risk	There is insufficient information to permit judgement.
Other bias	Unclear risk	Baseline intensity of A. Lumbricoides in- fection was higher in the placebo group than in the iron group. HIV not assessed at baseline, but at 4 months, and assumed to reflect baseline status; it is unclear what treatment was available for participants

Palupi 1997

Methods	Double-masked, randomised controlled field trial. 3-arm design with individual ran- domisation
Participants	299 children, both sexes (sex distribution not reported), aged 2-5 years, who were reg- istered at the West Javanese village of Setia Asih. Of 344 potential subjects, parental permission was obtained for 299 children. No further inclusion or exclusion criteria mentioned. Baseline prevalence of anaemia: 36.7%. Socioeconomic status not reported

Palupi 1997 (Continued)

Interventions	Participants were allocated to one of the following groups: Group 1 (n = 98): children received 30 mg elemental iron (as ferrous sulphate) once per week and anthelminthic treatment; Group 2 (n = 96): children received 30 mg elemental iron (as ferrous sulphate) once per week and placebo for anthelminthic treatment; Group 3 (n = 98): children received placebos for both iron supplements and anti- helminthic treatment. The placebo syrup did not contain ferrous sulphate, but was sim- ilar in taste and appearance to the iron-containing syrup Length of the intervention: 9 weeks For the purpose of this review only groups 2 and 3 were compared
Outcomes	Haemoglobin, haemoglobin mean change, anaemia, anthropometric measurements (Height-for-age Z-score, Weight-for-age Z-score, Weight-for-height Z-score change), helminthic infection
Notes	The anthelminthic tablets as well as the placebos were ingested under supervision of the researcher one week before iron supplementation started. The supplements were given to the children by their mothers and intake was not supervised by health centre staff or the researchers, but compliance was controlled by checking the iron content in the stool Z-scores used the National Center for Health Statistics data as a reference Malaria endemicity not reported.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Children were randomly divided into three, equal-sized treatment groups. Method of sequence generation not described
Allocation concealment (selection bias)	Low risk	Mothers received a bottle with 100 mL glu- cose syrup. Although the concealment is not clearly described, this is a double-blind trial and its unlikely that there was a selec- tion bias
Blinding (performance bias and detection bias) All outcomes	Low risk	Reported as double-masked trial. Participants: were not aware of the treat- ment Personnel: all mothers received a bottle with 100 mL glucose syrup containing or not iron Outcome assessors: unclear but probably blinded.
Incomplete outcome data (attrition bias) All outcomes	Low risk	289 (out of 299) children remained; 10(3%) dropped out because they had either moved or had become ill

Palupi 1997 (Continued)

Selective reporting (reporting bias)	Unclear risk	There is insufficient information to permit judgement.	
Other bias	Low risk	The study appears to be free of other sources of bias.	
Roschnik 2003 (C)			
Methods	Cluster-randomised trial. 2-arm desig by sponsorship status	Cluster-randomised trial. 2-arm design with randomisation at school level and stratified by sponsorship status	
Participants	and 12-14 y. The study included 40 p	1,160 children (752 followed up), both sexes (371 females (49.5%)), aged 7-8 years and 12-14 y. The study included 40 primary schools in the Mangochi District, Malawi. Baseline prevalence of anaemia: around 54%. Socioeconomic status not reported	
Interventions	Schools were randomly allocated to one of the following treatments: Group 1 (20 schools, n = 640): children received 65 mg of elemental iron (as 200 mg ferrous sulphate) and 250 μ g (0.25 mg) of folic acid once a week Group 2 (20 schools, n = 640): children received no intervention Length of the intervention: 15 weeks		
Outcomes	Haemoglobin concentration, bilharzia infection, school attendance, test scores and drop-out rate and repetition rate (at the school level).		
Notes	Results were stratified by age (<10 y, 10-14 y and 15+). For the purposes of this review we only included those data from children <10 years of age (192 in the intervention group and 190 in the control group), until we can obtain the data for all children <12 years A famine occurred in the region at the time of the study. Each study group included 10 sponsorship schools and 10 non-sponsorship schools, 10 coastal and 10 upland schools. All children in Coastal intervention and comparison schools, where the prevalence of bilharzia was over 50%, were dewormed with Prazi- quantel (600mg) just after the baseline survey A vitamin A capsule (200,000 IU) was given to all children in standard 2 and below 63% of children took 10 iron tablets or more. Analysis originally not adjusted by the effect of clustering. The effective sample was calculated by imputing the ICC from Roschnik 2004 (C), which has a similar study design; the estimated effective sample size was used in the analyses. Malaria endemicity not reported.		

Risk of bia	Rist	e of	bia
-------------	------	------	-----

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	40 primary schools in the Mangochi District were randomly divided into the intervention $(1^{st}$ iron group) and compari-

Roschnik 2003 (C) (Continued)

		son group (2 nd iron group). Each group in- cludes 10 sponsorship schools and 10 non- sponsorship schools. Method of sequence generation not specified
Allocation concealment (selection bias)	Low risk	Not reported. Since the intervention was allocated at school level, it is unlikely there was a selection bias at the individual level
Blinding (performance bias and detection bias) All outcomes	High risk	Participants: not reported. Personnel: not reported Outcome assessors: not reported.
Incomplete outcome data (attrition bias) All outcomes	High risk	1280 were randomised, 1160 had haemo- globin levels at baseline and 752 were fol- lowed up: 41.2% children lost to follow up
Selective reporting (reporting bias)	Unclear risk	There is insufficient information to permit judgement.
Other bias	Unclear risk	Children attending sponsored schools re- sponded better to the treatment

Roschnik 2004 (C)

Methods	Cluster-randomised trial. 2-arm design with randomisation at school level
Participants	1785 children (1510 followed up), both sexes (747 females (49.5%), aged 7-12 years. The study included 51 primary schools: 20 in Iloilo and 31 in Guimaras, Philippines. Baseline prevalence of anaemia: ~15%. Socioeconomic status not reported
Interventions	Schools were randomly allocated to one of the following treatments: Group 1 (25 schools, unclear the number of children randomised): children received 108 mg of elemental iron (as 325 mg ferrous sulphate); Group 2 (26 schools, unclear the number of children randomised): children received no intervention Length of the intervention: 10 weeks
Outcomes	Anaemia, haemoglobin, haemoglobin change.
Notes	Supplementation started between 1 and 7 weeks after the baseline survey and the second survey took place between 5 and 18 weeks after the end of the iron supplementation The consumption of each tablet was recorded by the teachers. Side effects were not recorded. All 10 iron tablets were taken by 93.4% of children 67% of children were infected with one or more intestinal worms Malaria endemicity not reported. Authors provided the ICC (0.1123) and design effect (4.35) to adjust data by the effect of clustering; the estimated effective sample size was used in the analyses.

Roschnik 2004 (C) (Continued)

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	All 51 schools were assigned to two groups using a random number table
Allocation concealment (selection bias)	Low risk	Not reported. Since the intervention was allocated at school level, it is unlikely there was a selection bias at the individual level
Blinding (performance bias and detection bias) All outcomes	High risk	Participants: not reported. Personnel: not reported Outcome assessors: not reported.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	15.4% of attrition. Losses presumably higher among the control group as two schools were dropped out because they were unable to collect the baseline measure- ments within the month allotted
Selective reporting (reporting bias)	Unclear risk	There is insufficient information to permit judgement.
Other bias	High risk	The second blood sample was withdrawn between 5 and 18 weeks after the end of the iron supplementation Fourteen of the 49 schools in the study had participated for about 2 months in the for- tified rice programme: six in the interven- tion group and eight in the control group. The mean haemoglobin concentration of children in the 14 schools that had partic- ipated in the programme was slightly but significantly higher than that of children in the other 25 schools (126.4 g/L versus 125. 0 g/L, P ¼ 0.031) Analysis was not adjusted by the effect of clustering in data

Schultink 1995

Methods	Randomised clinical trial. 2-arm design with individual randomisation
Participants	87 children, both sexes, aged 2-5 years, from Subdistrict Kelurahan Tenga of East Jakarta, Indonesia. The initial selection criterion was a haemoglobin concentration < 110 g/L. 96 children were invited to receive anthelmintic treatment before starting iron supple- mentation; only 87 accepted and were randomised

Schultink 1995 (Continued)

Interventions	Participants were allocated to one of the following groups: Group 1 ($n = 44$): children were supplemented daily with 30 mg elemental iron (as ferrous sulphate dissolved in 5 mL syrup); Group 2 ($n = 43$): children were supplemented twice a week with 30 mg elemental iron (as ferrous sulphate dissolved in 5 mL syrup) (total 60 mg of iron per week) Length of the intervention: 8 weeks.
Outcomes	Haemoglobin, ferritin, zinc protoporphyrin, mean changes of haematological variables (anaemia prevalence taken from Beaton 1999).
Notes	Parents and supervising health staff were instructed that each child should take 5 mL from the small bottle on Mondays and Fridays and 5 mL from the large bottle on the remaining days of the week using a standardized spoon for 8 wk. Bottles had similar appearance Malaria endemicity not reported.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Subjects were assigned at random to two groups. Method of sequence generation not described
Allocation concealment (selection bias)	Unclear risk	Not reported.
Blinding (performance bias and detection bias) All outcomes	Low risk	Participants: were not aware of the treat- ment Personnel: all mothers received two small bottles (each 80 mL) and two large bottles (each 170 mL), each containing a syrup of similar appearance Outcome assessors: supervising staff were not aware of the bottle content
Incomplete outcome data (attrition bias) All outcomes	High risk	A complete set of data was obtained for 33 subjects in the group supplemented twice weekly (group 1) (75%) and for 32 subjects in the group supplemented daily (group 2) (74.4%)
Selective reporting (reporting bias)	Unclear risk	There is insufficient information to permit judgement.
Other bias	High risk	Baseline haemoglobin concentrations were different between groups. The results include 25 children with Hb> 110 g/L and the initial description only

Schultink 1995 (Continued)

	mentions 16
Sen 2009 (C)	
Methods	Cluster-randomised controlled trial. 4-arm design with randomisation at school level
Participants	240 school age females, aged 9-13 years, attending four schools in Vadodara area of India. Females were excluded from the analysis if menstruation commenced. None of the Females were involved in athletic sports on a regular basis. Baseline prevalence of anaemia: 68.3%. Socioeconomic status not described in detail but participants were described as "underprivileged"
Interventions	Schools were allocated to one of the following groups: Group 1 (n = 65): females received 100 mg elemental iron (as ferrous gluconate) and 500 μ g (0.5 mg) folic acid folic acid oral once weekly; Group 2 (n = 89): females received the same supplement twice weekly (200 mg of elemental iron per week); Group 3 (n = 59): females received 100 mg elemental iron (as ferrous gluconate) daily; Group 4 (n = 41): females received no supplement. Length of the intervention: 1 year. Groups 1 and 2 were combined and compared with groups 3 and 4 as appropriate
Outcomes	Physical work capacity, haemoglobin change and adherence.
Notes	Malaria endemicity not reported. Analyses in this review include the estimated effective sample size only, after adjusting the data to account for the clustering effect

. 10

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Of 17 schools meeting the inclusion crite- ria, 4 schools were selected randomly us- ing a random numbers table. Once the four schools were selected, the chit system (chits representing school 1, 2, 3, 4) was used. The order of placing a school in a category was: the first school that is picked up (from the four) goes to daily; the chit is then put back; the next chit picked up goes to twice weekly; the next to once weekly and the one left over, to control so that all schools have an equal probability of being allocated to any of the four groups (information com- municated by the author)

Sen 2009 (C) (Continued)

Allocation concealment (selection bias)	Low risk	Not reported. Since allocation was at school level it is unlikely that there is selection bias at individual level
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Participants, personnel and outcome asses- sors: Each school received a different inter- vention, although it is unclear if the inter- vention was blinded
Incomplete outcome data (attrition bias) All outcomes	High risk	4 schools. In these schools a random sample of 240 children was selected. 163 had pre and postintervention data for work capac- ity (68% followed up). Females who started their periods were excluded from the anal- ysis. For cognitive tests results relate to a sub-sample of 161 females available pre and post-test
Selective reporting (reporting bias)	Unclear risk	There is insufficient information to permit judgement.
Other bias	High risk	The design effect was not taken into ac- count in the analysis

Siddiqui 2004

Methods	Randomised controlled trial with. 2-arm design with individual randomisation
Participants	60 children, both sexes (30 females (50%)), aged 5-10 years, attending a private school, blue collar workers, in Karachi Pakistan. Inclusion: anaemia (haemoglobin <110 g/L) . Exclusion criteria: acute disease (diarrhoea, fever, cough, running nose) or history of chronic disease (joint pain, bleeding disorders). Socioeconomic status not described
Interventions	Participants were allocated to one of the following groups: Group 1 (n = 30): Children took supplements containing 60 mg of elemental iron (as 200 mg ferrous sulphate) once a week for 2 months (8 doses total); Group 2 (n = 30): Children took 60 mg of elemental iron supplements (as 200 mg ferrous sulphate) daily for 56 days Length of the intervention: ~ 2 months (weekly dosing was 8 weeks but daily dosing only 56 days)
Outcomes	Haemoglobin, hematocrit, serum iron, total iron binding capacity, serum ferritin
Notes	Both groups de-wormed prior to start of study (mebendazole). Malaria endemicity not reported.
Risk of bias	

Siddiqui 2004 (Continued)

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Children were randomly assigned to one of the groups. Method of sequence generation not described
Allocation concealment (selection bias)	Unclear risk	Not reported.
Blinding (performance bias and detection bias) All outcomes	High risk	Participants: not reported. Personnel: not reported. Outcome assessors: not reported.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No losses.
Selective reporting (reporting bias)	Unclear risk	There is insufficient information to permit judgement.
Other bias	Unclear risk	Unclear whether 60 participants reflected all anaemic children in the school or whether (and if so how) the 30 males and 30 females were selected out of all eligible students in the school. Age in weekly group significantly different than those in daily group. Did not assess or adjust/exclude iron status indicators for inflammation

Sinisterra 1997 (C)

Methods	Cluster-randomised trial. 2-arm design with randomisation at school level (5 schools)
Participants	Children (909 randomised, 842 followed up), both sexes (408 female (48%)), aged 6- 13 years, attending rural schools in the district of Anton, Cocle, Panama. Exclusion criterion: severe anaemia (Hb \leq 90 g/L) and clinical conditions that could affect iron status. Baseline prevalence of anaemia: approximately 42.4%. Socioeconomic status not explicitly reported
Interventions	Schools received one of the following interventions: Group 1 (n = 176 at follow up, number randomised not clear): children received daily 60 mg of elemental iron (as ferrous sulphate) and "nutricrema"; Group 2 (n = 210 at follow up, number randomised not clear): "nutricrema" Group 3 (n = 225 at follow up, number randomised not clear): children received daily 60 mg of elemental iron (as ferrous sulphate) and "nutricrema" once a week; Group 4 (composed by two schools n=195 at follow up, number randomised not clear) : Milk plus a fortified cookie plus folic acid Length of the intervention: 6 months Only groups 1 and 3 were randomised and thus included in our analysis

Sinisterra 1997 (C) (Continued)

Outcomes	Anaemia (Hg < 120 g/L), haemoglobin, attitudes, beliefs, growth
Notes	Malaria endemicity not reported. We adjusted the results of this study to account for the effect of clustering in data; the estimated effective sample size was used in the analyses.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Groups allocated by drawing of lots (com- municated by the author)
Allocation concealment (selection bias)	Low risk	Not described. Since the intervention was allocated at school level, it is unlikely there was a selection bias at the individual level
Blinding (performance bias and detection bias) All outcomes	High risk	Participants: Not reported Personnel: Not reported Outcom assessors: Not reported
Incomplete outcome data (attrition bias) All outcomes	Low risk	7.3% of losses to follow up. Unclear whether they were balanced across groups
Selective reporting (reporting bias)	Unclear risk	There is insufficient information to permit judgement.
Other bias	High risk	The prevalence of anaemia among those receiving weekly supplementation was 20 percentage points higher than those receiv- ing daily supplementation (54.7% vs 34. 7%)

Soemantri 1997

Methods	Randomised controlled trial. 2-arm design with individual randomisation
Participants	97 children, both sexes (sex distribution not reported), aged 7-11 years, attending the primary school Batang, in Indonesia. Inclusion criteria: anaemia (Hb below 120 g/L); not taking iron supplements during the last six months; no evidence of hepatosplenomegaly, haemoglobinopathy, acute or chronic disease, severe anaemia. Baseline prevalence of anaemia: 67.36%. Socioeconomic status not reported
Interventions	Children were divided into 2 groups and randomly assigned Group 1 (n = 52): children received daily 3 mg of iron per kilogram (as ferrous sulphate) ; Group 2 (n = 45): children received once a week 3 mg of elemental iron per kilogram

Soemantri 1997 (Continued)

	(as ferrous sulphate) (approximately 85 mg of iron per week) Length of the intervention: 3 months.
Outcomes	Anthropometric measurements (weight for age Z-score, height for age Z-score) and haemoglobin
Notes	The solutions were given by the school teachers on school days with careful supervision All children with intestinal parasites were treated prior to supplementation Z-scores used the National Center for Health Statistics data as a reference Malaria endemicity not reported.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Children were randomly assigned to the study groups. Method of sequence genera- tion not described
Allocation concealment (selection bias)	Unclear risk	Not described.
Blinding (performance bias and detection bias) All outcomes	High risk	Participants: not reported. Personnel: not reported. Outcome assessors: not reported.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Two children (3.8%) were excluded from the daily group because of gastrointestinal side effects
Selective reporting (reporting bias)	Unclear risk	There is insufficient information to permit judgement.
Other bias	Low risk	The study appears to be free of other sources of bias.

Sungthong 2002

Methods	Double-blind, randomised, placebo-controlled trial. 3-arm design with individual ran- domisation
Participants	Of 50 government schools located outside the municipality, selected schools had to met the following criteria: 1) high prevalence of underweight according to school-records (no # or prevalence given to define "high"); 2) a least 150 students in school; 3) not >1 h away by car from research centre; 4) teachers willing to cooperate in study; 5) no previous iron supplementation programme implemented. Subsequently 2 schools selected 397 school age children in grades 1-6 (9.7 years of age in average), both sexes (212 females (53%)) only those with written parental consent included. Excluded those with severe Iron deficiency anaemia (Hb equal or lower than 80 g/L and serum ferritin equal

Sungthong 2002 (Continued)

	or lower than 20 μ g/L) severe malnutrition weight-for-height <3rd percentile of Thai reference, chronic illness such as thalassaemia, haemolytic disease and physical handicaps. Participants assigned to group stratified by anaemia status. Baseline prevalence of anaemia:~ 35%. This study took place in a socioeconomically disadvantaged community
Interventions	Participants were allocated to one of the following groups: Group1 (n = 134): each child received 2 bottles with tablets, the first was to be taken on Monday only while the second was to be taken for the remaining days of the week (60 mg of elemental iron (as ferrous sulphate) weekly; Group 2 (n = 140): each child received 2 bottles with tablets, the first was to be taken on Monday only while the second was to be taken for the remaining days of the week. Both bottles had 60 mg of elemental iron (as ferrous sulphate) daily); Group 3 (n = 123): Same procedure as groups 1 and 2 but children received placebo. The tablets were similar in colour, shape, size, and taste as the iron tablets Length of the intervention: 16 weeks
Outcomes	Haemoglobin, serum ferritin, mean changes of both, height, weight
Notes	This area is free from malaria

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Children were stratified by anaemic status to balance the proportion of anaemic and non anaemic children across the interven- tion groups. The children were then as- signed by simple random allocation within each stratum using a computer random number generator
Allocation concealment (selection bias)	Low risk	Tablets placed in packages labelled only with participants' name, content not known to any of the project personnel. 2 supplement packages similar in appear- ance: On Mondays received one packages which contained iron for daily and weekly group, but placebo for control group. Rest of week consumed tablets from other pack- age, which were iron for daily group and placebos for weekly and placebo control group
Blinding (performance bias and detection bias) All outcomes	Low risk	Participants: neither parents nor partic- ipants knew the content of supplement packages Personnel: researchers did not know the content of supplement packages

Sungthong 2002 (Continued)

		Outcome assessors: not reported but prob- ably blinded.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Only 6 of 397 enrolled lost to follow-up.
Selective reporting (reporting bias)	Unclear risk	There is insufficient information to permit judgement.
Other bias	Unclear risk	Baseline prevalence of anaemia was differ- ent among study arms (39, 40 & 28%, for daily, weekly and placebo, respectively), but haemoglobin concentrations were not sta- tistically different

Tavil 2003

Methods	Randomised clinical trial. 2-arm design wit	h randomisation at individual level
Participants	females (37.2%)), attending Dr Sami Ulus December 1999 to December 2000. Inclusi as haemoglobin (Hb) levels below 100 g/L, ferritin levels below 12 ng/mL) and negat	an age was 18 months of age), both sexes (35 Children's Hospital in Ankara, Turkey, from on criteria: iron deficiency anaemia (defined transferrin saturation levels below 12%, and ive supplement intake during the past 3-4 c, and genetic diseases. Socioeconomic status
Interventions	Participants were randomly allocated to one of the following groups: Group 1 (n = 48): children received daily 6 mg/kg of elemental iron as ferrous sulphate; Group 2 (n = 46): children received 6 mg/kg of elemental iron as ferrous sulphate 2 days a week (Tuesday and Friday) (120 mg of iron per week). Twenty-three healthy children whose age and gender distribution were compatible with the other groups were included in the study as the control group. This group was not included in the analyses Length of the intervention: 2 months	
Outcomes	Haemoglobin, hematocrit; red blood cell count, mean corpuscular volume, mean cor- puscular haemoglobin, mean corpuscular haemoglobin concentration, iron deficiency anaemia, serum iron, serum iron binding capacity, transferrin saturation, transferrin	
Notes	Malaria endemicity not reported.	
Risk of bias		
Bias	Authors' judgement	Support for judgement

Tavil 2003 (Continued)

Random sequence generation (selection bias)	Unclear risk	Participants were randomly divided into two groups. Method of sequence genera- tion not described
Allocation concealment (selection bias)	Unclear risk	Not described.
Blinding (performance bias and detection bias) All outcomes	High risk	Participants: not reported. Personnel: not reported. Outcome assessors: not reported.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	It is unclear the final number of participants per group. The report mentions that 'thirty three patients who had not been regularly conforming to the iron deficiency treat- ment as recommended or who were intoler- ant to the medication due to the side effects were excluded from the study. The patients presenting no increase in the Hb levels de- spite the iron treatment were reevaluated at the end of the first month, and those who were detected as thalassaemia traits were also excluded.' The tables do not present the final numbers
Selective reporting (reporting bias)	Unclear risk	There is insufficient information to permit judgement.
Other bias	Unclear risk	It is unclear the failure rate of the interven- tion and whether the results are biased be- cause of the exclusions
Taylor 2001		
Methods	Double-blind randomised controlled trial. Factorial design (6 arms) with individual randomisation	
Participants	425 children, both sexes (50% females), aged 6 -15 years (mean age 11.2 years), attending three rural primary schools in Kwa-Zulu Natal, South Africa. The sample was stratified by school, age and sex. Four children with anaemia were included in the study (Hb < 80 g/L) - all of these children were allocated to receive iron. Females over 12 years of age were excluded as the safety of albendazole in pregnancy has not been established. Socioeconomic status not reported although it was stated that the study was carried out in the third poorest province in South Africa. Anaemia at baseline was 35%	
Interventions	Children were allocated to 1 of the following groups: Group 1 (n = 56): children received 400 mg of albendazole weekly, 40 mg/kg of prazi- quantel weekly, and 65 mg of elemental iron (as 200 mg ferrous fumarate) plus 100 μ g (0.1 mg) of folic acid weekly;	

Taylor 2001 (Continued)

	Group 2 (n = 60): children received 400 mg of albendazole weekly, 40 mg/kg of prazi- quantel weekly, and placebo for iron and folic acid weekly; Group 3 (n = 60): children received 400 mg of albendazole for three days, 40 mg/kg of praziquantel weekly, and 65 mg of elemental iron (as 200 mg ferrous fumarate) plus 100 μ g (0.1 mg) of folic acid weekly; Group 4 (n = 57): children received 400 mg of albendazole for three days, 40 mg/kg of praziquantel weekly, and placebo for iron and folic acid weekly; Group 5 (n = 101): children received placebo for albendazole, placebo for praziquantel and 65 mg of elemental iron (as 200 mg ferrous fumarate) plus 100 μ g (0.1 mg) of folic acid weekly; Group 6 (n = 91): children received only placebos. For the purposes of this review only groups 5 and 6 were analysed Length of the intervention: 10 weeks, children were followed up for a year with measures at baseline, 6 months and 12 months
Outcomes	Height, weight, full blood count, anaemia (could not be extracted), presence of malarial parasites, presence of hookworm infection, urine infection or presence of blood in urine
Notes	All groups received interventions under supervision by teachers It was reported that the area is endemic for malaria, schistosomiasis and hookworm

וית	_ r	
Risk	nt	hine
ILISK	<i>U</i>	ouis

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised controlled trial, with individ- ual randomisation. 6-arm trial (factorial de- sign). Sample stratified by school, age and sex. Method of sequence generation not de- scribed
Allocation concealment (selection bias)	Low risk	Each pupil's treatment was individually packaged at each phase of the study. Both the field team and pupils were blinded as to the type of drugs used
Blinding (performance bias and detection bias) All outcomes	Low risk	Participants: all pupils were blinded to the type of supplement used Personnel: field team were blinded to the type of supplement used Outcome assessors: not reported.
Incomplete outcome data (attrition bias) All outcomes	High risk	428 children entered the study. 4 children who were anaemic at baseline were all allo- cated to receive iron treatment. It was stated that intention to treat analysis was not car- ried out as data was missing for children who were absent from school on the day specimens were collected. It was stated that

Taylor 2001 (Continued)

		the sample sizes varied at each phase of the study. There was considerable variation in the size of treatment groups - it was not clear why. The numbers available at each assessment point and missing data were not stated. The number with data on Hb at both 6 and 12 months follow up was 275 (64% of the original sample)
Selective reporting (reporting bias)	Unclear risk	There is insufficient information to permit judgement.
Other bias	High risk	It was stated that groups were similar at baseline for prevalence of anaemia and other variables. Although the figure sug- gests there was considerable variation in mean Hb levels at baseline - although the differences between groups were not signif- icant. Children with anaemia all received iron. The lack on information on attrition and missing data mean that results are dif- ficult to interpret

Thu 1999

Methods	Double-blind, placebo-controlled trial. 2-arm design with randomisation at individual level
Participants	68 children, both sexes (88 females (54%)) 6-24 months of age, living in the Chi Lang Bac commune, Thanh Mien district, Hai Duong province in Vietnam. Exclusion criteria: infectious disease at the time of enrolment and a birth weight < 2.5 kg according to the birth record. Baseline prevalence of anaemia: ~50%. Socioeconomic status not reported
Interventions	Participants were allocated to one of the following groups: Group 1 ($n = 55$): children received daily 8 mg elemental iron (as ferrous sulphate), 5 mg elemental zinc(as zinc sulphate), 333 mg retinol, and 20 mg vitamin C 5 d/wk for 3 mo; Group 2 ($n = 54$): children received 20 mg elemental iron (as ferrous sulphate), 17 mg zinc, 1700 mg retinol, and 20 mg vitamin C once a week (Thursdays); the rest of the week were given a placebo; Group 3 ($n = 54$): children received a placebo Monday to Friday that was similar in colour and appearance to the supplement Length of the intervention: 12 weeks.
Outcomes	Haemoglobin, serum retinol, zinc. weight and length (score z, measured 3 mo after the intervention ceased)

Thu 1999 (Continued)

Notes	The syrup was put into the children's mouth by syringe by a research staff member who visited the children daily between 0700 and 1000 Before the start of the study, the acceptability of the syrup was tested in 12 children. Mothers of these children reported good acceptance and no side effects. Acceptability
	throughout the study remained good, and the children took all of the supplements as intended
	Z-scores used the National Center for Health Statistics data as a reference Malaria endemicity not reported.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Children were randomly divided into 3 groups by using a table with randomly assorted digits
Allocation concealment (selection bias)	Low risk	Blind supplementation was guaranteed by coding the 3 treatment groups as A, B, and C and by putting the syrups to be used for each group in bottles having a correspond- ing code. Neither the main researcher and his assistants nor the mothers knew which supplement was rep- resented by which code
Blinding (performance bias and detection bias) All outcomes	Low risk	Blind supplementation was guaranteed by coding the 3 treatment groups as A, B, and C and by putting the syrups to be used for each group in bottles having a correspond- ing code Participants: children received a placebo similar in colour and appearance to the sup- plement Personnel: Neither the main researcher and his assistants nor the mothers knew which supplement was represented by which code Outcome assessors: Neither the main re- searcher and his assistants nor the mothers knew which supplement was represented by which code
Incomplete outcome data (attrition bias) All outcomes	Low risk	Of the 168 children enrolled at baseline, complete data sets were available for 163 children for anthropometric data and for 160 children for biochemical data. Reasons for attrition included families' moving to other places (n=3), mothers' refusing fur-

Thu 1999 (Continued)

		ther participation because of time limita- tions (n=2), and fear of blood collection $(n=3)$	
Selective reporting (reporting bias)	Unclear risk	There is insufficient information to permit judgement.	
Other bias	Low risk	The study appears to be free of other sources of bias.	
Verhoef 2002			
Methods	Double-blind, placebo-controlled vidual level	trial. 2x2 factorial design with randomisation at indi-	
Participants	during rainy seasons in the period 1 Kenya Children were randomly sampled study when they met the followi 110 g/L (anaemic); the axillary ter suggestive of malaria or anaemia, o a blood dipstick test result indica intended to stay in the study area o no allergy to sulfa drugs was repor	Children were randomly sampled. At screening, children were judged eligible for the study when they met the following criteria: the haemoglobin concentration was 60-110 g/L (anaemic); the axillary temperature was below $37.5C$; there were no symptoms suggestive of malaria or anaemia, or any systemic illness occurring in combination with a blood dipstick test result indicating current or recent malarial infection; the parents intended to stay in the study area during the intervention period and gave their consent; no allergy to sulfa drugs was reported; and no sulfa drugs had been used in the previous 3 weeks. Children with a positive malaria dipstick test result but without symptoms of	
Interventions	Participants were randomly assigned to one of four groups Group 1 ($n = 82$): children received intermittently sulphadoxine-pyrimethamine and iron supplement of 6 mg elemental iron (as ferrous fumarate) per kg body weight weekly (approximately 65 mg of elemental iron per week); Group 2 ($n = 82$): children received intermittently sulphadoxine-pyrimethamine and iron placebo; Group 3 ($n = 82$): children received intermittently sulphadoxine-pyrimethamine placebo and iron supplement of 6 mg elemental iron (as ferrous fumarate) per kg body weight weekly (approximately 65 mg of elemental iron per week); Group 4 ($n = 82$): children received intermittently sulphadoxine-pyrimethamine placebo and iron placebo Iron was administered twice per week as ferrous fumarate in a suspension at a target dose of Length of the intervention: 12 weeks For the purposes of this review, groups 1 and 3 were combined (iron) and compared with the combination of groups 2 and 4 (no iron)		
Outcomes	Malaria attacks, adverse drug reactions, anaemia, iron deficiency, serum ferritin (could not be extracted) and difference in mean haemoglobin change from that of placebo (we calculated final haemoglobin concentrations)		

Verhoef 2002 (Continued)

Notes	Sulphadoxine-pyrimethamine was administered by the clinical officer employed by the project once every 4 weeks at therapeutic doses. Iron was administered by community health-workers	
	Children in all groups were under intense health surveillance throughout the intervention period	
	Malaria transmission is highly seasonal in this area	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Balanced block randomisation (41 blocks) . The allocation schedule was generated by one of the researchers for each block, by means of tables with randomised permuta- tions, and only after acceptance of all chil- dren making up a block
Allocation concealment (selection bias)	Low risk	The order of the children listed in each block was concealed from the person gen- erating the allocation schedule. Both place- bos and active compounds were admin- istered as suspensions that were indistin- guishable in taste and appearance. Bottles were colour-coded, but none of the field investigators was aware of the code until after crude analysis and a plan for further analysis had been prepared
Blinding (performance bias and detection bias) All outcomes	Low risk	See above.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Of 328 children undergoing randomisa- tion, 307 (94%) completed the trial and 21 (6%) did not (migrated or moved tem- porarily from the study area, 13; parents withdrew consent, three; developed severe anaemia, one; died, one; developed malaria but treated elsewhere, one; unknown rea- sons, two). Balanced losses to follow-up
Selective reporting (reporting bias)	Unclear risk	There is insufficient information to permit judgement.
Other bias	Low risk	The study appears to be free of other sources of bias.

Yang 2004 (C)

Methods	Cluster-randomised trial. 3-arm trial with randomisation at classroom level
Participants	353 preschool children, both sexes 58 females (44.7%), aged 3-6 years, attending a kindergarten in Baotou City. Inclusion criterion: absence of major diseases, haemoglobin 90-140g/L
Interventions	Classrooms were allocated to one of the following groups: Group 1 (n = 120): children received tablets containing 30 mg elemental iron: 5 mg zinc, 300 μ g vitamin A, 50 mg vitamin C: 7.5 μ g vitamin D3, 150 μ g (0.15 mg) folic acid five times every week (Monday to Friday); Group 2 (n = 120): children received the same tablets as group 1 only once a week; Group 3 (n = 113): children received a placebo similar in colour and appearance to the iron supplement tablets. Placebo was given daily Length of the intervention: 14 weeks
Outcomes	Haemoglobin, serum ferritin, erythrocyte protoporphyrin, iron deficiency (serum ferritin <30 μ g/L), height-for-age Z-scores, weight-for-age Z-scores)
Notes	Study translated from Chinese. We attempted to contact the author to validate the extraction Teachers and nurses received iron supplement tablets from kindergarten doctors and helped children to take the tablets with semi-liquid food. All groups have the same food in the kindergarten except for the tablets We adjusted the results of this study to account for the effect of clustering in data; the estimated effective sample size was used in the analyses. Malaria endemicity not reported.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Children were randomly assigned to the treatment or the control according to their classroom. Method of sequence generation not described
Allocation concealment (selection bias)	Low risk	Every week, teachers and nurses received iron supplement tablets from kindergarten doctors and helped children to take the tablets. Since the intervention was allocated at classroom level, it is unlikely there was a selection bias at the individual level
Blinding (performance bias and detection bias) All outcomes	Low risk	Participants: children received a placebo similar in colour and appearance to the sup- plement Personnel: Every week, teachers and nurses received iron supplement tablets from kindergarten doctors

Yang 2004 (C) (Continued)

		Outcome assessors: Unclear
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Losses to follow up not reported.
Selective reporting (reporting bias)	Unclear risk	There is insufficient information to permit judgement.
Other bias	Unclear risk	The data was not adjusted by the effect of clustering.
Young 2001		
Methods	Randomised controlled trial. 2-arm v dren by anaemia status	with individual randomisation after stratifying chil-
Participants	577 Malawian children, both sexes (sex distribution not reported), 15 and 60 months of age, were enrolled as they attended the mobile child health clinic in their area. Exclusion criteria:children with severe anaemia (Hb < 70 g/L). Baseline prevalence of anaemia: 83%. Socioeconomic status not reported	
Interventions	Children were allocated to one of the following groups: Group 1 (n = 73 at follow up): children received 60 mg of iron once a week; Group 2 (n = 73 at follow up) children received 60 mg of elemental iron (as ferrous sulphate) plus 7500 IU vitamin A, 45 mg vitamin C, 600 IU vitamin D3, 3 mg vitamin B1, 1.5 mg B ₂ and 22.5 mg vitamin B ₃ once a week; Group 3 (n = 85 at follow up): children received 60 mg of elemental iron (as ferrous sulphate) daily Groups 1 and 2 were combined and reported independently for the relevant subgroup analysis Length of the intervention: 12 weeks	
Outcomes	Haemoglobin concentration.	
Notes	All children received treatment for hookworm at baseline with albendazole Adherence to the treatment, as reported by guardians along with a monthly tablet count, was similar in each group, approximately 52%. Reported adverse effects ranged from 2. 7% to 9.4%, with the weekly iron/vitamin group reporting the least adverse effects and the daily iron group the most Malaria endemicity not reported.	
Risk of bias		

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	The children were stratified according to haemoglobin (Hb) levels (using the HemoCue) and then randomised. Method

Young 2001 (Continued)

		of sequence generation not described			
Allocation concealment (selection bias)	Unclear risk	Supplements were administered by guardian but unclear whether he/she was aware of which treat- ment was being administered			
Blinding (performance bias and detection bias) All outcomes	High risk	Participants: Not reported. Personnel: Not reported. Outcome assessors: Not reported.			
Incomplete outcome data (attrition bias) All outcomes	High risk	Attrition of 60% (n=346). No description of why more than half of the sample was lost to follow-up			
Selective reporting (reporting bias)	Unclear risk	There is insufficient information to permit judgement.			
Other bias	Low risk	The study appears to be free of other sources of bias.			
Yurdakok 2004		Yurdakok 2004			
Methods	Randomised control trial. 3 arm design wit	h individual randomisation			
Methods Participants	79 infants, both sexes (sex distribution n identified for potential enrolment at Hacet Hospital Well Baby Clinic, Ankara Turkey. I 37 weeks, 2) birthweight >2500g, 3) single no perinatal disease, 6) breast milk as the on of iron supplementation or therapy, 8) no k pairs, 9) mother intended to breasted exclu breastfeeding with introduction of complen Infants or mothers with iron deficiency or i	h individual randomisation ot reported), 4 months of age at baseline, tepe University Ihsan Dogramaci Children's nclusion criteria: 1) gestational age more than ton birth, 4) no congential malformation,5) ly source of food on admission, 7) no history nown hematologic disorder of mother-infant sively until 6 months of age and to continue nentary foods no earlier than 7 months of age. ron deficiency anaemia identified at baseline alence of anaemia: unknown. Socioeconomic			

Yurdakok 2004 (Continued)

Outcomes	Haemoglobin, mean corpuscular volume, red cell distribution width, transferrin satura- tion, serum ferritin and adverse effects; Iron Deficiency or Iron Deficiency Anaemia are reported together
Notes	Mothers gave supplement at home in morning one hour before breastfeeding (this seems difficult to control/estimate, as it seems to assume there is no night nursing or on demand feeding) Malaria endemicity not reported.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised trial. Method of sequence generation not described
Allocation concealment (selection bias)	Unclear risk	Not reported.
Blinding (performance bias and detection bias) All outcomes	High risk	Participants: Not reported. Personnel: Not reported. Outcome assessors: Not reported.
Incomplete outcome data (attrition bias) All outcomes	Low risk	12 of 79 (15%) did not finish the study. 3 mothers withdrew from the study. Moth- ers that introduced complementary foods early or gave other milks (not breast milk) were removed from study (n=5), non-com- pliance for iron supplementation were re- moved from the study (n=2). Infants who contracted infectious disease were removed (n=2). Withdrawns did not significantly differ across three groups. No differences at baseline between those who completed the study and those who did not
Selective reporting (reporting bias)	Unclear risk	There is insufficient information to permit judgement.
Other bias	Low risk	The study appears to be free of other bias.

Characteristics of excluded studies [ordered by study ID]

Study	Reason for exclusion
Agarwal 2003	Prospective study conducted in government schools in Northeast Delhi. 2088 adolescent females partici- pated in the study, with 702 females receiving daily iron-folate supplementation, 695 females on weekly iron-folate supplementation and 691 females serving as controls. The authors concluded that though the weekly regimen took longer, it was as effective and practical as daily regimens in raising haemoglobin levels This study was excluded because the authors looked only at adolescent females, which is out of the scope of this review
Ahmed 2001	Randomised, double-blind, placebo-controlled study in a 2x2 factorial design conducted in urban Bangladesh. Female postmenarchal adolescent subjects were randomised to a placebo (for vitamin A and for iron/folic acid), vitamin A only, iron and folic acid only, and iron, folic acid and vitamin A weekly for 12 weeks. Haemoglobin concentrations were raised significantly more in response to iron and folic acid and iron, folic acid, and vitamin A when compared to vitamin A alone or to placebo This study was excluded because the study evaluated post-menarchal females specifically, which is out of the scope of this review
Ahmed 2005	Randomised double-blind clinical trial conducted in Bangladesh. Anemic (haemoglobin < 120 g/L) fe- males (n=197) aged 14-18 y from rural schools in Dhaka District were entered into a randomised double- blind trial and received twice-weekly supplements of iron and folic acid or multiple micronutrients (15 micronutrients, including iron and folic acid) for 12 wk. In conclusion, twice-weekly MMN supplementa- tion for 12 wk significantly improved the status of the micronutrients assessed but was not more efficacious than was supplementation with iron and folic acid alone in improving the hematologic status of anaemic adolescent females The study was excluded because the authors did not compare intermittent iron supplementation versus daily/placebo and hence the study is out of the scope of this review
Avila-Jimenez 2011	Randomised trial conducted in Mexico City, Mexico. The trial included 1,699 healthy, at term, singleton babies during their first year of life and excluded those with low weight at birth, unknown gestational age, bleeding disorder or any other medical conditions that may be associated with anaemia (i.e., malabsorption) Children were randomly assigned to receive a daily, weekly (7 mg/dose) or monthly dose of supplements containing 30 mg elemental iron (as either ferrous sulphate or aminochelate iron), for one year The study was excluded because the authors compared two intermittent iron supplementation regimens and such comparison is out of the scope of this review
Azeredo 2010	A prospective population study performed in the city of Viçosa, Southeastern Brazil, in 2007-8. A total of 103 non-anaemic children, aged between six and 18 months of age, were included and divided into two supplementation groups: daily dosage (group 1, n=34) and weekly dosage (group 2, n=69). After six months of supplementation, the daily dosage was found to be more effective than the weekly scheme to prevent anaemia in infants The study was excluded because it was not randomised.
Beasley 2000	Single-blind randomised trial performed in three rural villages of the Muheza district of Tanzania. Females between the ages of 12-18 were randomised to a treatment 12 doses of ferrous sulphate or a control of 12 doses of vitamin B_{12} over the 16 weeks following anti-helminthic treatment. The use of a strict placebo was not allowed due to ethical reasons. The authors found a significantly greater improvement in serum ferritin in the iron supplemented group but no significant differences in haemoglobin when compared to the control group

	This study was excluded because the study evaluated adolescent females which is out of the scope of this review
Briars 2003	Randomised clinical trial performed in Dunedin, New Zealand. Free-living healthy adult women of childbearing age (n=138) were randomised to receive a 2,800 μ g (2.8 mg) folic acid weekly, a daily 400 μ g (0.4 mg) folic acid supplement, or placebo. Authors found that a weekly high-dose folic acid supplement was as effective as a daily supplement in lowering homocysteine concentrations The study was excluded because vitamin and minerals were given as foodlets and they are out of the scope of this review
Februhartanty 2002	Single-blind experimental community study carried out in Kupang, East Nusa Tenggara, Indonesia. Post- menarchal adolescent females (n=150) were randomised to weekly iron supplementation, placebo, or sup- plementation during 4 consecutive days of their menstrual cycle. The authors found that weekly iron supplementation for 16 weeks led to a greater improvement in haemoglobin concentration, compared with supplementation during four consecutive days of menstruation This study was excluded because supplementation was administered to only postmenarchal adolescent females which is out of the scope of this review
Hafeez 1998	Randomised trial conducted at Combined Military Hospital (CMH), Lahore, Pakistan, from January 1996 to June 1996. 130 children aged 1-6 years (average 27 months), both sexes, with iron deficiency anaemia (Hb 110 g/L) were divided into 2 subgroups, group A in which children received daily oral dosage of 6 mg/kg of elemental iron as ferrous gluconate and group B, in which children received the same dosage of iron on three consecutive days per week. The intervention lasted 2 months. Haemoglobin and ferritin concentrations increased in both groups with no differences between them The study was excluded because the intermittent supplements were given on consecutive days
Нор 2005	Randomised, double-blind, placebo-controlled trial conducted in Vietnam. Infants aged 6-12 mo (n=138) were allocated to one of the following groups: daily multiple micronutrient, daily placebo, weekly multiple micronutrient, or daily iron supplements. All were supplemented for 6 mo, 7 d/wk, under supervision. DMM supplementation had the best overall performance of the micronutrient supplements tested; it reduced the rate of length-growth faltering and had the best hematinic effect The study was excluded because vitamin and minerals were given as foodLETs and they are out of the scope of this review
Jackson 2003	The objectives of this study were to ascertain whether, short-term supplementation with iron and folic acid could reduce anaemia and iron deficiency, and be well tolerated by adolescent females over an 8-week period. It included 608 postmenarchal adolescent schoolgirls with mild to moderate anaemia. The females were randomly assigned to three groups (iron alone, folic acid alone, and iron with folic acid) and given weekly supplements for eight weeks. Iron and folic acid tablets contained 60 mg elemental iron (as ferrous sulphate) and 3500 μ g (3.5 mg) folic acid, respectively. A fourth group of females who had normal Hb concentrations and received no treatment was also included at baseline and after eight weeks. Authors found that the females receiving iron (alone or in combination) had greater mean rise in Hb than females who received folic acid alone. Eight weeks of supplements given on a weekly basis were well tolerated, causing few symptoms and was effective in reducing anaemia by 30-40% The study was excluded because the control group was not randomised. Also the control group had normal Hb values while the females receiving the intervention were anaemic
Jaleel 2004	Prospective study that included 90 apparently healthy individuals. They were divided into 3 groups of 30 subjects each. First group comprised of male subjects of age between 25-45 years, second group

	was of postmenopausal women of age between 46-65 years and third group of reproductive age group that is between 15-45 years. Each group was further divided into 3 subgroups of 10 male subjects, 10 postmenopausal and 10 women of reproductive age groups. The first subgroup was given iron supplements (as ferrous sulphate 300 mg) daily. The second subgroup received supplementation (as ferrous sulphate 300 mg) on weekly basis that is 6 times for 36 days and third subgroup received iron supplements in double dose (ferrous sulphate 600 mg) on weekly basis that is 6 times for 36 days. It was concluded, that 600mg of iron given on a weekly gave similar results as that of subjects receiving 300 mg on a daily basis This study was excluded because the populations assessed are out of the scope of this review
Jayatissa 1999	In Sri Lanka 36% of all adolescents have inadequate iron intakes. Daily and weekly iron supplementation of 659 adolescent schoolgirls, divided into three groups, was studied in an eight-week double-blind trial. One group received 60 mg of elemental iron, 250 μ g (0.25 mg) of folic acid, and 100 mg of vitamin C daily. The second group was given the same doses on a weekly basis. The third group was given a placebo. All of the participants were de-wormed at the beginning of the study. Anaemia was more common among older adolescents. Haemoglobin levels increased significantly at the end of the study. The prevalence of anaemia was reduced from 25% to 9.5% by weekly supplementation and from 18.5% to 8.6% by daily supplementation. The difference in haemoglobin levels between the two groups receiving supplementation was not significant The study was excluded because it is not clear whether is randomised or not. Based on the methods the selection of participants was at random but not the allocation of the intervention
Kanal 2005	This was a community trial in which social marketing and community mobilization approaches were applied to introduce weekly iron-folic acid supplementation to prevent anaemia in Cambodian women of reproductive age. The programme was implemented in three very different environments: secondary schoolgirls, women working in garment factories in the vicinity of Phnom Penh, and women in rural villages. All three groups of women showed substantial improvements in knowledge about the causes, consequences, and prevention of anaemia, and the large majority reported interest in continuing to take the supplements The study was excluded because it was not randomised.
Kapur 2003	A community-based trial that compared the effect of nutrition education and/or iron supplementation (weekly) on iron status of 400 children, 9-36 months, living in an urban slum in Delhi Children and care takers were selected by using a random number table. Children were assigned to one of the following groups. Group 1, received nutrition education. Group 2, received supplements with 20 mg elemental iron. Group 3, received nutrition education with supplementation with 20 mg elemental iron and Group 4, control given placebo To ensure objectivity and to avoid spill over effect, specifically with respect to nutrition education, caution was maintained in forming groups and allocation of subjects therein. Subjects from the Anganwadis in Block A (A1, A2, A3 and A4) and Block B (including B1, B2, B3, B4, B5 and B6) (which were more or less adjoining) were allocated to experimental groups 3 (NE+ S) and 4 (NE), where nutrition education was a component. Control and Experimental group 2 (supplementation group), on the other hand, included subjects from Block C (including C1, C2 and C3), Block D (including D1, D2 and D3) and Block E (including E1, E2, E3, E4 and E5) which are situated at a distance of about 1 - 2 Km from the Experimental groups 3 and 4 (information provided by the author) The intervention program was of four months duration, with a treatment phase of 8 wk followed by 8 wk of no treatment. There was no significant effect of any of the intervention at 8 weeks. At 16 wk, there was significant positive effect of nutrition education group (p less than 0.05)

	This study was excluded because the allocation was not at random
Kianfar 2000	A randomised trial comparing the effects of daily and intermittent iron supplementation regimens in adolescent schoolgirls in the areas of Zahedan and Rasht, Iran. 1853 subjects were selected by stepwise random sampling and randomised to a daily group, supplemented with 50 mg elemental iron per day, a once weekly group supplemented with 50 mg elemental iron and a twice weekly group, also supplemented with 50 mg elemental iron. The authors concluded that the once and twice weekly regimens were effective in treating anaemia but that the daily schedule was more effective at increasing iron stores than a weekly dose in the short-term This study was excluded because it evaluated adolescent females which is out of the scope of this review
Lechtig 2006	This paper is one of a series of papers that describes the experiences of a multiple micronutrient intervention programme implemented in poor urban mothers and their young children of Chiclayo, Peru. It summarizes the lessons learned for consideration of future programming The study was excluded because the authors gave foodlets and that intervention is out of the scope of this review
Leenstra 2009	A double-blind, randomised controlled study using a factorial design carried out in primary schools in Kisumu, Western Kenya. The study aimed to evaluate the effect of weekly iron and vitamin A supple- mentation on haemoglobin, iron status, and malaria and non-malaria morbidity in adolescent schoolgirls. Weekly iron supplementation was found to greatly increase haemoglobin levels in menstruating and iron- deficient females but not in iron-replete and non menstruating females This study was excluded because it looked only at adolescent school females between the ages of 12-18 years which is out of the scope of this review
Lima 2006	A controlled, community-based intervention was carried out with 378 infant to evaluate the impact of weekly treatment with ferrous sulphate on haemoglobin level, morbidity and nutritional status in a sample of anaemic infants from Zona da Mata Meridional in the state of Pernambuco, Brazil. Participating infants were divided into three groups: two received 45 mg of elemental iron weekly, from 12 to 18 months of life (69 children with moderate/severe anaemia, and 111 with mild anaemia); the third group was composed of 65 non-anaemic children, who received no intervention. The remaining 133 children constituted the control group. Less than half the children without anaemia at baseline, who did not receive treatment, developed anaemia The study was excluded because it was not randomised.
Lin 2001	270 rural preschool children aged 3-7 years with low levels of vitamin A and iron living in Beijing, China. Participants were divided into four groups based on their determinations: control, lower serum vitamin A, lower iron, and both lower iron and serum vitamin A. Forty-one subjects who had lower iron and lower serum vitamin A (< 1.12 mumol/L) were divided into two groups: one of them supplemented with 30 mg elemental iron (as ferrous sulphate 0.15 g) once a day for 8 weeks, and the other group supplemented with iron and 12,500 IU vitamin A twice a week for 8 weeks. Authors concluded that supplementation with vitamin A and iron was helpful to improve body iron nutritional status and immunological function obviously in preschool children with iron-deficiency and sub-clinical deficiency of vitamin A The study was excluded because the daily and weekly groups did not receive the same nutrients
López de Romaña 2005	Randomised, double-blind, masked, controlled trial conducted in Peru. Infants aged 6 to 12 mo (n=313) were assigned to receive either a daily dose of iron, a daily dose of multiple micronutrients, a weekly dose of multiple micronutrients, or a placebo for 6 mo. None of the supplements tested prevented growth faltering

	or the morbidities common during infancy. The daily multiple micronutrient intervention was the most efficacious for preventing anaemia, iron, and zinc deficiencies, 15%, 20%, and 50% of this group still remained anaemic, zinc deficient, and iron deficient, respectively, at the end of the study The study was excluded because vitamin and minerals were given as foodLETs and they are out of the scope of this review
López de Romaña 2006	Randomised community trial undertook in 26 Peruvian communities with stunting rates above the average. Households were selected if they had at least one child under 5 years of age and at least one woman or adolescent females of childbearing age (12 through 44 years). A total of 866 households (448 in the intervention group and 418 in the comparison group-unclear) were selected. Women received Nutrivit capsules while children received Foodlets. Authors concluded that weekly supplementation with multi- micronutrients had a protective effect on the haemoglobin levels of both women and adolescent females of childbearing age and children under 5 years of age The study was excluded because vitamin and minerals were given as foodlets and they are out of the scope of this review
Menendez 1997	Randomized clinical trial in Tanzania. Newborns (n=832) were randomly assigned to group DI, receiving daily oral iron (2 mg/kg daily) plus weekly Deltaprim (3.125 mg pyrimethamine plus 25 mg dapsone); group IP, receiving iron plus weekly placebo; group DP, receiving daily placebo plus weekly Deltaprim; or group PP. supplementation was given from 8 to 24 weeks of age, and the weekly chemoprophylaxis from 8 to 48 weeks. The groups that received iron supplementation had a lower frequency of severe anaemia The study was excluded because only the malaria prophylaxis was given on a weekly basis
Mwanakasale 2009	Placebo-controlled intervention trial conducted in Nchelenge district in Luapula province of Zambia. Children between 9 and 15 years of age received once a week either 200 mg of ferrous sulphate or 100 mg of vitamin C. Both study groups received a single dose of praziquantel at baseline and the follow-up lasted 9 months The study was excluded because it was not randomised.
Perrin 2002	It is a commentary paper on Shah 2002.
Risonar 2008	242 Filipino schoolchildren aged 6-12 years with haemoglobin (Hb) concentration <120g/L and enrolled for school year 2003-2004. UNICEF iron-folate tablets containing 60mg elemental iron and 400 μ g (0. 40mg) folic acid were given weekly through directly observed supplementation by the teachers for 27 weeks. The intervention reduced anaemia prevalence among anaemic schoolchildren and resulted in high compliance to and coverage of iron supplementation The study was excluded because it does not have a control group
Rivera 1998	Report that presents the results of a regional program providing weekly iron supplements to school-age children attending 30 schools, between 1995 and 1997, in Chiriqui, Panama, This study was excluded because the study design (pre-post without a control group) is out of the scope of this review
Schümann 2009	Randomised doubly-masked, placebo-controlled trial undertook in Cambodia. Children aged 6-24 months (n= 250) received twice-weekly administration of 3 RDAs of iron and folic acid, with and without a complement of 2 RDAs of 11, and 1 RDA of 3 additional essential micronutrients as compared to a placebo control (PlbCON) given as foodLETs. Supplementation of micronutrients along with iron and folic acid mitigates the excess morbidity of iron-folate alone, without reducing its efficacy in correcting anaemia and building iron stores

	The study was excluded because vitamin and minerals were given as foodLETs and they are out of the scope of this review
Shah 2002	Randomised-controlled trial of healthy adolescent females in government female schools of Dharan, Nepal. The study aimed to compare the effectiveness of weekly versus daily iron folate supplementation. Females (n=209) were randomised to either a daily iron-folate group, a weekly iron-folate group, or a placebo group which did not receive any tablets. The authors concluded that once weekly iron folate supplementation was an effective alternative to daily regimens The study was excluded because it evaluated only adolescent females which is not in the scope of this review
Sharma 2000	Randomised experimental trial of adolescent females in poor communities in urban areas of Delhi and rural parts of Rajasthan. Subjects were randomised to either daily iron folate supplementation, weekly iron folate supplementation or weekly iron folate with vitamin C. The authors concluded that the response of haemoglobin levels was greater following daily iron folate supplementation when compared to weekly iron supplementation, but that the addition of vitamin C led to greater increases in haemoglobin than administration of iron and folate alone This study was excluded because it evaluated only adolescent females which is out of the scope of this review
Shobha 2003	Randomised trial of 244 adolescent females at an Andhra Pradesh residential social welfare school in the Ranga Reddy district of India. Females were stratified by anaemia status and then randomly assigned to either a daily or twice weekly supplementation regimen. Supervised administration of iron twice weekly was found to be similarly advantageous as daily supplementation in this population This study was excluded because it evaluated only adolescent females which is out of the scope of this review
Smuts 2005	Randomised trial undertook in South Africa. Infants aged 6-12 mo (n=265) were individually randomised to 1 of 4 intervention groups a daily multiple micronutrient supplement, a daily placebo supplement; a multiple micronutrient supplement 1 d of the week and placebo supplement on the other days of the week, and a daily iron supplement . For 6 mo, the blinded supplements were provided to mothers at monthly health clinic sessions, and consumption was verified during weekly household visits by community health workers, when morbidity was also checked. The DMM was the most effective intervention tested, not only for improving anaemia but also for improving iron, zinc, riboflavin, and tocopherol status The study was excluded because vitamin and minerals were given as foodlets and they are out of the scope of this review
Soekarjo 2004	A school-based grade-randomised intervention was conducted in rural and urban, East Java, Indonesia among adolescents. 1757 females and 1859 males were randomised to weekly supplementation (650 mg iron, 250 μ g (0.25 mg) folic acid), weekly vitamin A supplementation (10,000 IU), or both, were compared to a group not receiving any supplements. Weekly iron supplementation was not effective at raising haemoglobin levels, likely due to poor compliance and side effects This study was excluded because it evaluated an exclusively adolescent population, which is out of the scope of this review
Sotelo-Cruz 2002	20 anaemic children aged 2 to 5 years living in Hermosillo, Mexico. Group A received oral ferrous sulphate twice a day whereas group B received the some dose per kilogram of weight like that of group A once a week for three months. Haemoglobin concentrations improved in both groups The study was excluded because it is not randomised.

Tee 1999	Study that investigated whether long-term, weekly iron folate supplements administered at school would improve haemoglobin and ferritin concentrations in adolescent females, including those with mild-to-moderate anaemia and haemoglobin concentrations indicating borderline anaemia. 266 females with haemoglobin concentrations of 80-119.9 g/L (group A) and 358 females with haemoglobin concentrations of 120-130 g/L (group B) who were otherwise healthy. Two hundred sixty-six females in group A and 268 females in group B were randomly assigned to receive either 60 or 120 mg iron plus 3500 μ g (3.5 mg) folic acid weekly for 22 wk. Ninety of the females in group B were randomly assigned to receive only 5000 μ g (5 mg) folic acid weekly. Authors concluded that long-term, weekly iron-folate supplementation was found to be a practical, safe, effective, and inexpensive method for improving iron nutrition in adolescent schoolgirls. Study was excluded because children in both arms were given iron on a weekly basis. Group C did not receive supplements but was not followed up
Tomashek 2001	Randomised double-blind study, in which 215 anaemic children, initially treated for malaria and helminth infection, received 12 weeks of thrice-weekly oral iron and folic acid. Group I received placebo and chloro- quine treatment for symptomatic malaria infection (i.e., no presumptive anti-malarial treatment given). Group II received placebo and monthly presumptive treatment with sulphamethoxazole-pyrimethamine (SP). Group III also received monthly SP and thrice-weekly vitamins A and C (VAC). Mean haemoglobin concentration increased from 66 to 102 g/L, with no significant differences among groups Study was excluded because all the participants were given iron and folic acid on a weekly basis
UNICEF 2006	Report that presents the results of a National program providing weekly iron supplements (ferrous fumarate) to infants and pregnant women living in priority districts in the Republic of Panama This study was excluded because the study design (pre-post without a control group) is out of the scope of this review
Vir 2008	Study performed in school and non-school females aged 11 to 18 years that aimed to assess the effectiveness of weekly iron-folic acid supplementation in reducing the prevalence of anaemia in adolescent females. The project provided weekly iron-folic acid tablets, family life education, and deworming tablets every 6 months to 150,700 adolescent school females and non-school females of a total district population of 3,647,834. Groups were not evaluated simultaneously. In 4 years, the overall prevalence of anaemia was reduced from 73.3% to 25.4%. Hemoglobin levels and anaemia prevalence were influenced significantly at 6 months. No difference in the impact on haemoglobin or anaemia prevalence was observed between supervised and unsupervised females The study was excluded because it was not randomised.
Wijaya-Erhardt 2007	A double-blind, randomised, placebo-controlled trial. Indonesian infants. aged 6-12 mo were randomly allocated to 1 of 4 groups: daily multiple-micronutrients food like tablets (foodlets), weekly multiple-micronutrient foodlets, daily iron foodlets, or daily placebo Data were obtained at baseline and 23 wk. DI and daily multiple-micronutrients foodlets are efficacious in improving and weekly multiple-micronutrient is efficacious in maintaining iron stores The study was excluded because vitamin and minerals were given as foodlets and they are out of the scope of this review
Zavaleta 2000	A randomised, double-blind, placebo-controlled study conducted among adolescent school females in Lima, Peru. 312 adolescents females were randomly assigned to either 60mg ferrous sulphate Mon-Friday (daily), 60 mg of ferrous sulphate twice weekly with placebo 3 times per week, or a placebo five days per week. Both iron supplementation regimens were found to be effective at reducing iron deficiency and the

daily supplementation schedule was found to be more effective at raising haemoglobin concentration and reducing anaemia This study was excluded because it evaluated adolescent females which is out of the scope of this review

Characteristics of studies awaiting assessment [ordered by study ID]

Husseini 1999

Methods	Cluster-randomised trial. 2-arm design with randomisation at village level
Participants	822 children, both sexes, 5 to 26 months (average age 17.5 months). Inclusion criterion: haemoglobin <90 g/L
Interventions	Villages were allocated to one of the following groups> Group 1: children received 20 mg of iron daily; Group 2: children received 25 mg of iron once a week; Length of the intervention: 18 months with visits every 4 weeks Intervention supervised and unsupervised.
Outcomes	Anaemia, haemoglobin, ferritin
Notes	Information obtained from Beaton 1999

Kargarnovin 2010

Methods	Randomised trial. 2-arm design with individual randomisation
Participants	160 anaemic infants, both sexes, 6-24 months living in the South of Tehrna, Iran
Interventions	Children were allocated to one of the following groups: Group 1 (n=80): children were given daily containing 40 mg of elemental iron (as ferrous sulphate); Group 1 (n=80): children were given 40 mg of elemental iron (as ferrous sulphate) once a week on Friday mornings Length of the intervention: 6 months.
Outcomes	Haemoglobin, erythrocyte volume, total iron binding capacity, transferrin saturation, serum transferrin
Notes	Article written in Farsi. The author was contacted to obtain the information Figure 2 is not available in PDF and the author has been contacted to obtain this information The article concludes that weekly administration of iron compared with daily consumption seems superior due to similar effects, better compliance of mothers and lower costs for the treatment of anaemia in infants between 6 and 24 months

Reid 2001	
Methods	Double-blind randomised trial. 3 arm study with randomisation at individual level
Participants	125 Mexican preschoolers with low Hb, age 12-40 months of age
Interventions	Participants were allocated to one of the following treatments: Group 1: placebo Group 2: iron (Fe), Group 3: iron + B-12 (Fe+B-12), or Group 4: multiple micronutrients (MM = iron, vitamin B ₁₂ , vitamin B ₂ , vitamin B ₆ , vitamin A, vitamin E, folic acid zinc, cooper). Doses were 2 x RDA, 3 times/wk, under supervision Length of the intervention: 3 months
Outcomes	Anaemia, haematocrit, ferritin, retinol, serum B ₁₂
Notes	This study has not been published. If the data is made available to us, we will include it in future updates of the review

Characteristics of ongoing studies [ordered by study ID]

Zeeba Zaka-ur-Rab 2010

Trial name or title	A clinical trial to compare the effects of daily versus intermittent iron supplementation on markers of oxidative stress and anti-oxidant status in children with iron deficiency anaemia
Methods	Randomised, controlled trial. Method of generating randomisation sequence: random number table Method of allocation concealment: sequentially numbered, sealed, opaque envelopes Blinding and masking:Outcome Assessor Blinded
Participants	150 children between 1-15 years of age with iron deficiency anaemia. Exclusion criteria: children with history of fever within last 4 weeks, acute or chronic medical disorders, hemolytic anaemia, haemoglobin <6gm%, patients receiving iron/vitamin/mineral supplements (including herbal drugs), blood transfusion within 8 weeks
Interventions	Intervention: sodium feredetate: 6 mg/kg daily; Control: sodium feredetate: 6 mg/kg on day 1 and day 4. Length of the intervention: 8 weeks.
Outcomes	Changes in malonyl dialdehyde, oxidized glutathione, superoxide dismutase, glutathione peroxidase, catalase, changes in hemo globin, serum ferritin, total iron binding capacity and serum iron Timepoint: 8 weeks
Starting date	Date of first enrolment: 02-03-2009
Contact information	Dr. Zeeba Zaka-ur-Rab Deptt. of Pediatrics, J.N. Med. College, A.M.U. 2, Wazir Manzil, Luxmibai Marg, 202 001 Aligarh, UTTAR PRADESH India Tel: 0571 -2402928

Zeeba Zaka-ur-Rab 2010 (Continued)

	Email: zzrab@yahoo.co.in
Notes	

DATA AND ANALYSES

Comparison 1. Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Anaemia (ALL)	10	1824	Risk Ratio (M-H, Random, 95% CI)	0.51 [0.37, 0.72]
2 Anaemia (by dose of elemental	10	1824	Risk Ratio (M-H, Random, 95% CI)	0.51 [0.37, 0.72]
iron in the intermittent group)				
2.1 25 mg or less/week	2	157	Risk Ratio (M-H, Random, 95% CI)	0.15 [0.06, 0.37]
2.2 Greater than 25 mg to 75 mg/week	6	1256	Risk Ratio (M-H, Random, 95% CI)	0.54 [0.37, 0.80]
2.3 Greater than 75 mg/week	2	411	Risk Ratio (M-H, Random, 95% CI)	0.71 [0.48, 1.04]
3 Anaemia (by duration of the intervention)	10	1824	Risk Ratio (M-H, Random, 95% CI)	0.51 [0.37, 0.72]
3.1 0 to three months	5	1456	Risk Ratio (M-H, Random, 95% CI)	0.63 [0.49, 0.82]
3.2 More than three months	5	368	Risk Ratio (M-H, Random, 95% CI)	0.37 [0.14, 1.02]
4 Anaemia (by type of compound)	10	1824	Risk Ratio (M-H, Random, 95% CI)	0.51 [0.37, 0.72]
4.1 Ferrous sulphate	9	1517	Risk Ratio (M-H, Random, 95% CI)	0.47 [0.30, 0.75]
4.2 Ferrous fumarate	1	307	Risk Ratio (M-H, Random, 95% CI)	0.61 [0.49, 0.74]
4.3 Other	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
5 Anaemia (by anaemia status at baseline)	10	1824	Risk Ratio (M-H, Random, 95% CI)	0.51 [0.37, 0.72]
5.1 Anaemic	2	424	Risk Ratio (M-H, Random, 95% CI)	0.30 [0.07, 1.38]
5.2 Non-anaemic	1	64	Risk Ratio (M-H, Random, 95% CI)	0.78 [0.27, 2.31]
5.3 Mixed/unknown	7	1336	Risk Ratio (M-H, Random, 95% CI)	0.59 [0.41, 0.85]
6 Anaemia (by intermittent regimen)	10	1824	Risk Ratio (M-H, Random, 95% CI)	0.51 [0.37, 0.72]
6.1 One supplement a week	9	1517	Risk Ratio (M-H, Random, 95% CI)	0.47 [0.30, 0.75]
6.2 Other intermittent regimen	1	307	Risk Ratio (M-H, Random, 95% CI)	0.61 [0.49, 0.74]
7 Anaemia (by sex)	10	1824	Risk Ratio (M-H, Random, 95% CI)	0.55 [0.41, 0.73]
7.1 Girls	10	248	Risk Ratio (M-H, Random, 95% CI)	0.75 [0.59, 0.95]
7.2 Boys	1	253	Risk Ratio (M-H, Random, 95% CI)	0.81 [0.66, 1.00]
7.3 Mixed/unknown	9	1323	Risk Ratio (M-H, Random, 95% CI)	0.46 [0.30, 0.70]
8 Anaemia (by nutrient)	10	1824	Risk Ratio (M-H, Random, 95% CI)	0.51 [0.37, 0.72]
8.1 Iron alone	6	1074	Risk Ratio (M-H, Random, 95% CI)	0.48 [0.31, 0.74]
8.2 Iron + folic acid	2	593	Risk Ratio (M-H, Random, 95% CI)	0.83 [0.66, 1.03]
8.3 iron + vitamin C	1	50	Risk Ratio (M-H, Random, 95% CI)	0.06 [0.00, 0.97]
8.4 Iron + multiple	1	107	Risk Ratio (M-H, Random, 95% CI)	0.16 [0.06, 0.44]
micronutrients				
9 Haemoglobin (ALL)	19	3032	Mean Difference (IV, Random, 95% CI)	5.20 [2.51, 7.88]
10 Haemoglobin (by by dose of elemental iron in the	19	3032	Mean Difference (IV, Random, 95% CI)	5.20 [2.51, 7.88]
intermittent group)				
10.1 25 mg or less/week	3	324	Mean Difference (IV, Random, 95% CI)	8.19 [-4.01, 20.38]
10.2 Greater than 25 mg to 75 mg/week	12	2059	Mean Difference (IV, Random, 95% CI)	5.45 [2.31, 8.58]
10.3 Greater than 75 mg/week	4	649	Mean Difference (IV, Random, 95% CI)	1.84 [0.25, 3.44]

11 Haemoglobin (by duration of the intervention)	19	3032	Mean Difference (IV, Random, 95% CI)	5.20 [2.51, 7.88]
11.1 0 to three months	7	1616	Mean Difference (IV, Random, 95% CI)	5.16 [2.82, 7.51]
11.2 More than three months	12	1416	Mean Difference (IV, Random, 95% CI)	5.13 [0.90, 9.36]
12 Haemoglobin (by type of	19	3032	Mean Difference (IV, Random, 95% CI)	5.20 [2.51, 7.88]
compound)				
12.1 Ferrous sulphate	14	2288	Mean Difference (IV, Random, 95% CI)	5.57 [2.21, 8.92]
12.2 Ferrous fumarate	2	432	Mean Difference (IV, Random, 95% CI)	7.03 [3.36, 10.71]
12.3 Other	3	312	Mean Difference (IV, Random, 95% CI)	2.03 [-0.26, 4.33]
13 Haemoglobin (by anaemia status at baseline)	19	3032	Mean Difference (IV, Random, 95% CI)	5.20 [2.51, 7.88]
13.1 Anaemic	2	422	Mean Difference (IV, Random, 95% CI)	13.17 [3.07, 23.26]
13.2 Non-anaemic	1	64	Mean Difference (IV, Random, 95% CI)	2.0 [-2.46, 6.46]
13.3 Mixed/unknown	16	2546	Mean Difference (IV, Random, 95% CI)	4.35 [1.88, 6.82]
14 Haemoglobin (by intermittent regimen)	19	3032	Mean Difference (IV, Random, 95% CI)	5.15 [2.52, 7.79]
14.1 One supplement a week	15	2256	Mean Difference (IV, Random, 95% CI)	5.61 [2.13, 9.09]
14.2 Other intermittent	5	776	Mean Difference (IV, Random, 95% CI)	3.67 [1.05, 6.28]
regimen				
15 Haemoglobin (by sex)	19	3032	Mean Difference (IV, Random, 95% CI)	5.17 [2.56, 7.77]
15.1 Girls	1	248	Mean Difference (IV, Random, 95% CI)	4.0 [0.83, 7.17]
15.2 Boys	1	253	Mean Difference (IV, Random, 95% CI)	3.70 [0.58, 6.82]
15.3 Mixed/unknown	18	2531	Mean Difference (IV, Random, 95% CI)	5.31 [2.40, 8.22]
16 Haemoglobin (by nutrient)	19	3032	Mean Difference (IV, Random, 95% CI)	4.83 [2.25, 7.41]
16.1 Iron alone	11	1699	Mean Difference (IV, Random, 95% CI)	4.41 [1.32, 7.50]
16.2 Iron + folic acid	4	756	Mean Difference (IV, Random, 95% CI)	3.36 [1.51, 5.21]
16.3 iron + zinc	1	77	Mean Difference (IV, Random, 95% CI)	-1.60 [-8.09, 4.89]
16.4 Iron + vitamin C	1	50	Mean Difference (IV, Random, 95% CI)	20.70 [17.51, 23.89]
16.5 Iron + multiple micronutrients	4	450	Mean Difference (IV, Random, 95% CI)	5.47 [0.32, 10.61]
17 Iron deficiency (ALL)	3	431	Risk Ratio (M-H, Random, 95% CI)	0.24 [0.06, 0.91]
18 Ferritin (ALL)	5	550	Mean Difference (IV, Random, 95% CI)	14.17 [3.53, 24.81]
19 Ferritin (by dose of elemental	5	550	Mean Difference (IV, Random, 95% CI)	14.17 [3.53, 24.81]
iron in the intermittent group)				
19.1 25 mg or less/week	1	148	Mean Difference (IV, Random, 95% CI)	4.60 [-0.89, 10.09]
19.2 Greater than 25 mg to 75 mg/week	4	402	Mean Difference (IV, Random, 95% CI)	17.77 [8.21, 27.34]
19.3 Greater than 75 mg/week	0	0	Mean Difference (IV, Random, 95% CI)	$0.0 \ [0.0, 0.0]$
20 Ferritin (by duration of the supplementation)	5	550	Mean Difference (IV, Random, 95% CI)	14.17 [3.53, 24.81]
20.1 0 to three months	1	35	Mean Difference (IV, Random, 95% CI)	15.80 [-1.23, 32.83]
20.2 More than three months	4	515	Mean Difference (IV, Random, 95% CI)	13.82 [1.84, 25.81]
21 Ferritin (by type of compound)	5	550	Mean Difference (IV, Random, 95% CI)	14.17 [3.53, 24.81]
21.1 Ferrous sulphate	4	476	Mean Difference (IV, Random, 95% CI)	16.28 [4.68, 27.87]
21.2 Ferrous fumarate	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
21.3 Other	1	74	Mean Difference (IV, Random, 95% CI)	2.46 [-14.37, 19.29]
22 Ferritin (by anaemia status at	5	550	Mean Difference (IV, Random, 95% CI)	14.17 [3.53, 24.81]
baseline)				
22.1 Anaemic	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
22.2 Non-anaemic	1	74	Mean Difference (IV, Random, 95% CI)	2.46 [-14.37, 19.29]
22.3 Mixed/unknown	4	476	Mean Difference (IV, Random, 95% CI)	16.28 [4.68, 27.87]

regimen)			Mean Difference (IV, Random, 95% CI)	14.17 [3.53, 24.81]
23.1 One supplement a week	4	497	Mean Difference (IV, Random, 95% CI)	10.14 [1.74, 18.53]
23.2 Other intermittent	1	53	Mean Difference (IV, Random, 95% CI)	27.80 [22.88, 32.72]
regimen				
24 Ferritin (by sex)	5	550	Mean Difference (IV, Random, 95% CI)	14.17 [3.53, 24.81]
24.1 Girls	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
24.2 Boys	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
24.3 Mixed/unknown	5	550	Mean Difference (IV, Random, 95% CI)	14.17 [3.53, 24.81]
25 Ferritin (by nutrient)	5	550	Mean Difference (IV, Random, 95% CI)	11.41 [2.71, 20.11]
25.1 Iron alone	4	379	Mean Difference (IV, Random, 95% CI)	16.25 [5.41, 27.09]
25.2 Iron + folic acid	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
25.3 Iron + zinc	1	53	Mean Difference (IV, Random, 95% CI)	5.50 [-3.91, 14.91]
25.4 Iron + multiple	2	118	Mean Difference (IV, Random, 95% CI)	3.80 [-4.96, 12.56]
micronutrients				
26 All cause morbidity (ALL)	1	194	Risk Ratio (M-H, Random, 95% CI)	0.26 [0.03, 2.24]
27 Any side effects (ALL)	1	53	Risk Ratio (M-H, Fixed, 95% CI)	3.87 [0.19, 76.92]
28 Nausea	1	64	Risk Ratio (M-H, Random, 95% CI)	2.82 [0.12, 66.82]
29 Adherence (ALL)	2	289	Risk Ratio (M-H, Random, 95% CI)	1.04 [0.98, 1.09]
30 Mental development scale	1	172	Mean Difference (IV, Random, 95% CI)	2.0 [-2.40, 6.40]
(ALL)				
31 Orientation engagement (ALL)	1	172	Mean Difference (IV, Random, 95% CI)	8.40 [-1.79, 18.59]
32 Emotional regulation (ALL)	1	172	Mean Difference (IV, Random, 95% CI)	-2.5 [-11.58, 6.58]
33 Motor quality (ALL)	1	172	Mean Difference (IV, Random, 95% CI)	15.60 [7.66, 23.54]
34 Psychomotor development	1	172	Mean Difference (IV, Random, 95% CI)	6.90 [1.35, 12.45]
index (ALL)				
35 IQ (ALL)	1	252	Mean Difference (IV, Random, 95% CI)	-3.00 [-5.96, -0.04]
36 Thai language (ALL)	1	208	Mean Difference (IV, Random, 95% CI)	-0.30 [-0.50, -0.09]
37 Mathematics (ALL)	1	233	Mean Difference (IV, Random, 95% CI)	-0.27 [-0.44, -0.10]
38 WAZ	3	366	Std. Mean Difference (IV, Random, 95% CI)	-0.03 [-0.33, 0.27]
39 HAZ	3	366	Mean Difference (IV, Random, 95% CI)	0.03 [-0.04, 0.10]

Comparison 2. Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Anaemia (ALL)	6	980	Risk Ratio (M-H, Random, 95% CI)	1.23 [1.04, 1.47]
2 Anaemia (by dose of elemental iron in the intermittent group)	6	980	Risk Ratio (M-H, Random, 95% CI)	1.23 [1.04, 1.47]
2.1 25 mg or less/week	2	404	Risk Ratio (M-H, Random, 95% CI)	1.20 [0.98, 1.47]
2.2 Greater than 25 mg to 75 mg/week	4	576	Risk Ratio (M-H, Random, 95% CI)	1.34 [0.96, 1.88]
2.3 Intermittent group: greater than 75 mg/week	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
3 Anaemia (by duration of the supplementation)	6	980	Risk Ratio (M-H, Random, 95% CI)	1.23 [1.04, 1.47]
3.1 0 to three months	2	172	Risk Ratio (M-H, Random, 95% CI)	1.24 [0.55, 2.77]
3.2 More than three months	4	808	Risk Ratio (M-H, Random, 95% CI)	1.23 [1.03, 1.47]

				development in children under 12 years of age (Revi	
	15.1 Girls	19	42	Mean Difference (IV, Random, 95% CI) Mean Difference (IV, Random, 95% CI)	-0.60 [-1.34, 0.33] -2.0 [-5.43, 1.43]
	egimen Iaemoglobin (by sex)	19	2851	Mean Difference (IV, Random, 95% CI)	-0.60 [-1.54, 0.35]
	14.2 Other intermittent	8	1239	Mean Difference (IV, Random, 95% CI)	-1.42 [-3.02, 0.19]
	14.1 One supplement a week	14	1612	Mean Difference (IV, Random, 95% CI)	-0.25 [-1.57, 1.07]
	upplementation regimen)	• /	1/		
	Haemoglobin (by	19	2851	Mean Difference (IV, Random, 95% CI)	-0.70 [-1.70, 0.30]
	13.3 Mixed/unknown	10	1728	Mean Difference (IV, Random, 95% CI)	-0.76 [-2.00, 0.48]
	13.2 Non-anaemic	3	166	Mean Difference (IV, Random, 95% CI)	0.79 [-1.42, 2.99]
	13.1 Anaemic	7	957	Mean Difference (IV, Random, 95% CI)	-0.76 [-2.59, 1.07]
	tatus at baseline)				-
13 F	Haemoglobin (by anaemia	19	2851	Mean Difference (IV, Random, 95% CI)	-0.61 [-1.54, 0.32]
	12.3 Other	2	118	Mean Difference (IV, Random, 95% CI)	-0.46 [-4.24, 3.32]
	12.2 Ferrous fumarate	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
	12.1 Ferrous sulphate	17	2733	Mean Difference (IV, Random, 95% CI)	-0.60 [-1.60, 0.40]
	ompound)	1)	2071	main Difference (17, Nandolli, 77/0 Cl)	0.00 [1.94, 0.99]
	Haemoglobin (by type of	19	2851	Mean Difference (IV, Random, 95% CI)	-0.60 [-1.54, 0.35]
	11.2 More than three months	8	1387	Mean Difference (IV, Random, 95% CI)	-1.14 [-2.07, -0.22]
	11.1 0 to three months	11	1455	Mean Difference (IV, Random, 95% CI)	0.47 [-0.91, 1.84]
	Haemoglobin (by duration of he supplementation)	19	2842	Mean Difference (IV, Random, 95% CI)	-0.38 [-1.26, 0.50]
	10.3 Greater than 75 mg/week	2	137	Mean Difference (IV, Random, 95% CI)	1.00 [-4.68, 6.68]
	5 mg/week	2	127	Mar Difference (IV D 1 050/ CI)	
	10.2 Greater than 25 mg to	13	2078	Mean Difference (IV, Random, 95% CI)	-0.58 [-1.62, 0.45]
	10.1 25 mg or less/week	3	536	Mean Difference (IV, Random, 95% CI)	-2.42 [-4.18, -0.66]
	ntermittent group)				
	f elemental iron in the				
	Haemoglobin (by dose	18	2751	Mean Difference (IV, Random, 95% CI)	-0.62 [-1.60, 0.37]
	aemoglobin (ALL)	19	2851	Mean Difference (IV, Random, 95% CI)	-0.60 [-1.54, 0.35]
	nicronutrients				
	8.3 Iron + multiple	1	107	Risk Ratio (M-H, Random, 95% CI)	1.31 [0.31, 5.57]
	8.2 Iron + folic acid	1	366	Risk Ratio (M-H, Random, 95% CI)	1.55 [1.02, 2.36]
	8.1 Iron alone	4	507	Risk Ratio (M-H, Random, 95% CI)	1.17 [0.97, 1.42]
	naemia (by nutrient)	6	980	Risk Ratio (M-H, Random, 95% CI)	1.23 [1.04, 1.47]
	7.3 Mixed/unknown	6	980	Risk Ratio (M-H, Random, 95% CI)	1.23 [1.04, 1.47]
	7.2 Boys	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
	7.1 Girls	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
	naemia (by sex)	6	980	Risk Ratio (M-H, Random, 95% CI)	1.23 [1.04, 1.47]
	egimen	L	431	Risk Ratio (M-H, Random, 95% CI)	1.49 [1.02, 2.19]
	6.1 One supplement a week 6.2 Other intermittent	4	549 431	Risk Ratio (M-H, Random, 95% CI)	1.18 [0.97, 1.43]
	egimen) 6 1 One supplement e week	4	540	Piele Patie (M H Pandam 05% CI)	1 19 [0 07 1 /2]
	naemia (by supplementation	6	980	Risk Ratio (M-H, Random, 95% CI)	1.23 [1.04, 1.47]
	5.3 Mixed/unknown	4	797	Risk Ratio (M-H, Random, 95% CI)	1.26 [1.05, 1.51]
	5.2 Non-anaemic	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
	5.1 Anaemic	2	183	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.50, 1.82]
	aseline)				
5 Ar	naemia (by anaemia status at	6	980	Risk Ratio (M-H, Random, 95% CI)	1.23 [1.04, 1.47]
	4.3 Other	0	0	Risk Ratio (M-H, Random, 95% CI)	$0.0 \ [0.0, \ 0.0]$
	4.2 Ferrous fumarate	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
	4.1 Ferrous sulphate	6	980	Risk Ratio (M-H, Random, 95% CI)	1.23 [1.04, 1.47]
	naemia (by type of compound)	6	980	Risk Ratio (M-H, Random, 95% CI)	1.23 [1.04, 1.47]

15 2 D	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
15.2 Boys 15.3 Mixed/unknown	18	2809	Mean Difference (IV, Random, 95% CI)	-0.53 [-1.51, 0.46]
16 Haemoglobin (by nutrient)	19	2851	Mean Difference (IV, Random, 95% CI)	-0.59 [-1.52, 0.35]
16.1 Iron alone	15	2144	Mean Difference (IV, Random, 95% CI)	-0.51 [-1.61, 0.59]
16.2 Iron + folic acid	2	408	Mean Difference (IV, Random, 95% CI)	-2.26 [-4.30, -0.22]
16.3 Iron + multiple	3	299	Mean Difference (IV, Random, 95% CI)	0.61 [-2.04, 3.26]
micronutrients				
17 Iron deficiency (ALL)	1	76	Risk Ratio (M-H, Random, 95% CI)	4.0 [1.23, 13.05]
18 Ferritin (ALL)	10	902	Mean Difference (IV, Random, 95% CI)	-4.19 [-9.42, 1.05]
19 Ferritin (by dose of elemental	9	802	Mean Difference (IV, Random, 95% CI)	-4.34 [-10.20, 1.53]
iron in the intermittent group)				
19.1 by dose of elemental iron	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
in the intermittent group: 25				
mg or less/week				
19.2 by dose of elemental	9	802	Mean Difference (IV, Random, 95% CI)	-4.34 [-10.20, 1.53]
iron in the intermittent group:				
greater than 25 mg to 75 mg/				
week	0	0		
19.3 by dose of elemental iron in the intermittent group:	0	0	Mean Difference (IV, Random, 95% CI)	$0.0 \ [0.0, \ 0.0]$
greater than 75 mg/week				
20 Ferritin (by duration of the	10	902	Mean Difference (IV, Random, 95% CI)	-4.19 [-9.42, 1.05]
supplementation)	10	702	Wear Difference (17, Randolli, 9976 Ci)	-1.17 [-7.12, 1.07]
20.1 by duration of the	6	442	Mean Difference (IV, Random, 95% CI)	-1.06 [-6.62, 4.51]
supplementation: 0 to three	0			100 [0102, 1191]
months				
20.2 by duration of the	4	460	Mean Difference (IV, Random, 95% CI)	-9.58 [-23.08, 3.93]
supplementation: more than				
three months				
21 Ferritin (by type of compound)	10	902	Mean Difference (IV, Random, 95% CI)	-4.19 [-9.42, 1.05]
21.1 by type of compound:	9	826	Mean Difference (IV, Random, 95% CI)	-3.85 [-9.28, 1.59]
ferrous sulphate				
21.2 by type of compound:	0	0	Mean Difference (IV, Random, 95% CI)	$0.0 \ [0.0, \ 0.0]$
ferrous fumarate				
21.3 by type of compound:	1	76	Mean Difference (IV, Random, 95% CI)	-9.03 [-23.95, 5.89]
other	10			
22 Ferritin (by anaemia status at	10	902	Mean Difference (IV, Random, 95% CI)	-4.93 [-9.98, 0.12]
baseline)	E	205		204[1222 (24]
22.1 by anaemia status at baseline: anaemic	5	285	Mean Difference (IV, Random, 95% CI)	-2.94 [-12.23, 6.34]
	2	167	Mean Difference (IV, Random, 95% CI)	267[590.054]
22.2 by anaemia status at baseline: non-anaemic	3	10/	Mean Difference (IV, Kandolii, 9970 CI)	-2.67 [-5.89, 0.54]
22.3 by anaemia status at	3	450	Mean Difference (IV, Random, 95% CI)	-9.42 [-23.19, 4.35]
baseline: mixed/unknown	5	4)0	Wear Difference (17, Randolli, 9976 Ci)	-7.42 [-25.17, 4.57]
23 Ferritin (by supplementation	10	902	Mean Difference (IV, Random, 95% CI)	-4.48 [-9.68, 0.71]
regimen)		, U		
23.1 by supplementation	7	595	Mean Difference (IV, Random, 95% CI)	-7.34 [-16.12, 1.44]
regimen: one supplement a	-			
week				

23.2 by supplementation regimen: other intermittent	5	307	Mean Difference (IV, Random, 95% CI)	-0.93 [-3.94, 2.08]
regimen				
24 Ferritin (by sex)	10	902	Mean Difference (IV, Random, 95% CI)	-4.19 [-9.42, 1.05]
24.1 by sex: girls	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
24.2 by sex: boys	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
24.3 by sex: mixed/unknown	10	902	Mean Difference (IV, Random, 95% CI)	-4.19 [-9.42, 1.05]
25 Ferritin (by nutrient)	10	902	Mean Difference (IV, Random, 95% CI)	-4.19 [-9.42, 1.05]
25.1 By nutrient: iron alone	9	826	Mean Difference (IV, Random, 95% CI)	-3.85 [-9.28, 1.59]
25.2 By nutrient: iron + folic	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
acid				
25.3 By nutrient: iron +	1	76	Mean Difference (IV, Random, 95% CI)	-9.03 [-23.95, 5.89]
multiple micronutrients				
26 Increase in steps climbed (ALL)	1	65	Mean Difference (IV, Random, 95% CI)	-5.0 [-13.34, 3.34]
27 All cause morbidity (ALL)	2	599	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.83, 1.12]
28 Diarrhoea (ALL)	2	122	Risk Ratio (M-H, Random, 95% CI)	1.17 [0.60, 2.28]
29 Any side effects (ALL)	4	895	Risk Ratio (M-H, Random, 95% CI)	0.60 [0.19, 1.87]
30 Adherence (ALL)	5	1130	Risk Ratio (M-H, Random, 95% CI)	1.23 [0.98, 1.54]
31 IQ (ALL)	1	252	Mean Difference (IV, Random, 95% CI)	-3.00 [-5.96, -0.04]
32 Thai language (ALL)	1	208	Mean Difference (IV, Random, 95% CI)	-0.30 [-0.50, -0.09]
33 Mathematics (ALL)	1	233	Mean Difference (IV, Random, 95% CI)	-0.27 [-0.44, -0.10]
34 HAZ	3	279	Std. Mean Difference (IV, Random, 95% CI)	-0.26 [-0.80, 0.28]

Comparison 3. Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Anaemia (ALL)	4	658	Risk Ratio (M-H, Random, 95% CI)	0.43 [0.23, 0.80]
2 Anaemia (by dose of elemental iron in the intermittent group)	4	658	Risk Ratio (M-H, Random, 95% CI)	0.43 [0.23, 0.80]
2.1 25 mg or less/week	2	157	Risk Ratio (M-H, Random, 95% CI)	0.15 [0.06, 0.37]
2.2 Greater than 25 mg to 75 mg/week	2	501	Risk Ratio (M-H, Random, 95% CI)	0.61 [0.51, 0.74]
2.3 Greater than 75 mg/week	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
3 Anaemia (by duration of the supplementation)	4	658	Risk Ratio (M-H, Random, 95% CI)	0.43 [0.23, 0.80]
3.1 0 to three months	3	608	Risk Ratio (M-H, Random, 95% CI)	0.48 [0.27, 0.85]
3.2 More than three months	1	50	Risk Ratio (M-H, Random, 95% CI)	0.06 [0.00, 0.97]
4 Anaemia (by type of compound)	4	658	Risk Ratio (M-H, Random, 95% CI)	0.43 [0.23, 0.80]
4.1 Ferrous sulphate	3	351	Risk Ratio (M-H, Random, 95% CI)	0.26 [0.07, 1.03]
4.2 Ferrous fumarate	1	307	Risk Ratio (M-H, Random, 95% CI)	0.61 [0.49, 0.74]
4.3 Other	0	0	Risk Ratio (M-H, Random, 95% CI)	$0.0 \ [0.0, \ 0.0]$
5 Anaemia (by anaemia status at baseline)	4	658	Risk Ratio (M-H, Random, 95% CI)	0.43 [0.23, 0.80]
5.1 Anaemic	1	307	Risk Ratio (M-H, Random, 95% CI)	0.61 [0.49, 0.74]
5.2 Non-anaemic	0	0	Risk Ratio (M-H, Random, 95% CI)	$0.0 \ [0.0, \ 0.0]$
5.3 Mixed/unknown	3	351	Risk Ratio (M-H, Random, 95% CI)	0.26 [0.07, 1.03]

6 Anaemia (by intermittent regimen)	4	658	Risk Ratio (M-H, Random, 95% CI)	0.43 [0.23, 0.80]
6.1 One supplement a week	3	351	Risk Ratio (M-H, Random, 95% CI)	0.26 [0.07, 1.03]
6.2 Other intermittent	1	307	Risk Ratio (M-H, Random, 95% CI)	0.61 [0.49, 0.74]
regimen		0.07		
7 Anaemia (by sex)	4	658	Risk Ratio (M-H, Random, 95% CI)	0.43 [0.23, 0.80]
7.1 Girls	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
7.2 Boys	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
7.3 Mixed/unknown	4	658	Risk Ratio (M-H, Random, 95% CI)	0.43 [0.23, 0.80]
8 Anaemia (by nutrient)	4	658	Risk Ratio (M-H, Random, 95% CI)	0.43 [0.23, 0.80]
8.1 Iron alone	2	501	Risk Ratio (M-H, Random, 95% CI)	0.61 [0.51, 0.74]
8.2 Iron + folic acid	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
8.3 iron + vitamin C	1	50	Risk Ratio (M-H, Random, 95% CI)	0.06 [0.00, 0.97]
8.4 Iron + multiple	1	107	Risk Ratio (M-H, Random, 95% CI)	0.16 [0.06, 0.44]
micronutrients				
9 Haemoglobin (ALL)	9	1254	Mean Difference (IV, Random, 95% CI)	6.45 [2.36, 10.55]
10 Haemoglobin (by dose	9	1254	Mean Difference (IV, Random, 95% CI)	6.45 [2.36, 10.55]
of elemental iron in the				
intermittent group)				
10.1 25 mg or less/week	3	324	Mean Difference (IV, Random, 95% CI)	8.19 [-4.01, 20.38]
10.2 Greater than 25 mg to	6	930	Mean Difference (IV, Random, 95% CI)	5.50 [2.64, 8.36]
75 mg/week				
10.3 Greater than 75 mg/week	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
11 Haemoglobin (by duration of	9	1254	Mean Difference (IV, Random, 95% CI)	6.45 [2.36, 10.55]
the supplementation)				
11.1 0 to three months	4	643	Mean Difference (IV, Random, 95% CI)	6.64 [3.01, 10.27]
11.2 More than three months	5	611	Mean Difference (IV, Random, 95% CI)	6.16 [-1.55, 13.87]
12 Haemoglobin (by type of iron	9	1254	Mean Difference (IV, Random, 95% CI)	6.45 [2.36, 10.55]
compound)				
12.1 Ferrous sulphate	7	873	Mean Difference (IV, Random, 95% CI)	6.54 [1.44, 11.63]
12.2 Ferrous fumarate	1	307	Mean Difference (IV, Random, 95% CI)	8.0 [5.00, 11.00]
12.3 Other	1	74	Mean Difference (IV, Random, 95% CI)	4.06 [-1.32, 9.44]
13 Haemoglobin (by anaemia	9	1254	Mean Difference (IV, Random, 95% CI)	6.45 [2.36, 10.55]
status at baseline)				
13.1 Anaemic	1	307	Mean Difference (IV, Random, 95% CI)	8.0 [5.00, 11.00]
13.2 Non-anaemic	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
13.3 Mixed/unknown	8	947	Mean Difference (IV, Random, 95% CI)	6.25 [1.60, 10.90]
14 Haemoglobin (by	9	1254	Mean Difference (IV, Random, 95% CI)	6.45 [2.36, 10.55]
supplementation regimen)				
14.1 One supplement a week	6	699	Mean Difference (IV, Random, 95% CI)	7.35 [0.92, 13.77]
14.2 Other intermittent	3	555	Mean Difference (IV, Random, 95% CI)	4.68 [1.28, 8.08]
regimen				
15 Haemoglobin (by sex)	9	1254	Mean Difference (IV, Random, 95% CI)	6.45 [2.36, 10.55]
15.1 Girls	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
15.2 Boys	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
15.3 Mixed/unknown	9	1254	Mean Difference (IV, Random, 95% CI)	6.45 [2.36, 10.55]
16 Haemoglobin (by nutrient)	9	1254	Mean Difference (IV, Random, 95% CI)	6.01 [2.13, 9.89]
16.1 Iron alone	5	744	Mean Difference (IV, Random, 95% CI)	3.81 [1.61, 6.01]
16.2 Iron + folic acid	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
16.3 Iron + multiple micronutrients	5	510	Mean Difference (IV, Random, 95% CI)	8.46 [0.60, 16.32]

18 Ferritin (ALL)	4	310	Mean Difference (IV, Random, 95% CI)	13.15 [-2.28, 28.59]
19 Ferritin (by dose of iron in the	4	310	Mean Difference (IV, Random, 95% CI)	13.15 [-2.28, 28.59]
intermittent group)				
19.1 25 mg or less/week	1	148	Mean Difference (IV, Random, 95% CI)	4.60 [-0.89, 10.09]
19.2 Greater than 25 mg to	3	162	Mean Difference (IV, Random, 95% CI)	16.91 [0.99, 32.82]
75 mg/week				
19.3 Greater than 75 mg/week	0	0	Mean Difference (IV, Random, 95% CI)	$0.0 \ [0.0, \ 0.0]$
20 Ferritin (by duration of the	4	310	Mean Difference (IV, Random, 95% CI)	13.15 [-2.28, 28.59]
supplementation)				
20.1 0 to three months	1	35	Mean Difference (IV, Random, 95% CI)	15.80 [-1.23, 32.83]
20.2 More than three months	3	275	Mean Difference (IV, Random, 95% CI)	12.34 [-6.19, 30.87]
21 Ferritin (by type of iron	4	310	Mean Difference (IV, Random, 95% CI)	13.15 [-2.28, 28.59]
compound)				
21.1 Ferrous sulphate	3	236	Mean Difference (IV, Random, 95% CI)	16.12 [-1.81, 34.05]
21.2 Ferrous fumarate	0	0	Mean Difference (IV, Random, 95% CI)	$0.0 \ [0.0, \ 0.0]$
21.3 Other	1	74	Mean Difference (IV, Random, 95% CI)	2.46 [-14.37, 19.29]
22 Ferritin (by anaemia status at	4	310	Mean Difference (IV, Random, 95% CI)	13.15 [-2.28, 28.59]
baseline)				
22.1 by anaemia status at	0	0	Mean Difference (IV, Random, 95% CI)	$0.0 \ [0.0, \ 0.0]$
baseline: anaemic				
22.2 by anaemia status at	1	74	Mean Difference (IV, Random, 95% CI)	2.46 [-14.37, 19.29]
baseline: non-anaemic				
22.3 by anaemia status at	3	236	Mean Difference (IV, Random, 95% CI)	16.12 [-1.81, 34.05]
baseline: mixed/unknown				
23 Ferritin (by supplementation	4	310	Mean Difference (IV, Random, 95% CI)	13.15 [-2.28, 28.59]
regimen)				
23.1 One supplement a week	3	257	Mean Difference (IV, Random, 95% CI)	5.37 [0.39, 10.36]
23.2 Other intermittent	1	53	Mean Difference (IV, Random, 95% CI)	27.80 [22.88, 32.72]
regimen				
24 Ferritin (by sex)	4	310	Mean Difference (IV, Random, 95% CI)	13.15 [-2.28, 28.59]
24.1 Girls	0	0	Mean Difference (IV, Random, 95% CI)	$0.0 \ [0.0, \ 0.0]$
24.2 Boys	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
24.3 Mixed/unknown	4	310	Mean Difference (IV, Random, 95% CI)	13.15 [-2.28, 28.59]
25 Ferritin (by nutrient)	4	310	Mean Difference (IV, Random, 95% CI)	11.15 [-1.92, 24.22]
25.1 Iron alone	3	144	Mean Difference (IV, Random, 95% CI)	15.70 [-2.68, 34.08]
25.2 Iron + folic acid	0	0	Mean Difference (IV, Random, 95% CI)	$0.0 \ [0.0, \ 0.0]$
25.3 Iron + multiple	2	166	Mean Difference (IV, Random, 95% CI)	4.58 [-2.27, 11.43]
micronutrients				
26 All cause morbidity (ALL)	1	194	Risk Ratio (M-H, Random, 95% CI)	0.26 [0.03, 2.24]
27 Any side effects (ALL)	1	53	Risk Ratio (M-H, Random, 95% CI)	3.87 [0.19, 76.92]
28 Adherence (ALL)	2	289	Risk Ratio (M-H, Random, 95% CI)	1.04 [0.98, 1.09]
29 Mental development scale (ALL)	1	172	Mean Difference (IV, Random, 95% CI)	2.0 [-2.40, 6.40]
30 Orientation engagement (ALL)	1	172	Mean Difference (IV, Random, 95% CI)	8.40 [-1.79, 18.59]
31 Emotional regulation (ALL)	1	172	Mean Difference (IV, Random, 95% CI)	-2.5 [-11.58, 6.58]
32 Motor quality (ALL)	1	172	Mean Difference (IV, Random, 95% CI)	15.60 [7.66, 23.54]
33 Psychomotor development	1	172	Mean Difference (IV, Random, 95% CI)	6.90 [1.35, 12.45]
index (ALL)	1	1/2	ivican Difference (1v, Rahdolii, 7970 CI)	0.70 [1.33, 12.43]
34 HAZ	2	302	Mean Difference (IV, Random, 95% CI)	0.04 [-0.03, 0.11]
	4	502	mean Difference (17, Randolli, 77/0 CI)	0.04 [-0.03, 0.11]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Anaemia (ALL)	3	770	Risk Ratio (M-H, Random, 95% CI)	1.26 [1.05, 1.51]
2 Haemoglobin (ALL)	14	2270	Mean Difference (IV, Random, 95% CI)	-0.75 [-1.80, 0.29]
3 Haemoglobin (by dose	14	2438	Mean Difference (IV, Random, 95% CI)	-0.82 [-1.82, 0.18]
of elemental iron in the				
intermittent group)				
3.1 25 mg or less/week	3	536	Mean Difference (IV, Random, 95% CI)	-2.42 [-4.18, -0.66]
3.2 Greater than 25 mg to 75 mg/week	11	1902	Mean Difference (IV, Random, 95% CI)	-0.45 [-1.59, 0.68]
3.3 Greater than 75 mg/week	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
4 Haemoglobin (by duration of supplementation)	14	2270	Mean Difference (IV, Random, 95% CI)	-0.75 [-1.80, 0.29]
4.1 0 to three months	9	1309	Mean Difference (IV, Random, 95% CI)	-0.15 [-1.66, 1.36]
4.2 More than three months	5	961	Mean Difference (IV, Random, 95% CI)	-1.53 [-2.95, -0.11]
5 Haemoglobin (by type of compound)	14	2270	Mean Difference (IV, Random, 95% CI)	-0.75 [-1.80, 0.29]
5.1 Ferrous sulphate	13	2194	Mean Difference (IV, Random, 95% CI)	-0.85 [-1.91, 0.21]
5.2 Ferrous fumarate	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
5.3 Other	1	76	Mean Difference (IV, Random, 95% CI)	1.96 [-3.05, 6.97]
6 Haemoglobin (by anaemia status at baseline)	14	2270	Mean Difference (IV, Random, 95% CI)	-0.75 [-1.80, 0.29]
6.1 Anaemic	5	834	Mean Difference (IV, Random, 95% CI)	-0.57 [-2.81, 1.68]
6.2 Non-anaemic	2	113	Mean Difference (IV, Random, 95% CI)	1.99 [-0.72, 4.70]
6.3 Mixed/unknown	7	1323	Mean Difference (IV, Random, 95% CI)	-1.20 [-2.22, -0.19]
7 Haemoglobin (by	14	2270	Mean Difference (IV, Random, 95% CI)	-0.72 [-1.71, 0.27]
supplementation regimen)				
7.1 One supplement a week	9	1054	Mean Difference (IV, Random, 95% CI)	-0.23 [-1.67, 1.21]
7.2 Other intermittent regimen	7	1216	Mean Difference (IV, Random, 95% CI)	-1.14 [-2.57, 0.29]
8 Haemoglobin (by sex)	14	2270	Mean Difference (IV, Random, 95% CI)	-0.75 [-1.80, 0.29]
8.1 Girls	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
8.2 Boys	0	0	Mean Difference (IV, Random, 95% CI)	$0.0 \ [0.0, \ 0.0]$
8.3 Mixed/unknown	14	2270	Mean Difference (IV, Random, 95% CI)	-0.75 [-1.80, 0.29]
9 Haemoglobin (by nutrient)	14	2270	Mean Difference (IV, Random, 95% CI)	-0.75 [-1.80, 0.29]
9.1 Iron alone	10	1490	Mean Difference (IV, Random, 95% CI)	-0.80 [-2.05, 0.46]
9.2 Iron + folic acid	1	366	Mean Difference (IV, Random, 95% CI)	-2.40 [-4.94, 0.14]
9.3 Iron + multiple micronutrients	3	414	Mean Difference (IV, Random, 95% CI)	0.57 [-1.84, 2.98]
10 Iron deficiency (ALL)	1	76	Risk Ratio (M-H, Random, 95% CI)	4.0 [1.23, 13.05]
11 Ferritin (ALL)	8	582	Mean Difference (IV, Random, 95% CI)	-3.10 [-6.59, 0.39]
12 Ferritin (by dose of elemental iron in the intermittent subgroup)	8	582	Mean Difference (IV, Random, 95% CI)	-2.22 [-6.03, 1.59]
12.1 25 mg or less/week	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
12.2 Greater than 25 mg to 75 mg/week	8	582	Mean Difference (IV, Random, 95% CI)	-2.22 [-6.03, 1.59]
12.3 Greater than 75 mg/week	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]

Comparison 4. Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months

13 Ferritin (by duration of supplementation)	8	582	Mean Difference (IV, Random, 95% CI)	-3.10 [-6.59, 0.39]
13.1 0 to three months	5	382	Mean Difference (IV, Random, 95% CI)	-3.02 [-7.91, 1.87]
13.2 More than three months	3	200	Mean Difference (IV, Random, 95% CI)	-1.63 [-5.88, 2.62]
14 Ferritin (by type of compound)	8	582	Mean Difference (IV, Random, 95% CI)	-3.10 [-6.59, 0.39]
14.1 Ferrous sulphate	7	506	Mean Difference (IV, Random, 95% CI)	-2.69 [-6.42, 1.05]
14.2 Ferrous fumarate	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
14.3 Other	1	76	Mean Difference (IV, Random, 95% CI)	-9.03 [-23.95, 5.89]
15 Ferritin (by anaemia status at	8	582	Mean Difference (IV, Random, 95% CI)	-3.70 [-8.25, 0.86]
baseline)				
15.1 Anaemic	4	225	Mean Difference (IV, Random, 95% CI)	-4.47 [-15.45, 6.52]
15.2 Non-anaemic	3	167	Mean Difference (IV, Random, 95% CI)	-2.67 [-5.89, 0.54]
15.3 Mixed/unknown	2	190	Mean Difference (IV, Random, 95% CI)	-1.53 [-5.23, 2.17]
16 Ferritin (by supplementation	8	582	Mean Difference (IV, Random, 95% CI)	-3.27 [-7.87, 1.33]
regimen)				
16.1 One supplement a week	5	291	Mean Difference (IV, Random, 95% CI)	-6.21 [-12.98, 0.55]
16.2 Other intermittent	4	291	Mean Difference (IV, Random, 95% CI)	-0.81 [-3.89, 2.27]
regimen				
17 Ferritin (by sex)	8	582	Mean Difference (IV, Random, 95% CI)	-3.10 [-6.58, 0.39]
17.1 Girls	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
17.2 Boys	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
17.3 Mixed/unknown	8	582	Mean Difference (IV, Random, 95% CI)	-3.10 [-6.58, 0.39]
18 Ferritin (by nutrient)	8	582	Mean Difference (IV, Random, 95% CI)	-3.10 [-6.59, 0.39]
18.1 Iron alone	7	506	Mean Difference (IV, Random, 95% CI)	-2.69 [-6.42, 1.05]
18.2 Iron + folic acid	0	0	Mean Difference (IV, Random, 95% CI)	$0.0 \ [0.0, \ 0.0]$
18.3 Iron + multiple	1	76	Mean Difference (IV, Random, 95% CI)	-9.03 [-23.95, 5.89]
micronutrients				
19 All cause morbidity (ALL)	1	522	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.82, 1.16]
20 Diarrhoea (ALL)	1	45	Risk Ratio (M-H, Random, 95% CI)	2.88 [0.12, 67.03]
21 Any side effects (ALL)	4	895	Risk Ratio (M-H, Random, 95% CI)	0.60 [0.19, 1.87]
22 Adherence (ALL)	3	1185	Risk Ratio (M-H, Random, 95% CI)	1.29 [1.15, 1.45]
23 HAZ	1	109	Std. Mean Difference (IV, Random, 95% CI)	-0.15 [-0.52, 0.23]
24 WAZ	1	109	Std. Mean Difference (IV, Random, 95% CI)	-0.44 [-0.82, -0.06]

Comparison 5. Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Anaemia (ALL)	6	1166	Risk Ratio (M-H, Random, 95% CI)	0.54 [0.33, 0.90]
2 Anaemia (by dose)	6	1166	Risk Ratio (M-H, Random, 95% CI)	0.54 [0.33, 0.90]
2.1 25 mg or less/week	0	0	Risk Ratio (M-H, Random, 95% CI)	$0.0 \ [0.0, \ 0.0]$
2.2 Greater than 25 mg to 75 mg/week	4	755	Risk Ratio (M-H, Random, 95% CI)	0.47 [0.21, 1.02]
2.3 Greater than 75 mg/week	2	411	Risk Ratio (M-H, Random, 95% CI)	0.71 [0.48, 1.04]
3 Anaemia (by duration)	6	1166	Risk Ratio (M-H, Random, 95% CI)	0.54 [0.33, 0.90]
3.1 0 to three months	2	848	Risk Ratio (M-H, Random, 95% CI)	0.77 [0.67, 0.89]
3.2 More than three months	4	318	Risk Ratio (M-H, Random, 95% CI)	0.44 [0.16, 1.24]
4 Anaemia (by type of compound)	6	1166	Risk Ratio (M-H, Random, 95% CI)	0.54 [0.33, 0.90]
4.1 Ferrous sulphate	6	1166	Risk Ratio (M-H, Random, 95% CI)	0.54 [0.33, 0.90]

4.2 Ferrous fumarate	0	0	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
4.3 Other	0	0	Risk Ratio (M-H, Random, 95% CI)	$0.0 \ [0.0, \ 0.0]$
5 Anaemia (by anaemia status at	6	1166	Risk Ratio (M-H, Random, 95% CI)	0.54 [0.33, 0.90]
baseline)				
5.1 Anaemic	1	117	Risk Ratio (M-H, Random, 95% CI)	0.14 [0.07, 0.27]
5.2 Non-anaemic	1	64	Risk Ratio (M-H, Random, 95% CI)	0.78 [0.27, 2.31]
5.3 Mixed/unknown	4	985	Risk Ratio (M-H, Random, 95% CI)	0.73 [0.54, 0.98]
6 Anaemia (by intermittent regimen)	6	1166	Risk Ratio (M-H, Random, 95% CI)	0.54 [0.33, 0.90]
6.1 One supplement a week	6	1166	Risk Ratio (M-H, Random, 95% CI)	0.54 [0.33, 0.90]
6.2 Other intermittent	0	0	Risk Ratio (M-H, Random, 95% CI)	$0.0 \ [0.0, \ 0.0]$
regimen				
7 Anaemia (by sex)	6	1166	Risk Ratio (M-H, Random, 95% CI)	0.59 [0.40, 0.86]
7.1 Girls	1	248	Risk Ratio (M-H, Random, 95% CI)	0.75 [0.59, 0.95]
7.2 Boys	1	253	Risk Ratio (M-H, Random, 95% CI)	0.81 [0.66, 1.00]
7.3 Mixed/unknown	5	665	Risk Ratio (M-H, Random, 95% CI)	0.49 [0.24, 1.01]
8 Anaemia (by nutrient)	6	1166	Risk Ratio (M-H, Random, 95% CI)	0.54 [0.33, 0.90]
8.1 Iron alone	4	573	Risk Ratio (M-H, Random, 95% CI)	0.39 [0.17, 0.90]
8.2 Iron + folic acid	2	593	Risk Ratio (M-H, Random, 95% CI)	0.83 [0.66, 1.03]
8.3 Iron + multiple	0	0	Risk Ratio (M-H, Random, 95% CI)	$0.0 \ [0.0, \ 0.0]$
micronutrients				
9 Haemoglobin (ALL)	10	1778	Mean Difference (IV, Random, 95% CI)	4.04 [0.30, 7.78]
10 Haemoglobin (by dose	10	1778	Mean Difference (IV, Random, 95% CI)	4.04 [0.30, 7.78]
of elemental iron in the				
intermittent group)				
10.1 25 mg or less/week	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
10.2 Greater than 25 mg to	6	1129	Mean Difference (IV, Random, 95% CI)	5.24 [-0.78, 11.26]
75 mg/week				
10.3 Group: greater than 75	4	649	Mean Difference (IV, Random, 95% CI)	1.84 [0.25, 3.44]
mg/week	-	01)		101 [0129, 9111]
11 Haemoglobin (by duration of	10	1778	Mean Difference (IV, Random, 95% CI)	4.04 [0.30, 7.78]
the supplementation)				
11.1 0 to three months	3	973	Mean Difference (IV, Random, 95% CI)	3.13 [1.49, 4.77]
11.2 More than three months	7	805	Mean Difference (IV, Random, 95% CI)	4.38 [-1.20, 9.96]
12 Haemoglobin (by type of iron	10	1778	Mean Difference (IV, Random, 95% CI)	4.04 [0.30, 7.78]
compound)	10	1//0		1.01 [0.50, 7.70]
12.1 Ferrous sulphate	7	1415	Mean Difference (IV, Random, 95% CI)	4.59 [-0.30, 9.47]
12.2 Ferrous fumarate	1	125	Mean Difference (IV, Random, 95% CI)	3.4 [-4.09, 10.89]
12.3 Other	2	238	Mean Difference (IV, Random, 95% CI)	1.79 [-1.25, 4.84]
13 Haemoglobin (by anaemia	10	1778	Mean Difference (IV, Random, 95% CI)	4.04 [0.30, 7.78]
status at baseline)	10	1770	Wear Difference (17, Kandolin, 7) /0 Ci	4.04 [0.50, 7.70]
13.1 Anaemic	1	115	Mean Difference (IV, Random, 95% CI)	18.30 [15.55, 21.05]
13.2 Non-anaemic	1	64	Mean Difference (IV, Random, 95% CI)	2.0 [-2.46, 6.46]
13.3 Mixed/unknown	8	1599	Mean Difference (IV, Random, 95% CI)	2.37 [1.17, 3.57]
14 Haemoglobin (by	10	1868	Mean Difference (IV, Random, 95% CI)	4.04 [0.45, 7.62]
supplementation regimen)				
14.1 One supplement a week	9	1647	Mean Difference (IV, Random, 95% CI)	4.43 [0.21, 8.65]
14.2 Other intermittent	2	221	Mean Difference (IV, Random, 95% CI)	1.17 [-1.27, 3.61]
regimen				
15 Haemoglobin (by sex)	10	1778	Mean Difference (IV, Random, 95% CI)	4.03 [0.51, 7.55]
15.1 Girls	1	248	Mean Difference (IV, Random, 95% CI)	4.0 [0.83, 7.17]
				-

15.2 Boys	1	253	Mean Difference (IV, Random, 95% CI)	3.70 [0.58, 6.82]
15.3 Mixed/unknown	9	1277	Mean Difference (IV, Random, 95% CI)	4.05 [-0.37, 8.46]
16 Haemoglobin (by nutrient)	10	1778	Mean Difference (IV, Random, 95% CI)	4.04 [0.30, 7.78]
16.1 Iron alone	6	1022	Mean Difference (IV, Random, 95% CI)	4.98 [-0.71, 10.68]
16.2 Iron + folic acid	4	756	Mean Difference (IV, Random, 95% CI)	2.91 [0.65, 5.16]
16.3 Iron + multiple	0	0	Mean Difference (IV, Random, 95% CI)	$0.0 \ [0.0, \ 0.0]$
micronutrients				
17 Ferritin (ALL)	1	240	Mean Difference (IV, Random, 95% CI)	16.6 [11.12, 22.08]
18 All cause morbidity (ALL)	1	194	Risk Ratio (M-H, Random, 95% CI)	0.26 [0.03, 2.24]
19 Any side effects (ALL)	1	53	Risk Ratio (M-H, Random, 95% CI)	3.87 [0.19, 76.92]
20 Nausea	1	64	Risk Ratio (M-H, Random, 95% CI)	2.82 [0.12, 66.82]
21 IQ (ALL)	1	252	Mean Difference (IV, Random, 95% CI)	-3.00 [-5.96, -0.04]
22 Thai language (ALL)	1	208	Mean Difference (IV, Random, 95% CI)	-0.30 [-0.50, -0.09]
23 Mathematics (ALL)	1	233	Mean Difference (IV, Random, 95% CI)	-0.27 [-0.44, -0.10]
24 Increase in steps climbed (ALL)	1	60	Mean Difference (IV, Random, 95% CI)	8.0 [-0.72, 16.72]
25 WAZ	1	64	Std. Mean Difference (IV, Random, 95% CI)	-0.24 [-0.74, 0.25]
26 HAZ	1	64	Mean Difference (IV, Fixed, 95% CI)	-0.24 [-0.69, 0.21]

Comparison 6. Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Anaemia (ALL)	2	145	Risk Ratio (M-H, Random, 95% CI)	0.95 [0.47, 1.91]
2 Haemoglobin (ALL)	5	581	Mean Difference (IV, Random, 95% CI)	-0.31 [-2.59, 1.97]
3 Haemoglobin (by dose of elemental iron)	5	581	Mean Difference (IV, Random, 95% CI)	-0.31 [-2.59, 1.97]
3.1 25 mg or less/week	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
3.2 Greater than 25 mg to 75 mg/week	3	444	Mean Difference (IV, Random, 95% CI)	-1.10 [-3.01, 0.80]
3.3 Intermittent group: greater than 75 mg/week	2	137	Mean Difference (IV, Random, 95% CI)	1.00 [-4.68, 6.68]
4 Haemoglobin (by duration of the supplementation)	5	581	Mean Difference (IV, Random, 95% CI)	-0.31 [-2.59, 1.97]
4.1 0 to three months	2	155	Mean Difference (IV, Random, 95% CI)	0.32 [-6.54, 7.18]
4.2 More than three months	3	426	Mean Difference (IV, Random, 95% CI)	-0.64 [-2.12, 0.84]
5 Haemoglobin (by type of compound)	5	581	Mean Difference (IV, Random, 95% CI)	-0.31 [-2.59, 1.97]
5.1 Ferrous sulphate	4	539	Mean Difference (IV, Random, 95% CI)	0.04 [-2.63, 2.71]
5.2 Ferrous fumarate	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
5.3 Other	1	42	Mean Difference (IV, Random, 95% CI)	-2.0 [-5.43, 1.43]
6 Haemoglobin (by baseline prevalence of anaemia)	5	581	Mean Difference (IV, Random, 95% CI)	-0.31 [-2.59, 1.97]
6.1 Anaemic	3	271	Mean Difference (IV, Random, 95% CI)	0.37 [-3.44, 4.17]
6.2 Non-anaemic	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
6.3 Mixed/unknown	2	310	Mean Difference (IV, Random, 95% CI)	-1.22 [-3.08, 0.63]
7 Haemoglobin (by supplementation regimen)	5	581	Mean Difference (IV, Random, 95% CI)	-0.31 [-2.59, 1.97]

7.1 by supplementation regimen: one supplement a	5	581	Mean Difference (IV, Random, 95% CI)	-0.31 [-2.59, 1.97]
week				
7.2 by supplementation	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
regimen: other intermittent				
regimen				
8 Haemoglobin (by sex)	5	581	Mean Difference (IV, Random, 95% CI)	-0.31 [-2.59, 1.97]
8.1 Girls	1	42	Mean Difference (IV, Random, 95% CI)	-2.0 [-5.43, 1.43]
8.2 Boys	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
8.3 Mixed/unknown	4	539	Mean Difference (IV, Random, 95% CI)	0.04 [-2.63, 2.71]
9 Haemoglobin (by nutrient)	5	581	Mean Difference (IV, Random, 95% CI)	-0.31 [-2.59, 1.97]
9.1 Iron alone	4	539	Mean Difference (IV, Random, 95% CI)	0.04 [-2.63, 2.71]
9.2 Iron + folic acid	1	42	Mean Difference (IV, Random, 95% CI)	-2.0 [-5.43, 1.43]
9.3 By nutrient: iron +	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
multiple micronutrients				
10 Ferritin (ALL)	2	320	Mean Difference (IV, Random, 95% CI)	-11.57 [-38.75, 15.
				61]
11 All cause morbidity (ALL)	1	77	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.68, 1.24]
12 Diarrhoea (ALL)	1	77	Risk Ratio (M-H, Random, 95% CI)	1.12 [0.56, 2.22]
13 Adherence (ALL)	2	245	Risk Ratio (M-H, Random, 95% CI)	1.29 [0.44, 3.75]
14 IQ (ALL)	1	252	Mean Difference (IV, Random, 95% CI)	-3.00 [-5.96, -0.04]
15 Thai language (ALL)	1	208	Mean Difference (IV, Random, 95% CI)	-0.30 [-0.50, -0.09]
16 Mathematics (ALL)	1	233	Mean Difference (IV, Random, 95% CI)	-0.27 [-0.44, -0.10]
17 Increase in steps climbed (ALL)	1	65	Mean Difference (IV, Random, 95% CI)	-5.0 [-13.34, 3.34]
18 HAZ	2	170	Std. Mean Difference (IV, Random, 95% CI)	-0.32 [-1.26, 0.63]
19 WAZ	2	170	Std. Mean Difference (IV, Random, 95% CI)	0.09 [-0.21, 0.39]
20 WAZ	2	302	Std. Mean Difference (IV, Random, 95% CI)	0.04 [-0.34, 0.41]

Analysis I.I. Comparison I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years, Outcome I Anaemia (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years

Outcome: I Anaemia (ALL)

Study or subgroup	Intermittent iron suppl	No suppl/placebo	R	isk Ratio	Weight	Risk Ratio	
	n/N	n/N	H,Ran	M- dom,95% Cl		M- H,Random,95% Cl	
Evangelista-Salazar 2004	0/25	8/25	<u>، ا</u>		1.3 %	0.06 [0.00, 0.97]	
Aguayo 2000	5/33	6/31		_	6.0 %	0.78 [0.27, 2.31]	
Thu 1999	4/54	24/53			6.6 %	0.16 [0.06, 0.44]	
Arcanjo 2011 (C)	6/23	17/22			9.1 %	0.34 [0.16, 0.70]	
Berger 1997	8/59	55/58			10.0 %	0.14 [0.07, 0.27]	
Palupi 1997	17/96	26/98	-		11.3 %	0.67 [0.39, 1.15]	
Roschnik 2003 (C)	19/46	18/46	-	•	11.9 %	1.06 [0.64, 1.74]	
Roschnik 2004 (C)	29/163	47/184	-		13.0 %	0.70 [0.46, 1.05]	
Verhoef 2002	67/154	110/153			15.2 %	0.61 [0.49, 0.74]	
Hall 2002 (C)	123/248	160/253	-		15.6 %	0.78 [0.67, 0.92]	
Total (95% CI)	901	923	•		100.0 %	0.51 [0.37, 0.72]	
Total events: 278 (Intermittent i	ron suppl), 471 (No	suppl/placebo)					
Heterogeneity: Tau ² = 0.18; Ch	$i^2 = 47.6 I, df = 9 (I)$	P<0.0000∣); ² =8 %					
Test for overall effect: $Z = 3.93$	(P = 0.000083)						
Test for subgroup differences: N	lot applicable						
			0.001 0.01 0.1	10 100 1000			
			Intermittent iron suppl	No suppl/placebo			

Analysis 1.2. Comparison I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years, Outcome 2 Anaemia (by dose of elemental iron in the intermittent group).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years

Outcome: 2 Anaemia (by dose of elemental iron in the intermittent group)

Study or subgroup	Intermittent iron suppl	No suppl/placebo	Risk Ratio M-	Weight	Risk Ratio M-
	n/N	n/N	H,Random,95% Cl		H,Random,9 Cl
I 25 mg or less/week					
Evangelista-Salazar 2004	0/25	8/25	•	1.3 %	0.06 [0.00, 0.97]
Thu 1999	4/54	24/53		6.6 %	0.16 [0.06, 0.44]
Subtotal (95% CI)	79	78	•	7 .9 %	0.15 [0.06, 0.37]
Total events: 4 (Intermittent irc	on suppl), 32 (No sup	ppl/placebo)			
Heterogeneity: Tau ² = 0.0; Chi	² = 0.48, df = 1 (P =	= 0.49); I ² =0.0%			
Test for overall effect: Z = 4.05	(P = 0.000052)				
2 Greater than 25 mg to 75 mg	g/week				
Arcanjo 2011 (C)	6/23	17/22		9.1 %	0.34 [0.16, 0.70]
Berger 1997	8/59	55/58		10.0 %	0.14 [0.07, 0.27]
Palupi 1997	17/96	26/98	-	11.3 %	0.67 [0.39, 1.15]
Roschnik 2003 (C)	19/46	18/46	-	11.9 %	1.06 [0.64, 1.74]
Verhoef 2002	67/154	110/153	-	15.2 %	0.61 [0.49, 0.74]
Hall 2002 (C)	123/248	160/253	-	15.6 %	0.78 [0.67, 0.92]
Subtotal (95% CI)	626	630	•	73.2 %	0.54 [0.37, 0.80]
Total events: 240 (Intermittent	iron suppl), 386 (No	suppl/placebo)			
Heterogeneity: $Tau^2 = 0.17$; Cł	$hi^2 = 35.16$, df = 5 (F	² <0.00001); l ² =86%			
Test for overall effect: $Z = 3.14$	(P = 0.0017)	,			
3 Greater than 75 mg/week					
Aguayo 2000	5/33	6/31		6.0 %	0.78 [0.27, 2.31]
Roschnik 2004 (C)	29/163	47/184	-	13.0 %	0.70 [0.46, 1.05]
Subtotal (95% CI)	196	215	•	18.9 %	0.71 [0.48, 1.04]
Total events: 34 (Intermittent ir	ron suppl), 53 (No su	uppl/placebo)			
Heterogeneity: Tau ² = 0.0; Chi	² = 0.04, df = 1 (P =	= 0.84); l ² =0.0%			
Test for overall effect: Z = 1.77	' (P = 0.077)				
Total (95% CI)	901	923	•	100.0 %	0.51 [0.37, 0.72]
Total events: 278 (Intermittent	iron suppl), 471 (No	suppl/placebo)			
Heterogeneity: Tau ² = 0.18; Cł	$hi^2 = 47.6 I, df = 9 (F$	°<0.00001); I ² =81%			
Test for overall effect: Z = 3.93	(P = 0.000083)				
Test for subgroup differences: (Chi ² = 9.41, df = 2 (I	$P = 0.01$), $I^2 = 79\%$			
			0.01 0.1 1 10 100		
		I			
		Intern	nittent iron suppl No suppl/place	:00	

Analysis 1.3. Comparison I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years, Outcome 3 Anaemia (by duration of the intervention).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years

Outcome: 3 Anaemia (by duration of the intervention)

Study or subgroup	Intermittent iron suppl	No suppl/placebo	Risk Ratio M-	Weight	Risk Ratio	
	n/N	n/N	H,Random,95% Cl		M- H,Random,95% Cl	
I 0 to three months						
Thu 1999	4/54	24/53		6.6 %	0.16 [0.06, 0.44]	
Palupi 1997	17/96	26/98		11.3 %	0.67 [0.39, 1.15]	
Roschnik 2004 (C)	29/163	47/184	-	13.0 %	0.70 [0.46, 1.05]	
Verhoef 2002	67/154	110/153	-	15.2 %	0.61 [0.49, 0.74]	
Hall 2002 (C)	123/248	160/253	-	15.6 %	0.78 [0.67, 0.92]	
Subtotal (95% CI)	715	741	•	61.7 %	0.63 [0.49, 0.82]	
Total events: 240 (Intermittent	iron suppl), 367 (No	o suppl/placebo)				
Heterogeneity: $Tau^2 = 0.05$; Ch	$hi^2 = 12.69, df = 4$ ($P = 0.01$; $I^2 = 68\%$				
Test for overall effect: $Z = 3.40$	(P = 0.00068)					
2 More than three months						
Evangelista-Salazar 2004	0/25	8/25	← →→	1.3 %	0.06 [0.00, 0.97]	
Aguayo 2000	5/33	6/31		6.0 %	0.78 [0.27, 2.31]	
Arcanjo 2011 (C)	6/23	17/22		9.1 %	0.34 [0.16, 0.70]	
Berger 1997	8/59	55/58		10.0 %	0.14 [0.07, 0.27]	
Roschnik 2003 (C)	19/46	18/46	+	11.9 %	1.06 [0.64, 1.74]	
Subtotal (95% CI)	186	182	•	38.3 %	0.37 [0.14, 1.02]	
Total events: 38 (Intermittent in	ron suppl), 104 (No	suppl/placebo)				
Heterogeneity: Tau ² = 1.02; Ch	ni ² = 29.25, df = 4 (P<0.00001); I ² =86%				
Test for overall effect: $Z = 1.92$	(P = 0.054)					
Total (95% CI)	901	923	*	100.0 %	0.51 [0.37, 0.72]	
Total events: 278 (Intermittent	iron suppl), 471 (No	o suppl/placebo)				
Heterogeneity: $Tau^2 = 0.18$; Ch		P<0.00001); l ² =81%				
Test for overall effect: $Z = 3.93$	(P = 0.000083)					
Test for subgroup differences: C	$Chi^2 = 1.01, df = 1$ ($P = 0.32$), $I^2 = I\%$				
			0.01 0.1 1 10 10			
		Inter	mittent iron suppl No suppl/plac	ebo		

Analysis 1.4. Comparison I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years, Outcome 4 Anaemia (by type of compound).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years

Outcome: 4 Anaemia (by type of compound)

Study or subgroup	Intermittent iron suppl	No suppl/placebo	Risk Ratio M-	Weight	Risk Ratio M-
	n/N	n/N	H,Random,95% Cl		H,Random,95% Cl
I Ferrous sulphate					
Evangelista-Salazar 2004	0/25	8/25	←	1.3 %	0.06 [0.00, 0.97]
Aguayo 2000	5/33	6/31		6.0 %	0.78 [0.27, 2.31]
Thu 1999	4/54	24/53		6.6 %	0.16 [0.06, 0.44]
Arcanjo 2011 (C)	6/23	17/22		9.1 %	0.34 [0.16, 0.70]
Berger 1997	8/59	55/58		10.0 %	0.14 [0.07, 0.27]
Palupi 1997	17/96	26/98		11.3 %	0.67 [0.39, 1.15]
Roschnik 2003 (C)	19/46	18/46	+	11.9 %	1.06 [0.64, 1.74]
Roschnik 2004 (C)	29/163	47/184	-	13.0 %	0.70 [0.46, 1.05]
Hall 2002 (C)	123/248	160/253	-	15.6 %	0.78 [0.67, 0.92]
Subtotal (95% CI)	747	770	•	84.8 %	0.47 [0.30, 0.75]
Total events: 211 (Intermittent i Heterogeneity: Tau ² = 0.33; Ch Test for overall effect: Z = 3.23 2 Ferrous fumarate Verhoef 2002	$i^2 = 47.78$, df = 8 (F			15.2 %	0.61 [0.49, 0.74]
Subtotal (95% CI)	154	153	•	15.2 %	0.61 [0.49, 0.74]
Total events: 67 (Intermittent in Heterogeneity: not applicable Test for overall effect: $Z = 4.79$		suppl/placebo)			
3 Other Subtotal (95% CI)	0	0			Not estimable
Total events: 0 (Intermittent iron Heterogeneity: not applicable	•	-			not estimatic
			0.01 0.1 10 100)	
		Interm	nittent iron suppl No suppl/plac		
					(Continued)

(... Continued)

Study or subgroup	Intermittent iron suppl	No suppl/placebo			Risk Ratio M- ndom,95%		Weight	Risk Ratio M- H,Random,95%
Test (en en en ll effecte est est	n/N	n/N			CI			U
Test for overall effect: not app	licable							
Total (95% CI)	901	923		•			100.0 %	0.51 [0.37, 0.72]
Total events: 278 (Intermitten	t iron suppl), 471 (No	suppl/placebo)						
Heterogeneity: Tau ² = 0.18; C	Chi ² = 47.61, df = 9 (F	P<0.00001); I ² =81%						
Test for overall effect: Z = 3.9	3 (P = 0.000083)							
Test for subgroup differences:	$Chi^2 = 0.92, df = 1$ (F	P = 0.34), I ² =0.0%						
0 1	,			-				
			0.01	0.1	1 10	100		
		Inte	ermittent i	on suppl	No supp	l/placebo		

Analysis 1.5. Comparison I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years, Outcome 5 Anaemia (by anaemia status at baseline).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years

Outcome: 5 Anaemia (by anaemia status at baseline)

Study or subgroup	Intermittent iron suppl	No suppl/placebo		Risk Ratio M-	Weight	Risk Ratio M-
	n/N	n/N	H,Rar	idom,95% Cl		H,Random,95% Cl
l Anaemic						
Berger 1997	8/59	55/58			10.0 %	0.14 [0.07, 0.27]
Verhoef 2002	67/154	110/153	-		15.2 %	0.61 [0.49, 0.74]
Subtotal (95% CI)	213	211	-	-	25.3 %	0.30 [0.07, 1.38]
Total events: 75 (Intermittent Heterogeneity: Tau ² = 1.14; C Test for overall effect: Z = 1.5 2 Non-anaemic Aguayo 2000	$Chi^2 = 20.01, df = 1 (P)$,			6.0 %	0.78 [0.27, 2.31]
Subtotal (95% CI)	33	31			6.0 %	0.78 [0.27, 2.31]
Total events: 5 (Intermittent ir Heterogeneity: not applicable	,	l/placebo)				
			0.01 0.1	1 10 100		
		In	termittent iron suppl	No suppl/placebo		(Continued)

(... Continued)

					(Continued)
Study or subgroup	Intermittent iron suppl	No suppl/placebo	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M- H,Random,95% Cl		M- H,Random,95% Cl
Test for overall effect: Z = 0.44		17/1 8	Ci		<u> </u>
3 Mixed/unknown					
Evangelista-Salazar 2004	0/25	8/25		1.3 %	0.06 [0.00, 0.97]
Thu 1999	4/54	24/53		6.6 %	0.16 [0.06, 0.44]
Arcanjo 2011 (C)	6/23	17/22		9.1 %	0.34 [0.16, 0.70]
Palupi 1997	17/96	26/98		11.3 %	0.67 [0.39, 1.15]
Roschnik 2003 (C)	19/46	18/46	+	11.9 %	1.06 [0.64, 1.74]
Roschnik 2004 (C)	29/163	47/184	-	13.0 %	0.70 [0.46, 1.05]
Hall 2002 (C)	123/248	160/253	-	15.6 %	0.78 [0.67, 0.92]
Subtotal (95% CI)	655	681	•	68.8 %	0.59 [0.41, 0.85]
Test for overall effect: Z = 2.82 Total (95% CI) Total events: 278 (Intermittent Heterogeneity: Tau ² = 0.18; CH	901 iron suppl), 471 (No		•	100.0 %	0.51 [0.37, 0.72]
Total (95% CI)	901	923	•	100.0 %	0.51 [0.37, 0.72]
Test for subgroup differences: (Chi ² = 1.00, df = 2 (l	$P = 0.61$), $I^2 = 0.0\%$			
		0.	01 0.1 1 10 100)	
		Intermitte	ent iron suppl No suppl/place	ebo	

Analysis I.6. Comparison I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years, Outcome 6 Anaemia (by intermittent regimen).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years

Outcome: 6 Anaemia (by intermittent regimen)

Study or subgroup	Intermittent iron suppl	No suppl/placebo	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M- H,Random,95% Cl		M- H,Random,95% Cl
l One supplement a week					
Aguayo 2000	5/33	6/31		6.0 %	0.78 [0.27, 2.31]
Arcanjo 2011 (C)	6/23	17/22	-	9.1 %	0.34 [0.16, 0.70]
Berger 1997	8/59	55/58		10.0 %	0.14 [0.07, 0.27]
Evangelista-Salazar 2004	0/25	8/25	 	1.3 %	0.06 [0.00, 0.97]
Hall 2002 (C)	123/248	160/253	-	15.6 %	0.78 [0.67, 0.92]
Palupi 1997	17/96	26/98	-	11.3 %	0.67 [0.39, 1.15]
Roschnik 2003 (C)	19/46	18/46	-	11.9 %	1.06 [0.64, 1.74]
Roschnik 2004 (C)	29/163	47/184	-	13.0 %	0.70 [0.46, 1.05]
Thu 1999	4/54	24/53		6.6 %	0.16 [0.06, 0.44]
Subtotal (95% CI)	747	770	•	84.8 %	0.47 [0.30, 0.75]
Total events: 211 (Intermittent Heterogeneity: Tau ² = 0.33; C Test for overall effect: Z = 3.2 2 Other intermittent regimen Verhoef 2002	$chi^2 = 47.78, df = 8$ (F	· · · · · ·		15.2 %	0.61 [0.49, 0.74]
Subtotal (95% CI)	154	153	•	15.2 %	0.61 [0.49, 0.74]
Total events: 67 (Intermittent i Heterogeneity: not applicable Test for overall effect: $Z = 4.7$	iron suppl), 110 (No				
Total (95% CI)	901	923	•	100.0 %	0.51 [0.37, 0.72]
Total events: 278 (Intermittent Heterogeneity: Tau ² = 0.18; C Test for overall effect: $Z = 3.9$. Test for subgroup differences:	$chi^2 = 47.61, df = 9$ (F 3 (P = 0.000083)	P<0.00001); I ² =81%			
lest for subgroup differences.	Chi = 0.72, di = 1 (- 0.34), 1 -0.0%			
		Favo	0.01 0.1 1 10 100 urs experimental Favours contro	I	

Analysis 1.7. Comparison I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years, Outcome 7 Anaemia (by sex).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years

Outcome: 7 Anaemia (by sex)

Study or subgroup	Intermittent iron suppl	No suppl/placebo	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M- H,Random,95% Cl		-M H,Random,9 Cl
l Girls					
Hall 2002 (C)	56/122	77/126	-	13.4 %	0.75 [0.59, 0.95]
Subtotal (95% CI)	122	126	•	13.4 %	0.75 [0.59, 0.95]
Total events: 56 (Intermittent i	ron suppl), 77 (No si	uppl/placebo)			
Heterogeneity: not applicable fest for overall effect: $Z = 2.36$	(D - 0.010)				
Boys	s (1 – 0.018)				
Hall 2002 (C)	67/126	83/127	-	13.7 %	0.81 [0.66, 1.00]
Subtotal (95% CI)	126	127	•	13.7 %	0.81 [0.66, 1.00]
Fotal events: 67 (Intermittent i	ron suppl), 83 (No si	uppl/placebo)			
Heterogeneity: not applicable	(D. 0.051)				
Test for overall effect: Z = 1.95 3 Mixed/unknown	P = 0.051				
Aguayo 2000	5/33	6/31		4.9 %	0.78 [0.27, 2.31]
Arcanjo 2011 (C)	6/23	17/22		7.7 %	0.34 [0.16, 0.70]
Berger 1997	8/59	55/58		8.5 %	0.14 [0.07, 0.27]
Evangelista-Salazar 2004	0/25	8/25	←	1.0 %	0.06 [0.00, 0.97]
Palupi 1997	17/96	26/98		9.8 %	0.67 [0.39, 1.15]
Roschnik 2003 (C)	19/46	18/46	+	10.3 %	1.06 [0.64, 1.74]
Roschnik 2004 (C)	29/163	47/184	•	11.4 %	0.70 [0.46, 1.05]
Thu 1999	4/54	24/53		5.5 %	0.16 [0.06, 0.44]
Verhoef 2002	67/154	110/153	•	13.8 %	0.61 [0.49, 0.74]
Subtotal (95% CI)	653	670	•	72.8 %	0.46 [0.30, 0.70]
Total events: 155 (Intermittent Heterogeneity: Tau ² = 0.28; C	11,7	,			
Test for overall effect: $Z = 3.5$		<0.00001), 1 -77%			
Total (95% CI)	901	923	•	100.0 %	0.55 [0.41, 0.73]
Total events: 278 (Intermittent	iron suppl), 471 (No	suppl/placebo)			
Heterogeneity: $Tau^2 = 0.15$; C		(P<0.00001); I ² =79%			
Test for overall effect: $Z = 4.04$	· · · · ·				
Test for subgroup differences: (Chi ² = 5.63, df = 2 ($P = 0.06$), $ ^2 = 64\%$			
		(0.01 0.1 1 10 100)	
			tent iron suppl No suppl/place		

Analysis 1.8. Comparison I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years, Outcome 8 Anaemia (by nutrient).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years

Outcome: 8 Anaemia (by nutrient)

Study or subgroup	Intermittent iron suppl	No suppl/placebo	Risk Ratio M-	Weight	Risk Ratio M-
	n/N	n/N	H,Random,95% Cl		H,Random,95 Cl
l Iron alone					
Aguayo 2000	5/33	6/31		6.0 %	0.78 [0.27, 2.31]
Arcanjo 2011 (C)	6/23	17/22		9.1 %	0.34 [0.16, 0.70]
Berger 1997	8/59	55/58		10.0 %	0.14 [0.07, 0.27]
Palupi 1997	17/96	26/98		11.3 %	0.67 [0.39, 1.15]
Roschnik 2004 (C)	29/163	47/184	-	13.0 %	0.70 [0.46, 1.05]
Verhoef 2002	67/154	110/153	-	15.2 %	0.61 [0.49, 0.74]
Subtotal (95% CI)	528	546	•	64.6 %	0.48 [0.31, 0.74]
2 Iron + folic acid Roschnik 2003 (C)	19/46	18/46	+	11.9 %	1.06 [0.64, 1.74]
Test for overall effect: $Z = 3.35$ 2 Iron + folic acid	(F – 0.00082)				
Roschnik 2003 (C)	19/46	18/46		11.9 %	1.06 [0.64, 1.74]
Hall 2002 (C)	123/248	160/253	•	15.6 %	0.78 [0.67, 0.92]
Subtotal (95% CI)	294	299	•	27.5 %	0.83 [0.66, 1.03]
Total events: 142 (Intermittent Heterogeneity: Tau ² = 0.01; CP Test for overall effect: $Z = 1.70$ 3 iron + vitamin C	$hi^2 = 1.25, df = 1 (P)$,			
Evangelista-Salazar 2004	0/25	8/25	←	1.3 %	0.06 [0.00, 0.97]
Subtotal (95% CI)	25	25		1.3 %	0.06 [0.00, 0.97]
Total events: 0 (Intermittent irc Heterogeneity: not applicable Test for overall effect: Z = 1.98 4 Iron + multiple micronutrient	(P = 0.047)	ol/placebo)			
Thu 1999	4/54	24/53		6.6 %	0.16 [0.06, 0.44]
Subtotal (95% CI)	54	53	•	6.6 %	0.16 [0.06, 0.44]
			0.01 0.1 1 10 100		
		Inte	rmittent iron suppl No suppl/placet	00	(Continued

(Continued . . .)

(... Continued)

Study or subgroup	Intermittent iron suppl	No suppl/placebo			Risk Ratio		Weight	Risk Ratio
Study of subgroup	iron suppr	i vo suppi/placebo			M-		vveignt	M-
	n/N	n/N		H,Rar	idom,95% Cl			H,Random,95% Cl
Total events: 4 (Intermittent in	on suppl), 24 (No sup	pl/placebo)						
Heterogeneity: not applicable								
Test for overall effect: $Z = 3.5$	9 (P = 0.00033)							
Total (95% CI)	901	923		•			100.0 %	0.51 [0.37, 0.72]
Total events: 278 (Intermittent	t iron suppl), 471 (No	suppl/placebo)						
Heterogeneity: $Tau^2 = 0.18$; C	$2hi^2 = 47.6I, df = 9$ (P	<0.00001); 2 =81%						
Test for overall effect: $Z = 3.92$	3 (P = 0.000083)							
Test for subgroup differences:	$Chi^2 = 16.45, df = 3$ ($P = 0.00$), $I^2 = 82\%$						
			0.01	0.1	1 10	100		
		Interm	nittent in	on suppl	No suppl	/placebo		

Analysis 1.9. Comparison I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years, Outcome 9 Haemoglobin (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years

Outcome: 9 Haemoglobin (ALL)

Study or subgroup	Intermittent iron suppl N	Mean(SD)	No suppl/placebo N	Mean(SD)		Mean ference lom,95% Cl	Weight	Mean Difference IV,Random,95% Cl
Taylor 2001	64	-2.4 (11.65)	61	-5.8 (27.6)			4.0 %	3.40 [-4.09, 10.89]
, Yang 2004 (C)	38	134.16 (12.79)	36	30. (10.78)			4.7 %	4.06 [-1.32, 9.44]
Roschnik 2003 (C)	46	110 (12.3)	46	.5 (2.5)	_		4.9 %	-1.50 [-6.57, 3.57]
Sen 2009 (C)	30	120 (4)	8	116 (6.3)			5.0 %	4.00 [-0.59, 8.59]
Aguayo 2000	33	155 (9.2)	31	153 (9)	-		5.1 %	2.00 [-2.46, 6.46]
Ekvall 2000	98	95 (16)	97	92 (14)			5.1 %	3.00 [-1.22, 7.22]
Thu 1999	54	23.5 (0.3)	53	.4 (0.6)			5.2 %	2. 0 [8. 4, 6.06]
Baqui 2003	179	105.1 (14.1)	60	105.3 (13)	-	<u></u>	5.2 %	-0.20 [-4.08, 3.68]
				-20	D -10	0 10 20)	

No suppl/placebo Intermittent iron suppl

(Continued ...)

Study or subgroup	Intermittent iron suppl		No suppl/placebo		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI		IV,Random,95% CI
Arcanjo 2011 (C)	23	119 (7.6)	22	114 (5.4)		5.2 %	5.00 [1.16, 8.84]
Evangelista-Salazar 2004	25	132.7 (6.1)	25	112 (5.4)		5.4 %	20.70 [17.51, 23.89]
Verhoef 2002	154	106.4 (14.7)	153	98.4 (12)		5.5 %	8.00 [5.00, 11.00]
Palupi 1997	96	8.4 (.4)	98	115.2 (9.4)		5.5 %	3.20 [0.26, 6.14]
Berger 1997	58	150.5 (6.9)	57	32.2 (8.1)	-=+	5.5 %	18.30 [15.55, 21.05]
Yurdakok 2004	19	116 (5)	16	2 (3)		5.5 %	4.00 [1.31, 6.69
Olsen 2000	108	8.5 (2.4)	92	117.8 (5.98)	-	5.6 %	0.70 [-1.94, 3.34
Roschnik 2004 (C)	163	24.5 (.6)	184	22.3 (2.8)		5.6 %	2.20 [-0.37, 4.77
Sungthong 2002	130	126.9 (9.2)	121	125.3 (9.3)		5.6 %	1.60 [-0.69, 3.89
Hall 2002 (C)	248	6.4 (2.7)	253	2.6 (2.7)		5.6 %	3.80 [1.58, 6.02
Ermis 2002	30	116 (2.9)	23	3 (4)	-	5.7 %	3.00 [1.06, 4.94
otal (95% CI)	1596		1436		•	100.0 %	5.20 [2.51, 7.88
eterogeneity: $Tau^2 = 32.00$); Chi ² = 245.2	26, df = 18 (P<0	0.0000 l); l ² =93%				
est for overall effect: $Z = 3$.	.79 (P = 0.000	5)					
est for subgroup difference	s: Not applicab	ble					

No suppl/placebo Intermittent iron suppl

Analysis 1.10. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years, Outcome 10 Haemoglobin (by by dose of elemental iron in the intermittent group).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years

Outcome: 10 Haemoglobin (by by dose of elemental iron in the intermittent group)

Study or subgroup	Intermittent iron suppl		No suppl/placebo		Mean Difference	Weight	Mea Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI		IV,Random,95% C
I 25 mg or less/week							
Baqui 2003	179	105.1 (14.1)	60	105.3 (13)		5.2 %	-0.20 [-4.08, 3.68
Evangelista-Salazar 2004	25	32.7 (6.1)	25	112 (5.4)	-	5.4 %	20.70 [17.51, 23.89
Yurdakok 2004	19	116 (5)	16	112 (3)	-#-	5.5 %	4.00 [1.31, 6.69
Subtotal (95% CI)	223		101			16.2 %	8.19 [-4.01, 20.38
Heterogeneity: $Tau^2 = 3$.	29; Chi ² = 86	.12, df = 2 (P <c< td=""><td>.00001); I² =98%</td><td></td><td></td><td></td><td></td></c<>	.00001); I ² =98%				
Test for overall effect: $Z = 1$.32 (P = 0.19)					
2 Greater than 25 mg to 75	mg/week						
Taylor 2001	64	-2.4 (11.65)	61	-5.8 (27.6)		4.0 %	3.40 [-4.09, 10.89
Yang 2004 (C)	38	34. 6 (2.79)	36	30. (0.78)		4.7 %	4.06 [-1.32, 9.44
Roschnik 2003 (C)	46	110 (12.3)	46	111.5 (12.5)		4.9 %	-1.50 [-6.57, 3.57
Ekvall 2000	98	95 (16)	97	92 (14)		5.1 %	3.00 [-1.22, 7.22
Thu 1999	54	123.5 (10.3)	53	.4 (0.6)		5.2 %	12.10 [8.14, 16.06
Arcanjo 2011 (C)	23	119 (7.6)	22	114 (5.4)		5.2 %	5.00 [1.16, 8.84
Verhoef 2002	154	106.4 (14.7)	153	98.4 (12)		5.5 %	8.00 [5.00, 11.00
Palupi 1997	96	8.4 (.4)	98	115.2 (9.4)		5.5 %	3.20 [0.26, 6.14
Berger 1997	58	150.5 (6.9)	57	32.2 (8.1)	-#•	5.5 %	18.30 [15.55, 21.05
Sungthong 2002	130	126.9 (9.2)	121	125.3 (9.3)		5.6 %	1.60 [-0.69, 3.89
Hall 2002 (C)	248	116.4 (12.7)	253	112.6 (12.7)	-=-	5.6 %	3.80 [1.58, 6.02
Ermis 2002	30	116 (2.9)	23	113 (4)	-=-	5.7 %	3.00 [1.06, 4.94
Subtotal (95% CI)	1039		1020		•	62.6 %	5.45 [2.31, 8.58
Heterogeneity: Tau ² = 26.7	2; Chi ² = 127		:0.00001); ² =91%				
Test for overall effect: $Z = 3$	8.41 (P = 0.00	065)					
3 Greater than 75 mg/week	(
Sen 2009 (C)	30	120 (4)	8	116 (6.3)		5.0 %	4.00 [-0.59, 8.59
Aguayo 2000	33	155 (9.2)	31	153 (9)		5.1 %	2.00 [-2.46, 6.46
Olsen 2000	108	8.5 (2.4)	92	117.8 (5.98)	-	5.6 %	0.70 [-1.94, 3.34

No suppl/placebo Intermittent iron suppl

(Continued ...)

								(Continued)
Study or subgroup	Intermittent iron suppl		No suppl/placebo		Dif	Mean ference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Rand	dom,95% Cl		IV,Random,95% CI
Roschnik 2004 (C)	163	24.5 (.6)	184	22.3 (2.8)		-	5.6 %	2.20 [-0.37, 4.77]
Subtotal (95% CI)	334		315			•	21.2 %	1.84 [0.25, 3.44]
Heterogeneity: $Tau^2 = 0.0$;	$Chi^2 = 1.65, dt$	f = 3 (P = 0.65);	$ ^2 = 0.0\%$					
Test for overall effect: $Z =$	2.26 (P = 0.024	ł)						
Total (95% CI)	1596		1436			•	100.0 %	5.20 [2.51, 7.88]
Heterogeneity: $Tau^2 = 32.0$	00; Chi ² = 245.	26, df = 18 (P<	0.00001); I ² =93%					
Test for overall effect: $Z =$	3.79 (P = 0.000)15)						
Test for subgroup difference	ces: Chi ² = 4.84	df = 2 (P = 0.0	19), l ² =59%					
							1	
				-20	-10	0 10	20	

No suppl/placebo Intermittent iron suppl

Analysis I.I.I. Comparison I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years, Outcome 11 Haemoglobin (by duration of the intervention).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years

Outcome: II Haemoglobin (by duration of the intervention)

Study or subgroup	Intermittent iron suppl N	Mean(SD)	No suppl/placebo N	Mean(SD)		Mean fference dom,95% Cl	Weight	Mean Difference IV,Random,95% Cl
0 to three months								
Taylor 2001	64	-2.4 (11.65)	61	-5.8 (27.6)	-		4.0 %	3.40 [-4.09, 10.89]
Thu 1999	54	123.5 (10.3)	53	.4 (0.6)			5.2 %	2. 0 [8. 4, 6.06]
Verhoef 2002	154	106.4 (14.7)	153	98.4 (12)			5.5 %	8.00 [5.00, .00]
Palupi 1997	96	8.4 (.4)	98	115.2 (9.4)			5.5 %	3.20 [0.26, 6.14]
Yurdakok 2004	19	116 (5)	16	112 (3)			5.5 %	4.00 [1.31, 6.69]
Roschnik 2004 (C)	163	24.5 (.6)	184	122.3 (12.8)			5.6 %	2.20 [-0.37, 4.77]
Hall 2002 (C)	248	6.4 (2.7)	253	2.6 (2.7)		-	5.6 %	3.80 [1.58, 6.02]
Subtotal (95% CI)	798		818			•	36.9 %	5.16 [2.82, 7.51]
					20 -10 suppl/placebo	0 I0 2 Intermittent i		(Continued)

Intermittent iron supplementation for improving nutrition and development in children under 12 years of age (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

117

Roschnik 2003 (C) 46 110 (12.3) 46 111.5 (12.5) 4.9 % -1.50 [-6.57 Sen 2009 (C) 30 120 (4) 8 116 (6.3) 5.0 % 4.00 [-0.59 Aguayo 2000 33 155 (9.2) 31 153 (9) 5.1 % 2.00 [-2.46 Ekvall 2000 98 95 (16) 97 92 (14) 5.1 % 3.00 [-1.22 Baqui 2003 179 105.1 (14.1) 60 105.3 (13) 5.2 % -0.20 [-4.08 Arcanjo 2011 (C) 23 119 (7.6) 22 114 (5.4) 5.2 % 5.00 [1.16 Evangelista-Salazar 2004 25 132.7 (6.1) 25 112 (5.4) - 5.5 % 18.30 [1555, Olsen 2000 108 118.5 (12.4) 92 117.8 (5.98) - 5.6 % 0.70 [-1.94 Sungthong 2002 130 126.9 (9.2) 121 125.3 (9.3) - 5.6 % 1.60 [-0.69	Study or subgroup	Intermittent iron suppl N	Mean(SD)	No suppl/placebo N	Mean(SD)	Mean Difference IV,Random,95% Cl	Weight	(Continue Mear Difference IV,Random,95% C
2 More than three months Yang 2004 (C) 38 134.16 (12.79) 36 130.1 (10.78) 47% 4.06 [-1.32 Roschnik 2003 (C) 46 110 (12.3) 46 111.5 (12.5) 49% .1.50 [-6.57 Sen 2009 (C) 30 120 (4) 8 116 (6.3) 50% 4.00 [-0.59 Aguayo 2000 33 155 (9.2) 31 153 (9) 5.1% 2.00 [-2.46 Ekvall 2000 98 95 (16) 97 92 (14) 5.1% 3.00 [-1.22 Baqui 2003 179 105.1 (14.1) 60 105.3 (13) 52% .0.20 [-4.08 Arcanjo 2011 (C) 23 119 (7.6) 22 114 (5.4) 52% .0.20 [-4.08 Arcanjo 2011 (C) 23 119 (7.6) 22 114 (5.4) 52% .50.00 [1.16 Evangelista-Salazar 2004 25 132.7 (6.1) 25 112 (5.4) -55% 18.30 [15.55, Olsen 2000 108 118.5 (12.4) 92 117.8 (5.98) 56% 0.70 [-1.94 Sungthong 2002 130 126.9 (9.2) 121 125.3 (9.3) Ermis 2002 30 116 (2.9) 23 113 (4) 57% 3.00 [1.06 Subtotal (95% CI) 798 618 Heterogeneity: Tau ² = 52.12; Ch ² = 22043, df = 11 (P<0.00001); l ² = 95\% Test for overall effect: Z = 2.38 (P = 0.017) Total (95% CI) 1596 1436 Heterogeneity: Tau ² = 32.00; Chi ² = 245.26, df = 18 (P<0.00001); l ² = 93\%	Heterogeneity: Tau ² = 6.99	; Chi ² = 23.70	, df = 6 (P = 0.0	0059); l ² =75%				
Yang 2004 (C)38134.16 (12.79)36130.1 (10.78) 4.7% 4.06 [-1.32Roschnik 2003 (C)46110 (12.3)46111.5 (12.5) 4.9% -1.50 [-6.57Sen 2009 (C)30120 (4)8116 (6.3) 5.0% 4.00 [-0.59Aguayo 200033155 (9.2)31153 (9) 5.1% 2.00 [-2.46Ekvall 20009895 (16)9792 (14) 5.1% 3.00 [-1.22Baqui 2003179105.1 (14.1)60105.3 (13) 5.2% -0.20 [-4.08Arcanjo 2011 (C)23119 (7.6)22114 (5.4) 5.2% 5.0% [1.16Evangelista-Salazar 200425132.7 (6.1)25112 (5.4) $$	Test for overall effect: $Z = 4$	4.32 (P = 0.000	016)					
Roschnik 2003 (C)46110 (12.3)46111.5 (12.5) 4.9% -1.50 [-6.57Sen 2009 (C)30120 (4)8116 (6.3) 5.0% 4.00 [-0.59Aguayo 200033155 (9.2)31153 (9) 5.1% 2.00 [-2.46Ekvall 20009895 (16)9792 (14) 5.1% 3.00 [-1.22Baqui 2003179105.1 (14.1)60105.3 (13) 5.2% -0.20 [-4.08Arcanjo 2011 (C)23119 (7.6)22114 (5.4) 5.2% 5.00 [1.16Evangelista-Salazar 200425132.7 (6.1)25112 (5.4) $$ 5.4% 20.70 [17.51,Berger 199758150.5 (6.9)57132.2 (8.1) $$ 5.6% 0.70 [-1.94Sungthong 2002130126.9 (9.2)121125.3 (9.3) $$ 5.6% 1.60 [-0.69Ermis 200230116 (2.9)23113 (4) $$ 5.7% 3.00 [1.06Subtoral (95% CI)798618 $$ 63.1% 5.13 [0.90, 9Heterogeneity: Tau ² = 32.00; Chi ² = 245.26, df = 18 (P<0.00001); i ² = 95\% $$ $$ Total (95% CI)15961436 $$	2 More than three months							
Sen 2009 (C)30120 (4)8116 (6.3) 5.0% 4.00 [-0.59Aguayo 200033155 (9.2)31153 (9) 5.1% 2.00 [-2.46Ekvall 20009895 (16)9792 (14) 5.1% 3.00 [-1.22Baqui 2003179105.1 (14.1)60105.3 (13) 5.2% -0.20 [-4.08Arcanjo 2011 (C)23119 (7.6)22114 (5.4) 5.2% 5.00 [1.16Evangelista-Salazar 200425132.7 (6.1)25112 (5.4) $$ 5.5% 18.30 [15.55,Olsen 2000108118.5 (12.4)92117.8 (5.98) $$ 5.6% 1.60 [-0.69Sungthong 2002130126.9 (9.2)121125.3 (9.3) $$ 5.6% 1.60 [-0.69Ermis 200230116 (2.9)23113 (4) $$ 5.7% 3.00 [1.16Subtotal (95% CI)798618 -63.1% 5.13 [$0.90, 5\%$ Heterogeneity: Tau ² = 52.12; Chi ² = 220.43, df = 11 (P<0.00001); l ² = 95\% $$ $$ 100.0% 5.20 [$2.51, 7\%$ Total (95% CI)15961436 $$ $$ $$ $$ $$ $$	Yang 2004 (C)	38	34. 6 (2.79)	36	30. (0.78)	+	4.7 %	4.06 [-1.32, 9.44]
Aguayo 200033155 (9.2)31153 (9) 5.1% $2.00 [-2.46]$ Ekvall 20009895 (16)9792 (14) 5.1% $3.00 [-1.22]$ Baqui 2003179105.1 (14.1)60105.3 (13) 5.2% $-0.20 [-4.08]$ Arcanjo 2011 (C)23119 (7.6)22114 (5.4) 5.2% $5.0\% [1.16]$ Evangelista-Salazar 200425132.7 (6.1)25112 (5.4) $$ 5.4% $20.70 [17.51]$,Berger 199758150.5 (6.9)57132.2 (8.1) $$ 5.5% $18.30 [15.55,$ Olsen 2000108118.5 (12.4)92117.8 (5.98) 5.6% $0.70 [-1.94]$ Sungthong 2002130126.9 (9.2)121125.3 (9.3) $$ 5.6% $1.60 [-0.69]$ Ermis 200230116 (2.9)23113 (4) $$ 5.7% $3.00 [1.06]$ Subtotal (95% CI)798618 $$ 63.1% $5.13 [0.90, 9]$ Heterogeneity: Tau ² = 52.12; Chi ² = 220.43, df = 11 (P<0.00001); l ² = 95\% $$ 100.0% $5.20 [2.51, 7]$ Total (95% CI)15961436 $$ 100.0% $5.20 [2.51, 7]$	Roschnik 2003 (C)	46	0 (2.3)	46	.5 (2.5)		4.9 %	-1.50 [-6.57, 3.57]
Edual 20009895 (16)9792 (14)Baqui 2003179105.1 (14.1)60105.3 (13)Arcanjo 2011 (C)23119 (7.6)22114 (5.4)Evangelista-Salazar 200425132.7 (6.1)25112 (5.4)Berger 199758150.5 (6.9)57132.2 (8.1)Olsen 2000108118.5 (12.4)92117.8 (5.98)Sungthong 2002130126.9 (9.2)121125.3 (9.3)Ermis 200230116 (2.9)23113 (4)Subtoral (95% CI)798618Heterogeneity: Tau ² = 52.12; Ch ² = 220.43, df = 11 (P<0.00001); l ² = 95%Test for overall effect: Z = 2.38 (P = 0.017)1436Total (95% CI)15961436Heterogeneity: Tau ² = 32.00; Chi ² = 245.26, df = 18 (P<0.00001); l ² = 93%	Sen 2009 (C)	30	120 (4)	8	116 (6.3)		5.0 %	4.00 [-0.59, 8.59]
Baqui 2003 179 105.1 (14.1) 60 105.3 (13) Arcanjo 2011 (C)23 119 (7.6) 22 114 (5.4) Evangelista-Salazar 200425 132.7 (6.1) 25 112 (5.4) Berger 199758 150.5 (6.9) 57 132.2 (8.1) Olsen 2000108 118.5 (12.4) 92 117.8 (5.98) Sungthong 2002130 126.9 (9.2) 121 125.3 (9.3) Ermis 200230 116 (2.9) 23 113 (4) Subtotal (95% CI)798 618 63.1 5.13 $[0.90, 9]$ Heterogeneity: Tau ² = 52.12; Chi ² = 220.43, df = 11 $(P<0.00001); l2 = 95\%$ $= 63.1$ 5.20 $[2.51, 7]$ Total (95% CI)15961436 $= 100.0$ 5.20 $[2.51, 7]$	Aguayo 2000	33	155 (9.2)	31	153 (9)		5.1 %	2.00 [-2.46, 6.46]
Arcanjo 2011 (C)23119 (7.6)22114 (5.4)Evangelista-Salazar 200425132.7 (6.1)25112 (5.4)Berger 199758150.5 (6.9)57132.2 (8.1)Olsen 2000108118.5 (12.4)92117.8 (5.98)Sungthong 2002130126.9 (9.2)121125.3 (9.3)Ermis 200230116 (2.9)23113 (4)Subtotal (95% CI)798618Heterogeneity: Tau ² = 52.12; Chi ² = 220.43, df = 11 (P<0.00001); l ² = 95%Test for overall effect: Z = 2.38 (P = 0.017)Total (95% CI)15961436Heterogeneity: Tau ² = 32.00; Chi ² = 245.26, df = 18 (P<0.00001); l ² = 93%	Ekvall 2000	98	95 (16)	97	92 (14)		5.1 %	3.00 [-1.22, 7.22]
Evangelista-Salazar 200425 $132.7 (6.1)$ 25 $112 (5.4)$ Berger 199758 $150.5 (6.9)$ 57 $132.2 (8.1)$ Olsen 2000108 $118.5 (12.4)$ 92 $117.8 (5.98)$ Sungthong 2002130 $126.9 (9.2)$ 121 $125.3 (9.3)$ Ermis 200230 $116 (2.9)$ 23 $113 (4)$ Subtotal (95% CI)798618Heterogeneity: Tau ² = 52.12; Chi ² = 220.43, df = 11 (P<0.00001); l ² = 95%Total (95% CI)15961436Heterogeneity: Tau ² = 32.00; Chi ² = 245.26, df = 18 (P<0.00001); l ² = 93%	Baqui 2003	179	105.1 (14.1)	60	105.3 (13)		5.2 %	-0.20 [-4.08, 3.68
Berger 199758150.5 (6.9)57132.2 (8.1)Olsen 2000108118.5 (12.4)92117.8 (5.98)Sungthong 2002130126.9 (9.2)121125.3 (9.3)Ermis 200230116 (2.9)23113 (4)Subtotal (95% CI)798618Heterogeneity: Tau ² = 52.12; Chi ² = 220.43, df = 11 (P<0.00001); l ² = 95%Test for overall effect: Z = 2.38 (P = 0.017)Total (95% CI)15961436Heterogeneity: Tau ² = 32.00; Chi ² = 245.26, df = 18 (P<0.00001); l ² = 93%	Arcanjo 2011 (C)	23	119 (7.6)	22	114 (5.4)		5.2 %	5.00 [1.16, 8.84
Olsen 2000 108 118.5 (12.4) 92 117.8 (5.98) 5.6% 0.70 [-1.94 Sungthong 2002 130 126.9 (9.2) 121 125.3 (9.3) 5.6% 1.60 [-0.69 Ermis 2002 30 116 (2.9) 23 113 (4) 5.7% 3.00 [1.06 Subtotal (95% CI) 798 618 63.1% 5.13 [$0.90, 9$ Heterogeneity: Tau ² = 52.12 ; Chi ² = 220.43 , df = 11 (P<0.00001); l ² = 95% 618 63.1% 5.13 [$0.90, 9$ Test for overall effect: Z = 2.38 (P = 0.017) 1596 1436 100.0% 5.20 [$2.51, 7$ Heterogeneity: Tau ² = 32.00 ; Chi ² = 245.26 , df = 18 (P<0.00001); l ² = 93% 129% 100.0% 5.20 [$2.51, 7$	Evangelista-Salazar 2004	25	32.7 (6.1)	25	112 (5.4)	-	5.4 %	20.70 [17.51, 23.89
Sungthong 2002130126.9 (9.2)121125.3 (9.3) 5.6% 1.60 [-0.69Ermis 200230116 (2.9)23113 (4) $ 5.7\%$ 3.00 [1.06Subtotal (95% CI)798618 63.1% 5.13 [$0.90, 9$ Heterogeneity: Tau ² = 52.12; Chi ² = 220.43, df = 11 (P<0.00001); l ² = 95% $ 63.1\%$ 5.13 [$0.90, 9$ Total (95% CI)15961436 $ 100.0\%$ 5.20 [$2.51, 7$ Heterogeneity: Tau ² = 32.00; Chi ² = 245.26, df = 18 (P<0.00001); l ² = 93% $ -$	Berger 1997	58	150.5 (6.9)	57	32.2 (8.1)		5.5 %	18.30 [15.55, 21.05
Ermis 200230116 (2.9)23113 (4) 5.7% $3.00 [1.06]$ Subtotal (95% CI)798618 63.1% $5.13 [0.90, 9]$ Heterogeneity: Tau ² = 52.12; Chi ² = 220.43, df = 11 (P<0.00001); l ² = 95% 63.1% $5.13 [0.90, 9]$ Total (95% CI)15961436 100.0% $5.20 [2.51, 7]$ Heterogeneity: Tau ² = 32.00; Chi ² = 245.26, df = 18 (P<0.00001); l ² = 93% 100.0% $5.20 [2.51, 7]$	Olsen 2000	108	8.5 (2.4)	92	117.8 (5.98)	-	5.6 %	0.70 [-1.94, 3.34
Subtotal (95% CI) 798 618 Heterogeneity: Tau ² = 52.12; Chi ² = 220.43, df = 11 (P<0.00001); l ² = 95% Test for overall effect: Z = 2.38 (P = 0.017) Total (95% CI) 1596 1436 Heterogeneity: Tau ² = 32.00; Chi ² = 245.26, df = 18 (P<0.00001); l ² = 93%	Sungthong 2002	130	126.9 (9.2)	121	125.3 (9.3)		5.6 %	1.60 [-0.69, 3.89
Heterogeneity: Tau ² = 52.12; Chi ² = 220.43, df = 11 (P<0.00001); l ² = 95% Test for overall effect: $Z = 2.38$ (P = 0.017) Total (95% CI) 1596 1436 100.0 % 5.20 [2.51, 7 Heterogeneity: Tau ² = 32.00; Chi ² = 245.26, df = 18 (P<0.00001); l ² = 93%	Ermis 2002	30	116 (2.9)	23	3 (4)		5.7 %	3.00 [1.06, 4.94
Heterogeneity: Tau ² = 52.12; Chi ² = 220.43, df = 11 (P<0.00001); l ² = 95% Test for overall effect: $Z = 2.38$ (P = 0.017) Total (95% CI) 1596 1436 \bullet 100.0 % 5.20 [2.51, 7 Heterogeneity: Tau ² = 32.00; Chi ² = 245.26, df = 18 (P<0.00001); l ² = 93%	Subtotal (95% CI)	798		618		-	63.1 %	5.13 [0.90, 9.36
Total (95% CI) 1596 1436 Heterogeneity: Tau ² = 32.00; Chi ² = 245.26, df = 18 (P<0.00001); l ² = 93% ■ 100.0 % 5.20 [2.51, 7	Heterogeneity: Tau ² = 52.1	2; Chi ² = 220.	43, df = 11 (P<0	0.00001); I ² =95%				
Heterogeneity: Tau ² = 32.00; Chi ² = 245.26, df = 18 (P<0.00001); l ² =93%	Test for overall effect: $Z = 2$	2.38 (P = 0.01	7)					
	Total (95% CI)	1596		1436		•	100.0 %	5.20 [2.51, 7.88]
Test for evently effect: $7 = 3.79$ (P = 0.00015)	Heterogeneity: Tau ² = 32.0	0; Chi ² = 245.	26, df = 18 (P<0	0.00001); I ² =93%				
			,					
Test for subgroup differences: Chi ² = 0.00, df = 1 (P = 0.99), $I^2 = 0.0\%$	Test for subgroup difference	es: $Chi^2 = 0.00$), df = 1 (P = 0.9	9), I ² =0.0%				

No suppl/placebo

Intermittent iron suppl

Analysis 1.12. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years, Outcome 12 Haemoglobin (by type of compound).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years

Outcome: 12 Haemoglobin (by type of compound)

Study or subgroup	Intermittent iron suppl		No suppl/placebo		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI		IV,Random,95% CI
I Ferrous sulphate							
Roschnik 2003 (C)	46	110 (12.3)	46	.5 (2.5)	<u> </u>	4.9 %	-1.50 [-6.57, 3.57]
Aguayo 2000	33	155 (9.2)	31	153 (9)		5.1 %	2.00 [-2.46, 6.46]
Ekvall 2000	98	95 (16)	97	92 (14)		5.1 %	3.00 [-1.22, 7.22]
Thu 1999	54	123.5 (10.3)	53	.4 (0.6)		5.2 %	12.10 [8.14, 16.06]
Baqui 2003	179	105.1 (14.1)	60	105.3 (13)		5.2 %	-0.20 [-4.08, 3.68]
Arcanjo 2011 (C)	23	119 (7.6)	22	114 (5.4)		5.2 %	5.00 [1.16, 8.84]
Evangelista-Salazar 2004	25	132.7 (6.1)	25	112 (5.4)	-	5.4 %	20.70 [17.51, 23.89]
Palupi 1997	96	8.4 (.4)	98	115.2 (9.4)		5.5 %	3.20 [0.26, 6.14]
Berger 1997	58	150.5 (6.9)	57	32.2 (8.1)	-=+	5.5 %	18.30 [15.55, 21.05]
Yurdakok 2004	19	116 (5)	16	112 (3)		5.5 %	4.00 [1.31, 6.69]
Roschnik 2004 (C)	163	24.5 (.6)	184	122.3 (12.8)		5.6 %	2.20 [-0.37, 4.77]
Sungthong 2002	130	126.9 (9.2)	121	125.3 (9.3)		5.6 %	1.60 [-0.69, 3.89]
Hall 2002 (C)	248	6.4 (2.7)	253	2.6 (2.7)	-	5.6 %	3.80 [1.58, 6.02]
Ermis 2002	30	116 (2.9)	23	113 (4)		5.7 %	3.00 [1.06, 4.94]
Subtotal (95% CI)	1202		1086		•	75.2 %	5.57 [2.21, 8.92]
Heterogeneity: $Tau^2 = 38.0$	0; Chi ² = 229.	80, df = 13 (P<	0.00001); 2 =94%				
Test for overall effect: $Z = 2$	8.25 (P = 0.00))					
2 Ferrous fumarate Taylor 2001	64	-2.4 (11.65)	61	-5.8 (27.6)		4.0 %	3.40 [-4.09, 10.89]
Verhoef 2002	154	106.4 (14.7)	153	98.4 (12)		5.5 %	8.00 [5.00, 11.00]
Subtotal (95% CI)	218		214		•	9.5 %	7.03 [3.36, 10.71]
Heterogeneity: $Tau^2 = 2.10$; $Chi^2 = 1.25$,	df = (P = 0.26)	6); l ² =20%				
Test for overall effect: $Z = 3$	8.75 (P = 0.000)	018)					
3 Other Yang 2004 (C)	20	134.16 (12.79)	24	30. (0.78)		4.7 %	4.06 [-1.32, 9.44]
3 ()		. ,		. ,	_		
Sen 2009 (C)	30	120 (4)	8	116 (6.3)		5.0 %	4.00 [-0.59, 8.59]

No suppl/placebo Intermittent iron suppl

(Continued ...)

								(Continued)
Study or subgroup	Intermittent iron suppl		No suppl/placebo		Di	Mean fference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Ran	dom,95% Cl		IV,Random,95% CI
Olsen 2000	108	8.5 (2.4)	92	7.8 (5.98)		-	5.6 %	0.70 [-1.94, 3.34]
Subtotal (95% CI)	176		136			•	15.3 %	2.03 [-0.26, 4.33]
Heterogeneity: $Tau^2 = 0.47$	7; Chi ² = 2.22, c	If = 2 (P = 0.33); ² = 0%					
Test for overall effect: $Z =$	I.74 (P = 0.082)						
Total (95% CI)	1596		1436			•	100.0 %	5.20 [2.51, 7.88]
Heterogeneity: Tau ² = 32.0	00; Chi ² = 245.2	26, df = 18 (P<0	0.00001); I ² =93%					
Test for overall effect: $Z =$	3.79 (P = 0.000	15)						
Test for subgroup differenc	es: Chi ² = 6.28,	df = 2 (P = 0.0)	14), l ² =68%					
				I			1	
				-20	-10	0 10	20	

No suppl/placebo Intermittent iron suppl

Analysis 1.13. Comparison I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years, Outcome 13 Haemoglobin (by anaemia status at baseline).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years

Outcome: 13 Haemoglobin (by anaemia status at baseline)

Study or subgroup	Intermittent iron suppl		No suppl/placebo		۲ Differe	1ean ence	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Randor	n,95% Cl		IV,Random,95% Cl
I Anaemic								
Verhoef 2002	154	106.4 (14.7)	153	98.4 (12)			5.5 %	8.00 [5.00, 11.00]
Berger 1997	58	150.5 (6.9)	57	32.2 (8.1)			5.5 %	18.30 [15.55, 21.05]
Subtotal (95% CI) Heterogeneity: Tau ² = 50.89 Test for overall effect: Z = 2		``	210				• 11.0 %	13.17 [3.07, 23.26]
2 Non-anaemic Aguayo 2000	33	155 (9.2)	31	153 (9)		—	5.1 %	2.00 [-2.46, 6.46]
Subtotal (95% CI) Heterogeneity: not applicabl	33		31			•	5.1 %	2.00 [-2.46, 6.46]
				-20 No su	0 -10 0 ppl/placebo	10 2 Intermittent	20 iron suppl	(Continued)

Test for overall effect: Z = 0.88 3 Mixed/unknown	N		No suppl/placebo		Mean Difference	Weight	Mean Difference
3 Mixed/unknown	(D - 0.20)	Mean(SD)	Ν	Mean(SD)	IV,Random,95% Cl		IV,Random,95% CI
	(1 – 0.50))					
Taylor 200 I	64	-2.4 (11.65)	61	-5.8 (27.6)	 •	4.0 %	3.40 [-4.09, 10.89]
Yang 2004 (C)	38	34. 6 (2.79)	36	30. (0.78)	+	4.7 %	4.06 [-1.32, 9.44]
Roschnik 2003 (C)	46	110 (12.3)	46	.5 (2.5)		4.9 %	-1.50 [-6.57, 3.57]
Sen 2009 (C)	30	120 (4)	8	116 (6.3)		5.0 %	4.00 [-0.59, 8.59]
Ekvall 2000	98	95 (16)	97	92 (14)		5.1 %	3.00 [-1.22, 7.22]
Thu 1999	54	123.5 (10.3)	53	.4 (0.6)		5.2 %	12.10 [8.14, 16.06]
Baqui 2003	179	105.1 (14.1)	60	105.3 (13)		5.2 %	-0.20 [-4.08, 3.68]
Arcanjo 2011 (C)	23	119 (7.6)	22	114 (5.4)		5.2 %	5.00 [1.16, 8.84]
Evangelista-Salazar 2004	25	32.7 (6.1)	25	112 (5.4)	-	➡ 5.4 %	20.70 [17.51, 23.89]
Palupi 1997	96	8.4 (.4)	98	115.2 (9.4)		5.5 %	3.20 [0.26, 6.14]
Yurdakok 2004	19	116 (5)	16	2 (3)		5.5 %	4.00 [1.31, 6.69]
Olsen 2000	108	118.5 (12.4)	92	7.8 (5.98)	-	5.6 %	0.70 [-1.94, 3.34]
Roschnik 2004 (C)	163	124.5 (11.6)	184	22.3 (2.8)		5.6 %	2.20 [-0.37, 4.77]
Sungthong 2002	130	126.9 (9.2)	121	125.3 (9.3)		5.6 %	1.60 [-0.69, 3.89]
Hall 2002 (C)	248	116.4 (12.7)	253	2.6 (2.7)	-	5.6 %	3.80 [1.58, 6.02]
Ermis 2002	30	116 (2.9)	23	113 (4)		5.7 %	3.00 [1.06, 4.94]
Subtotal (95% CI)	1351		1195		•	84.0 %	4.35 [1.88, 6.82]
Heterogeneity: Tau ² = 21.69; C	$Chi^2 = 144.$.08, df = 15 (P<	$(0.0000); ^2 = 90\%$				
Test for overall effect: Z = 3.45	(P = 0.000	055)					
Total (95% CI)	1596		1436		•	100.0 %	5.20 [2.51, 7.88]
Heterogeneity: $Tau^2 = 32.00$; C		,	:0.00001); l ² =93%				
Test for overall effect: $Z = 3.79$	`	,	1 () 12 500(
Test for subgroup differences: C	_hı∸ = 3.98	s, dt = 2 (P = 0.)	14), 14 =50%				
				-20	-10 0 10	20	

Analysis 1.14. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years, Outcome 14 Haemoglobin (by intermittent regimen).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years

Outcome: 14 Haemoglobin (by intermittent regimen)

Study or subgroup	Experimental N	Mean(SD)	Control N	Mean(SD)	Mean Difference IV,Random,95% Cl	Weight	Mean Difference IV,Random,95% Cl
One supplement a week							
Aguayo 2000	33	155 (9.2)	31	153 (9)	+	4.9 %	2.00 [-2.46, 6.46]
Arcanjo 2011 (C)	23	119 (7.6)	22	114 (5.4)	=	5.1 %	5.00 [1.16, 8.84]
Baqui 2003	179	105.1 (14.1)	60	105.3 (13)	+	5.0 %	-0.20 [-4.08, 3.68]
Berger 1997	58	150.5 (6.9)	57	32.2 (8.1)	-	5.3 %	18.30 [15.55, 21.05]
Evangelista-Salazar 2004	25	132.7 (6.1)	25	112 (5.4)	-	5.2 %	20.70 [17.51, 23.89]
Hall 2002 (C)	248	6.4 (2.7)	253	2.6 (2.7)	-	5.4 %	3.80 [1.58, 6.02]
Palupi 1997	96	8.4 (.4)	98	115.2 (9.4)	-	5.3 %	3.20 [0.26, 6.14]
Roschnik 2003 (C)	46	0 (2.3)	46	.5 (2.5)	+	4.7 %	-1.50 [-6.57, 3.57]
Roschnik 2004 (C)	163	124.5 (11.6)	184	22.3 (2.8)	-	5.4 %	2.20 [-0.37, 4.77]
Sen 2009 (C)	13	120 (4)	4	116 (6.3)	+	4.2 %	4.00 [-2.55, 10.55]
Sungthong 2002	130	126.9 (9.2)	121	125.3 (9.3)	-	5.4 %	1.60 [-0.69, 3.89]
Taylor 2001	64	-2.4 (11.65)	61	-5.8 (27.6)	+-	3.9 %	3.40 [-4.09, 10.89]
Thu 1999	54	123.5 (10.3)	53	.4 (0.6)	-	5.0 %	12.10 [8.14, 16.06]
Yang 2004 (C)	38	34. 6 (2.79)	36	30. (0.78)	+	4.6 %	4.06 [-1.32, 9.44]
Yurdakok 2004	19	116 (5)	16	112 (3)	-	5.3 %	4.00 [1.31, 6.69]
Subtotal (95% CI)	1189		1067		•	74.7 %	5.61 [2.13, 9.09]
Heterogeneity: Tau ² = 42.88; C Test for overall effect: Z = 3.16 2 Other intermittent regimen); ² =949	%			
Ekvall 2000	98	95 (16)	97	92 (14)	+	4.9 %	3.00 [-1.22, 7.22]
Ermis 2002	30	116 (2.9)	23	113 (4)	-	5.5 %	3.00 [1.06, 4.94]
Olsen 2000	108	8.5 (2.4)	92	117.8 (5.98)	÷	5.4 %	0.70 [-1.94, 3.34]
Sen 2009 (C)	17	120 (4)	4	116 (6.3)	+	4.2 %	4.00 [-2.46, 10.46]
Verhoef 2002	154	106.4 (14.7)	153	98.4 (12)	-	5.3 %	8.00 [5.00, 11.00]
Subtotal (95% CI)	407		369		•	25.3 %	3.67 [1.05, 6.28]

Favours experimental Favours control

(Continued ...)

(... Continued) Mean Mean Study or subgroup Experimental Control Difference Weight Difference IV.Random.95% CI Ν Mean(SD) Ν Mean(SD) IV,Random,95% Cl Heterogeneity: Tau² = 5.72; Chi² = 13.28, df = 4 (P = 0.01); l² = 70% Test for overall effect: Z = 2.75 (P = 0.0059) Total (95% CI) 1596 1436 100.0 % 5.15 [2.52, 7.79] Heterogeneity: Tau² = 31.86; Chi² = 245.26, df = 19 (P<0.00001); l² =92% Test for overall effect: Z = 3.84 (P = 0.00012) Test for subgroup differences: $Chi^2 = 0.77$, df = 1 (P = 0.38), $I^2 = 0.0\%$ -100 -50 0 50 100 Favours control Favours experimental

Analysis 1.15. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years, Outcome 15 Haemoglobin (by sex).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years

Outcome: 15 Haemoglobin (by sex)

Study or subgroup	Intermittent iron suppl N	Mean(SD)	No suppl/placebo N	Mean(SD)		Mean ifference ndom,95% Cl	Weight	Mean Difference IV,Random,95% CI
		r icuri(SB)		r icuit(SD)	1 4,1 441			
l Girls								
Hall 2002 (C)	122	7 (2.4)	126	3 (3.)			5.2 %	4.00 [0.83, 7.17]
Subtotal (95% CI)	122		126			•	5.2 %	4.00 [0.83, 7.17]
Heterogeneity: not applicab	ble							
Test for overall effect: $Z = 2$	2.47 (P = 0.014)							
2 Boys								
Hall 2002 (C)	126	5.9 (2.9)	127	2.2 (2.4)			5.2 %	3.70 [0.58, 6.82]
Subtotal (95% CI)	126		127			•	5.2 %	3.70 [0.58, 6.82]
Heterogeneity: not applicab	ble							
Test for overall effect: $Z = 2$	2.33 (P = 0.020)							
3 Mixed/unknown								
Aguayo 2000	33	155 (9.2)	31	153 (9)			4.8 %	2.00 [-2.46, 6.46]
Arcanjo 2011 (C)	23	119 (7.6)	22	114 (5.4)			5.0 %	5.00 [1.16, 8.84]
				-20	0 -10	0 10 20	2	
					ppl/placebo	Intermittent i		
				140 50	рри ріасеро	intermittent i	ЧЧЧЧЧЧ	(Continued)

							(Continued
Study or subgroup	Intermittent iron suppl		No suppl/placebo		Mean Difference	Weight	Mean Difference
	N	Mean(SD)	N	Mean(SD)	IV,Random,95% CI		IV,Random,95% CI
Baqui 2003	179	05. (4.)	60	105.3 (13)		5.0 %	-0.20 [-4.08, 3.68]
Berger 1997	58	150.5 (6.9)	57	132.2 (8.1)	-	► 5.3 %	8.30 [5.55, 2 .05]
Ekvall 2000	98	95 (16)	97	92 (14)		4.9 %	3.00 [-1.22, 7.22]
Ermis 2002	30	116 (2.9)	23	113 (4)	-	5.4 %	3.00 [1.06, 4.94]
Evangelista-Salazar 2004	25	32.7 (6.1)	25	112 (5.4)		→ 5.2 %	20.70 [17.51, 23.89]
Olsen 2000	108	8.5 (2.4)	92	117.8 (5.98)		5.3 %	0.70 [-1.94, 3.34]
Palupi 1997	96	8.4 (.4)	98	115.2 (9.4)		5.2 %	3.20 [0.26, 6.14]
Roschnik 2003 (C)	46	4.8 (5.4)	46	6. (5.)	-	4.2 %	-1.30 [-7.53, 4.93]
Roschnik 2004 (C)	163	24.5 (.6)	184	22.3 (2.8)		5.3 %	2.20 [-0.37, 4.77]
Sen 2009 (C)	30	120 (4)	8	116 (6.3)	<u> </u>	4.8 %	4.00 [-0.59, 8.59]
Sungthong 2002	130	126.9 (9.2)	121	125.3 (9.3)		5.4 %	1.60 [-0.69, 3.89]
Taylor 2001	64	-2.4 (11.65)	61	-5.8 (27.6)		3.8 %	3.40 [-4.09, 10.89]
Thu 1999	54	123.5 (10.3)	53	.4 (0.6)		5.0 %	12.10 [8.14, 16.06]
Verhoef 2002	154	106.4 (14.7)	153	98.4 (12)		5.2 %	8.00 [5.00, .00]
Yang 2004 (C)	38	34. 6 (2.79)	36	30. (0.78)	<u> </u>	4.5 %	4.06 [-1.32, 9.44]
Yurdakok 2004	19	116 (5)	16	112 (3)		5.3 %	4.00 [1.31, 6.69]
ubtotal (95% CI)	1348		1183		•	89.6 %	5.31 [2.40, 8.22]
leterogeneity: Tau ² = 35.5	8; Chi ² = 241.	.06, df = 17 (P<0	0.00001); I ² =93%				
est for overall effect: $Z = 3$	8.58 (P = 0.000)	034)					
otal (95% CI)	1596		1436		•	100.0 %	5.17 [2.56, 7.77]
eterogeneity: $Tau^2 = 31.5$			0.00001); I ² =92%				
est for overall effect: $Z = 3$	8.89 (P = 0.000)	010)					
est for subgroup difference	es: Chi ² = 0.63	8, df = 2 (P = 0.7	3), I ² =0.0%				

-20 -10 0 No suppl/placebo

10 Intermittent iron suppl

20

Analysis 1.16. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years, Outcome 16 Haemoglobin (by nutrient).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years

Outcome: 16 Haemoglobin (by nutrient)

Study or subgroup	Intermittent iron suppl		No suppl/placebo		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% Cl		IV,Random,95% C
l Iron alone							
Baqui 2003	68	104.6 (9.9)	20	105.3 (13)		4.2 %	-0.70 [-6.86, 5.46]
Aguayo 2000	33	155 (9.2)	31	153 (9)		4.7 %	2.00 [-2.46, 6.46]
Arcanjo 2011 (C)	23	119 (7.6)	22	4 (5.4)		4.9 %	5.00 [1.16, 8.84]
Verhoef 2002	154	106.4 (14.7)	153	98.4 (12)		5.1 %	8.00 [5.00, .00]
Palupi 1997	96	8.4 (.4)	98	115.2 (9.4)		5.1 %	3.20 [0.26, 6.14]
Berger 1997	58	150.5 (6.9)	57	32.2 (8.1)		• 5.1 %	8.30 [5.55, 2 .05]
Yurdakok 2004	19	116 (5)	16	112 (3)		5.2 %	4.00 [1.31, 6.69]
Olsen 2000	108	8.5 (2.4)	92	7.8 (5.98)		5.2 %	0.70 [-1.94, 3.34]
Roschnik 2004 (C)	163	24.5 (.6)	184	22.3 (2.8)	-	5.2 %	2.20 [-0.37, 4.77]
Sungthong 2002	130	126.9 (9.2)	121	125.3 (9.3)		5.2 %	1.60 [-0.69, 3.89]
Ermis 2002	30	116 (2.9)	23	113 (4)	-	5.3 %	3.00 [1.06, 4.94]
Subtotal (95% CI)	882		817		•	55.1 %	4.41 [1.32, 7.50]
Heterogeneity: Tau ² = 24.4	18; Chi ² = 126	18, df = 10 (P	<0.00001); I ² =92%				
Test for overall effect: $Z =$	2.80 (P = 0.00)	51)					
2 Iron + folic acid Taylor 2001	64	-2.4 (11.65)	61	-5.8 (27.6)		3.7 %	3.40 [-4.09, 10.89]
,		. ,		()			
Roschnik 2003 (C)	46	4.8 (5.4)	46	6. (5.)		4.1 %	-1.30 [-7.53, 4.93]
Sen 2009 (C)	30	120 (4)	8	116 (6.3)		4.7 %	4.00 [-0.59, 8.59]
Hall 2002 (C)	248	6.4 (2.7)	253	2.6 (2.7)		5.2 %	3.80 [1.58, 6.02]
Subtotal (95% CI)	388		368		•	17.8 %	3.36 [1.51, 5.21]
Heterogeneity: Tau ² = 0.0; Test for overall effect: Z =); I ² =0.0%				
3 iron + zinc	3.37 (F — 0.00	030)					
Baqui 2003	57	103.7 (12)	20	105.3 (13)		4.1 %	-1.60 [-8.09, 4.89]
Subtotal (95% CI)	57		20			4.1 %	-1.60 [-8.09, 4.89]
Heterogeneity: not applical	ole						

No suppl/placebo Intermittent iron suppl

(Continued ...)

Intermittent iron supplementation for improving nutrition and development in children under 12 years of age (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. 125

(... Continued)

							(Continued)
Study or subgroup	Intermittent iron suppl		No suppl/placebo		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI		IV,Random,95% CI
Test for overall effect: $Z = 0$).48 (P = 0.63))					
4 Iron + vitamin C							
Evangelista-Salazar 2004	25	132.7 (6.1)	25	112 (5.4)		→ 5.0 %	20.70 [17.51, 23.89]
Subtotal (95% CI)	25		25			5.0 % 2	20.70 [17.51, 23.89]
Heterogeneity: not applicab	le						
Test for overall effect: $Z = I$	2.70 (P < 0.00	0001)					
5 Iron + multiple micronutr	ients						
Baqui 2003	54	106.9 (13)	20	105.3 (13)		4.0 %	1.60 [-5.07, 8.27]
Yang 2004 (C)	38	34. 6 (2.79)	36	130.1 (10.78)	+	4.4 %	4.06 [-1.32, 9.44]
Ekvall 2000	98	95 (16)	97	92 (14)		4.8 %	3.00 [-1.22, 7.22]
Thu 1999	54	123.5 (10.3)	53	.4 (0.6)		4.8 %	2. 0 [8. 4, 6.06]
Subtotal (95% CI)	244		206		-	18.0 %	5.47 [0.32, 10.61]
Heterogeneity: $Tau^2 = 20.9$	0; Chi ² = 13.1	6, df = 3 (P = 0	0.004); I ² =77%				
Test for overall effect: $Z = 2$	2.08 (P = 0.03)	7)					
Total (95% CI)	1596		1436		•	100.0 %	4.83 [2.25, 7.41]
Heterogeneity: $Tau^2 = 31.6$	7; Chi ² = 244.	.17, df = 20 (P<	:0.00001); I ² =92%				
Test for overall effect: $Z = 3$	8.67 (P = 0.000	024)					
Test for subgroup difference	es: Chi ² = 94.9	94, df = 4 (P = 0	0.00), l ² =96%				
						1	
				-20	-10 0 10	20	
				N.a. aug	nl/nlacobo	ant iron cunnl	

No suppl/placebo

Intermittent iron suppl

Analysis 1.17. Comparison I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years, Outcome 17 Iron deficiency (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years

Outcome: 17 Iron deficiency (ALL)

Study or subgroup	Intermittent iron suppl	No suppl/placebo		isk Ratio M- dom,95%	Weight	Risk Ratio M- H.Random,95%
	n/N	n/N	l I,I \dll	Cl		CI
Evangelista-Salazar 2004	0/25	4/25		_	14.6 %	0.11 [0.01, 1.96]
Verhoef 2002	14/154	105/153	-		42.9 %	0.13 [0.08, 0.22]
Yang 2004 (C)	12/38	20/36	-		42.5 %	0.57 [0.33, 0.99]
Total (95% CI)	217	214	-		100.0 %	0.24 [0.06, 0.91]
Total events: 26 (Intermittent ir	ron suppl), 129 (No	suppl/placebo)				
Heterogeneity: $Tau^2 = 1.01$; Cł	$mi^2 = 16.40, df = 2$ (F	$P = 0.00027$); $I^2 = 88\%$				
Test for overall effect: $Z = 2.10$	(P = 0.036)					
Test for subgroup differences: N	Vot applicable					
			i i i			
		0.	005 0.1	10 200		
		Intermitt	ent iron suppl	No suppl/placebo		

Analysis 1.18. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years, Outcome 18 Ferritin (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years

Outcome: 18 Ferritin (ALL)

Study or subgroup	Intermittent iron suppl		No suppl/placebo		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI		IV,Random,95% CI
Yurdakok 2004	19	59.7 (27.7)	16	43.9 (23.7)		15.1 %	15.80 [-1.23, 32.83]
Yang 2004 (C)	38	64.14 (33.63)	36	61.68 (39.8)		15.2 %	2.46 [-14.37, 19.29]
Baqui 2003	111	8.9 (6)	37	4.3 (4.3)	-	23.1 %	4.60 [-0.89, 10.09]
Sungthong 2002	123	54 (24.2)	117	37.4 (18.9)	-	23.1 %	16.60 [11.12, 22.08]
Ermis 2002	30	45 (12.7)	23	17.2 (4.6)	-	23.4 %	27.80 [22.88, 32.72]
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: Test for subgroup diffe	Z = 2.61 (P =	= 0.0091)	229 (P<0.00001); I ² =905	8	•	100.0 %	14.17 [3.53, 24.81]

-100 -50 0 50 100

No suppl/placebo Intermittent iron suppl

Analysis 1.19. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years, Outcome 19 Ferritin (by dose of elemental iron in the intermittent group).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years

Outcome: 19 Ferritin (by dose of elemental iron in the intermittent group)

Study or subgroup	Intermittent iron suppl	Ν	lo suppl/placebo		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI		IV,Random,95% CI
1 25 mg or less/week							
Baqui 2003	111	8.9 (6)	37	14.3 (14.3)	-	23.1 %	4.60 [-0.89, 10.09]
Subtotal (95% CI)	111		37		•	23.1 %	4.60 [-0.89, 10.09]
Heterogeneity: not applical	ble						
Test for overall effect: Z =	1.64 (P = 0.1	0)					
2 Greater than 25 mg to 7	5 mg/week						
Ermis 2002	30	45 (12.7)	23	17.2 (4.6)	-	23.4 %	27.80 [22.88, 32.72]
Sungthong 2002	123	54 (24.2)	117	37.4 (18.9)	-	23.1 %	6.60 [. 2, 22.08]
Yang 2004 (C)	38	64.14 (33.63)	36	61.68 (39.8)	-	15.2 %	2.46 [-14.37, 19.29]
Yurdakok 2004	19	59.7 (27.7)	16	43.9 (23.7)		15.1 %	15.80 [-1.23, 32.83]
Subtotal (95% CI)	210		192		•	76.9 %	17.77 [8.21, 27.34]
Heterogeneity: $Tau^2 = 65$.	16; Chi ² = 14	.72, df = 3 (P = 0.	002); l ² =80%				
Test for overall effect: Z =	3.64 (P = 0.0	0027)					
3 Greater than 75 mg/wee	k						
Subtotal (95% CI)	0		0				Not estimable
Heterogeneity: not applical	ble						
Test for overall effect: not a	applicable						
Total (95% CI)	321		229		•	100.0 %	14.17 [3.53, 24.81]
Heterogeneity: Tau ² = 119			20001 ; $l^2 = 90\%$				
Test for overall effect: Z =		,					
Test for subgroup difference	es: Chi ² = 5.4	48, df = 1 (P = 0.0	2), 1² =82%				
				- I OC	-50 0 50	100	
				No sup	pl/placebo Intermittent	t iron suppl	

Analysis 1.20. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years, Outcome 20 Ferritin (by duration of the supplementation).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years

Outcome: 20 Ferritin (by duration of the supplementation)

Study or subgroup	Intermittent iron suppl	No s	uppl/placebo		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI		IV,Random,95% CI
0 to three months							
Yurdakok 2004	19	59.7 (27.7)	16	43.9 (23.7)		15.1 %	5.80 [-1.23, 32.83]
Subtotal (95% CI)	19		16		•	15.1 %	15.80 [-1.23, 32.83]
Heterogeneity: not applicat	ble						
Test for overall effect: $Z =$	I.82 (P = 0.0	69)					
2 More than three months							
Baqui 2003	111	18.9 (16)	37	4.3 (4.3)	-	23.1 %	4.60 [-0.89, 10.09]
Ermis 2002	30	45 (12.7)	23	17.2 (4.6)	-	23.4 %	27.80 [22.88, 32.72]
Sungthong 2002	123	54 (24.2)	117	37.4 (18.9)	-	23.1 %	6.60 [.12, 22.08]
Yang 2004 (C)	38	64.14 (33.63)	36	61.68 (39.8)	-	15.2 %	2.46 [-14.37, 19.29]
Subtotal (95% CI)	302		213		•	84.9 %	13.82 [1.84, 25.81]
Heterogeneity: $Tau^2 = 130$.03; $Chi^2 = 4$	1.01, df = 3 (P<0.000	01); I ² =93%				
Test for overall effect: $Z =$	2.26 (P = 0.0	24)					
Total (95% CI)	321		229		•	100.0 %	14.17 [3.53, 24.81]
Heterogeneity: $Tau^2 = 119$.72; Chi ² = 4	1.02, df = 4 (P<0.000	01); 12 =90%				
Test for overall effect: $Z =$	2.61 (P = 0.0	091)					
Test for subgroup difference	es: $Chi^2 = 0.0$	03, df = 1 (P = 0.85),	$ ^2 = 0.0\%$				
						1	

No suppl/placebo Intermittent iron suppl

Analysis 1.21. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years, Outcome 21 Ferritin (by type of compound).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years

Outcome: 21 Ferritin (by type of compound)

Study or subgroup	Intermittent iron suppl		No suppl/placebo		Mean Difference	Weight	Mean Difference	
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% Cl	-	IV,Random,95% Cl	
l Ferrous sulphate								
Baqui 2003	111	18.9 (16)	37	14.3 (14.3)	-	23.1 %	4.60 [-0.89, 10.09]	
Ermis 2002	30	45 (12.7)	23	17.2 (4.6)	-	23.4 %	27.80 [22.88, 32.72]	
Sungthong 2002	123	54 (24.2)	7	37.4 (18.9)	-	23.1 %	16.60 [11.12, 22.08]	
Yurdakok 2004	19	59.7 (27.7)	16	43.9 (23.7)		15.1 %	5.80 [-1.23, 32.83]	
Subtotal (95% CI)	283		193		•	84.8 %	16.28 [4.68, 27.87]	
Heterogeneity: Tau ² = 12	20.53; Chi ² = 3	8.18, df = 3 (P<	<0.00001); 2 =92%					
Test for overall effect: Z =	= 2.75 (P = 0.0	059)						
2 Ferrous fumarate								
Subtotal (95% CI)	0		0				Not estimable	
Heterogeneity: not applic	able							
Test for overall effect: not	applicable							
3 Other								
Yang 2004 (C)	38	64.14 (33.63)	36	61.68 (39.8)		15.2 %	2.46 [-14.37, 19.29]	
Subtotal (95% CI)	38		36		•	15.2 %	2.46 [-14.37, 19.29]	
Heterogeneity: not applic	able							
Test for overall effect: Z =	= 0.29 (P = 0.7	7)						
Total (95% CI)	321		229		•	100.0 %	14.17 [3.53, 24.81]	
Heterogeneity: $Tau^2 = $	9.72; Chi ² = 4	1.02, df = 4 (P	<0.00001); 12 =90%					
Test for overall effect: Z =	= 2.61 (P = 0.0	091)						
Test for subgroup differer	nces: $Chi^2 = 1.7$	75, df = 1 (P =	0.19), l ² =43%					

-100 -50 0 50 100

No suppl/placebo

Intermittent iron suppl

Intermittent iron supplementation for improving nutrition and development in children under 12 years of age (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Analysis 1.22. Comparison I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years, Outcome 22 Ferritin (by anaemia status at baseline).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years

Outcome: 22 Ferritin (by anaemia status at baseline)

Study or subgroup	Intermittent iron suppl		No suppl/placebo		Mean Difference	Weight	Mean Difference
	N	Mean(SD)	N	Mean(SD)	IV,Random,95% Cl		IV,Random,95% C
Anaemic							
Subtotal (95% CI)	0		0				Not estimable
Heterogeneity: not applica	able						
Fest for overall effect: not	applicable						
2 Non-anaemic							
Yang 2004 (C)	38	64.14 (33.63)	36	61.68 (39.8)		15.2 %	2.46 [-14.37, 19.29]
Subtotal (95% CI)	38		36		+	15.2 %	2.46 [-14.37, 19.29]
Heterogeneity: not applica	able						
Test for overall effect: Z =	0.29 (P = 0.7	77)					
3 Mixed/unknown							
Baqui 2003	111	18.9 (16)	37	4.3 (4.3)	-	23.1 %	4.60 [-0.89, 10.09]
Ermis 2002	30	45 (12.7)	23	17.2 (4.6)	-	23.4 %	27.80 [22.88, 32.72]
Sungthong 2002	123	54 (24.2)	117	37.4 (18.9)	-	23.1 %	6.60 [. 2, 22.08]
Yurdakok 2004	19	59.7 (27.7)	16	43.9 (23.7)		15.1 %	5.80 [-1.23, 32.83]
Subtotal (95% CI)	283		193		*	84.8 %	16.28 [4.68, 27.87]
Heterogeneity: $Tau^2 = 120$	0.53; Chi ² = 3	38.18, df = 3 (P<	0.00001); 1 ² =92%				
Test for overall effect: Z =	2.75 (P = 0.0	0059)					
Fotal (95% CI)	321		229		•	100.0 %	14.17 [3.53, 24.81]
Heterogeneity: Tau ² = 119	9.72; Chi ² = 4	11.02, df = 4 (P<	0.00001); 1 ² =90%				
Fest for overall effect: Z =	2.61 (P = 0.0	0091)					
Fest for subgroup differen	ces: $Chi^2 = 1$.	75, df = 1 (P = 0	.19), I ² =43%				
Test for overall effect: $Z =$	2.61 (P = 0.0)091)	,	-100	50 0 50	100	

No suppl/placebo

Intermittent iron suppl

Analysis 1.23. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years, Outcome 23 Ferritin (by supplementation regimen).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years

Outcome: 23 Ferritin (by supplementation regimen)

Study or subgroup	Intermittent iron suppl		No suppl/placebo		Mean Difference	Weight	Mean Difference
	N	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI	-	IV,Random,95% Cl
I One supplement a wee	k						
Baqui 2003	111	18.9 (16)	37	14.3 (14.3)	-	23.1 %	4.60 [-0.89, 10.09]
Sungthong 2002	123	54 (24.2)	117	37.4 (18.9)	-	23.1 %	6.60 [. 2, 22.08]
Yang 2004 (C)	38	64.14 (33.63)	36	61.68 (39.8)		15.2 %	2.46 [-14.37, 19.29]
Yurdakok 2004	19	59.7 (27.7)	16	43.9 (23.7)		15.1 %	5.80 [-1.23, 32.83]
Subtotal (95% CI)	291		206		•	76.6 %	10.14 [1.74, 18.53]
Heterogeneity: $Tau^2 = 45$.04; $Chi^2 = 10$	0.45, df = 3 (P :	= 0.02); I ² =71%				
Test for overall effect: Z =	= 2.37 (P = 0.0	018)					
2 Other intermittent regir	men						
Ermis 2002	30	45 (12.7)	23	17.2 (4.6)	•	23.4 %	27.80 [22.88, 32.72]
Subtotal (95% CI)	30		23		•	23.4 %	27.80 [22.88, 32.72]
Heterogeneity: not applica	able						
Test for overall effect: Z =	= .08 (P < 0).00001)					
Total (95% CI)	321		229		◆	100.0 %	14.17 [3.53, 24.81]
Heterogeneity: $Tau^2 = $	9.72; Chi ² = -	41.02, df = 4 (P	<0.00001); 12 =90%				
Test for overall effect: Z =	= 2.61 (P = 0.0	0091)					
Test for subgroup differen	ces: $Chi^2 = 1$	2.67, df = 1 (P	= 0.00), I ² =92%				
						1	
				-10	0 -50 0 50	100	

No suppl/placebo Intermittent iron suppl

Analysis 1.24. Comparison I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years, Outcome 24 Ferritin (by sex).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years

Outcome: 24 Ferritin (by sex)

Study or subgroup	Intermittent iron suppl	No s	No suppl/placebo		Mean Difference	Weight	Mean Difference	
	N	Mean(SD)	N	Mean(SD)	IV,Random,95% Cl	-	IV,Random,95% CI	
l Girls								
Subtotal (95% CI)	0		0				Not estimable	
Heterogeneity: not applica	able							
Test for overall effect: not	applicable							
2 Boys								
Subtotal (95% CI)	0		0				Not estimable	
Heterogeneity: not applica	able							
Test for overall effect: not	applicable							
3 Mixed/unknown								
Baqui 2003	111	18.9 (16)	37	14.3 (14.3)	-	23.1 %	4.60 [-0.89, 10.09]	
Ermis 2002	30	45 (12.7)	23	17.2 (4.6)	-	23.4 %	27.80 [22.88, 32.72]	
Sungthong 2002	123	54 (24.2)	117	37.4 (18.9)	-	23.1 %	6.60 [. 2, 22.08]	
Yang 2004 (C)	38	64.14 (33.63)	36	61.68 (39.8)	-+-	15.2 %	2.46 [-14.37, 19.29]	
Yurdakok 2004	19	59.7 (27.7)	16	43.9 (23.7)		15.1 %	15.80 [-1.23, 32.83]	
Subtotal (95% CI)	321		229		*	100.0 %	14.17 [3.53, 24.81]	
Heterogeneity: $Tau^2 = 11$	9.72; Chi ² = 4	1.02, df = 4 (P<0.000	01); 12 =90%					
Test for overall effect: Z =	= 2.61 (P = 0.0	0091)						
Total (95% CI)	321		229		•	100.0 %	14.17 [3.53, 24.81]	
Heterogeneity: $Tau^2 = 11$	9.72; Chi ² = 4	1.02, df = 4 (P<0.000	01); I ² =90%					
Test for overall effect: Z =	= 2.61 (P = 0.0	0091)						
Test for subgroup differen	ices: Not appli	cable						
				-100	0 -50 0 50	100		
				No su	ppl/placebo Intermitten	t iron suppl		
				No su	ppl/placebo Intermitten	t iron suppl		

Analysis 1.25. Comparison I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years, Outcome 25 Ferritin (by nutrient).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years

Outcome: 25 Ferritin (by nutrient)

Study or subgroup	Intermittent iron suppl N	Mean(SD)	No suppl/placebo N	Mean(SD)	Mean Difference IV,Random,95% Cl	Weight	Mear Difference IV,Random,95% Cl
l Iron alone							
Baqui 2003	38	17.6 (14.4)	13	4.6 (4.3)	+	15.1 %	3.00 [-6.02, 12.02]
Ermis 2002	30	45 (12.7)	23	17.2 (4.6)	-	17.1 %	27.80 [22.88, 32.72]
Sungthong 2002	123	54 (24.2)	117	37.4 (18.9)	-	16.9 %	6.60 [. 2, 22.08]
Yurdakok 2004	19	59.7 (27.7)	16	43.9 (23.7)		10.7 %	5.80 [-1.23, 32.83]
Subtotal (95% CI)	210		169		•		16.25 [5.41, 27.09]
Heterogeneity: $Tau^2 = 99$		01, df = 3 (P =				<i>,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,</i>	[,,_,_,
Test for overall effect: Z =							
2 Iron + folic acid		,					
Subtotal (95% CI)	0		0				Not estimable
Heterogeneity: not applic	able						
Test for overall effect: not	applicable						
3 Iron + zinc							
Baqui 2003	41	20.1 (15.7)	12	14.6 (14.3)		14.9 %	5.50 [-3.91, 14.91]
Subtotal (95% CI)	41		12		•	14.9 %	5.50 [-3.91, 14.91]
Heterogeneity: not applic	able						
Test for overall effect: Z =	= 1.15 (P = 0.25	5)					
4 Iron + multiple micronu	itrients						
Baqui 2003	32	18.9 (18.2)	12	14.6 (14.3)	-	14.5 %	4.30 [-5.96, 14.56]
Yang 2004 (C)	38	64.14 (33.63)	36	61.68 (39.8)	-	10.8 %	2.46 [-14.37, 19.29]
Subtotal (95% CI)	70		48		•	25.2 %	3.80 [-4.96, 12.56]
Heterogeneity: Tau ² = 0.0); $Chi^2 = 0.03$,	df = 1 (P = 0.8)	35); I ² =0.0%				
Test for overall effect: Z =	= 0.85 (P = 0.39	9)					
Total (95% CI)	321		229		*	100.0 %	11.41 [2.71, 20.11]
Heterogeneity: Tau ² = 10	8.79; Chi ² = 42	2.24, df = 6 (P·	<0.00001); 2 =86%				
Test for overall effect: Z =	= 2.57 (P = 0.0	10)					
Test for subgroup differen	ices: $Chi^2 = 3.3$	6, df = 2 (P =	0.19), l ² =40%				
Test for subgroup differen	ices: Chi ² = 3.3	6, df = 2 (P =	0.19), l ² =40%				

No suppl/placebo


Intermittent iron suppl

Analysis 1.26. Comparison I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years, Outcome 26 All cause morbidity (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years

Outcome: 26 All cause morbidity (ALL)



Analysis 1.27. Comparison I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years, Outcome 27 Any side effects (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years

Outcome: 27 Any side effects (ALL)

Study or subgroup	Intermittent iron suppl n/N	No suppl/placebo n/N			Risk Ratio xed,95% Cl		Weight	Risk Ratio M-H,Fixed,95% Cl
Ermis 2002	2/30	0/23			-		100.0 %	3.87 [0.19, 76.92]
Total (95% CI)	30	23				-	100.0 %	3.87 [0.19, 76.92]
Total events: 2 (Intermitte	ent iron suppl), 0 (No	suppl/placebo)						
Heterogeneity: not applic	able							
Test for overall effect: Z =	= 0.89 (P = 0.37)							
Test for subgroup differer	nces: Not applicable							
						ı		
			0.01	0.1	1 10	100		
		Inter	rmittent i	ron suppl	No supp	lementation		

Analysis 1.28. Comparison I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years, Outcome 28 Nausea.

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years

Outcome: 28 Nausea

Study or subgroup	Intermittent iron suppl n/N	No suppl/placebo n/N	Risk Ratio M- H,Random,95% Cl	Weight	Risk Ratio M- H,Random,95 Cl
Aguayo 2000	1/33	0/31		100.0 %	2.82 [0.12, 66.82]
Total (95% CI)	33	31		100.0 %	2.82 [0.12, 66.82]
Total events: (Intermit	tent iron suppl), 0 (Nc	suppl/placebo)			
Heterogeneity: not appli	icable				
Test for overall effect: Z	= 0.64 (P = 0.52)				
Test for subgroup differe	ences: Not applicable				
			<u> </u>		
			01 0.1 1 10 100		
		Intermitte	ent iron suppl No interventio	on/placebo	

Analysis 1.29. Comparison I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years, Outcome 29 Adherence (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years

Outcome: 29 Adherence (ALL)

Study or subgroup	Intermittent iron suppl	No suppl/placebo		Risk Ratio M-	Weight	Risk Ratio M-
	n/N	n/N	H,F	Random,95% Cl		H,Random,95% Cl
Baqui 2003	43/49	40/45	-	-	13.7 %	0.99 [0.85, 1.14]
Ekvall 2000	96/98	91/97			86.3 %	1.04 [0.98, 1.11]
Total (95% CI)	147	142		•	100.0 %	1.04 [0.98, 1.09]
Total events: 139 (Interm	nittent iron suppl), 131	(No suppl/placebo)				
Heterogeneity: $Tau^2 = 0$.0; $Chi^2 = 0.60$, $df = 1$	(P = 0.44); I ² =0.0%				
Test for overall effect: Z	= 1.28 (P = 0.20)					
Test for subgroup differe	nces: Not applicable					
			0.5 0.7	I I.5 2		

Intermittent iron suppl

No supplementation

Analysis 1.30. Comparison I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years, Outcome 30 Mental development scale (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years

Outcome: 30 Mental development scale (ALL)

Study or subgroup	Intermittent iron suppl N	Mean(SD)	No suppl/placebo N	Mean(SD)		Mean ference Iom,95% Cl	Weight	Mean Difference IV,Random,95% CI
Baqui 2003	127	104.7 (11.2)	45	102.7 (13.5)		+	100.0 %	2.00 [-2.40, 6.40]
Total (95% CI)	127		45			•	100.0 %	2.00 [-2.40, 6.40]
Heterogeneity: not ap	plicable							
Test for overall effect:	Z = 0.89 (P =	0.37)						
Test for subgroup diff	erences: Not ap	plicable						
				-100	-50	0 50	100	
				Intermittent	iron suppl	No supple	ementation	

Analysis 1.31. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years, Outcome 31 Orientation engagement (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years

Outcome: 31 Orientation engagement (ALL)


Study or subgroup	Intermittent iron suppl	Maga (SD)	No suppl/placebo N	Mean(SD)	Mean Difference IV,Random,95% C	Weight	Mean Difference IV,Random,95% CI
Baqui 2003	N 127	Mean(SD) 75.4 (26.8)	45	67 (31)	IV,random,75% C	100.0 %	8.40 [-1.79, 18.59]
		75.1 (20.0)		07 (51)			
Total (95% CI) Heterogeneity: not ap	127		45			100.0 %	8.40 [-1.79, 18.59]
Test for overall effect:		011)					
Test for subgroup diff							
				ı			
				-10	0 -50 0 50	100	
				Intermitter	it iron suppl No sup	oplementation	

Analysis 1.32. Comparison I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years, Outcome 32 Emotional regulation (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years

Outcome: 32 Emotional regulation (ALL)



Analysis 1.33. Comparison I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years, Outcome 33 Motor quality (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years

Outcome: 33 Motor quality (ALL)


Study or subgroup	Intermittent iron suppl N	Mean(SD)	No suppl/placebo N	Mean(SD)		Mean ference dom,95% Cl	Weight	Mean Difference IV,Random,95% Cl
Baqui 2003	127	37.7 (30.5)	45	22.1 (20.2)			100.0 %	5.60 [7.66, 23.54]
Total (95% CI)	127		45			•	100.0 %	15.60 [7.66, 23.54]
Heterogeneity: not ap	oplicable							
Test for overall effect:	Z = 3.85 (P =	0.00012)						
Test for subgroup diff	erences: Not ap	oplicable						
					1 1	<u> </u>	1	
				-	100 -50	0 50 I	00	
				Intermit	ent iron suppl	No supplem	nentation	

Analysis 1.34. Comparison I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years, Outcome 34 Psychomotor development index (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years

Outcome: 34 Psychomotor development index (ALL)



Analysis 1.35. Comparison I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years, Outcome 35 IQ (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years

Outcome: 35 IQ (ALL)

Study or subgroup	Intermittent iron suppl N	Mean(SD)	No suppl/placebo N	Mean(SD)	Mean Difference IV,Random,95% CI	Weight	Mean Difference IV,Random,95% CI
Sungthong 2002	130	83 (12)	122	86 (12)	•	100.0 %	-3.00 [-5.96, -0.04]
Total (95% CI) Heterogeneity: not ap	130 plicable		122		•	100.0 %	-3.00 [-5.96, -0.04]
Test for overall effect:	Z = 1.98 (P = 0	0.047)					
Test for subgroup diffe	erences: Not ap	plicable					
				-100	0 -50 0 50	100	
				No supple	ementation Intermitt	ent iron suppl	
itermittent iron su	pplementatio	on for impro	ving nutrition and o	development in	children under 12 ye	ars of age (Revi	ew) I

Analysis 1.36. Comparison I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years, Outcome 36 Thai language (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years

Outcome: 36 Thai language (ALL)

Study or subgroup	Intermittent iron suppl		No suppl/placebo			Di		Mean rence		Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)		IV,Ran	Iobi	m,95% Cl			IV,Random,95% CI
Sungthong 2002	105	0.001 (0.8)	103	0.3 (0.7)			Ļ			100.0 %	-0.30 [-0.50, -0.09]
Total (95% CI)	105		103							100.0 %	-0.30 [-0.50, -0.09]
Heterogeneity: not ap	plicable										
Test for overall effect:	Z = 2.87 (P =	0.0041)									
Test for subgroup diff	erences: Not ap	plicable									
							_				
					-100	-50	0	50	100		
				No su	pplem	entation		Intermitt	ent iro	n suppl	

Analysis 1.37. Comparison I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years, Outcome 37 Mathematics (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years

Outcome: 37 Mathematics (ALL)

Study or subgroup	Intermittent iron suppl		No suppl/placebo		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI		IV,Random,95% Cl
Sungthong 2002	130	0.03 (0.7)	103	0.3 (0.65)		100.0 %	-0.27 [-0.44, -0.10]
Total (95% CI)	130		103			100.0 %	-0.27 [-0.44, -0.10]
Heterogeneity: not ap	oplicable						
Test for overall effect:	Z = 3.04 (P =	0.0023)					
Test for subgroup diffe	erences: Not ap	plicable					
0 1							
				-10	0 -50 0 50	100	
				-10 No supe		100 t iron suppl	
					0 -50 0 50 lementation Intermitten		

Analysis 1.38. Comparison I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years, Outcome 38 WAZ.

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years

Outcome: 38 WAZ

Study or subgroup	Intermittent iron suppl		No suppl/placebo		Di	Std. Mean fference	Weight	Std. Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Rand	om,95% Cl		IV,Random,95% Cl
Aguayo 2000	33	-0.98 (0.92)	31	-0.79 (0.56)			24.1 %	-0.24 [-0.74, 0.25]
Palupi 1997	96	0.14 (0.36)	98	0.06 (0.41)	I	•	42.9 %	0.21 [-0.08, 0.49]
Thu 1999	54	-1.77 (0.78)	54	-1.64 (0.67)	I	•	32.9 %	-0.18 [-0.56, 0.20]
Total (95% CI)	183		183				100.0 %	-0.03 [-0.33, 0.27]
Heterogeneity: Tau ² :	$= 0.03; Chi^2 = 3$	3.83, df = 2 (P =	= 0.15); I ² =48%					
Test for overall effect:	Z = 0.19 (P =	0.85)						
Test for subgroup diff	erences: Not ap	oplicable						
				-	100 -50	0 50	100	
				No su	oplementation	Intermitter	nt iron suppl	

Analysis 1.39. Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years, Outcome 39 HAZ.

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: I Intermittent iron supplementation versus placebo or no intervention: children 0 - 12 years

Outcome: 39 HAZ

Study or subgroup	Intermittent iron suppl		No suppl/placebo			Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IN	/,Random,95% Cl		IV,Random,95% CI
Aguayo 2000	33	-1.59 (1.06)	31	-1.35 (0.78)			2.5 %	-0.24 [-0.69, 0.21]
Palupi 1997	96	0.07 (0.27)	98	0.03 (0.26)		-	91.5 %	0.04 [-0.03, 0.11]
Thu 1999	54	-1.81 (0.84)	54	-1.82 (0.7)		•	6.0 %	0.01 [-0.28, 0.30]
Total (95% CI)	183		183				100.0 %	0.03 [-0.04, 0.10]
Heterogeneity: Tau ²	$= 0.0; Chi^2 = 1.4$	44, df = 2 (P = 0.4	19); I ² =0.0%					
Test for overall effect	Z = 0.86 (P =	0.39)						
Test for subgroup diff	erences: Not ap	plicable						
					-100 -5	0 0 50	100	

No supplementation In

Intermittent iron suppl

Analysis 2.1. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years, Outcome 1 Anaemia (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years

Outcome: I Anaemia (ALL)

Study or subgroup	Intermittent iron suppl	Daily iron suppl	Risk Ratio M-	Weight	Risk Ratio M-
	n/N	n/N	H,Random,95% Cl		H,Random,95% Cl
Thu 1999	4/54	3/53		1.4 %	1.31 [0.31, 5.57]
Sinisterra 1997 (C)	5/15	3/12		2.0 %	1.33 [0.40, 4.49]
Schultink 1995	7/32	6/33		3.2 %	1.20 [0.45, 3.19]
Berger 1997	8/59	10/59	<u> </u>	4.1 %	0.80 [0.34, 1.88]
Awasthi 2005 (C)	46/185	29/181		17.3 %	1.55 [1.02, 2.36]
Engstrom 2008 (C)	89/147	76/150		71.9 %	1.19 [0.97, 1.47]
Total (95% CI)	492	488	•	100.0 %	1.23 [1.04, 1.47]
			0.05 0.2 I 5 20 ent iron suppl Daily iron suppl		

Analysis 2.2. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years, Outcome 2 Anaemia (by dose of elemental iron in the intermittent group).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years

Outcome: 2 Anaemia (by dose of elemental iron in the intermittent group)

Study or subgroup	Intermittent iron suppl	Daily iron suppl	Risk Ratio M-	Weight	Risk Ratio M-
	n/N	n/N	H,Random,95% Cl		H,Random,95% Cl
1 25 mg or less/week					
Thu 1999	4/54	3/53		1.4 %	1.31 [0.31, 5.57]
Engstrom 2008 (C)	89/147	76/150		71.9 %	1.19 [0.97, 1.47]
Subtotal (95% CI)	201	203	•	73.3 %	1.20 [0.98, 1.47]
Total events: 93 (Intermittent	iron suppl), 79 (Daily	y iron suppl)			
Heterogeneity: $Tau^2 = 0.0$; Cl	$hi^2 = 0.02, df = 1 (P$	= 0.90); I ² =0.0%			
Test for overall effect: $Z = 1.7$	· /				
2 Greater than 25 mg to 75 r	0				
Sinisterra 1997 (C)	5/15	3/12		2.0 %	1.33 [0.40, 4.49]
Schultink 1995	7/32	6/33		3.2 %	1.20 [0.45, 3.19]
Berger 1997	8/59	10/59		4.1 %	0.80 [0.34, 1.88]
Awasthi 2005 (C)	46/185	29/181	-	17.3 %	1.55 [1.02, 2.36]
Subtotal (95% CI)	291	285	•	26.7 %	1.34 [0.96, 1.88]
Total events: 66 (Intermittent	iron suppl), 48 (Daily	y iron suppl)			
Heterogeneity: $Tau^2 = 0.0$; Ch	$hi^2 = 1.92, df = 3 (P$	= 0.59); I ² =0.0%			
Test for overall effect: $Z = 1.7$	72 (P = 0.085)				
3 Intermittent group: greater	than 75 mg/week				
Subtotal (95% CI)	0	0			Not estimable
Total events: 0 (Intermittent in	ron suppl), 0 (Daily ir	ron suppl)			
Heterogeneity: not applicable					
Test for overall effect: not app					
Total (95% CI)	492	488	•	100.0 %	1.23 [1.04, 1.47]
Total events: 159 (Intermitten		, ,,,,			
Heterogeneity: $Tau^2 = 0.0$; Cl		$= 0.81$; $ ^2 = 0.0\%$			
Test for overall effect: $Z = 2.3$	· ,				
Test for subgroup differences:	$Chi^2 = 0.33, df = 1$	$(P = 0.56), I^2 = 0.0\%$			
			0.01 0.1 1 10 100		
		Intermit	ent iron suppl Daily iron supp	4	

Analysis 2.3. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years, Outcome 3 Anaemia (by duration of the supplementation).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years

Outcome: 3 Anaemia (by duration of the supplementation)

Study or subgroup	Intermittent iron suppl	Daily iron suppl	Risk Ratio M-	Weight	Risk Ratio M-
	n/N	n/N	H,Random,95% Cl		H,Random,955 Cl
0 to three months					
Thu 1999	4/54	3/53		1.4 %	1.31 [0.31, 5.57]
Schultink 1995	7/32	6/33	_ 	3.2 %	1.20 [0.45, 3.19]
Subtotal (95% CI)	86	86	•	4.6 %	1.24 [0.55, 2.77]
Total events: 11 (Intermittent Heterogeneity: Tau ² = 0.0; C Test for overall effect: $Z = 0.1$ 2 More than three months	$hi^2 = 0.01, df = 1 (P)$,			
Sinisterra 1997 (C)	5/15	3/12		2.0 %	1.33 [0.40, 4.49]
Berger 1997	8/59	10/59		4.1 %	0.80 [0.34, 1.88]
Awasthi 2005 (C)	46/185	29/181	-	17.3 %	1.55 [1.02, 2.36]
Engstrom 2008 (C)	89/147	76/150		71.9 %	1.19 [0.97, 1.47]
Subtotal (95% CI)	406	402	•	95.4 %	1.23 [1.03, 1.47]
	492	488	•	100.0 %	1.23 [1.04, 1.47]
Total (95% CI)	· · · ·	488	•	100.0 %	1.23 [1.04, 1.47]
Total events: 159 (Intermitter	,				
Heterogeneity: $Tau^2 = 0.0$; C Test for overall effect: $Z = 2.2$		– 0.81); 1 ² –0.0%			
Test for subgroup differences	· ,	$(P = .00), ^2 = 0.0\%$			
			0.01 0.1 1 10 100)	
		Intern	nittent iron suppl Daily iron supp	pl	

Analysis 2.4. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years, Outcome 4 Anaemia (by type of compound).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years

Outcome: 4 Anaemia (by type of compound)

Study or subgroup	Intermittent iron suppl	Daily iron suppl	Risk Ratio M-	Weight	Risk Ratio M-
	n/N	n/N	H,Random,95% Cl		H,Random,95 Cl
I Ferrous sulphate					
Thu 1999	4/54	3/53	<u> </u>	1.4 %	.3 [0.3 , 5.57]
Sinisterra 1997 (C)	5/15	3/12		2.0 %	1.33 [0.40, 4.49]
Schultink 1995	7/32	6/33	_ <u>_</u>	3.2 %	1.20 [0.45, 3.19]
Berger 1997	8/59	10/59		4.1 %	0.80 [0.34, 1.88]
Awasthi 2005 (C)	46/185	29/181	+	17.3 %	1.55 [1.02, 2.36]
Engstrom 2008 (C)	89/147	76/150	-	71.9 %	1.19 [0.97, 1.47]
Subtotal (95% CI)	492	488	•	100.0 %	1.23 [1.04, 1.47]
Total events: 159 (Intermitter Heterogeneity: $Tau^2 = 0.0$; C	,				
Test for overall effect: $Z = 2.3$	38 (P = 0.017)				
2 Ferrous fumarate					
Subtotal (95% CI)	0	0			Not estimable
Total events: 0 (Intermittent i	ron suppl), 0 (Daily ir	on suppl)			
Heterogeneity: not applicable	2				
Test for overall effect: not app	plicable				
3 Other					
Subtotal (95% CI)	0	0			Not estimable
Total events: 0 (Intermittent i		on suppl)			
Heterogeneity: not applicable					
Test for overall effect: not app		(00			
Total (95% CI)	492	488	•	100.0 %	1.23 [1.04, 1.47]
Total events: 159 (Intermitter					
Heterogeneity: $Tau^2 = 0.0$; C	,	$= 0.81$); $ ^2 = 0.0\%$			
Test for overall effect: $Z = 2.3$,				
Test for subgroup differences	: Not applicable				
			0.01 0.1 1 10 100		
		Intermitt	ent iron suppl Daily iron supp	ol	

Analysis 2.5. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years, Outcome 5 Anaemia (by anaemia status at baseline).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years

Outcome: 5 Anaemia (by anaemia status at baseline)

Study or subgroup	Intermittent iron suppl	Daily iron suppl	Risk Ratio	Weight	Risk Ratio M-
	n/N	n/N	H,Random,95% Cl		H,Random,95 Cl
I Anaemic					
Schultink 1995	7/32	6/33	_ 	3.2 %	1.20 [0.45, 3.19]
Berger 1997	8/59	10/59		4.1 %	0.80 [0.34, 1.88]
Subtotal (95% CI)	91	92	+	7.3 %	0.96 [0.50, 1.82]
Total events: 15 (Intermittent	t iron suppl), 16 (Daily	iron suppl)			
Heterogeneity: Tau ² = 0.0; C	$chi^2 = 0.38, df = 1 (P =$	= 0.54); l ² =0.0%			
Test for overall effect: $Z = 0$.	14 (P = 0.89)				
2 Non-anaemic					
Subtotal (95% CI)	0	0			Not estimable
Total events: 0 (Intermittent i	iron suppl), 0 (Daily irc	on suppl)			
Heterogeneity: not applicable	2				
Test for overall effect: not ap	plicable				
3 Mixed/unknown					
Thu 1999	4/54	3/53		1.4 %	1.31 [0.31, 5.57]
Sinisterra 1997 (C)	5/15	3/12		2.0 %	1.33 [0.40, 4.49]
Awasthi 2005 (C)	46/185	29/181	-	17.3 %	1.55 [1.02, 2.36]
Engstrom 2008 (C)	89/147	76/150	•	71.9 %	1.19 [0.97, 1.47]
Subtotal (95% CI)	401	396	•	92. 7 %	1.26 [1.05, 1.51]
Total events: 144 (Intermitter	nt iron suppl), 111 (Da	ily iron suppl)			
Heterogeneity: Tau ² = 0.0; C	:hi ² = 1.33, df = 3 (P =	= 0.72); I ² =0.0%			
Test for overall effect: $Z = 2.5$	51 (P = 0.012)				
Total (95% CI)	492	488	•	100.0 %	1.23 [1.04, 1.47]
Total events: 159 (Intermitter					
Heterogeneity: $Tau^2 = 0.0$; C		= 0.8 I); I ² =0.0%			
Test for overall effect: $Z = 2.3$, ,				
Test for subgroup differences	: Chi ² = 0.66, df = 1 ($P = 0.42$), $I^2 = 0.0\%$			
			<u> </u>		
		(0.01 0.1 1 10 100		
		Intermit	tent iron suppl Daily iron supp	bl	

Analysis 2.6. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years, Outcome 6 Anaemia (by supplementation regimen).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years

Outcome: 6 Anaemia (by supplementation regimen)

Study or subgroup	Intermittent iron suppl	Daily iron suppl	Risk Ratio M-	Weight	Risk Ratio M-
	n/N	n/N	H,Random,95% Cl		H,Random,95 Cl
I One supplement a week					
Thu 1999	4/54	3/53	<u> </u>	1.4 %	.3 [0.3 , 5.57]
Sinisterra 1997 (C)	5/15	3/12	_ 	2.0 %	1.33 [0.40, 4.49]
Berger 1997	8/59	10/59		4.1 %	0.80 [0.34, 1.88]
Engstrom 2008 (C)	89/147	76/150		71.9 %	1.19 [0.97, 1.47]
Subtotal (95% CI)	275	274	•	79.5 %	1.18 [0.97, 1.43]
Total events: 106 (Intermitter Heterogeneity: Tau ² = 0.0; Cl Test for overall effect: $Z = 1.6$ 2 Other intermittent regimen	$hi^2 = 0.88, df = 3 (P$ 53 (P = 0.10)	, , , , ,			
Schultink 1995	7/32	6/33	<u> </u>	3.2 %	1.20 [0.45, 3.19]
Awasthi 2005 (C)	46/185	29/181	-	17.3 %	1.55 [1.02, 2.36]
Subtotal (95% CI)	217	214	•	20.5 %	1.49 [1.02, 2.19]
Total events: 53 (Intermittent Heterogeneity: Tau ² = 0.0; Cl Test for overall effect: $Z = 2.0$	$hi^2 = 0.22, df = 1 (P$				
Total (95% CI)	492	488	•	100.0 %	1.23 [1.04, 1.47]
Total events: 159 (Intermitter Heterogeneity: Tau ² = 0.0; Cl Test for overall effect: Z = 2.3 Test for subgroup differences:	$hi^2 = 2.29, df = 5 (P)$ 38 (P = 0.017)	$= 0.8 $); $ ^2 = 0.0\%$			
			0.01 0.1 10 100 tent iron suppl Daily iron supp		

Analysis 2.7. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years, Outcome 7 Anaemia (by sex).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years

Outcome: 7 Anaemia (by sex)

Study or subgroup	Intermittent iron suppl	Daily iron suppl	Risk Ratio M-	Weight	Risk Ratic M-
	n/N	n/N	H,Random,95% Cl		H,Random, Cl
I Girls					
Subtotal (95% CI)	0	0			Not estimable
Total events: 0 (Intermittent in	on suppl), 0 (Daily iro	n suppl)			
Heterogeneity: not applicable					
Test for overall effect: not appl	licable				
2 Boys	0	0			N
Subtotal (95% CI)	0	0			Not estimable
Total events: 0 (Intermittent in Heterogeneity: not applicable	on suppi), 0 (Daily iro	n suppi)			
Test for overall effect: not appl	licable				
3 Mixed/unknown					
Thu 1999	4/54	3/53		1.4 %	1.31 [0.31, 5.57]
Sinisterra 1997 (C)	5/15	3/12		2.0 %	1.33 [0.40, 4.49]
Schultink 1995	7/32	6/33	<u> </u>	3.2 %	1.20 [0.45, 3.19]
Berger 1997	8/59	10/59	- _	4.1 %	0.80 [0.34, 1.88]
Awasthi 2005 (C)	46/185	29/181	-	17.3 %	1.55 [1.02, 2.36]
Engstrom 2008 (C)	89/147	76/150		71.9 %	1.19 [0.97, 1.47]
Subtotal (95% CI)	492	488	•	100.0 %	1.23 [1.04, 1.47]
Total events: 159 (Intermittent	t iron suppl), 127 (Dai	ly iron suppl)			
Heterogeneity: $Tau^2 = 0.0$; Ch	$m^2 = 2.29$, df = 5 (P =	0.81); 12 =0.0%			
Test for overall effect: $Z = 2.38$	· /				
Total (95% CI)	492	488	•	100.0 %	1.23 [1.04, 1.47]
Total events: 159 (Intermittent Heterogeneity: $Tau^2 = 0.0$; Ch					
Test for overall effect: $Z = 2.38$		0.01), 1 -0.078			
Test for subgroup differences:	. ,				
		0	.01 0.1 1 10 100)	
		Intermitt	ent iron suppl Daily iron supp	pl	
		in red fille		∠ 1	

Analysis 2.8. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years, Outcome 8 Anaemia (by nutrient).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years

Outcome: 8 Anaemia (by nutrient)

Study or subgroup	Intermittent iron suppl	Daily iron suppl	Risk Ratio M-	Weight	Risk Ratio M-
	n/N	n/N	H,Random,95% Cl		H,Random,955 Cl
l Iron alone					
Sinisterra 1997 (C)	5/15	3/12		2.0 %	1.33 [0.40, 4.49]
Schultink 1995	7/32	6/33		3.2 %	1.20 [0.45, 3.19]
Berger 1997	8/59	10/59		4.1 %	0.80 [0.34, 1.88]
Engstrom 2008 (C)	89/147	76/150	-	71.9 %	1.19 [0.97, 1.47]
Subtotal (95% CI)	253	254	•	81.2 %	1.17 [0.97, 1.42]
Heterogeneity: Tau ² = 0.0; Cl Test for overall effect: $Z = 1.6$ 2 Iron + folic acid	64 (P = 0.10)			17.2.07	
Awasthi 2005 (C) Subtotal (95% CI)	46/185 185	29/181		17.3 % 17.3 %	1.55 [1.02, 2.36]
Total events: 46 (Intermittent Heterogeneity: not applicable Test for overall effect: Z = 2.0 3 Iron + multiple micronutrie Thu 1999)7 (P = 0.039)	3/53		1.4 %	1.31 [0.31, 5.57]
Subtotal (95% CI)	54	53	-	1.4 %	1.31 [0.31, 5.57]
Total events: 4 (Intermittent in Heterogeneity: not applicable Test for overall effect: Z = 0.3	:				
Total (95% CI)	492	488	+	100.0 %	1.23 [1.04, 1.47]
Total events: 159 (Intermitter Heterogeneity: Tau ² = 0.0; Cl	$hi^2 = 2.29, df = 5 (P)$, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			
Test for overall effect: Z = 2.3 Test for subgroup differences:	(/	$(P = 0.49), I^2 = 0.0\%$			
			0.01 0.1 10 100)	
		Intermi	ttent iron suppl Daily iron supp	bl	

Analysis 2.9. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years, Outcome 9 Haemoglobin (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years

Outcome: 9 Haemoglobin (ALL)

Study or subgroup	Intermittent iron suppl		Daily iron suppl		Mean Difference	Weight	Mea Difference
	N	Mean(SD)	N	Mean(SD)	IV,Random,95% CI		IV,Random,95%
Awasthi 2005 (C)	185	108.5 (12.9)	181	0.9 (.9)	-=-	5.9 %	-2.40 [-4.94, 0.14
Berger 1997	58	150.5 (6.9)	58	150.1 (6.7)	-	6.1 %	0.40 [-2.08, 2.88
Desai 2004 (C)	266	97.2 (13.7)	261	101.4 (13.8)	-	6.3 %	-4.20 [-6.55, -1.85
Engstrom 2008 (C)	147	106.16 (13.203)	150	108.72 (14.832)	_+_	4.7 %	-2.56 [-5.75, 0.63
Ermis 2002	30	116 (2.9)	60	116.5 (3)	+	8.7 %	-0.50 [-1.79, 0.79
Faqih 2006	42	121.9 (5.5)	21	120.1 (5.04)		5.6 %	1.80 [-0.92, 4.5]
Khademloo 2009	50	23 (0.)	50	123 (8)	-	4.2 %	0.0 [-3.57, 3.5]
Liu 1995 (C)	55	133.4 (7)	30	34.3 (7.3)		4.7 %	-0.90 [-4.10, 2.3
Nguyen 2002	65	120.5 (7.2)	67	23.6 (7.8)		5.9 %	-3.10 [-5.66, -0.5
Schultink 1995	32	117 (8)	33	4 (0)	<u> </u>	3.2 %	3.00 [-1.40, 7.4
Sen 2009 (C)	30	120 (4)	12	122 (5.5)		4.4 %	-2.00 [-5.43, 1.4
Siddiqui 2004	30	121.2 (6)	30	124.4 (5.4)		5.3 %	-3.20 [-6.09, -0.3
Soemantri 1997	45	127.1 (5.1)	50	123.3 (8)	-	5.7 %	3.80 [1.13, 6.4
Sungthong 2002	130	126.9 (9.2)	138	127.8 (9.2)		6.6 %	-0.90 [-3.10, 1.3
Tavil 2003	48	123 (4)	46	124 (4)	-	7.9 %	-1.00 [-2.62, 0.6
Thu 1999	54	123.5 (10.3)	53	124.3 (9.3)		4.0 %	-0.80 [-4.52, 2.9
Yang 2004 (C)	38	34. 6 (2.79)	38	32.2 (9.21)	_ 	2.7 %	1.96 [-3.05, 6.9
Young 2001	146	104.5 (15.3)	85	103.2 (15.3)	_ 	3.5 %	1.30 [-2.79, 5.3
Yurdakok 2004	19	116 (5)	18	114 (5)		4.7 %	2.00 [-1.22, 5.2
otal (95% CI)	1470		1381		•	100.0 %	-0.60 [-1.54, 0.3
eterogeneity: $Tau^2 = 2$			= 0.00 l); l ² =56%				
est for overall effect: Z est for subgroup differe	`	,					

-20 -10 0 10 20

Daily iron suppl Intermittent iron suppl

Analysis 2.10. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years, Outcome 10 Haemoglobin (by dose of elemental iron in the intermittent group).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age


Comparison: 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years

Outcome: 10 Haemoglobin (by dose of elemental iron in the intermittent group)

Study or subgroup	Intermittent iron suppl		Daily iron suppl		Mean Difference	Weight	Mea Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% Cl		IV,Random,95% C
25 mg or less/week							
Thu 1999	54	23.5 (0.3)	53	24.3 (9.3)	•	4.2 %	-0.80 [-4.52, 2.92
Engstrom 2008 (C)	147	106.16 (13.203)	150	108.72 (14.832)		5.0 %	-2.56 [-5.75, 0.63
Nguyen 2002	65	120.5 (7.2)	67	123.6 (7.8)	• •	6.1 %	-3.10 [-5.66, -0.54
Subtotal (95% CI)	266		270			15.3 %	-2.42 [-4.18, -0.66
Heterogeneity: Tau ² = 0.0); Chi ² = 1.01	, df = 2 (P = 0.60)); I ² =0.0%				
Fest for overall effect: Z =	= 2.70 (P = 0.	0070)					
2 Greater than 25 mg to 3	75 mg/week						
Yang 2004 (C)	38	34. 6 (2.79)	38	32.2 (9.21)		2.8 %	1.96 [-3.05, 6.97
Schultink 1995	32	117 (8)	33	114 (10)		3.4 %	3.00 [-1.40, 7.40
Young 2001	146	104.5 (15.3)	85	103.2 (15.3)		3.7 %	1.30 [-2.79, 5.39
Yurdakok 2004	19	116 (5)	18	114 (5)		4.9 %	2.00 [-1.22, 5.22
Liu 1995 (C)	55	133.4 (7)	30	34.3 (7.3)	•	5.0 %	-0.90 [-4.10, 2.30
Siddiqui 2004	30	121.2 (6)	30	124.4 (5.4)		5.5 %	-3.20 [-6.09, -0.31
Faqih 2006	42	121.9 (5.5)	21	120.1 (5.04)		5.8 %	I.80 [-0.92, 4.52
Awasthi 2005 (C)	185	108.5 (12.9)	181	0.9 (.9)		6.2 %	-2.40 [-4.94, 0.14
Berger 1997	58	150.5 (6.9)	58	150.1 (6.7)		6.3 %	0.40 [-2.08, 2.88
Desai 2004 (C)	266	97.2 (13.7)	261	101.4 (13.8)	•	6.6 %	-4.20 [-6.55, -1.85
Sungthong 2002	130	126.9 (9.2)	138	127.8 (9.2)		6.9 %	-0.90 [-3.10, 1.30
Tavil 2003	48	123 (4)	46	124 (4)		8.2 %	-1.00 [-2.62, 0.62
Ermis 2002	30	116 (2.9)	60	116.5 (3)		8.9 %	-0.50 [-1.79, 0.79
Subtotal (95% CI)	1079		999		-	74.1 %	-0.58 [-1.62, 0.45
Heterogeneity: $Tau^2 = 1.6$	58; Chi ² = 24	.81, df = 12 (P =	0.02); I ² =52%				
Test for overall effect: Z =	= 1.10 (P = 0.	27)					
3 Greater than 75 mg/we	ek						
Sen 2009 (C)	30	120 (4)	12	122 (5.5)	←	4.6 %	-2.00 [-5.43, 1.43
Soemantri 1997	45	127.1 (5.1)	50	123.3 (8)		5.9 %	3.80 [1.13, 6.47

Daily iron suppl Intermittent iron suppl

(Continued ...)



Analysis 2.11. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years, Outcome 11 Haemoglobin (by duration of the supplementation).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years

Outcome: II Haemoglobin (by duration of the supplementation)

Study or subgroup	Intermittent iron suppl N	Mean(SD)	Daily iron suppl N	Mean(SD)		Mean ference Iom,95% CI	Weight	Mean Difference IV,Random,95% Cl
0 to three months								
Desai 2004 (C)	266	97.2 (13.7)	252	101.4 (261)	•		→ 0.1 %	-4.20 [-36.47, 28.07]
Schultink 1995	32	117 (8)	33	4 (0)			→ 3.1 %	3.00 [-1.40, 7.40]
Young 2001	146	104.5 (15.3)	85	103.2 (15.3)		,	→ 3.4 %	1.30 [-2.79, 5.39]
Thu 1999	54	123.5 (10.3)	53	124.3 (9.3)	،		4.0 %	-0.80 [-4.52, 2.92]
Khademloo 2009	50	23 (0.)	50	123 (8)			- 4.2 %	0.0 [-3.57, 3.57]
Yurdakok 2004	19	116 (5)	18	114 (5)		,	→ 4.8 %	2.00 [-1.22, 5.22]
Liu 1995 (C)	55	33.4 (7)	30	34.3 (7.3)	• • •		4.9 %	-0.90 [-4.10, 2.30]
Siddiqui 2004	30	121.2 (6)	30	124.4 (5.4)	←∎		5.5 %	-3.20 [-6.09, -0.31]
Faqih 2006	42	121.9 (5.5)	21	120.1 (5.04)	_		→ 5.9 %	1.80 [-0.92, 4.52]
					-4 -2 aily iron suppl	0 2 Intermitte	4 ent iron suppl	

(Continued . . .)

Intermittent iron supplementation for improving nutrition and development in children under 12 years of age (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

155

Study or subgroup	Intermittent iron suppl N	Mean(SD)	Daily iron suppl N	Mean(SD)	Mean Difference IV,Random,95% CI	Weight	(Continued Mean Difference IV,Random,95% CI
Soemantri 1997	45	27. (5.)	50	123.3 (8)		• 6.0 %	3.80 [1.13, 6.47]
Tavil 2003	48	123 (4)	46	124 (4)		9.3 %	-1.00 [-2.62, 0.62]
Subtotal (95% CI)	787		668			51.1 %	0.47 [-0.91, 1.84]
Heterogeneity: $Tau^2 = 2.3$	9; Chi ² = 19.	58, df = 10 (P =	0.03); I ² =49%				
Test for overall effect: Z =	0.66 (P = 0.5)	51)					
2 More than three month	5						
Yang 2004 (C)	38	34. 6 (2.79)	38	132.2 (9.21)		→ 2.5 %	1.96 [-3.05, 6.97]
Sen 2009 (C)	30	120 (4)	12	122 (5.5)	· · · · · · · · · · · · · · · · · · ·	4.4 %	-2.00 [-5.43, 1.43]
Engstrom 2008 (C)	147	106.16 (13.203)	150	108.72 (14.832)	•	4.9 %	-2.56 [-5.75, 0.63]
Nguyen 2002	65	120.5 (7.2)	67	123.6 (7.8)	·	6.3 %	-3.10 [-5.66, -0.54]
Awasthi 2005 (C)	185	108.5 (12.9)	181	0.9 (.9)	← B	6.4 %	-2.40 [-4.94, 0.14]
Berger 1997	58	150.5 (6.9)	58	150.1 (6.7)		6.5 %	0.40 [-2.08, 2.88]
Sungthong 2002	130	126.9 (9.2)	138	127.8 (9.2)		7.3 %	-0.90 [-3.10, 1.30]
Ermis 2002	30	116 (2.9)	60	116.5 (3)		10.5 %	-0.50 [-1.79, 0.79]
Subtotal (95% CI)	683		704		-	48.9 %	-1.14 [-2.07, -0.22]
Heterogeneity: $Tau^2 = 0.2$	5; Chi ² = 8.1	3, df = 7 (P = 0.3	2); $ ^2 = 4\%$				
Test for overall effect: Z =		015)					
Total (95% CI)	1470		1372		•	100.0 %	-0.38 [-1.26, 0.50]
Heterogeneity: $Tau^2 = 1.4$,	0.02); I ² =44%				
Test for overall effect: Z =	· · · · · · · · · · · · · · · · · · ·	,					
Test for subgroup differen	ces: $Chi^2 = 3$.	62, df = $ (P = C)$.06), I ² =72%				
						1	

Daily iron suppl Intermittent iron suppl


Analysis 2.12. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years, Outcome 12 Haemoglobin (by type of compound).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years

Outcome: 12 Haemoglobin (by type of compound)

Study or subgroup	Intermittent iron suppl		Daily iron suppl		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI		IV,Random,95% CI
I Ferrous sulphate							
Schultink 1995	32	117 (8)	33	114 (10)		→ 3.2 %	3.00 [-1.40, 7.40]
Young 2001	146	104.5 (15.3)	85	103.2 (15.3)		→ 3.5 %	1.30 [-2.79, 5.39]
Thu 1999	54	123.5 (10.3)	53	124.3 (9.3)		4.0 %	-0.80 [-4.52, 2.92]
Khademloo 2009	50	23 (0.)	50	123 (8)		4.2 %	0.0 [-3.57, 3.57]
Yurdakok 2004	19	116 (5)	18	114 (5)		→ 4.7 %	2.00 [-1.22, 5.22]
Liu 1995 (C)	55	33.4 (7)	30	34.3 (7.3)	• • • •	4.7 %	-0.90 [-4.10, 2.30]
Engstrom 2008 (C)	147	106.16 (13.203)	150	108.72 (14.832)	•	4.7 %	-2.56 [-5.75, 0.63]
Siddiqui 2004	30	121.2 (6)	30	124.4 (5.4)	← <u>∎</u>	5.3 %	-3.20 [-6.09, -0.31]
Faqih 2006	42	121.9 (5.5)	21	120.1 (5.04)		→ 5.6 %	1.80 [-0.92, 4.52]
Soemantri 1997	45	27. (5.)	50	123.3 (8)		5 .7 %	3.80 [1.13, 6.47]
Nguyen 2002	65	120.5 (7.2)	67	123.6 (7.8)	←∎	5.9 %	-3.10 [-5.66, -0.54]
Awasthi 2005 (C)	185	108.5 (12.9)	181	0.9 (.9)	← B	5.9 %	-2.40 [-4.94, 0.14]
Berger 1997	58	150.5 (6.9)	58	150.1 (6.7)		6.1 %	0.40 [-2.08, 2.88]
Desai 2004 (C)	266	97.2 (13.7)	261	101.4 (13.8)	<u> </u>	6.3 %	-4.20 [-6.55, -1.85]
Sungthong 2002	130	126.9 (9.2)	138	127.8 (9.2)		6.6 %	-0.90 [-3.10, 1.30]
Tavil 2003	48	123 (4)	46	124 (4)		7.9 %	-1.00 [-2.62, 0.62]
Ermis 2002	30	116 (2.9)	60	116.5 (3)		8.7 %	-0.50 [-1.79, 0.79]
Subtotal (95% CI)	1402		1331			930%	-0.60 [-1.60, 0.40]
Heterogeneity: $Tau^2 = 2.42$ Test for overall effect: $Z = 2$ Ferrous fumarate							
Subtotal (95% CI) Heterogeneity: not applical			0				Not estimable
Test for overall effect: not a 3 Other	applicable						
Yang 2004 (C)	38	34. 6 (2.79)	38	132.2 (9.21)		→ 2.7 %	1.96 [-3.05, 6.97]
					-4 -2 0 2 raily iron suppl Intermit	4 ent iron suppl	(Continued



Analysis 2.13. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years, Outcome 13 Haemoglobin (by anaemia status at baseline).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years

Outcome: 13 Haemoglobin (by anaemia status at baseline)

Study or subgroup	Intermittent iron suppl N	Mean(SD)	Daily iron suppl N	Mean(SD)		Mean erence om,95% Cl	Weight	Mean Difference IV,Random,95% Cl
I Anaemic								
Liu 1995 (C)	20	3 .2 (8.6)	12	3 .5 (8.7)	•		1.8 %	-0.30 [-6.50, 5.90]
Schultink 1995	32	117 (8)	33	114 (10)			3.1 %	3.00 [-1.40, 7.40]
Siddiqui 2004	30	121.2 (6)	30	124.4 (5.4)	←∎		5.2 %	-3.20 [-6.09, -0.31]
Faqih 2006	42	121.9 (5.5)	21	120.1 (5.04)	—		5.5 %	1.80 [-0.92, 4.52]
Berger 1997	58	150.5 (6.9)	58	150.1 (6.7)		•	6.0 %	0.40 [-2.08, 2.88]
Desai 2004 (C)	266	97.2 (13.7)	261	101.4 (13.8)			6.2 %	-4.20 [-6.55, -1.85]
Tavil 2003	48	123 (4)	46	124 (4)		-	7.9 %	-1.00 [-2.62, 0.62]
Subtotal (95% CI)	496		461		-	-	35.8 %	-0.76 [-2.59, 1.07]
					-4 -2 Paily iron suppl	0 2 4 Intermittent i		(Continued)

Intermittent iron supplementation for improving nutrition and development in children under 12 years of age (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. 158

Study or subgroup	Intermittent iron suppl N	Mean(SD)	Daily iron suppl N	Mean(SD)	Mean Difference IV.Random.95% C	Weight	(Continue Mear Difference IV.Random.95% C
Heterogeneity: Tau ² = 3. ²		()		T lean(SD)	TV, Kandoni, 7576 C		14,14110011,7570 C
Test for overall effect: Z =			,,.				
2 Non-anaemic							
Yang 2004 (C)	38	34. 6 (2.79)	38	32.2 (9.2)		2.6 %	1.96 [-3.05, 6.97
Liu 1995 (C)	34	134.7 (6.1)	19	136 (6.5)	•	4.1 %	-1.30 [-4.87, 2.27
Yurdakok 2004	19	116 (5)	18	114 (5)		4.6 %	2.00 [-1.22, 5.22
Subtotal (95% CI)	91		75			- 11.3 %	0.79 [-1.42, 2.99
Heterogeneity: $Tau^2 = 0$.	$13; Chi^2 = 2.07$	7, df = 2 (P = 0.3	6); I ² =3%				
Test for overall effect: Z =	= 0.70 (P = 0.4	8)					
3 Mixed/unknown	146		85			→ <u>⊃</u> 5 0/	
Young 2001		104.5 (15.3)		103.2 (15.3)	_	→ 3.5 %	1.30 [-2.79, 5.39
Thu 1999	54	123.5 (10.3)	53	124.3 (9.3)		- 3.9 %	-0.80 [-4.52, 2.92
Khademloo 2009	50	123 (10.1)	50	123 (8)		4.1 %	0.0 [-3.57, 3.57
Sen 2009 (C)	30	120 (4)	12	122 (5.5)	• • • • • • • • • • • • • • • • • • •	4.3 %	-2.00 [-5.43, 1.43
Engstrom 2008 (C)	147	106.16 (13.203)	150	108.72 (14.832)	•	4.7 %	-2.56 [-5.75, 0.63
Soemantri 1997	45	127.1 (5.1)	50	123.3 (8)		5.6 %	3.80 [1.13, 6.47
Nguyen 2002	65	120.5 (7.2)	67	123.6 (7.8)	←∎	5.8 %	-3.10 [-5.66, -0.54
Awasthi 2005 (C)	185	108.5 (12.9)	181	0.9 (.9)	← ∎	5.8 %	-2.40 [-4.94, 0.14
Sungthong 2002	130	126.9 (9.2)	138	127.8 (9.2)		6.6 %	-0.90 [-3.10, 1.30
Ermis 2002	30	116 (2.9)	60	116.5 (3)		8.7 %	-0.50 [-1.79, 0.79
Subtotal (95% CI)	882		846			52.9 %	-0.76 [-2.00, 0.48
Heterogeneity: $Tau^2 = 1.9$	94; Chi ² = 19.0	04, df = 9 (P = 0	02); I ² =53%				
Test for overall effect: Z =	· · · · · · · · · · · · · · · · · · ·	.3)	1202			100.0.0/	
Total (95% CI) Heterogeneity: $Tau^2 = 2$.	1469) df - 10 (D - 1	1382			100.0 %	-0.61 [-1.54, 0.32
Test for overall effect: Z =			J.UUZ); 1 ⁼ -34%				
Test for subgroup differer		,	.46), I ² =0.0%				
5 .		`					
					-4 -2 0 2	4	

Analysis 2.14. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years, Outcome 14 Haemoglobin (by supplementation regimen).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years

Outcome: 14 Haemoglobin (by supplementation regimen)

Mean Difference	Weight	Mean Difference		Daily iron suppl		Intermittent iron suppl	Study or subgroup
IV,Random,95% Cl		IV,Random,95% CI	Mean(SD)	Ν	Mean(SD)	Ν	
						ek	I One supplement a wee
-7.00 [-14.25, 0.25]	1.6 %		122 (5.5)	6	115 (10.6)	13	Sen 2009 (C)
1.96 [-3.05, 6.97]	2.8 %		32.2 (9.21)	38	34. 6 (2.79)	38	Yang 2004 (C)
0.10 [-4.41, 4.61]	3.2 %	<u> </u>	134.3 (7.3)	15	34.4 (7)	28	Liu 1995 (C)
1.30 [-2.79, 5.39]	3.6 %		103.2 (15.3)	85	104.5 (15.3)	146	Young 2001
2.10 [-1.81, 6.01]	3.8 %		120.1 (5.04)	10	122.2 (5.49)	21	Faqih 2006
-0.80 [-4.52, 2.92]	4.0 %		124.3 (9.3)	53	123.5 (10.3)	54	Thu 1999
0.0 [-3.57, 3.57]	4.2 %		123 (8)	50	123 (10.1)	50	Khademloo 2009
2.00 [-1.22, 5.22]	4.7 %		114 (5)	18	116 (5)	19	Yurdakok 2004
-2.56 [-5.75, 0.63]	4.7 %		108.72 (14.832)	150	106.16 (13.203)	147	Engstrom 2008 (C)
-3.20 [-6.09, -0.31]	5.2 %		124.4 (5.4)	30	121.2 (6)	30	Siddiqui 2004
3.80 [1.13, 6.47]	5.5 %		123.3 (8)	50	127.1 (5.1)	45	Soemantri 1997
-3.10 [-5.66, -0.54]	5.7 %		123.6 (7.8)	67	120.5 (7.2)	65	Nguyen 2002
0.40 [-2.08, 2.88]	5.8 %	-	150.1 (6.7)	58	150.5 (6.9)	58	Berger 1997
-0.90 [-3.10, 1.30]	6.3 %		127.8 (9.2)	138	126.9 (9.2)	130	Sungthong 2002
0.25 [-1.57, 1.07]	61.2 %	•		768		844	Subtotal (95% CI)
				0.01); I ² =54%	21, df = 13 (P = 0	20; Chi ² = 28.	Heterogeneity: $Tau^2 = 3$.
					71)	`	Test for overall effect: Z
-11.00 [-19.26, -2.74]	1.3 %		122 (5.5)	6	(4.7)	men 17	2 Other intermittent regi Sen 2009 (C)
-2.00 [-6.54, 2.54]	3.2 %		134.3 (7.3)	15	32.3 (7)	27	Liu 1995 (C)
3.00 [-1.40, 7.40]	3.3 %		4 (0)	33	117 (8)	32	Schultink 1995
1.50 [-2.29, 5.29]	4.0 %		120.1 (5.04)	11	121.6 (5.49)	21	Faqih 2006
-2.40 [-4.94, 0.14]	5.7 %		0.9 (.9)	181	108.5 (12.9)	185	Awasthi 2005 (C)
-4.20 [-6.55, -1.85]	6.1 %		101.4 (13.8)	261	97.2 (3.7)	266	Desai 2004 (C)
-1.00 [-2.62, 0.62]	7.4 %	-	124 (4)	46	123 (4)	48	Tavil 2003

Daily iron suppl Intermittent iron suppl

(Continued ...)

(... Continued)

								(continued)
Study or subgroup	Intermittent iron suppl	Dail	y iron suppl		۲ Diffen	1ean ence	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Randor	n,95% Cl		IV,Random,95% CI
Ermis 2002	30	116 (2.9)	60	116.5 (3)	-		7.9 %	-0.50 [-1.79, 0.79]
Subtotal (95% CI)	626		613		•		38.8 %	-1.42 [-3.02, 0.19]
Heterogeneity: $Tau^2 = 2$.	.85; Chi ² = 19.31	, df = 7 (P = 0.01); l	² =64%					
Test for overall effect: Z	= 1.73 (P = 0.08	3)						
Total (95% CI)	1470		1381		•		100.0 %	-0.70 [-1.70, 0.30]
Heterogeneity: $Tau^2 = 2$.	.88; Chi ² = 49.81	, df = 21 (P = 0.000	39); l ² =58%					
Test for overall effect: Z	= 1.37 (P = 0.17))						
Test for subgroup differen	nces: $Chi^2 = 1.22$	2, df = 1 (P = 0.27), I	² = 18%					
							1	
				-20	-10 0	10	20	
				Daily	iron suppl	Intermitten	t iron suppl	

Analysis 2.15. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years, Outcome 15 Haemoglobin (by sex).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years

Outcome: 15 Haemoglobin (by sex)

Study or subgroup	Intermittent iron suppl N	Mean(SD)	Daily iron suppl N	Mean(SD)		Mean Ference Iom,95% Cl	Weight	Mean Difference IV,Random,95% CI
l Girls								
Sen 2009 (C)	30	120 (4)	12	122 (5.5)	د ،		4.4 %	-2.00 [-5.43, 1.43]
Subtotal (95% CI) Heterogeneity: not applie			12				4.4 %	-2.00 [-5.43, 1.43]
Test for overall effect: Z	= 1.14 (P = 0.25)						
2 Boys								
Subtotal (95% CI)	0		0					Not estimable
Heterogeneity: not applie	cable							
Test for overall effect: no	ot applicable							
3 Mixed/unknown								
Yang 2004 (C)	38	34. 6 (2.79)	38	32.2 (9.21)			2.7 %	1.96 [-3.05, 6.97]
					-4 -2	0 2 4		
				D	aily iron suppl	Intermittent ir	on suppl	
								(Continued)

	ermittent on suppl		Daily iron suppl		Mean Difference	Weight	(Continue Mear Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI		IV,Random,95% C
chultink 1995	32	117 (8)	33	4 (0)		→ 3.2 %	3.00 [-1.40, 7.40]
oung 2001	146	104.5 (15.3)	85	103.2 (15.3)		→ 3.5 %	1.30 [-2.79, 5.39
hu 1999	54	123.5 (10.3)	53	124.3 (9.3)	•	4.0 %	-0.80 [-4.52, 2.92]
hademloo 2009	50	123 (10.1)	50	123 (8)		4.2 %	0.0 [-3.57, 3.57
urdakok 2004	19	116 (5)	18	114 (5)		→ 4.7 %	2.00 [-1.22, 5.22
u 1995 (C)	55	33.4 (7)	30	34.3 (7.3)	•	4.7 %	-0.90 [-4.10, 2.30
ngstrom 2008 (C)	147	106.16 (13.203)	150	108.72 (14.832)	•	4.7 %	-2.56 [-5.75, 0.63
ddiqui 2004	30	121.2 (6)	30	124.4 (5.4)	← ∎	5.3 %	-3.20 [-6.09, -0.3
aqih 2006	42	121.9 (5.5)	21	20. (5.04)		→ 5.6 %	I.80 [-0.92, 4.52
pemantri 1997	45	127.1 (5.1)	50	123.3 (8)		- 5.7 %	3.80 [1.13, 6.47
lguyen 2002	65	120.5 (7.2)	67	123.6 (7.8)	←∎───	5.9 %	-3.10 [-5.66, -0.54
wasthi 2005 (C)	185	108.5 (12.9)	181	0.9 (.9)	•	5.9 %	-2.40 [-4.94, 0.14
erger 1997	58	150.5 (6.9)	58	150.1 (6.7)		6.1 %	0.40 [-2.08, 2.88
esai 2004 (C)	266	97.2 (13.7)	261	101.4 (13.8)		6.3 %	-4.20 [-6.55, -1.85
ungthong 2002	130	126.9 (9.2)	138	127.8 (9.2)		6.6 %	-0.90 [-3.10, 1.30
avil 2003	48	123 (4)	46	124 (4)		7.9 %	-1.00 [-2.62, 0.62
rmis 2002	30	116 (2.9)	60	116.5 (3)		8.7 %	-0.50 [-1.79, 0.79
ototal (95% CI)	1440		1369		-	95.6 %	-0.53 [-1.51, 0.46
erogeneity: Tau ² = 2.39; C for overall effect: Z = 1.05			0.001); 1~ =58%				
al (95% CI) progeneity: Tau ² = 2.26; C for overall effect: Z = 1.2:	1470 hi ² = 41.	10, df = 18 (P =	1381 0.001); I ² =56%		-	100.0 %	-0.60 [-1.54, 0.35
for subgroup differences:			1.42), I ² =0.0%				

Daily iron suppl Intermittent iron suppl

Intermittent iron supplementation for improving nutrition and development in children under 12 years of age (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Analysis 2.16. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years, Outcome 16 Haemoglobin (by nutrient).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years

Outcome: 16 Haemoglobin (by nutrient)

Study or subgroup	Intermittent iron suppl		Daily iron suppl		Diffe	Mean rence	Weight	Mean Difference
	N	Mean(SD)	Ν	Mean(SD)	IV,Rando	m,95% Cl		IV,Random,95% Cl
I Iron alone Young 2001	73	103.6 (15.3)	42	103.2 (15.3)	•		2.1 %	0.40 [-5.41, 6.21]
Schultink 1995	32	7 (8)	33	4 (10)			3.2 %	3.00 [-1.40, 7.40]
Khademloo 2009	50	123 (10.1)	50	123 (8)			4.1 %	0.0 [-3.57, 3.57]
Yurdakok 2004	19	116 (5)	18	114 (5)			4.7 %	2.00 [-1.22, 5.22]
Liu 1995 (C)	55	133.4 (7)	30	34.3 (7.3)	• • • •		4.7 %	-0.90 [-4.10, 2.30]
Engstrom 2008 (C)	147	106.16 (13.203)	150	108.72 (14.832)	• •	_	4.7 %	-2.56 [-5.75, 0.63]
Siddiqui 2004	30	121.2 (6)	30	124.4 (5.4)	- -		5.2 %	-3.20 [-6.09, -0.31]
Faqih 2006	42	121.9 (5.5)	21	120.1 (5.04)			5.5 %	1.80 [-0.92, 4.52]
Soemantri 1997	45	127.1 (5.1)	50	123.3 (8)			5.6 %	3.80 [1.13, 6.47]
Nguyen 2002	65	120.5 (7.2)	67	123.6 (7.8)	← ∎────		5.8 %	-3.10 [-5.66, -0.54]
Berger 1997	58	150.5 (6.9)	58	150.1 (6.7)			6.0 %	0.40 [-2.08, 2.88]
Desai 2004 (C)	266	97.2 (13.7)	261	101.4 (13.8)	•		6.3 %	-4.20 [-6.55, -1.85]
Sungthong 2002	130	126.9 (9.2)	138	127.8 (9.2)	e		6.6 %	-0.90 [-3.10, 1.30]
		. ,		()		_		
Tavil 2003	48	123 (4)	46	124 (4)	_		7.9 %	-1.00 [-2.62, 0.62]
Ermis 2002	30	116 (2.9)	60	116.5 (3)			8.7 %	-0.50 [-1.79, 0.79]
Subtotal (95% CI) Heterogeneity: $Tau^2 = 2$ Test for overall effect: Z	.65; Chi ² = 36.		1054 0.00076); I ² =62%	,		-	81.1 %	-0.51 [-1.61, 0.59]
2 Iron + folic acid	0.71 (1 0.	50)						
Sen 2009 (C)	30	120 (4)	12	122 (5.5)	• •		4.3 %	-2.00 [-5.43, 1.43]
Awasthi 2005 (C)	185	108.5 (12.9)	181	0.9 (.9)	· •		5.9 %	-2.40 [-4.94, 0.14]
Subtotal (95% CI) Heterogeneity: $Tau^2 = 0$	-	, df = 1 (P = 0.8!	193 5); I ² =0.0%				10.2 %	-2.26 [-4.30, -0.22]
Test for overall effect: Z	`	030)						
3 Iron + multiple micron	utrients 73	105 4 (15 2)	43	102.2 (15.2)			2.1 %	2201 254 7941
Young 2001	/3	105.4 (15.3)	43	103.2 (15.3)			2.1 %	2.20 [-3.56, 7.96]
					-4 -2 0	2 4	+	
				C	aily iron suppl	Intermittent i	ron suppl	(Continued)

								(Continued)
Study or subgroup	Intermittent iron suppl		Daily iron suppl		Dif	Mean ference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Rano	lom,95% Cl		IV,Random,95% CI
Yang 2004 (C)	38	34. 6 (2.79)	38	132.2 (9.21)		+	→ 2.6 %	1.96 [-3.05, 6.97]
Thu 1999	54	123.5 (10.3)	53	24.3 (9.3)	، ،		3.9 %	-0.80 [-4.52, 2.92]
Subtotal (95% CI) 165		134				8.6 %	0.61 [-2.04, 3.26]
Heterogeneity: $Tau^2 = 0$	0.0; Chi ² = 1.12	df = 2 (P = 0.57);	l ² =0.0%					
Test for overall effect: Z	= 0.45 (P = 0.6)	65)						
Total (95% CI)	1470		1381		-	•	100.0 %	-0.59 [-1.52, 0.35]
Heterogeneity: $Tau^2 = 2$	2.18; Chi ² = 41.	29, df = 19 (P = 0.	002); I ² =54%					
Test for overall effect: Z	= 1.23 (P = 0.2	22)						
Test for subgroup differe	ences: $Chi^2 = 3$.	29, df = 2 (P = 0.1	9), I ² =39%					
							1	
					4 -2	0 2	4	

Daily iron suppl Intermittent iron suppl

Analysis 2.17. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years, Outcome 17 Iron deficiency (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years

Outcome: 17 Iron defi	ciency (ALL)					
Study or subgroup	Intermittent iron suppl	Daily iron suppl		Risk Ratio M- ndom,95%	Weight	Risk Ratio M- H,Random,95%
	n/N	n/N	11,10	Cl		CI
Yang 2004 (C)	12/38	3/38			100.0 %	4.00 [1.23, 13.05]
Total (95% CI)	38	38		-	100.0 %	4.00 [1.23, 13.05]
Total events: 12 (Intermit	tent iron suppl), 3 (Da	aily iron suppl)				
Heterogeneity: not applic	able					
Test for overall effect: Z =	= 2.30 (P = 0.022)					
Test for subgroup differer	nces: Not applicable					
			0.01 0.1	1 10 100		
		Inte	ermittent iron suppl	Daily iron suppl		

Analysis 2.18. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years, Outcome 18 Ferritin (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years

Outcome: 18 Ferritin (ALL)

Intermittent iron suppl Daily iron suppl	Mean Difference	Weight	Mean Difference
N Mean(SD) N	ean(SD) IV,Random,95% Cl		IV,Random,95% CI
19 59.7 (27.7) 18	7 (26.4)	→ 5.5 %	4.00 [-13.43, 21.43]
38 64.14 (33.63) 38 7	(32.72)	6.5 %	-9.03 [-23.95, 5.89]
32 41.2 (30) 33	9 (28.7)	→ 6.8 %	6.30 [-7.98, 20.58]
22 47.1 (14.13) 12	7 (14.1)	9.2 %	-3.07 [-13.00, 6.86]
48 41.7 (22.2) 46	9 (22.8)	9.8 %	-0.20 [-9.30, 8.90]
123 54 (24.2) 137	7 (36.6) +	10.8 %	-25.70 [-33.17, -18.23]
50 21.4 (15.9) 50	3 (12.3)	12.0 %	-2.90 [-8.47, 2.67]
30 45 (12.7) 60	45 (7.8)	12.3 %	-0.45 [-5.40, 4.50]
57 36.9 (6.3) 29	14.8 (7)	13.2 %	-7.90 [-10.93, -4.87]
30 22.78 (0.6) 30 3	4 (0.54)	13.8 %	2.04 [1.75, 2.33]
449 453	-	100.0 %	-4.19 [-9.42, 1.05]
51.56; Chi ² = 100.90, df = 9 (P<0.00001); $I^2 = 91\%$			
= 1.57 (P = 0.12)			
ences: Not applicable			

Daily iron suppl Intermittent iron suppl

Analysis 2.19. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years, Outcome 19 Ferritin (by dose of elemental iron in the intermittent group).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years

Outcome: 19 Ferritin (by dose of elemental iron in the intermittent group)

Study or subgroup	Intermittent iron suppl	C	Daily iron suppl		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI		IV,Random,95% CI
I by dose of elemental irc	on in the interr	nittent group: 25 n	ng or less/week				
Subtotal (95% CI)	0		0				Not estimable
Heterogeneity: not applica							
Test for overall effect: not							
2 by dose of elemental iro		0 1 0	0	0			
Yurdakok 2004	19	59.7 (27.7)	18	55.7 (26.4)		6.5 %	4.00 [-13.43, 21.43]
Yang 2004 (C)	38	64.14 (33.63)	38	73.17 (32.72)		7.7 %	-9.03 [-23.95, 5.89]
Schultink 1995	32	41.2 (30)	33	34.9 (28.7)		8.0 %	6.30 [-7.98, 20.58]
Faqih 2006	22	47. (4. 3)	12	50.17 (14.1)	-	10.6 %	-3.07 [-13.00, 6.86]
Tavil 2003	48	41.7 (22.2)	46	41.9 (22.8)	+	11.2 %	-0.20 [-9.30, 8.90]
Sungthong 2002	123	54 (24.2)	137	79.7 (36.6)		12.2 %	-25.70 [-33.17, -18.23]
Ermis 2002	30	45 (12.7)	60	45.45 (7.8)	+	13.8 %	-0.45 [-5.40, 4.50]
Liu 1995 (C)	57	36.9 (6.3)	29	44.8 (7)	-	14.7 %	-7.90 [-10.93, -4.87]
Siddiqui 2004	30	22.78 (0.6)	30	20.74 (0.54)	-	15.3 %	2.04 [1.75, 2.33]
Subtotal (95% CI)	399		403		•	100.0 %	-4.34 [-10.20, 1.53]
Heterogeneity: $Tau^2 = 58$.50; Chi ² = 98	.06, df = 8 (P<0.00	0001); I ² =92%				
Test for overall effect: Z =	= 1.45 (P = 0.1	5)	,				
3 by dose of elemental irc	on in the interr	nittent group: grea	ter than 75 mg/	week			
Subtotal (95% CI)	0		0				Not estimable
Heterogeneity: not applica	able						
Test for overall effect: not	applicable						
Total (95% CI)	399		403		•	100.0 %	-4.34 [-10.20, 1.53]
Heterogeneity: $Tau^2 = 58$.50; Chi ² = 98	.06, df = 8 (P<0.00	0001); I ² =92%				
Test for overall effect: Z =	= 1.45 (P = 0.1	5)					
Test for subgroup differen	ces: Not appli	cable					
						i	
				- 1 00	0 -50 0 50	100	
				Daily	r iron suppl Intermitter	it iron suppl	

Analysis 2.20. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years, Outcome 20 Ferritin (by duration of the supplementation).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years

Outcome: 20 Ferritin (by duration of the supplementation)

Study or subgroup	Intermittent iron suppl	C	aily iron suppl		Mean Difference	Weight	Mean Difference
	N	Mean(SD)	N	Mean(SD)	IV,Random,95% Cl	-	IV,Random,95% CI
I by duration of the supp	lementation: 0	to three months					
Yurdakok 2004	19	59.7 (27.7)	18	55.7 (26.4)		5.5 %	4.00 [-13.43, 21.43]
Schultink 1995	32	41.2 (30)	33	34.9 (28.7)		6.8 %	6.30 [-7.98, 20.58]
Tavil 2003	48	41.7 (22.2)	46	41.9 (22.8)	+	9.8 %	-0.20 [-9.30, 8.90]
Khademloo 2009	50	21.4 (15.9)	50	24.3 (12.3)	-	12.0 %	-2.90 [-8.47, 2.67]
Liu 1995 (C)	57	36.9 (6.3)	29	44.8 (7)	-	13.2 %	-7.90 [-10.93, -4.87]
Siddiqui 2004	30	22.78 (0.6)	30	20.74 (0.54)	•	13.8 %	2.04 [1.75, 2.33]
Subtotal (95% CI)	236		206		•	61.1 %	-1.06 [-6.62, 4.51]
Heterogeneity: $Tau^2 = 32$. 19: Chi ² = 44	1.56. df = 5 (P<0.00	$00 $); $ ^2 = 89\%$				
Test for overall effect: Z =							
2 by duration of the supp		,	nths				
Yang 2004 (C)	38	64.14 (33.63)	38	73.17 (32.72)		6.5 %	-9.03 [-23.95, 5.89]
Faqih 2006	22	47.1 (14.13)	12	50.17 (14.1)	+	9.2 %	-3.07 [-13.00, 6.86]
Sungthong 2002	123	54 (24.2)	137	79.7 (36.6)	+	10.8 %	-25.70 [-33.17, -18.23]
Ermis 2002	30	45 (12.7)	60	45.45 (7.8)	+	12.3 %	-0.45 [-5.40, 4.50]
Subtotal (95% CI)	213		247		•	38.9 %	-9.58 [-23.08, 3.93]
Heterogeneity: $Tau^2 = 16$	5.62; Chi ² = 3	81.37, df = 3 (P<0.0	0001); 12 =90%	6			
Test for overall effect: Z =	= 1.39 (P = 0.1	6)					
Total (95% CI)	449		453		•	100.0 %	-4.19 [-9.42, 1.05]
Heterogeneity: $Tau^2 = 5I$.56; $Chi^2 = 10$	00.90, df = 9 (P<0.0	0001); 2 =91%	6			
Test for overall effect: Z =	= 1.57 (P = 0.1	2)					
Test for subgroup differen	ices: $Chi^2 = 1.2$	31, df = 1 (P = 0.25	5), I ² =23%				

Daily iron suppl

0

-100 -50

50

100

Intermittent iron suppl

Intermittent iron supplementation for improving nutrition and development in children under 12 years of age (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Analysis 2.21. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years, Outcome 21 Ferritin (by type of compound).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years

Outcome: 21 Ferritin (by type of compound)

Study or subgroup	Intermittent iron suppl N	Mean(SD)	Daily iron suppl N	Mean(SD)	Mean Difference IV,Random,95% Cl	Weight	Mean Difference IV,Random,95% CI
I by type of compound: fe	errous sulphate	e					
Yurdakok 2004	19	59.7 (27.7)	18	55.7 (26.4)		5.5 %	4.00 [-13.43, 21.43]
Schultink 1995	32	41.2 (30)	33	34.9 (28.7)		6.8 %	6.30 [-7.98, 20.58]
Faqih 2006	22	47. (4. 3)	12	50.17 (14.1)	+	9.2 %	-3.07 [-13.00, 6.86]
Tavil 2003	48	41.7 (22.2)	46	41.9 (22.8)	+	9.8 %	-0.20 [-9.30, 8.90]
Sungthong 2002	123	54 (24.2)	137	79.7 (36.6)	-	10.8 %	-25.70 [-33.17, -18.23]
Khademloo 2009	50	21.4 (15.9)	50	24.3 (12.3)	-	12.0 %	-2.90 [-8.47, 2.67]
Ermis 2002	30	45 (12.7)	60	45.45 (7.8)	+	12.3 %	-0.45 [-5.40, 4.50]
Liu 1995 (C)	57	36.9 (6.3)	29	44.8 (7)	-	13.2 %	-7.90 [-10.93, -4.87]
Siddigui 2004	30	22.78 (0.6)	30	20.74 (0.54)	-	13.8 %	2.04 [1.75, 2.33]
Subtotal (95% CI)	411	. ,	415		•	93.5 %	-3.85 [-9.28, 1.59]
Heterogeneity: Tau ² = 51. Test for overall effect: Z = 2 by type of compound: fo Subtotal (95% CI) Heterogeneity: not applica	: 1.39 (P = 0.1 errous fumarat 0 able	7)	0				Not estimable
Test for overall effect: not							
3 by type of compound: c Yang 2004 (C)		64.14 (33.63)	38	73.17 (32.72)		6.5 %	-9.03 [-23.95, 5.89]
Subtotal (95% CI) Heterogeneity: not applica			38		•	6.5 %	-9.03 [-23.95, 5.89]
Test for overall effect: Z = Total (95% CI)	449	,	453		•	100.0 %	-4.19 [-9.42, 1.05]
Heterogeneity: Tau ² = 51. Test for overall effect: Z = Test for subgroup differen	1.57 (P = 0.1	2)	,				

Intermittent iron suppl Daily iron suppl

Analysis 2.22. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years, Outcome 22 Ferritin (by anaemia status at baseline).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years

Outcome: 22 Ferritin (by anaemia status at baseline)

Study or subgroup	Intermittent iron suppl		Daily iron suppl		Mean Difference	Weight	Mea Differenc
	N	Mean(SD)	N	Mean(SD)	IV,Random,95% CI	-	IV,Random,95% C
I by anaemia status at bas	seline: anaemic						
Schultink 1995	32	41.2 (30)	33	34.9 (28.7)		6.2 %	6.30 [-7.98, 20.58
Faqih 2006	22	47. (4. 3)	12	50.17 (14.1)	-	8.3 %	-3.07 [-13.00, 6.86
Tavil 2003	48	41.7 (22.2)	46	41.9 (22.8)	+	8.8 %	-0.20 [-9.30, 8.90
Liu 1995 (C)	20	38.1 (6.9)	12	55.2 (8.4)	•	10.6 %	-17.10 [-22.73, -11.47
Siddiqui 2004	30	22.78 (0.6)	30	20.74 (0.54)	-	12.3 %	2.04 [1.75, 2.33
Subtotal (95% CI)	152		133		•	46.2 %	-2.94 [-12.23, 6.34
Heterogeneity: $Tau^2 = 93$.10; Chi ² = 45	.80, df = 4 (P<0	0.00001); I ² =91%				
Test for overall effect: Z =	= 0.62 (P = 0.5	3)					
2 by anaemia status at bas	seline: non-ana	emic					
Yurdakok 2004	19	59.7 (27.7)	18	55.7 (26.4)		5.0 %	4.00 [-13.43, 21.43
Yang 2004 (C)	38	64.14 (33.63)	38	73.17 (32.72)		5.9 %	-9.03 [-23.95, 5.89
Liu 1995 (C)	34	36.1 (6)	20	38.7 (6.1)	-	11.6 %	-2.60 [-5.95, 0.75
Subtotal (95% CI)	91		76		•	22.5 %	-2.67 [-5.89, 0.54
Heterogeneity: Tau ² = 0.0); Chi ² = 1.26,	df = 2 (P = 0.5	3); l ² =0.0%				
Test for overall effect: Z =	= 1.63 (P = 0.1	0)					
3 by anaemia status at bas	seline: mixed/u	nknown					
Sungthong 2002	123	54 (24.2)	137	79.7 (36.6)	+	9.7 %	-25.70 [-33.17, -18.23
Khademloo 2009	50	21.4 (15.9)	50	24.3 (12.3)	-	10.7 %	-2.90 [-8.47, 2.67
Ermis 2002	30	45 (12.7)	60	45.45 (7.8)	+	11.0 %	-0.45 [-5.40, 4.50
Subtotal (95% CI)	203		247		•	31.3 %	-9.42 [-23.19, 4.35
Heterogeneity: Tau ² = 13	8.53; Chi ² = 3	2.67, df = 2 (P<	<0.00001); 12 =949	%			
Test for overall effect: Z =	= 1.34 (P = 0.1	8)					
Total (95% CI)	446		456		•	100.0 %	-4.93 [-9.98, 0.12
Heterogeneity: Tau ² = 54	$15; Chi^2 = 11$	1.29, df = 10 (F	°<0.0000∣); ² =9	1%			
Test for overall effect: Z =	= 1.91 (P = 0.0	56)					

-100 -50 0 50 Daily iron suppl Intermit

Intermittent iron suppl

100

Analysis 2.23. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years, Outcome 23 Ferritin (by supplementation regimen).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years

Outcome: 23 Ferritin (by supplementation regimen)

Study or subgroup	Intermittent iron suppl N	Mean(SD)	Daily iron suppl N	Mean(SD)	Mean Difference IV,Random,95% Cl	Weight	Mean Difference IV,Random,95% CI
l by supplementation reg	imen: one sup	plement a week					
Faqih 2006		47.43 (14.14)	6	50.17 (14.1)	-	6.3 %	-2.74 [-16.57, 11.09]
Khademloo 2009	50	21.4 (15.9)	50	24.3 (12.3)	-	10.1 %	-2.90 [-8.47, 2.67]
Liu 1995 (C)	29	31.2 (5)	15	44.8 (7)	-	10.7 %	-13.60 [-17.58, -9.62]
Siddiqui 2004	30	22.78 (0.6)	30	20.74 (0.54)	-	11.4 %	2.04 [1.75, 2.33]
Sungthong 2002	123	54 (24.2)	137	79.7 (36.6)	-	9.2 %	-25.70 [-33.17, -18.23]
Yang 2004 (C)	38	64.14 (33.63)	38	73.17 (32.72)		5.9 %	-9.03 [-23.95, 5.89]
Yurdakok 2004	19	59.7 (27.7)	18	55.7 (26.4)		5.0 %	4.00 [-13.43, 21.43]
Subtotal (95% CI) Heterogeneity: Tau ² = 11 Test for overall effect: Z =	= 1.64 (P = 0.	0)		%	•	58.5 %	-7.34 [-16.12, 1.44]
2 by supplementation reg Ermis 2002	imen: other in 30	termittent regin 45 (12.7)	ien 60	45.45 (7.8)	+	10.3 %	-0.45 [-5.40, 4.50]
Fagih 2006	10	46.7 (14.13)	6	50.17 (14.1)		6.1 %	-3.47 [-17.75, 10.81]
,	27	42.8 (7.7)	15	44.8 (7)	_	10.5 %	-2.00 [-6.58, 2.58]
Liu 1995 (C)		~ /		~ / /			
Schultink 1995	32	41.2 (30)	33	34.9 (28.7)	-	6.1 %	6.30 [-7.98, 20.58]
Tavil 2003	48	41.7 (22.2)	46	41.9 (22.8)	-	8.4 %	-0.20 [-9.30, 8.90]
Subtotal (95% CI) Heterogeneity: $Tau^2 = 0.0$ Test for overall effect: Z =			160 5); l ² =0.0%		ł	41.5 %	-0.93 [-3.94, 2.08]
Total (95% CI)	448	,	454		•	100.0 %	-4.48 [-9.68, 0.71]
Heterogeneity: $Tau^2 = 6I$.59; Chi ² = 12	21.61, df = 11 (F	<0.00001); ² =9	%			
Test for overall effect: Z = Test for subgroup differer		,	0.18), I ² =46%		.		
					00 -50 0 50 ily iron suppl Intermitte	100 nt iron suppl	

Analysis 2.24. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years, Outcome 24 Ferritin (by sex).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years

Outcome: 24 Ferritin (by sex)

Study or subgroup	iron suppl	nittent suppl Daily iror			Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI		IV,Random,95% C
by sex: girls							
Subtotal (95% CI)	0		0				Not estimable
Heterogeneity: not applicable	9						
Fest for overall effect: not ap	plicable						
2 by sex: boys							
Subtotal (95% CI)	0		0				Not estimable
Heterogeneity: not applicable							
Test for overall effect: not ap	plicable						
3 by sex: mixed/unknown							
Yurdakok 2004	19	59.7 (27.7)	18	55.7 (26.4)		5.5 %	4.00 [-13.43, 21.43]
Yang 2004 (C)	38	64.14 (33.63)	38	73.17 (32.72)		6.5 %	-9.03 [-23.95, 5.89]
Schultink 1995	32	41.2 (30)	33	34.9 (28.7)		6.8 %	6.30 [-7.98, 20.58]
Faqih 2006	22	47.1 (14.1)	12	50.17 (14.1)	-	9.3 %	-3.07 [-12.99, 6.85]
Tavil 2003	48	41.7 (22.2)	46	41.9 (22.8)	+	9.8 %	-0.20 [-9.30, 8.90]
Sungthong 2002	123	54 (24.2)	137	79.7 (36.6)	+	10.8 %	-25.70 [-33.17, -18.23]
Khademloo 2009	50	21.4 (15.9)	50	24.3 (12.3)	-	12.0 %	-2.90 [-8.47, 2.67]
Ermis 2002	30	45 (12.7)	60	45.45 (7.8)	+	12.3 %	-0.45 [-5.40, 4.50]
Liu 1995 (C)	57	36.9 (6.3)	29	44.8 (7)	-	13.2 %	-7.90 [-10.93, -4.87]
Siddiqui 2004	30	22.78 (0.6)	30	20.74 (0.54)	-	13.8 %	2.04 [1.75, 2.33]
Subtotal (95% CI)	449		453		•	100.0 %	-4.19 [-9.42, 1.05]
Heterogeneity: Tau ² = 51.56	; Chi ² = 10	0.90, df = 9 (P<0.00	0001); l ² =91%				
Test for overall effect: $Z = 1$.	57 (P = 0.1	2)					
Total (95% CI)	449		453		•	100.0 %	-4.19 [-9.42, 1.05]
Heterogeneity: Tau ² = 51.56	; Chi ² = 10	0.90, df = 9 (P<0.00	0001); l ² =91%				
Test for overall effect: $Z = 1$.	57 (P = 0.1	2)					
Test for subgroup differences	: Not appli	cable					
					<u> </u>	1	
				-10	00 -50 0 50	100	
				Da	ily iron suppl Intermitten	t iron suppl	

Analysis 2.25. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years, Outcome 25 Ferritin (by nutrient).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years

Outcome: 25 Ferritin (by nutrient)

Mean Difference IV,Random,95% CI	Weight	Mean Difference IV,Random,95% CI	Mean(SD)	Daily iron suppl N	Mean(SD)	Intermittent iron suppl N	Study or subgroup
							By nutrient: iron alone
4.00 [-13.43, 21.43]	5.5 %		55.7 (26.4)	18	59.7 (27.7)	19	, Yurdakok 2004
6.30 [-7.98, 20.58]	6.8 %		34.9 (28.7)	33	41.2 (30)	32	Schultink 1995
-3.07 [-13.00, 6.86]	9.2 %	-	50.17 (14.1)	12	47.1 (14.13)	22	Faqih 2006
-0.20 [-9.30, 8.90]	9.8 %	+	41.9 (22.8)	46	41.7 (22.2)	48	Tavil 2003
-25.70 [-33.17, -18.23]	10.8 %	+	79.7 (36.6)	137	54 (24.2)	123	Sungthong 2002
-2.90 [-8.47, 2.67]	12.0 %	-	24.3 (12.3)	50	21.4 (15.9)	50	Khademloo 2009
-0.45 [-5.40, 4.50]	12.3 %	+	45.45 (7.8)	60	45 (12.7)	30	Ermis 2002
-7.90 [-10.93, -4.87]	13.2 %	-	44.8 (7)	29	36.9 (6.3)	57	Liu 1995 (C)
2.04 [1.75, 2.33]	13.8 %	-	20.74 (0.54)	30	22.78 (0.6)	30	Siddigui 2004
-3.85 [-9.28, 1.59]	93.5 %			415		411	Subtotal (95% CI)
				0.00001); l ² =92%		= 1.39 (P = 0.13	Heterogeneity: Tau ² = 51. Test for overall effect: Z = 2 By nutrient: iron + folic
Not estimable -9.03 [-23.95, 5.89]	6.5 %	-	73.17 (32.72)	0	ents 64.14 (33.63)	applicable iple micronutrie	Subtotal (95% CI) Heterogeneity: not applica Test for overall effect: not 3 By nutrient: iron + multi Yang 2004 (C)
-9.03 [-23.95, 5.89]	6504			38	()	38	Subtotal (95% CI)
-9.05 [-25.95, 5.89]	0.5 %			58	4)	able	Heterogeneity: not applica Test for overall effect: Z =
-4.19 [-9.42, 1.05]	100.0 %	•	5	,	2)	= 1.57 (P = 0.12	Total (95% CI) Heterogeneity: Tau ² = 51. Test for overall effect: $Z =$ Test for subgroup difference

-100 -50 0 Daily iron suppl II


Intermittent iron suppl

Analysis 2.26. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years, Outcome 26 Increase in steps climbed (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years

Outcome: 26 Increase in steps climbed (ALL)



Analysis 2.27. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years, Outcome 27 All cause morbidity (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years

Outcome: 27 All cause morbidity (ALL)

Study or subgroup	Intermittent iron suppl n/N	Daily iron suppl			Risk Ratio M- ndom,95% Cl		Weight	Risk Ratio M- H,Random,95% Cl
Da Silva 2008	25/38	28/39			+		24.1 %	0.92 [0.68, 1.24]
Desai 2004 (C)	135/271	128/251		I	+		75.9 %	0.98 [0.82, 1.16]
Total (95% CI)	309	290			•		100.0 %	0.96 [0.83, 1.12]
Total events: 160 (Interm	11.7	· · · · · · · · · · · · · · · · · · ·						
Heterogeneity: $Tau^2 = 0.0$	$0; Chi^2 = 0.13, df = 1$	$(P = 0.71); I^2 = 0.0\%$						
Test for overall effect: Z =	= 0.51 (P = 0.61)							
Test for subgroup differer	nces: Not applicable							
p								
			0.01	0.1	1 10	100		
			Intermittent i	ron suppl	Daily in	on suppl		

Analysis 2.28. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years, Outcome 28 Diarrhoea (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years

Outcome: 28 Diarrhoea (ALL)

n/N n/N Cl Cl Yurdakok 2004 1/23 0/22 4.5 % 2.88 [0.12, 67.03] Da Silva 2008 12/38 11/39 95.5 % 1.12 [0.56, 2.22]	Study or subgroup	Intermittent iron suppl	Daily iron suppl		Risk Ratio M-	Weight	Risk Ratio M-
Da Silva 2008 12/38 11/39 95.5 % 1.12 [0.56, 2.22] Total (95% CI) 61 61 100.0 % 1.17 [0.60, 2.28] Total events: 13 (Intermittent iron suppl), 11 (Daily iron suppl) 11 (Daily iron suppl) 100.0 % 1.17 [0.60, 2.28] Heterogeneity: Tau ² = 0.0; Chi ² = 0.33, df = 1 (P = 0.56); l ² = 0.0% Test for overall effect: Z = 0.46 (P = 0.65) 100.0 % Test for subgroup differences: Not applicable 0.01 0.1 10 100		n/N	n/N	H,Ra	ndom,95% Cl		H,Random,95% Cl
Total (95% CI) 61 61 100.0 % 1.17 [0.60, 2.28] Total events: 13 (Intermittent iron suppl), 11 (Daily iron suppl) Heterogeneity: Tau ² = 0.0; Chi ² = 0.33, df = 1 (P = 0.56); l ² = 0.0% 100.0 % 1.17 [0.60, 2.28] Heterogeneity: Tau ² = 0.0; Chi ² = 0.33, df = 1 (P = 0.56); l ² = 0.0% Test for overall effect: Z = 0.46 (P = 0.65) 100.0 % 1.17 [0.60, 2.28] Test for subgroup differences: Not applicable 0.01 0.1 10 100	Yurdakok 2004	1/23	0/22		+	4.5 %	2.88 [0.12, 67.03]
Total events: 13 (Intermittent iron suppl), 11 (Daily iron suppl) Heterogeneity: Tau ² = 0.0; Chi ² = 0.33, df = 1 (P = 0.56); l ² =0.0% Test for overall effect: Z = 0.46 (P = 0.65) Test for subgroup differences: Not applicable 0.01 0.1 10 100	Da Silva 2008	12/38	/39		-	95.5 %	1.12 [0.56, 2.22]
Total events: 13 (Intermittent iron suppl), 11 (Daily iron suppl) Heterogeneity: Tau ² = 0.0; Chi ² = 0.33, df = 1 (P = 0.56); l ² =0.0% Test for overall effect: Z = 0.46 (P = 0.65) Test for subgroup differences: Not applicable 0.01 0.1 10 100	Total (95% CI)	61	61		•	100.0 %	1.17 [0.60, 2.28]
	Heterogeneity: Tau ² = 0. Test for overall effect: Z	.0; Chi ² = 0.33, df = 1 (= 0.46 (P = 0.65)					
				0.01 0.1	10 100		

Analysis 2.29. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years, Outcome 29 Any side effects (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years

Outcome: 29 Any side effects (ALL)

Study or subgroup	Intermittent iron suppl	Daily iron suppl	Risk Ratio M-	Weight	Risk Ratio M-
	n/N	n/N	H,Random,95% Cl		H,Random,95% Cl
Ermis 2002	1/30	3/60		14.4 %	0.67 [0.07, 6.14]
Liu 1995 (C)	9/154	31/84	+	28.2 %	0.16 [0.08, 0.32]
Yurdakok 2004	12/22	8/23	-	28.4 %	1.57 [0.80, 3.09]
Desai 2004 (C)	19/271	22/251	-	29.1 %	0.80 [0.44, 1.44]
Total (95% CI)	477	418	•	100.0 %	0.60 [0.19, 1.87]
Total events: 41 (Intermit	tent iron suppl), 64 (D	aily iron suppl)			
Heterogeneity: $Tau^2 = 1$.	07; Chi ² = 23.53, df =	3 (P = 0.00003); I ² =87%			
Test for overall effect: Z	= 0.89 (P = 0.38)				
Test for subgroup differe	nces: Not applicable				
			0.01 0.1 1 10 100		

Intermittent iron suppl

Daily iron suppl

Analysis 2.30. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years, Outcome 30 Adherence (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years

Outcome: 30 Adherence (ALL)

Study or subgroup	Intermittent iron suppl	Daily iron suppl	Risk Ratio M-	Weight	Risk Ratio M-
	n/N	n/N	H,Random,95% Cl		H,Random,95% Cl
Sen 2009 (C)	/ 8	3/8		4.6 %	1.63 [0.62, 4.29]
Desai 2004 (C)	148/262	106/243	+	22.8 %	1.29 [1.08, 1.55]
Awasthi 2005 (C)	82/93	57/91	-	22.9 %	.4 [.18, .68]
Engstrom 2008 (C)	112/147	98/150	-	23.8 %	1.17 [1.01, 1.35]
Berger 1997	59/59	57/59	-	26.0 %	1.03 [0.98, 1.10]
Total (95% CI) Total events: 412 (Intermitte Heterogeneity: Tau ² = 0.05; Test for overall effect: Z = 1. Test for subgroup differences	Chi ² = 39.49, df = $\frac{1}{2}$ 77 (P = 0.077)	, ,, ,,	•	100.0 %	1.23 [0.98, 1.54]
			0.1 0.2 0.5 1 2 5 10		


Daily iron suppl Intermittent iron suppl

Analysis 2.31. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years, Outcome 31 IQ (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years

Outcome: 31 IQ (ALL)



Analysis 2.32. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years, Outcome 32 Thai language (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years

Outcome: 32 Thai language (ALL)

Study or subgroup	Intermittent iron suppl N	Mean(SD)	Daily iron suppl N	Mean(SD)		Mean ference dom,95% Cl	Weight	Mean Difference IV,Random,95% Cl
Sungthong 2002	105	0.001 (0.8)	103	0.3 (0.7)	I		100.0 %	-0.30 [-0.50, -0.09]
Total (95% CI) Heterogeneity: not ap Test for overall effect: Test for subgroup diff	Z = 2.87 (P =	,	103		-100 -50 Daily iron suppl	0 50 I Intermittent	100.0 %	-0.30 [-0.50, -0.09]

Analysis 2.33. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years, Outcome 33 Mathematics (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years

Outcome: 33 Mathematics (ALL)

Study or subgroup	Intermittent iron suppl N	Mean(SD)	Daily iron suppl N	Mean(SD)		Mean erence om,95% Cl	Weight	Mean Difference IV,Random,95% Cl
Sungthong 2002	130	0.03 (0.7)	103	0.3 (0.65)			100.0 %	-0.27 [-0.44, -0.10]
Total (95% CI)	130		103				100.0 %	-0.27 [-0.44, -0.10]
Heterogeneity: not ap	plicable							
Test for overall effect:	Z = 3.04 (P = 0)	0.0023)						
Test for subgroup diffe	erences: Not app	plicable						
							1	
					-100 -50	0 50 I	00	
					Daily iron suppl	Intermittent	iron suppl	

Analysis 2.34. Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years, Outcome 34 HAZ.

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 2 Intermittent iron supplementation versus daily iron supplementation: children 0 - 12 years

Outcome: 34 HAZ

Study or subgroup	Intermittent iron suppl N	Mean(SD)	Daily iron suppl N	Mean(SD)		Std. Mean ifference Iom,95% CI	Weight	Std. Mean Difference IV.Random,95% Cl
Da Silva 2008	39	0.283 (1.308)	36	0.08 (0.983)	TV, Fulle		32.1 %	0.17 [-0.28, 0.62]
Soemantri 1997	45	0 (0.1)	50	0.08 (0.1)		•	33.3 %	-0.79 [-1.21, -0.37]
Thu 1999	54	-1.81 (0.84)	55	-1.7 (0.63)		•	34.6 %	-0.15 [-0.52, 0.23]
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect:			141 = 0.01); I ² =80%				100.0 %	-0.26 [-0.80, 0.28]
Test for subgroup diff	erences: Not ap	oplicable					_	
					-100 -50 Daily iron suppl	0 50 Intermitt	100 ent iron suppl	

Analysis 3.1. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months, Outcome I Anaemia (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months

Outcome: I Anaemia (ALL)

Study or subgroup	Intermittent iron suppl	No suppl/placebo		Risk Ratio M-	Weight	Risk Ratio M-
	n/N	n/N	H,Random,95% Cl	Ċ.		H,Random,95% Cl
Evangelista-Salazar 2004	0/25	8/25	<u>← </u> ,	-	4.6 %	0.06 [0.00, 0.97]
Thu 1999	4/54	24/53			21.1 %	0.16 [0.06, 0.44]
Palupi 1997	17/96	26/98	-	F	32.9 %	0.67 [0.39, 1.15]
Verhoef 2002	67/154	110/153			41.4 %	0.61 [0.49, 0.74]
Total (95% CI)	329	329	+		100.0 %	0.43 [0.23, 0.80]
Total events: 88 (Intermittent in	ron suppl), 168 (No s	suppl/placebo)				
Heterogeneity: Tau ² = 0.24; Cł	$mi^2 = 10.33$, df = 3 (F	P = 0.02); I ² =71%				
Test for overall effect: $Z = 2.64$	(P = 0.0083)					
Test for subgroup differences: N	Vot applicable					
			0.01 0.1	1 10 100		

0.01 0.1 1 10 100 Intermittent iron suppl No suppl/placebo

Analysis 3.2. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months, Outcome 2 Anaemia (by dose of elemental iron in the intermittent group).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months

Outcome: 2 Anaemia (by dose of elemental iron in the intermittent group)

Study or subgroup	Intermittent iron suppl	No suppl/placebo		sk Ratio M-	Weight	Risk Ratio M-
	n/N	n/N	H,Rand	om,95% Cl		H,Random,95% Cl
1 25 mg or less/week						
Evangelista-Salazar 2004	0/25	8/25	4		4.6 %	0.06 [0.00, 0.97]
Thu 1999	4/54	24/53			21.1 %	0.16 [0.06, 0.44]
Subtotal (95% CI)	79	78	•		25.7 %	0.15 [0.06, 0.37]
Total events: 4 (Intermittent iro	n suppl), 32 (No sup	ppl/placebo)				
Heterogeneity: $Tau^2 = 0.0$; Chi ²	² = 0.48, df = 1 (P =	= 0.49); l ² =0.0%				
Test for overall effect: $Z = 4.05$	(P = 0.000052)					
2 Greater than 25 mg to 75 mg	g/week					
Palupi 1997	17/96	26/98	-		32.9 %	0.67 [0.39, 1.15]
Verhoef 2002	67/154	110/153	•		41.4 %	0.61 [0.49, 0.74]
Subtotal (95% CI)	250	251	•		74.3 %	0.61 [0.51, 0.74]
Total events: 84 (Intermittent in	on suppl), 136 (No	suppl/placebo)				
Heterogeneity: $Tau^2 = 0.0$; Chi^2	² = 0.11, df = 1 (P =	= 0.73); l ² =0.0%				
Test for overall effect: $Z = 5.00$	(P < 0.00001)					
3 Greater than 75 mg/week						
Subtotal (95% CI)	0	0				Not estimable
Total events: 0 (Intermittent iro	n suppl), 0 (No supp	pl/placebo)				
Heterogeneity: not applicable						
Test for overall effect: not applie	cable					
Total (95% CI)	329	329	•		100.0 %	0.43 [0.23, 0.80]
Total events: 88 (Intermittent in	on suppl), 168 (No	suppl/placebo)				
Heterogeneity: $Tau^2 = 0.24$; Ch	$m^2 = 10.33$, df = 3 (F	$P = 0.02$; $I^2 = 7 I\%$				
Test for overall effect: $Z = 2.64$	(P = 0.0083)					
Test for subgroup differences: C	$Chi^2 = 8.72, df = 1$ ($P = 0.00$), $I^2 = 89\%$				
			0.01 0.1 1	10 100		
		Inte	ermittent iron suppl	No suppl/placebo		

Analysis 3.3. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months, Outcome 3 Anaemia (by duration of the supplementation).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months

Outcome: 3 Anaemia (by duration of the supplementation)

Study or subgroup	Intermittent iron suppl	No suppl/placebo	Risk Ratio M-	Weight	Risk Ratio
	n/N	n/N	H,Random,95% Cl		H,Random,95% Cl
I 0 to three months					
Thu 1999	4/54	24/53		21.1 %	0.16 [0.06, 0.44]
Palupi 1997	17/96	26/98	-	32.9 %	0.67 [0.39, 1.15]
Verhoef 2002	67/154	110/153	-	41.4 %	0.61 [0.49, 0.74]
Subtotal (95% CI)	304	304	•	95.4 %	0.48 [0.27, 0.85]
Total events: 88 (Intermittent in	ron suppl), 160 (No	suppl/placebo)			
Heterogeneity: $Tau^2 = 0.17$; Ch	$hi^2 = 7.14, df = 2$ (P	= 0.03); I ² =72%			
Test for overall effect: $Z = 2.50$) (P = 0.012)				
2 More than three months					
Evangelista-Salazar 2004	0/25	8/25	←	4.6 %	0.06 [0.00, 0.97]
Subtotal (95% CI)	25	25		4.6 %	0.06 [0.00, 0.97]
Total events: 0 (Intermittent irc	on suppl), 8 (No sup	pl/placebo)			
Heterogeneity: not applicable					
Test for overall effect: $Z = 1.98$	8 (P = 0.047)				
Total (95% CI)	329	329	•	100.0 %	0.43 [0.23, 0.80]
Total events: 88 (Intermittent in	ron suppl), 168 (No	suppl/placebo)			
Heterogeneity: Tau ² = 0.24; Ch	$hi^2 = 10.33, df = 3$ ($P = 0.02$; $ ^2 = 7 \%$			
Test for overall effect: $Z = 2.64$	(P = 0.0083)				
Test for subgroup differences: ($Chi^2 = 2.08, df = 1$ ($P = 0.15$), $I^2 = 52\%$			
			0.01 0.1 1 10 100	1	
		Interr	nittent iron suppl No suppl/place	ebo	

Analysis 3.4. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months, Outcome 4 Anaemia (by type of compound).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months

Outcome: 4 Anaemia (by type of compound)

Study or subgroup	Intermittent iron suppl	No suppl/placebo	Risk Ratio	Weight	Risk Ratio M-
	n/N	n/N	H,Random,95% Cl		H,Random,95 Cl
I Ferrous sulphate					
Evangelista-Salazar 2004	0/25	8/25	•	4.6 %	0.06 [0.00, 0.97]
Thu 1999	4/54	24/53		21.1 %	0.16 [0.06, 0.44]
Palupi 1997	17/96	26/98		32.9 %	0.67 [0.39, 1.15]
Subtotal (95% CI)	175	176	-	58.6 %	0.26 [0.07, 1.03]
Total events: 21 (Intermittent irc Heterogeneity: Tau ² = 1.00; Chi Test for overall effect: Z = 1.92 2 Ferrous fumarate	$r^2 = 8.81$, df = 2 (P	,			
Verhoef 2002	67/154	110/153	-	41.4 %	0.61 [0.49, 0.74]
Subtotal (95% CI)	154	153	•	41.4 %	0.61 [0.49, 0.74]
Total events: 67 (Intermittent irc Heterogeneity: not applicable Test for overall effect: Z = 4.79 3 Other		suppl/placebo)			
Subtotal (95% CI)	0	0			Not estimable
Total events: 0 (Intermittent iror Heterogeneity: not applicable Test for overall effect: not applic		bl/placebo)			
Total (95% CI)	329	329	•	100.0 %	0.43 [0.23, 0.80]
Total events: 88 (Intermittent irc Heterogeneity: Tau ² = 0.24; Chi Test for overall effect: Z = 2.64 Test for subgroup differences: C	$P^2 = 10.33$, df = 3 (F (P = 0.0083)	$P = 0.02$; $ ^2 = 71\%$			
			0.01 0.1 10	100	
		Interr	mittent iron suppl No suppl/p		

Analysis 3.5. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months, Outcome 5 Anaemia (by anaemia status at baseline).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months

Outcome: 5 Anaemia (by anaemia status at baseline)

Study or subgroup	Intermittent iron suppl	No suppl/placebo	Risk Ratio M-	Weight	Risk Ratio M-
	n/N	n/N	H,Random,95% Cl		H,Random,959 Cl
I Anaemic					
Verhoef 2002	67/154	110/153	-	41.4 %	0.61 [0.49, 0.74]
Subtotal (95% CI)	154	153	•	41.4 %	0.61 [0.49, 0.74]
Total events: 67 (Intermittent i	ron suppl), 110 (No s	suppl/placebo)			
Heterogeneity: not applicable					
Test for overall effect: $Z = 4.79$	9 (P < 0.00001)				
2 Non-anaemic					
Subtotal (95% CI)	0	0			Not estimable
Total events: 0 (Intermittent in	on suppl), 0 (No supp	l/placebo)			
Heterogeneity: not applicable					
Test for overall effect: not appl	licable				
3 Mixed/unknown					
Evangelista-Salazar 2004	0/25	8/25	←	4.6 %	0.06 [0.00, 0.97]
Thu 1999	4/54	24/53		21.1 %	0.16 [0.06, 0.44]
Palupi 1997	17/96	26/98	-	32.9 %	0.67 [0.39, 1.15]
Subtotal (95% CI)	175	176	-	58.6 %	0.26 [0.07, 1.03]
Total events: 21 (Intermittent i	ron suppl), 58 (No su	ippl/placebo)			
Heterogeneity: Tau ² = 1.00; C	$hi^2 = 8.8 I$, $df = 2 (P$	= 0.01); I ² =77%			
Test for overall effect: $Z = 1.92$	2 (P = 0.055)				
Total (95% CI)	329	329	•	100.0 %	0.43 [0.23, 0.80]
Total events: 88 (Intermittent i	ron suppl), 168 (No s	suppl/placebo)			
Heterogeneity: Tau ² = 0.24; C	$hi^2 = 10.33, df = 3$ (F	$P = 0.02$; $ ^2 = 7 \%$			
Test for overall effect: $Z = 2.64$	4 (P = 0.0083)				
Test for subgroup differences:	$Chi^2 = 1.41, df = 1$ (F	P = 0.24), I ² =29%			
			0.01 0.1 1 10 100		
		Interm	ittent iron suppl No suppl/place	bo	

Analysis 3.6. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months, Outcome 6 Anaemia (by intermittent regimen).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months

Outcome: 6 Anaemia (by intermittent regimen)

Study or subgroup	Intermittent iron suppl	No suppl/placebo	R	isk Ratio M-	Weight	Risk Ratio	
	n/N	n/N		dom,95% Cl		H,Random,95% Cl	
I One supplement a week							
Evangelista-Salazar 2004	0/25	8/25	•		4.6 %	0.06 [0.00, 0.97]	
Palupi 1997	17/96	26/98	-		32.9 %	0.67 [0.39, 1.15]	
Thu 1999	4/54	24/53			21.1 %	0.16 [0.06, 0.44]	
Subtotal (95% CI)	175	176	-		58.6 %	0.26 [0.07, 1.03]	
Total events: 21 (Intermittent in	ron suppl), 58 (No s	uppl/placebo)					
Heterogeneity: $Tau^2 = 1.00$; Ch	$hi^2 = 8.81, df = 2$ (P	= 0.01); l ² =77%					
Test for overall effect: $Z = 1.92$	(P = 0.055)						
2 Other intermittent regimen							
Verhoef 2002	67/154	110/153	•		41.4 %	0.61 [0.49, 0.74]	
Subtotal (95% CI)	154	153	•		41.4 %	0.61 [0.49, 0.74]	
Total events: 67 (Intermittent in	ron suppl), 110 (No	suppl/placebo)					
Heterogeneity: not applicable							
Test for overall effect: $Z = 4.79$	(P < 0.00001)						
Total (95% CI)	329	329	+		100.0 %	0.43 [0.23, 0.80]	
Total events: 88 (Intermittent in	ron suppl), 168 (No	suppl/placebo)					
Heterogeneity: Tau ² = 0.24; Cł	$hi^2 = 10.33, df = 3$ (1)	$P = 0.02$; $ ^2 = 7 \%$					
Test for overall effect: $Z = 2.64$	(P = 0.0083)						
Test for subgroup differences: ($Chi^2 = 1.41, df = 1$ (P = 0.24), I ² =29%					
			0.01 0.1 1	10 100			
			Favours experimental	Favours control			

Analysis 3.7. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months, Outcome 7 Anaemia (by sex).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months

Outcome: 7 Anaemia (by sex)

Study or subgroup	Intermittent iron suppl	No suppl/placebo	Risk Ratio M-	Weight	Risk Ratio M-
	n/N	n/N	H,Random,95% Cl		H,Random,959 Cl
l Girls					
Subtotal (95% CI)	0	0			Not estimable
Total events: 0 (Intermittent iro	on suppl), 0 (No supp	ol/placebo)			
Heterogeneity: not applicable					
Test for overall effect: not appli	icable				
2 Boys					
Subtotal (95% CI)	0	0			Not estimable
Total events: 0 (Intermittent iro	on suppl), 0 (No supp	ol/placebo)			
Heterogeneity: not applicable					
Test for overall effect: not appli	icable				
3 Mixed/unknown					
Evangelista-Salazar 2004	0/25	8/25	←	4.6 %	0.06 [0.00, 0.97]
Palupi 1997	17/96	26/98	-	32.9 %	0.67 [0.39, 1.15]
Thu 1999	4/54	24/53		21.1 %	0.16 [0.06, 0.44]
Verhoef 2002	67/154	110/153	-	41.4 %	0.61 [0.49, 0.74]
Subtotal (95% CI)	329	329	•	100.0 %	0.43 [0.23, 0.80]
Total events: 88 (Intermittent ir	ron suppl), 168 (No	suppl/placebo)			
Heterogeneity: Tau ² = 0.24; Cł	$hi^2 = 10.33, df = 3$ (F	$P = 0.02$; $ ^2 = 7 \%$			
Test for overall effect: Z = 2.64	+ (P = 0.0083)				
Total (95% CI)	329	329	•	100.0 %	0.43 [0.23, 0.80]
Total events: 88 (Intermittent ir	ron suppl), 168 (No	suppl/placebo)			
Heterogeneity: Tau ² = 0.24; Ch	$hi^2 = 10.33, df = 3$ (F	$P = 0.02$; $ ^2 = 7 \%$			
Test for overall effect: $Z = 2.64$	+ (P = 0.0083)				
Test for subgroup differences: N	Not applicable				
			<u></u>		
			0.01 0.1 1 10 100		
		Intermitt	ent iron suppl No suppl/place	bo	

Analysis 3.8. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months, Outcome 8 Anaemia (by nutrient).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months

Outcome: 8 Anaemia (by nutrient)

n/N n/N Cl Cl Cl I Iron alone Palupi 1997 17.96 26.98 32.9 % 0.67 [0.39, 1.15] Verhoef 2002 67/154 110/153 41.4 % 0.61 [0.49, 0.74] Subtoal (95% CI) 250 251 74.3 % 0.61 [0.51, 0.74] Total events: B4 (Intermittent iron suppl), 136 (No suppl/placebo) Heterogeneity: Tav2 = 0.0; (P < 0.00001) 74.3 % 0.61 [0.51, 0.74] I terrogeneity: Tav2 = 0.0; (P < 0.00001) 2 00 0 Not estimable Total events: 0 (Intermittent iron suppl), 0 (No suppl/placebo) 0 0 Not estimable Total events: 0 (Intermittent iron suppl), 24 (No suppl/placebo) 46 % 0.06 [0.000, 0.97] Subtocal (95% CI) 25 25 4.6 % 0.06 [0.00, 0.97] Subtocal (95% CI) 25 25 4.6 % 0.06 [0.00, 0.97] Total events: 0 (Intermittent iron suppl), 8 (No suppl/placebo) 4/54 24/53 21.1 % 0.16 [0.06, 0.44] Total events: 8 (Intermittent iron suppl), 24 (No suppl/placebo) 53 100.0 % 0.43 [0.23, 0.80] 100.0 % <	Study or subgroup	Intermittent iron suppl	No suppl/placebo	Risk Ratio M-	Weight	Risk Ratio M-
Palupi 1997 17.96 26.98 32.9% $0.67 [0.39, 1.15]$ Verhoef 2002 $67/154$ $110/153$ 41.4% $0.61 [0.49, 0.74]$ Subtocal (95% CI) 250 251 74.3% $0.61 [0.51, 0.74]$ Total events: 84 (Intermittent iron suppl), 136 (No suppl/placebo) Test for overall effect: $Z = 5.00 (P < 0.00001)$ Z T T Subtocal (95% CI) 0 0 0 T		n/N	n/N			H,Random,959 Cl
Vertoef 2002 $67/154$ $110/153$ 41.4 % 0.61 [$0.49, 0.74$] Subtocal (95% CI) 250 251 74.3 % 0.61 [$0.51, 0.74$] Tatal events: 84 (intermittent iron suppl), 136 (No suppl/placebo) Heterogeneity: Tau ² = 0.0; Chi ² = 0.11, df = 1 ($P = 0.73$); $P = 0.00$ Test for overall effect: 2 = 5.00 ($P < 0.0000$] Not estimable Tatal events: 0 (intermittent iron suppl), 0 (No suppl/placebo) Not estimable Not estimable Tatal events: 0 (intermittent iron suppl), 0 (No suppl/placebo) Not estimable Not estimable 3 iron + vitamin C Exangelista-Salazar 2004 0.25 8/25 46.6 % 0.06 [0.00, 0.97] Subtocal (95% CI) 25 25 46.6 % 0.06 [0.00, 0.97] Tatal events: 0 (intermittent iron suppl) 8 (No suppl/placebo) Heterogeneity: not applicable 21.1 % 0.16 [0.06, 0.44] Total events: 4 (intermittent iron suppl), 24 (No suppl/placebo) 41.4 % 0.41 [0.06, 0.44] 21.1 % 0.16 [0.06, 0.44] Subtocal (95% CI) 54 53 21.1 % 0.16 [0.06, 0.44] 21.1 % 0.16 [0.06, 0.44] 21.1 % 0.16 [0.06, 0.44] 21.1 % 0.16 [0.06, 0.44] 21.1 % 0.16 [0.06, 0.44] 21.1 % 0.	l Iron alone					
Subcoal (95% Cl) 250 251 74.3 % 0.61 [0.51, 0.74] Subcoal (95% Cl) 250 251 74.3 % 0.61 [0.51, 0.74] Total events: 81 (Intermittent iron suppl), 13 (No suppl/placebo) Peterogeneity: Tau ² = 0.0; Ch ² = 0.11, df = 1 ($P = 0.73$; $P = 0.0\%$ 74.3 % 0.61 [0.51, 0.74] Subcoal (95% Cl) 0 0 0 0 Not estimable Total events: 0 (Intermittent iron suppl), 0 (No suppl/placebo) Peterogeneity: not applicable Not estimable 3 ron + vitamin C Exangelista-Salazar 2004 0.25 8/25 4.6 % 0.06 [0.00, 0.97] Subtotal (95% Cl) 25 25 4.6 % 0.06 [0.00, 0.97] Subtotal (95% Cl) 25 25 4.6 % 0.06 [0.00, 0.97] Subtotal (95% Cl) 54 53 21.1 % 0.16 [0.06, 0.44] Subtotal (95% Cl) 54 53 21.1 % 0.16 [0.06, 0.44] Subtotal vents: 4 (Intermittent iron suppl), 24 (No suppl/placebo) 100.0 % 0.43 [0.23, 0.80] 100.0 % 0.43 [0.23, 0.80] Total vents: 88 (Intermittent iron suppl), 24 (No suppl/placebo) 329 329 100.0 % 0.43 [0.23, 0.80] 100.0 %	Palupi 1997	17/96	26/98	-	32.9 %	0.67 [0.39, 1.15]
Total events: 84 (Intermittent iron suppl), 136 (No suppl/placebo) Heterogeneity: Tau ² = 0.0; Chi ² = 0.11, df = 1 (P = 0.73); I ² = 0.0% Test for overall effect: 2 = 5.00 (P < 0.00001)	Verhoef 2002	67/154	110/153	-	41.4 %	0.61 [0.49, 0.74]
Heterogeneity: Tau ² = 0.0; Ch ² = 0.11, df = 1 (P = 0.73); l ² = 0.0% Test for overall effect: Z = 5.00 (P < 0.00001) 2 hon + folic acid Subtocal (95% CI) 0 0 0 Total events: 0 (Intermittent iron suppl), 0 (No suppl/placebo) Heterogeneity: not applicable Test for overall effect: Z = 1.98 (P = 0.047) 4 hon + multiple micronutrients Thu 1999 4/54 24/53 4 Subtocal (95% CI) 54 53 Total events: 4 (Intermittent iron suppl), 24 (No suppl/placebo) Heterogeneity: not applicable Test for overall effect: Z = 1.98 (P = 0.047) 4 hon + multiple micronutrients Thu 1999 4/54 24/53 4 21.1 % 0.16 [0.06, 0.44] Total events: 4 (Intermittent iron suppl), 24 (No suppl/placebo) Heterogeneity: not applicable Test for overall effect: Z = 3.59 (P = 0.00033) Total events: 88 (Intermittent iron suppl), 168 (No suppl/placebo) Heterogeneity: Tau ² = 0.24; Ch ² = 1.033, df = 3 (P = 0.02); l ² = 71% Test for overall effect: Z = 2.64 (P = 0.0083) Test for overall effect: Z = 2	Subtotal (95% CI)	250	251	•	74.3 %	0.61 [0.51, 0.74]
Test for overall effect: $Z = 5.00 (P < 0.00001)$ 2 Iron + folic acid Not estimable Subtotal (95% CI) 0 0 0 Test arevents: 0 (Intermittent iron suppl), 0 (No suppl/placebo) Heterogeneity: not applicable Subtotal (95% CI) 25 4.6 % 0.06 [0.00, 0.97] Subtotal (95% CI) 25 25 4.6 % 0.06 [0.00, 0.97] Subtotal (95% CI) 25 25 4.6 % 0.06 [0.00, 0.97] Subtotal (95% CI) 25 25 4.6 % 0.06 [0.00, 0.97] Subtotal (95% CI) 25 25 4.6 % 0.06 [0.00, 0.97] Subtotal (95% CI) 25 25 4.6 % 0.06 [0.00, 0.97] Subtotal (95% CI) 54 53 21.1 % 0.16 [0.06, 0.44] Subtotal (95% CI) 54 53 21.1 % 0.16 [0.06, 0.44] Test for overall effect: Z = 3.59 (P = 0.00033) 21.1 % 0.16 [0.06, 0.44] 21.1 % 0.16 [0.06, 0.44] Test for overall effect: Z = 2.64 (P = 1.0033) 329 329 100.0 % 0.43 [0.23, 0.80] 100.0 % 0.43 [0.23, 0.80] Test for subgroup differences: Ch ² = 9.18, df = 2 (P = 0.01), l ² =	Total events: 84 (Intermittent i	ron suppl), 136 (No	suppl/placebo)			
2 Iron + folic acid Subtotal (95% CI) 0 0 0 Total events: 0 (Intermittent iron suppl), 0 (No suppl/placebo) Heterogeneity: not applicable Test for overall effect: not applicable Test for overall effect: $Z = 1.98$ ($P = 0.047$) 4 Iron + multiple micronutrients Thu 1999 4/54 24/53 4 Subtotal (95% CI) 54 53 5 Subtotal (95% CI) 54 53 2 Total events: 4 (Intermittent iron suppl), 24 (No suppl/placebo) Heterogeneity: not applicable Test for overall effect: $Z = 3.59$ ($P = 0.0033$) Total events: 88 (Intermittent iron suppl), 168 (No suppl/placebo) Heterogeneity: not applicable Total events: 88 (Intermittent iron suppl), 168 (No suppl/placebo) Heterogeneity: Tau ² = 0.24; Ch ² = 10.33, df = 3 ($P = 0.001$); $I^2 = 71\%$ Test for overall effect: $Z = 2.64$ ($P = 0.0083$) Test for overall effect: $Z = 2.64$ ($P = 0.0083$) Test for subgroup differences: Ch ² = 9.18, df = 2 ($P = 0.01$), $I^2 = 78\%$	Heterogeneity: $Tau^2 = 0.0$; Ch	$i^2 = 0.11$, $df = 1$ (P =	= 0.73); l ² =0.0%			
Subtoci (95% CI) 0 0 Not estimable Total events: 0 (Intermittent iron suppl), 0 (No suppl/placebo) Heterogeneity: not applicable Not estimable Test for overall effect: not applicable 3 iron + vitamin C 46 % 0.06 [0.00, 0.97] Subtocal (95% CI) 25 25 4.6 % 0.06 [0.00, 0.97] Total events: 0 (Intermittent iron suppl), 8 (No suppl/placebo) Heterogeneity: not applicable 4.6 % 0.06 [0.00, 0.97] Total events: 0 (Intermittent iron suppl), 8 (No suppl/placebo) Heterogeneity: not applicable 21.1 % 0.16 [0.00, 0.97] Total events: 4 (Intermittent iron suppl), 24 (No suppl/placebo) 54 53 21.1 % 0.16 [0.00, 0.44] Subtocal (95% CI) 54 53 21.1 % 0.16 [0.06, 0.44] 21.1 % 0.16 [0.06, 0.44] Subtocal (95% CI) 54 53 21.1 % 0.16 [0.06, 0.44] 21.1 % 0.16 [0.06, 0.44] 21.1 % 0.16 [0.06, 0.44] 21.1 % 0.16 [0.06, 0.44] 21.1 % 0.16 [0.06, 0.44] 21.1 % 0.16 [0.06, 0.44] 21.1 % 0.16 [0.06, 0.44] 21.1 % 0.16 [0.06, 0.44] 21.1 % 0.16 [0.06, 0.44] 21.1 % 0.16 [0.06, 0.44] 21.1 % </td <td>Test for overall effect: $Z = 5.00$</td> <td>0 (P < 0.00001)</td> <td></td> <td></td> <td></td> <td></td>	Test for overall effect: $Z = 5.00$	0 (P < 0.00001)				
Total events: 0 (Intermittent iron suppl), 0 (No suppl/placebo) Heterogeneity: not applicable 3 iron + vitamin C Evangelista-Salazar 2004 0/25 8/25 4.6 % 0.06 [0.00, 0.97] Subtocal (95% CI) 25 25 Total events: 0 (Intermittent iron suppl), 8 (No suppl/placebo) Heterogeneity: not applicable 4.6 % 0.06 [0.00, 0.97] Total events: 0 (Intermittent iron suppl), 8 (No suppl/placebo) Heterogeneity: not applicable 21.1 % 0.16 [0.06, 0.44] Total events: 4 (Intermittent iron suppl), 24 (No suppl/placebo) 53 21.1 % 0.16 [0.06, 0.44] Subtocal (95% CI) 54 53 21.1 % 0.16 [0.06, 0.44] Total events: 4 (Intermittent iron suppl), 24 (No suppl/placebo) Heterogeneity: not applicable 21.1 % 0.16 [0.06, 0.44] Total events: 88 (Intermittent iron suppl), 168 (No suppl/placebo) Heterogeneity: Tau ² = 0.24; Ch ² = 10.33, df = 3 (P = 0.02); I ² = 71% 100.0 % 0.43 [0.23, 0.80] Total events: 88 (Intermittent iron suppl), 168 (No suppl/placebo) Heterogeneity: Tau ² = 0.24; Ch ² = 9.18, df = 2 (P = 0.01), I ² = 78% 0.01 0.1 10 100 0.43 [0.23, 0.80]	2 Iron + folic acid					
Heterogeneity: not applicable Test for overall effect: not applicable Test for overall effect: not applicable Test for overall effect: $2 = 1.98$ (P = 0.047) 4 Iron + multiple micronutrients Thu 1999 4/54 24/53 4 4.6 % 0.06 [0.00, 0.97] Subtotal (95% CI) 54 53 4 1.1 % 0.16 [0.06, 0.44] Subtotal (95% CI) 54 53 1 1.1 % 0.16 [0.06, 0.44] Total events: 4 (Intermittent iron suppl), 24 (No suppl/placebo) Heterogeneity: not applicable Test for overall effect: $Z = 3.59$ (P = 0.00033) Total (95% CI) 329 329 100.0 % 0.43 [0.23, 0.80] Total events: 88 (Intermittent iron suppl), 168 (No suppl/placebo) Heterogeneity: Tau ² = 0.24; Ch ² = 10.33, df = 3 (P = 0.02); l ² = 71% Test for overall effect: $Z = 2.64$ (P = 0.01), l ² = 78%	Subtotal (95% CI)	0	0			Not estimable
Test for overall effect: not applicable 3 iron + vitamin C Evangelista-Salazar 2004 0/25 8/25 4.6 $\%$ 0.06 [0.00, 0.97] Subtocal (95% CI) 25 25 4.6 $\%$ 0.06 [0.00, 0.97] Total events: 0 (Intermittent iron suppl), 8 (No suppl/placebo) Heterogeneity: not applicable Test for overall effect: Z = 1.98 (P = 0.047) 4 Iron + multiple micronutrients Thu 1999 4/54 24/53 4 21.1 $\%$ 0.16 [0.06, 0.44] Subtocal (95% CI) 54 53 21.1 $\%$ 0.16 [0.06, 0.44] Total events: 4 (Intermittent iron suppl), 24 (No suppl/placebo) Heterogeneity: not applicable Test for overall effect: Z = 3.59 (P = 0.00033) Total (95% CI) 329 329 100.0 $\%$ 0.43 [0.23, 0.80] Total events: 88 (Intermittent iron suppl), 168 (No suppl/placebo) Heterogeneity: Tau ² = 0.24; Chi ² = 10.33, df = 3 (P = 0.02); I ² = 71% Test for subgroup differences: Chi ² = 9.18, df = 2 (P = 0.01), I ² = 78%	Total events: 0 (Intermittent in	on suppl), 0 (No supp	ol/placebo)			
3 iron + vitamin C Evangelista-Salazar 2004 $0/25$ $8/25$ 4.6% $0.06 [0.00, 0.97]$ Subtotal (95% CI) 25 25 4.6% $0.06 [0.00, 0.97]$ Total events: 0 (Intermittent iron suppl), 8 (No suppl/placebo) Heterogeneity: not applicable 4.6% $0.06 [0.00, 0.97]$ Total events: 0 (Intermittent iron suppl), 8 (No suppl/placebo) Heterogeneity: not applicable 54 53 21.1% $0.16 [0.06, 0.44]$ Subtotal (95% CI) 54 53 21.1% $0.16 [0.06, 0.44]$ 21.1% $0.16 [0.06, 0.44]$ Total events: 4 (Intermittent iron suppl), 24 (No suppl/placebo) Heterogeneity: not applicable 21.1% $0.16 [0.06, 0.44]$ Total events: 88 (Intermittent iron suppl), 168 (No suppl/placebo) 329 329 4000% $0.43 [0.23, 0.80]$ 100.0% $0.43 [0.23, 0.80]$ Total events: 88 (Intermittent iron suppl), 168 (No suppl/placebo) Heterogeneity: Tau ² = 0.24; Ch ² = 10.33, df = 3 (P = 0.02); l ² = 71\% 100.0% $0.43 [0.23, 0.80]$ $0.01 = 0.1$ $10 = 100$	Heterogeneity: not applicable					
Evangelista-Salazar 2004 0.25 $8/25$ 46 % $0.06 [0.00, 0.97]$ Subtotal (95% CI) 25 25 46 % $0.06 [0.00, 0.97]$ Total events: 0 (Intermittent iron suppl), 8 (No suppl/placebo) Heterogeneity: not applicable 46 % $0.06 [0.00, 0.97]$ Test for overall effect: $Z = 1.98 (P = 0.047)$ 4 /54 $24/53$ 21.1 % $0.16 [0.06, 0.44]$ Subtotal (95% CI) 54 53 21.1 % $0.16 [0.06, 0.44]$ Total events: 4 (Intermittent iron suppl), 24 (No suppl/placebo) Heterogeneity: not applicable 21.1 % $0.16 [0.06, 0.44]$ Total (95% CI) 329 329 459 453 453 453 Total events: 4 (Intermittent iron suppl), 24 (No suppl/placebo) Heterogeneity: not applicable 100.0 % $0.43 [0.23, 0.80]$ 100.0 % $0.43 [0.23, 0.80]$ Total events: 88 (Intermittent iron suppl), 168 (No suppl/placebo) Heterogeneity: Tau ² = 0.24; Chi ² = 10.33, df = 3 (P = 0.02); l ² = 71% 100.0 % $0.43 [0.23, 0.80]$ Test for overall effect: $Z = 2.64 (P = 0.0083)$ $0.01 0.1$ $10 100$ $10 100$	Test for overall effect: not appl	licable				
Subtocal (95% CI) 25 25 Total events: 0 (Intermittent iron suppl), 8 (No suppl/placebo) Heterogeneity: not applicable Test for overall effect: $Z = 1.98$ (P = 0.047) 4 Iron + multiple micronutrients Thu 1999 4/54 24/53 Subtotal (95% CI) 54 54 53 Total events: 4 (Intermittent iron suppl), 24 (No suppl/placebo) Heterogeneity: not applicable Test for overall effect: $Z = 3.59$ (P = 0.00033) Total (95% CI) 329 329 329 Total events: 88 (Intermittent iron suppl), 168 (No suppl/placebo) Heterogeneity: Tau ² = 0.24; Ch ² = 10.33, df = 3 (P = 0.02); l ² = 71% Test for overall effect: $Z = 2.64$ (P = 0.0083) Test for subgroup differences: Ch ² = 9.18, df = 2 (P = 0.01), l ² = 78%						
Total events: 0 (Intermittent iron suppl), 8 (No suppl/placebo) Heterogeneity: not applicable Test for overall effect: $Z = 1.98$ ($P = 0.047$) 4 Iron + multiple micronutrients Thu 1999 4/54 24/53 Subtotal (95% CI) 54 54 53 Total events: 4 (Intermittent iron suppl), 24 (No suppl/placebo) Heterogeneity: not applicable Test for overall effect: $Z = 3.59$ ($P = 0.00033$) Total (95% CI) 329 329 329 Total events: 88 (Intermittent iron suppl), 168 (No suppl/placebo) Heterogeneity: Tau ² = 0.24; Chi ² = 10.33, df = 3 ($P = 0.02$); $I^2 = 71\%$ Test for overall effect: $Z = 2.64$ ($P = 0.0083$) Test for subgroup differences: Chi ² = 9.18, df = 2 ($P = 0.01$), $I^2 = 78\%$	Evangelista-Salazar 2004	0/25	8/25	<	4.6 %	0.06 [0.00, 0.97]
Heterogeneity: not applicable Test for overall effect: $Z = 1.98$ (P = 0.047) 4 Iron + multiple micronutrients Thu 1999 4/54 24/53 $-$ 21.1 % 0.16 [0.06, 0.44] Subtotal (95% CI) 54 53 $-$ 21.1 % 0.16 [0.06, 0.44] Total events: 4 (Intermittent iron suppl), 24 (No suppl/placebo) Heterogeneity: not applicable Test for overall effect: $Z = 3.59$ (P = 0.00033) Total (95% CI) 329 329 $-$ 100.0 % 0.43 [0.23, 0.80] Total events: 88 (Intermittent iron suppl), 168 (No suppl/placebo) Heterogeneity: Tau ² = 0.24; Chi ² = 10.33, df = 3 (P = 0.02); l ² = 71% Test for overall effect: $Z = 2.64$ (P = 0.0083) Test for subgroup differences: Chi ² = 9.18, df = 2 (P = 0.01), l ² = 78%	Subtotal (95% CI)	25	25		4.6 %	0.06 [0.00, 0.97]
Test for overall effect: $Z = 1.98 (P = 0.047)$ 4 Iron + multiple micronutrients Thu 1999 4/54 24/53 Subtotal (95% CI) 54 53 21.1 % 0.16 [0.06, 0.44] Subtotal (95% CI) 54 53 21.1 % 0.16 [0.06, 0.44] Total events: 4 (Intermittent iron suppl), 24 (No suppl/placebo) Heterogeneity: not applicable 21.1 % 0.16 [0.06, 0.44] Total (95% CI) 329 329 329 100.0 % 0.43 [0.23, 0.80] Total events: 88 (Intermittent iron suppl), 168 (No suppl/placebo) Heterogeneity: Tau ² = 0.24; Chi ² = 10.33, df = 3 (P = 0.02); l ² = 71% 100.0 % 0.43 [0.23, 0.80] Test for overall effect: $Z = 2.64 (P = 0.0083)$ 0.01 0.1 10 100	Total events: 0 (Intermittent in	on suppl), 8 (No supp	ol/placebo)			
4 Iron + multiple micronutrients $1/54$ $24/53$ 21.1% $0.16 [0.06, 0.44]$ Subtotal (95% CI) 54 53 21.1% $0.16 [0.06, 0.44]$ Total events: 4 (Intermittent iron suppl), 24 (No suppl/placebo) 21.1% $0.16 [0.06, 0.44]$ Heterogeneity: not applicable 21.1% $0.16 [0.06, 0.44]$ Total (95% CI) 329 329 100.0% Total events: 88 (Intermittent iron suppl), 168 (No suppl/placebo) 100.0% $0.43 [0.23, 0.80]$ Heterogeneity: Tau ² = 0.24; Chi ² = 10.33, df = 3 (P = 0.02); l ² = 71\% 100.0% $0.43 [0.23, 0.80]$ Test for subgroup differences: Chi ² = 9.18, df = 2 (P = 0.01), l ² = 78\% $10 10$ $10 100$	• · · · ·					
Thu 1999 $4/54$ $24/53$ 21.1% $0.16 [0.06, 0.44]$ Subtotal (95% CI) 54 53 21.1% $0.16 [0.06, 0.44]$ Total events: 4 (Intermittent iron suppl), 24 (No suppl/placebo) $4/54$ 53 21.1% $0.16 [0.06, 0.44]$ Heterogeneity: not applicable 753 54 53 53 53 100.0% $0.16 [0.06, 0.44]$ Total (95% CI) 329 329 549 100.0% $0.43 [0.23, 0.80]$ 100.0% $0.43 [0.23, 0.80]$ Total events: 88 (Intermittent iron suppl), 168 (No suppl/placebo) 100.0% $0.43 [0.23, 0.80]$ 100.0% $0.43 [0.23, 0.80]$ 100.0% $0.43 [0.23, 0.80]$ Test for overall effect: $Z = 2.64$ (P = 0.008) $Z = 0.02$; $I^2 = 71\%$ $Z = 0.01$, $I^2 = 78\%$ $I = 0.001$ $I = 0.001$ $I = 0.001$ 0.01 0.1 $I = 0.100$ $I = 0.001$,				
Subtotal (95% CI) 54 53 Total events: 4 (Intermittent iron suppl), 24 (No suppl/placebo) 21.1% $0.16 [0.06, 0.44]$ Heterogeneity: not applicable Total (95% CI) 329 329 Total (95% CI) 329 329 100.0% $0.43 [0.23, 0.80]$ Total (95% CI) 329 329 100.0% $0.43 [0.23, 0.80]$ Total events: 88 (Intermittent iron suppl), 168 (No suppl/placebo) 100.0% $0.43 [0.23, 0.80]$ Heterogeneity: Tau ² = 0.24; Chi ² = 10.33, df = 3 (P = 0.02); l ² = 71% 100.0% $0.43 [0.23, 0.80]$ Test for overall effect: Z = 2.64 (P = 0.0083) 100.0% $0.43 [0.23, 0.80]$ Test for subgroup differences: Chi ² = 9.18, df = 2 (P = 0.01), l ² = 78% $100 0\%$						
Total events: 4 (Intermittent iron suppl), 24 (No suppl/placebo) Heterogeneity: not applicable Test for overall effect: $Z = 3.59$ (P = 0.00033) Total (95% CI) 329 329 100.0 % 0.43 [0.23, 0.80] Total events: 88 (Intermittent iron suppl), 168 (No suppl/placebo) Heterogeneity: Tau ² = 0.24; Chi ² = 10.33, df = 3 (P = 0.02); l ² = 71% Test for overall effect: $Z = 2.64$ (P = 0.0083) Test for subgroup differences: Chi ² = 9.18, df = 2 (P = 0.01), l ² = 78%	Thu 1999	4/54	24/53		21.1 %	0.16 [0.06, 0.44]
Heterogeneity: not applicable Test for overall effect: $Z = 3.59$ (P = 0.00033) Total (95% CI) 329 329 329 Total events: 88 (Intermittent iron suppl), 168 (No suppl/placebo) Heterogeneity: Tau ² = 0.24; Chi ² = 10.33, df = 3 (P = 0.02); l ² = 71% Test for overall effect: $Z = 2.64$ (P = 0.0083) Test for subgroup differences: Chi ² = 9.18, df = 2 (P = 0.01), l ² = 78% 0.01 0.1 10 10	Subtotal (95% CI)	54	53	•	21.1 %	0.16 [0.06, 0.44]
Test for overall effect: $Z = 3.59$ (P = 0.00033) Total (95% CI) 329 329 Total events: 88 (Intermittent iron suppl), 168 (No suppl/placebo) Heterogeneity: Tau ² = 0.24; Chi ² = 10.33, df = 3 (P = 0.02); l ² = 71% Test for overall effect: $Z = 2.64$ (P = 0.0083) Test for subgroup differences: Chi ² = 9.18, df = 2 (P = 0.01), l ² = 78% 0.01 0.1 10 10	Total events: 4 (Intermittent in	on suppl), 24 (No sup	opl/placebo)			
Total (95% CI) 329 329 → 100.0 % 0.43 [0.23, 0.80] Total events: 88 (Intermittent iron suppl), 168 (No suppl/placebo) Heterogeneity: Tau ² = 0.24; Chi ² = 10.33, df = 3 (P = 0.02); l ² = 71% 100.0 % 0.43 [0.23, 0.80] Test for overall effect: Z = 2.64 (P = 0.0083) Test for subgroup differences: Chi ² = 9.18, df = 2 (P = 0.01), l ² = 78% 100.0 % 10 100	o , 11					
Total events: 88 (Intermittent iron suppl), 168 (No suppl/placebo) Heterogeneity: $Tau^2 = 0.24$; $Chi^2 = 10.33$, $df = 3$ (P = 0.02); $l^2 = 71\%$ Test for overall effect: Z = 2.64 (P = 0.0083) Test for subgroup differences: $Chi^2 = 9.18$, $df = 2$ (P = 0.01), $l^2 = 78\%$ 0.01 0.1 10 100		· · · ·				
Heterogeneity: Tau ² = 0.24; Chi ² = 10.33, df = 3 (P = 0.02); l ² =71% Test for overall effect: Z = 2.64 (P = 0.0083) Test for subgroup differences: Chi ² = 9.18, df = 2 (P = 0.01), l ² =78%		• •		•	100.0 %	0.43 [0.23, 0.80]
Test for overall effect: Z = 2.64 (P = 0.0083) Test for subgroup differences: Chi ² = 9.18, df = 2 (P = 0.01), l ² = 78% 0.01 0.1 10 100	,					
Test for subgroup differences: Chi ² = 9.18, df = 2 (P = 0.01), l ² = 78%	8 ,		= 0.02, $1 = 71/8$			
0.01 0.1 1 10 100		· /	$P = 0.01$) $l^2 = 78\%$			
	ication subgroup differences.	Ciii — 7.10, di — 2 (i – 0.01), i –7070			
				0.01 0.1 1 10 100		
indextification applying the ap			Inte		bo	

Analysis 3.9. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months, Outcome 9 Haemoglobin (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months

Outcome: 9 Haemoglobin (ALL)


Study or subgroup	Intermittent iron suppl		No suppl/placebo		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% Cl		IV,Random,95% Cl
Yang 2004 (C)	38	34. 6 (2.79)	36	30. (0.78)		10.0 %	4.06 [-1.32, 9.44]
Ekvall 2000	98	95 (16)	97	92 (14)		10.7 %	3.00 [-1.22, 7.22]
Thu 1999	54	123.5 (10.3)	53	111.4 (10.6)		10.9 %	12.10 [8.14, 16.06]
Baqui 2003	179	105.1 (14.1)	60	105.3 (13)		10.9 %	-0.20 [-4.08, 3.68]
Evangelista-Salazar 2004	25	132.7 (6.1)	25	112 (5.4)	-	H 11.3 %	20.70 [17.51, 23.89]
Verhoef 2002	154	106.4 (14.7)	153	98.4 (12)		11.4 %	8.00 [5.00, 11.00]
Palupi 1997	96	8.4 (.4)	98	115.2 (9.4)		11.4 %	3.20 [0.26, 6.14]
Yurdakok 2004	19	116 (5)	16	112 (3)		11.5 %	4.00 [1.31, 6.69]
Ermis 2002	30	116 (2.9)	23	113 (4)	-#-	11.8 %	3.00 [1.06, 4.94]
Total (95% CI)	693		561		•	100.0 %	6.45 [2.36, 10.55]
Heterogeneity: Tau ² = 35.98	8; Chi ² = 119	.27, df = 8 (P<0	.00001); I ² =93%				
Test for overall effect: $Z = 3$	8.09 (P = 0.00	20)					
Test for subgroup difference	es: Not applica	able					
						1	

-20 -10 0

No suppl/placebo

Intermittent iron suppl

10 20



Analysis 3.10. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months, Outcome 10 Haemoglobin (by dose of elemental iron in the intermittent group).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months

Outcome: 10 Haemoglobin (by dose of elemental iron in the intermittent group)

Study or subgroup	Intermittent iron suppl N	Mean(SD)	No suppl/placebo N	Mean(SD)	Mean Difference IV,Random,95% Cl	Weight	Mean Difference IV,Random,95% CI
1 25 mg or less/week							
Baqui 2003	179	105.1 (14.1)	60	105.3 (13)		10.9 %	-0.20 [-4.08, 3.68]
Evangelista-Salazar 2004	25	32.7 (6.1)	25	112 (5.4)		→ II.3 %	20.70 [17.51, 23.89]
Yurdakok 2004	19	116 (5)	16	2 (3)		11.5 %	4.00 [1.31, 6.69]
Subtotal (95% CI) Heterogeneity: Tau ² = 113.			101 .00001); I ² =98%			- 33.7 %	8.19 [-4.01, 20.38]
Test for overall effect: $Z = 1$ 2 Greater than 25 mg to 75	`)					
Yang 2004 (C)	0	34. 6 (2.79)	36	30. (0.78)		10.0 %	4.06 [-1.32, 9.44]
Ekvall 2000	98	95 (16)	97	92 (14)		10.7 %	3.00 [-1.22, 7.22]
Thu 1999	54	123.5 (10.3)	53	.4 (0.6)		10.9 %	12.10 [8.14, 16.06]
Verhoef 2002	154	106.4 (14.7)	153	98.4 (12)		11.4 %	8.00 [5.00, 11.00]
Palupi 1997	96	8.4 (.4)	98	5.2 (9.4)		11.4 %	3.20 [0.26, 6.14]
I		. ,		~ /			
Ermis 2002	30	116 (2.9)	23	113 (4)	-	11.8 %	3.00 [1.06, 4.94]
Subtotal (95% CI) Heterogeneity: Tau ² = 9.46 Test for overall effect: Z = 3 3 Greater than 75 mg/week	9.77 (P = 0.00		460 00040); I ² =78%		•	66.3 %	5.50 [2.64, 8.36]
Subtotal (95% CI) Heterogeneity: not applicab Test for overall effect: not a	0		0				Not estimable
Total (95% CI)	693		561		•	100.0 %	6.45 [2.36, 10.55]
Heterogeneity: Tau ² = 35.9 Test for overall effect: Z = 3 Test for subgroup difference	0.09 (P = 0.00)	20)	,				
5			*			1	

No suppl/placebo

Intermittent iron suppl

Analysis 3.11. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months, Outcome 11 Haemoglobin (by duration of the supplementation).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months

Outcome: II Haemoglobin (by duration of the supplementation)

Study or subgroup	Intermittent iron suppl		No suppl/placebo		Mean Difference	Weight	Mean Difference
	N	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI	-	IV,Random,95% CI
l 0 to three months							
Thu 1999	54	123.5 (10.3)	53	.4 (0.6)		10.9 %	12.10 [8.14, 16.06]
Verhoef 2002	154	106.4 (14.7)	153	98.4 (12)		11.4 %	8.00 [5.00, 11.00]
Palupi 1997	96	8.4 (.4)	98	115.2 (9.4)		11.4 %	3.20 [0.26, 6.14]
Yurdakok 2004	19	116 (5)	16	112 (3)		11.5 %	4.00 [1.31, 6.69]
Subtotal (95% CI)	323		320		•	45.2 %	6.64 [3.01, 10.27]
Heterogeneity: $Tau^2 = . $	0; Chi ² = 16.4	+2, df = 3 (P = 0	0.00093); I ² =82%				
Test for overall effect: Z =	3.59 (P = 0.00	033)					
2 More than three months							
Yang 2004 (C)	38	34. 6 (2.79)	36	30. (10.78)		10.0 %	4.06 [-1.32, 9.44]
Ekvall 2000	98	95 (16)	97	92 (14)		10.7 %	3.00 [-1.22, 7.22]
Baqui 2003	179	105.1 (14.1)	60	105.3 (13)		10.9 %	-0.20 [-4.08, 3.68]
Evangelista-Salazar 2004	25	32.7 (6.1)	25	112 (5.4)		→ .3 %	20.70 [17.51, 23.89]
Ermis 2002	30	116 (2.9)	23	113 (4)	-	11.8 %	3.00 [1.06, 4.94]
Subtotal (95% CI)	370		241			54.8 %	6.16 [-1.55, 13.87]
Heterogeneity: $Tau^2 = 73.4$	- • •	.85. df = 4 (P<0				5 - 10 / 1	
Test for overall effect: Z =		,	,				
Total (95% CI)	693	, ,	561		•	100.0 %	6.45 [2.36, 10.55]
Heterogeneity: $Tau^2 = 35.9$	98; Chi ² = 119.	.27, df = 8 (P<0	.00001); I ² =93%				
Test for overall effect: Z =	3.09 (P = 0.00	20)					
Test for subgroup difference	es: Chi ² = 0.01	, $df = 1$ (P = 0.	91), I ² =0.0%				

-20 -10 0 10

No suppl/placebo Intermittent iron suppl

20

Analysis 3.12. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months, Outcome 12 Haemoglobin (by type of iron compound).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months

Outcome: 12 Haemoglobin (by type of iron compound)

Study or subgroup	Intermittent iron suppl N	Mean(SD)	No suppl/placebo N	Mean(SD)	Mean Difference IV,Random,95% CI	Weight	Mean Difference IV,Random,95% CI
I Ferrous sulphate							
Ekvall 2000	98	95 (16)	97	92 (14)		10.7 %	3.00 [-1.22, 7.22]
Thu 1999	54	23.5 (0.3)	53	.4 (0.6)		10.9 %	12.10 [8.14, 16.06]
Baqui 2003	179	105.1 (14.1)	60	105.3 (13)		10.9 %	-0.20 [-4.08, 3.68]
Evangelista-Salazar 2004	25	132.7 (6.1)	25	112 (5.4)	-	+ II.3 %	20.70 [17.51, 23.89]
Palupi 1997	96	8.4 (.4)	98	115.2 (9.4)		11.4 %	3.20 [0.26, 6.14]
Yurdakok 2004	19	116 (5)	16	2 (3)		11.5 %	4.00 [1.31, 6.69]
Ermis 2002	30	116 (2.9)	23	3 (4)	-#-	11.8 %	3.00 [1.06, 4.94]
Subtotal (95% CI)	501		372		-	78.6%	6.54 [1.44, 11.63]
Heterogeneity: Tau ² = 44.4 Test for overall effect: Z = 2 2 Ferrous fumarate Verhoef 2002			153	98.4 (12)	-	11.4 %	8.00 [5.00, 11.00]
Subtotal (95% CI) Heterogeneity: not applicab Test for overall effect: Z = 5 3 Other		01)	153		•	11.4 %	8.00 [5.00, 11.00]
Yang 2004 (C)	38	134.16 (12.79)	36	30. (10.78)		10.0 %	4.06 [-1.32, 9.44]
Subtotal (95% CI) Heterogeneity: not applicab Test for overall effect: Z =			36		-	10.0 %	4.06 [-1.32, 9.44]
Total (95% CI)	693		561		•	100.0 %	6.45 [2.36, 10.55]
Heterogeneity: $Tau^2 = 35.9$ Test for overall effect: $Z = 3$ Test for subgroup difference	3.09 (P = 0.002	0)	,				

10 20 -20 -10 0 No suppl/placebo

Intermittent iron suppl

Analysis 3.13. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months, Outcome 13 Haemoglobin (by anaemia status at baseline).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months

Outcome: 13 Haemoglobin (by anaemia status at baseline)

Study or subgroup	Intermittent iron suppl N	Mean(SD)	No suppl/placebo N	Mean(SD)	Mean Difference IV,Random,95% Cl	Weight	Mean Difference IV,Random,95% CI
I Anaemic							
Verhoef 2002	154	106.4 (14.7)	153	98.4 (12)		11.4 %	8.00 [5.00, 11.00]
Subtotal (95% CI) Heterogeneity: not applicat	154		153		•	11.4 %	8.00 [5.00, 11.00]
Test for overall effect: $Z =$	5.22 (P < 0.00	001)					
2 Non-anaemic							
Subtotal (95% CI)	0		0				Not estimable
Heterogeneity: not applical							
Test for overall effect: not a	pplicable						
3 Mixed/unknown	20		24			10.0.0/	4045 100 044
Yang 2004 (C)	38	34. 6 (2.79)	36	30. (0.78)		10.0 %	4.06 [-1.32, 9.44]
Ekvall 2000	98	95 (16)	97	92 (14)	+	10.7 %	3.00 [-1.22, 7.22]
Thu 1999	54	123.5 (10.3)	53	.4 (0.6)		10.9 %	12.10 [8.14, 16.06]
Baqui 2003	179	105.1 (14.1)	60	105.3 (13)		10.9 %	-0.20 [-4.08, 3.68]
Evangelista-Salazar 2004	25	132.7 (6.1)	25	112 (5.4)	-	▪ II.3 %	20.70 [17.51, 23.89]
Palupi 1997	96	8.4 (.4)	98	115.2 (9.4)		11.4 %	3.20 [0.26, 6.14]
Yurdakok 2004	19	116 (5)	16	112 (3)		11.5 %	4.00 [1.31, 6.69]
Ermis 2002	30	116 (2.9)	23	113 (4)		11.8 %	3.00 [1.06, 4.94]
Subtotal (95% CI)	539		408		-	88.6 %	6.25 [1.60, 10.90]
Heterogeneity: $Tau^2 = 41.6$	57; Chi ² = 117	.35, df = 7 (P<0	.00001); 12 =94%				
Test for overall effect: $Z =$		84)					
Total (95% CI)	693		561		-	100.0 %	6.45 [2.36, 10.55]
Heterogeneity: $Tau^2 = 35.9$.00001); 1 ² =93%				
Test for overall effect: $Z =$,					
Test for subgroup difference	es: Chi ² = 0.38	B, df = 1 (P = 0.5)	54), l ² =0.0%				

No suppl/placebo

Intermittent iron suppl

Analysis 3.14. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months, Outcome 14 Haemoglobin (by supplementation regimen).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months

Outcome: 14 Haemoglobin (by supplementation regimen)

Study or subgroup	Intermittent iron suppl		No suppl/placebo		Mean Difference	Weight	
	N	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI		IV,Random,95% CI
I One supplement a week							
Yang 2004 (C)	38	34. 6 (2.79)	36	30. (0.78)		10.0 %	4.06 [-1.32, 9.44]
Thu 1999	54	123.5 (10.3)	53	.4 (0.6)		10.9 %	12.10 [8.14, 16.06]
Baqui 2003	179	105.1 (14.1)	60	105.3 (13)		10.9 %	-0.20 [-4.08, 3.68]
Evangelista-Salazar 2004	25	132.7 (6.1)	25	112 (5.4)	-	• 11.3 %	20.70 [17.51, 23.89]
Palupi 1997	96	8.4 (.4)	98	115.2 (9.4)		11.4 %	3.20 [0.26, 6.14]
Yurdakok 2004	19	116 (5)	16	2 (3)		11.5 %	4.00 [1.31, 6.69]
Subtotal (95% CI)	411		288		-	66.1 %	7.35 [0.92, 13.77]
Heterogeneity: $Tau^2 = 60.7$	6; Chi ² = 102	.20, df = 5 (P<0	.00001); I ² =95%				
Test for overall effect: $Z = 2$	2.24 (P = 0.02	5)					
2 Other intermittent regime	en						
Ekvall 2000	98	95 (16)	97	92 (14)	+	10.7 %	3.00 [-1.22, 7.22]
Verhoef 2002	154	106.4 (14.7)	153	98.4 (12)		11.4 %	8.00 [5.00, 11.00]
Ermis 2002	30	116 (2.9)	23	113 (4)		11.8 %	3.00 [1.06, 4.94]
Subtotal (95% CI)	282		273		•	33.9 %	4.68 [1.28, 8.08]
Heterogeneity: $Tau^2 = 6.59$; Chi ² = 7.94,	df = 2 (P = 0.02)	2); I ² =75%				
Test for overall effect: $Z = 2$	2.70 (P = 0.00	69)					
Total (95% CI)	693		561		-	100.0 %	6.45 [2.36, 10.55]
Heterogeneity: Tau ² = 35.9			.00001); I ² =93%				
Test for overall effect: $Z = 3$	`	,					
Test for subgroup difference	es: Chi ² = 0.52	$P_{\rm e},\mathrm{df}=1(\mathrm{P}=0.4)$	47), l ² =0.0%				

-20 -10 0 10

No suppl/placebo Intermittent iron suppl

20

Analysis 3.15. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months, Outcome 15 Haemoglobin (by sex).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months

Outcome: 15 Haemoglobin (by sex)

Intermittent iron suppl		No suppl/placebo		Mean Difference	Weight	Mear Difference
Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI		IV,Random,95% C
0		0				Not estimable
e						
oplicable						
0		0				Not estimabl
oplicable						
38	34. 6 (2.79)	36	30. (10.78)		10.0 %	4.06 [-1.32, 9.44
98	95 (16)	97	92 (14)		10.7 %	3.00 [-1.22, 7.22
54	23.5 (0.3)	53	.4 (0.6)		10.9 %	12.10 [8.14, 16.06
179	105.1 (14.1)	60	105.3 (13)		10.9 %	-0.20 [-4.08, 3.68
25	32.7 (6.1)	25	112 (5.4)	-	→ 1.3 %	20.70 [17.51, 23.89
154	106.4 (14.7)	153	98.4 (12)		11.4 %	8.00 [5.00, 11.00
96	8.4 (.4)	98	5.2 (9.4)		11.4 %	3.20 [0.26, 6.14
19	116 (5)	16	112 (3)		11.5 %	4.00 [1.31, 6.69
30	116 (2.9)	23	113 (4)	-=-	11.8 %	3.00 [1.06, 4.94
693		561		•	100.0 %	6.45 [2.36, 10.55
B; Chi ² = 119	.27, df = 8 (P<0	.00001); 12 =93%				
.09 (P = 0.00	20)					
693		561		•	100.0 %	6.45 [2.36, 10.55
B; Chi ² = 119	.27, df = 8 (P<0	.00001); I ² =93%				
.09 (P = 0.00	20)					
s: Not applica	ıble					
	iron suppl N N N N N N N N N N N N N N N N N N	N Mean(SD) N Mean(SD) I 0 I 0 I 0 I 0 I 38 134.16 (12.79) 98 95 54 123.5 179 105.1 154 106.4 19 116 30 116 30 116 30 116 30 16 30 16 30 16 30 16 30 16 30 16 30 16 30 16 30 16 30 16 30 13	iron suppl No suppl/placebo N Mean(SD) N 0 0 0 le oplicable 0 0 0 0 0 0 le oplicable 0 0 38 134.16 (12.79) 36 98 95 (16) 97 54 123.5 (10.3) 53 179 105.1 (14.1) 60 25 132.7 (6.1) 25 154 106.4 (14.7) 153 96 118.4 (11.4) 98 19 116 (5) 16 30 116 (2.9) 23 693 561 8; Chi ² = 119.27, df = 8 (P<0.00001); l ² =93% 693 561 8; Chi ² = 119.27, df = 8 (P<0.00001); l ² =93% 39 (P = 0.0020) 561	iron suppl No suppl/placebo N Mean(SD) N Mean(SD) 0 0 0 0 le oplicable 0 0 0 le oplicable 38 134.16 (12.79) 36 130.1 (10.78) 9 98 95 (16) 97 92 (14) 54 123.5 (10.3) 53 111.4 (10.6) 179 105.1 (14.1) 60 105.3 (13) 25 112 (5.4) 154 106.4 (14.7) 153 98.4 (12) 96 118.4 (11.4) 98 115.2 (9.4) 19 116 (5) 16 112 (3) 30 113 (4) 693 561 33 (4) 693 561 33 (4) 3; Chi ² = 119.27, df = 8 (P<0.00001); l ² = 93% 561 33 (2) 36 561 3; Chi ² = 119.27, df = 8 (P<0.00001); l ² = 93% 561 33 (2) 561 33 (2) 39 (P = 0.0020) 693 561 34 (2) 35 (2) 36 (2)	iron suppl No suppl/placebo Difference N Mean(SD) N Mean(SD) N/Random,95% CI 0 0 0 0 0 le 0 0 0 0 le 38 134.16 (12.79) 36 130.1 (10.78) 98 95 (16) 97 92 (14) 54 123.5 (10.3) 53 111.4 (10.6) 179 105.1 (14.1) 60 105.3 (13) 25 132.7 (6.1) 25 112 (5.4) 154 106.4 (14.7) 153 98.4 (12) 96 118.4 (11.4) 98 115.2 (9.4) 19 116 (5) 16 112 (3) 30 116 (2.9) 23 113 (4) 693 561 561 3; Chi ² = 119.27, df = 8 (P<0.00001); l ² = 93% 561 3; Chi ² = 119.27, df = 8 (P<0.00001); l ² = 93% 561 3; Chi ² = 119.27, df = 8 (P<0.00001); l ² = 93% 561 4; Op (P = 0.0020) 561	iron suppl No suppl/placebo Difference Weight N Mean(SD) N Mean(SD) IV/Random,95% CI 0 0 0 0 0 le 0 0 0 0 oplicable 0 0 0 0 as 134.16 (12.79) 36 130.1 (10.78) 100.9 % 98 95 (16) 97 92 (14) 10.9 % 54 123.5 (10.3) 53 111.4 (10.6) 10.9 % 179 105.1 (14.1) 60 105.3 (13) 11.3 % 154 106.4 (14.7) 153 98.4 (12) 11.4 % 96 118.4 (11.4) 98 115.2 (9.4) 11.5 % 19 116 (5) 16 112 (3) 11.8 % 693 561 100.0 % 8; Chi ² = 119.27, df = 8 (P<0.00001); l ² = 93% 561

No suppl/placebo

Intermittent iron suppl

Analysis 3.16. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months, Outcome 16 Haemoglobin (by nutrient).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months

Outcome: 16 Haemoglobin (by nutrient)

Study or subgroup	Intermittent iron suppl		No suppl/placebo		Mean Difference	Weight	Mean Difference
	N	Mean(SD)	N	Mean(SD)	IV,Random,95% CI	-	IV,Random,95% Cl
l Iron alone							
Baqui 2003	125	104.6 (9.9)	30	105.3 (13)		9.4 %	-0.70 [-5.67, 4.27]
Verhoef 2002	154	106.4 (14.7)	153	98.4 (12)		10.4 %	8.00 [5.00, 11.00]
Palupi 1997	96	8.4 (.4)	98	115.2 (9.4)		10.5 %	3.20 [0.26, 6.14]
Yurdakok 2004	19	116 (5)	16	112 (3)		10.6 %	4.00 [1.31, 6.69]
Ermis 2002	30	116 (2.9)	23	113 (4)	-#-	10.8 %	3.00 [1.06, 4.94]
Subtotal (95% CI)	424		320		*	51.7 %	3.81 [1.61, 6.01]
Heterogeneity: $Tau^2 = 3.92$	B; Chi ² = 11.51	, df = 4 (P = 0.0	02); I ² =65%				
Test for overall effect: $Z =$	3.39 (P = 0.000	069)					
2 Iron + folic acid							
Subtotal (95% CI)	0		0				Not estimable
Heterogeneity: not applica	ble						
Test for overall effect: not a	applicable						
3 Iron + multiple micronut	rients						
Baqui 2003	54	106.9 (13)	30	105.3 (13)		8.9 %	1.60 [-4.20, 7.40]
Yang 2004 (C)	38	134.16 (12.79)	36	30. (10.78)		9.2 %	4.06 [-1.32, 9.44]
Ekvall 2000	98	95 (16)	97	92 (14)		9.8 %	3.00 [-1.22, 7.22]
Thu 1999	54	123.5 (10.3)	53	.4 (0.6)		10.0 %	12.10 [8.14, 16.06]
Evangelista-Salazar 2004	ł 25	132.7 (6.1)	25	112 (5.4)		→ 10.4 %	20.70 [17.51, 23.89]
Subtotal (95% CI)	269		241		-	48.3 %	8.46 [0.60, 16.32]
Heterogeneity: $Tau^2 = 74.9$	97; Chi ² = 65.9	9, df = 4 (P<0.0	0001); I ² =94%				
Test for overall effect: Z =	2.11 (P = 0.03	5)	,				
Total (95% CI)	693		561		•	100.0 %	6.01 [2.13, 9.89]
Heterogeneity: $Tau^2 = 35$.	$18; Chi^2 = 118.$	68, df = 9 (P<0.	00001); I ² =92%				
Test for overall effect: Z =	3.04 (P = 0.002	24)					
Test for subgroup difference	es: $Chi^2 = 1.24$	df = 1 (P = 0)	$(26) ^2 = 20\%$				

-20 -10 0 No suppl/placebo

0 10 20 Intermittent iron suppl

Analysis 3.17. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months, Outcome 17 Iron deficiency (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months

Outcome: 17 Iron deficiency (ALL)

Study or subgroup	Intermittent iron suppl	No suppl/placebo		Risk Ratio M- ndom,95%	Weight	Risk Ratio M- H,Random,95%
	n/N	n/N		CI		CI
Evangelista-Salazar 2004	0/25	4/25		<u> </u>	14.6 %	0.11 [0.01, 1.96]
Verhoef 2002	14/154	105/153	-		42.9 %	0.13 [0.08, 0.22]
Yang 2004 (C)	12/38	20/36	-	-	42.5 %	0.57 [0.33, 0.99]
Total (95% CI)	217	214	-		100.0 %	0.24 [0.06, 0.91]
Total events: 26 (Intermittent	iron suppl), 129 (No s	suppl/placebo)				
Heterogeneity: Tau ² = 1.01; C	$Chi^2 = 16.40, df = 2$ (F	$P = 0.00027$); $I^2 = 88\%$				
Test for overall effect: Z = 2.1	0 (P = 0.036)					
Test for subgroup differences:	Not applicable					
			0.01 0.1	1 10 100		
		Interr	mittent iron suppl	No suppl/placebo		

Analysis 3.18. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months, Outcome 18 Ferritin (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months

Outcome: 18 Ferritin (ALL)

Study or subgroup	Intermittent iron suppl		No suppl/placebo			Mean erence	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Rando	om,95% Cl		IV,Random,95% CI
Yurdakok 2004	19	59.7 (27.7)	16	43.9 (23.7)			21.6 %	5.80 [-1.23, 32.83]
Yang 2004 (C)	38	64.14 (33.63)	36	61.68 (39.8)	-	-	21.7 %	2.46 [-14.37, 19.29]
Baqui 2003	111	18.9 (16)	37	14.3 (14.3)			28.2 %	4.60 [-0.89, 10.09]
Ermis 2002	30	45 (12.7)	23	17.2 (4.6)		-	28.4 %	27.80 [22.88, 32.72]
Total (95% CI)	198		112			•	100.0 %	13.15 [-2.28, 28.59]
Heterogeneity: Tau ²	= 211.68; Chi ²	= 41.02, df = 3	(P<0.00001); I ² =93	%				
Test for overall effect	Z = 1.67 (P =	= 0.095)						
Test for subgroup diff	erences: Not a	applicable						
				-	100 -50 (0 50	100	

No suppl/placebo

Intermittent iron suppl

Intermittent iron supplementation for improving nutrition and development in children under 12 years of age (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Analysis 3.19. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months, Outcome 19 Ferritin (by dose of iron in the intermittent group).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months

Outcome: 19 Ferritin (by dose of iron in the intermittent group)

Study or subgroup	Intermittent iron suppl	No	suppl/placebo		Dif	Mean ference	Weight	Mean Difference
,	N	Mean(SD)	N	Mean(SD)	IV,Ranc	lom,95% Cl	-	IV,Random,95% Cl
1 25 mg or less/week								
Baqui 2003	111	18.9 (16)	37	14.3 (14.3)		-	28.2 %	4.60 [-0.89, 10.09]
Subtotal (95% CI)	111		37			•	28.2 %	4.60 [-0.89, 10.09]
Heterogeneity: not applica	able							
Test for overall effect: Z =	1.64 (P = 0.1	0)						
2 Greater than 25 mg to 7	75 mg/week							
Ermis 2002	30	45 (12.7)	23	17.2 (4.6)		-	28.4 %	27.80 [22.88, 32.72]
Yang 2004 (C)	38	64.14 (33.63)	36	61.68 (39.8)	-	•	21.7 %	2.46 [-14.37, 19.29]
Yurdakok 2004	19	59.7 (27.7)	16	43.9 (23.7)			21.6 %	5.80 [-1.23, 32.83]
Subtotal (95% CI)	8 7		75			•	71.8 %	16.91 [0.99, 32.82]
Heterogeneity: $Tau^2 = 15$	1.72; Chi ² = 9	.25, df = 2 (P = 0.01); l ² =78%					
Test for overall effect: Z =	2.08 (P = 0.0	37)						
3 Greater than 75 mg/wee	ek							
Subtotal (95% CI)	0		0					Not estimable
Heterogeneity: not applica	able							
Test for overall effect: not	applicable							
Total (95% CI)	198		112			•	100.0 %	13.15 [-2.28, 28.59]
Heterogeneity: $Tau^2 = 21$	1.68; Chi ² = 4	1.02, df = 3 (P<0.00	001); I ² =93%					
Test for overall effect: Z =	I.67 (P = 0.0	95)						
Test for subgroup difference	ces: $Chi^2 = 2.0$	05, df = 1 (P = 0.15)	$ ^2 = 5 \%$					
					I	_	1	
				-10	0 -50	0 50	100	
				No su	ppl/placebo	Intermitten	t iron suppl	

Analysis 3.20. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months, Outcome 20 Ferritin (by duration of the supplementation).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months

Outcome: 20 Ferritin (by duration of the supplementation)

Study or subgroup	Intermittent iron suppl	No si	uppl/placebo		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI		IV,Random,95% CI
0 to three months							
Yurdakok 2004	19	59.7 (27.7)	16	43.9 (23.7)		21.6 %	5.80 [-1.23, 32.83]
Subtotal (95% CI)	19		16		•	21.6 %	15.80 [-1.23, 32.83]
Heterogeneity: not applica	able						
Test for overall effect: Z =	I.82 (P = 0.06	69)					
2 More than three month	S						
Baqui 2003	111	18.9 (16)	37	4.3 (4.3)	-	28.2 %	4.60 [-0.89, 10.09]
Ermis 2002	30	45 (12.7)	23	17.2 (4.6)	•	28.4 %	27.80 [22.88, 32.72]
Yang 2004 (C)	38	64.14 (33.63)	36	61.68 (39.8)		21.7 %	2.46 [-14.37, 19.29]
Subtotal (95% CI)	179		96		-	7 8.4 %	12.34 [-6.19, 30.87]
Heterogeneity: Tau ² = 24	2.21; Chi ² = 4	1.01, df = 2 (P<0.000	01); I ² =95%				
Test for overall effect: Z =	: 1.31 (P = 0.19	9)					
Total (95% CI)	198		112		•	100.0 %	13.15 [-2.28, 28.59]
Heterogeneity: Tau ² = 21	1.68; $Chi^2 = 4$	1.02, df = 3 (P<0.000	01); I ² =93%				
Test for overall effect: Z =	I.67 (P = 0.09	95)					
Test for subgroup differen	ces: $Chi^2 = 0.0$	07, df = 1 (P = 0.79),	l ² =0.0%				

-100 -50 0

No suppl/placebo Intermittent iron suppl

50 100

Analysis 3.21. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months, Outcome 21 Ferritin (by type of iron compound).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months

Outcome: 21 Ferritin (by type of iron compound)

Study or subgroup	Intermittent iron suppl		No suppl/placebo		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI		IV,Random,95% CI
I Ferrous sulphate							
Baqui 2003	111	18.9 (16)	37	14.3 (14.3)	-	28.2 %	4.60 [-0.89, 10.09]
Ermis 2002	30	45 (12.7)	23	17.2 (4.6)	-	28.4 %	27.80 [22.88, 32.72]
Yurdakok 2004	19	59.7 (27.7)	16	43.9 (23.7)		21.6 %	15.80 [-1.23, 32.83]
Subtotal (95% CI)	160		76		•	78.3 %	16.12 [-1.81, 34.05]
Heterogeneity: Tau ² = 22	24.94; Chi ² = 3	8.13, df = 2 (P•	<0.00001); I ² =95%				
Test for overall effect: Z =	= 1.76 (P = 0.0	78)					
2 Ferrous fumarate							
Subtotal (95% CI)	0		0				Not estimable
Heterogeneity: not applic	able						
Test for overall effect: not	applicable						
3 Other							
Yang 2004 (C)	38	64.14 (33.63)	36	61.68 (39.8)		21.7 %	2.46 [-14.37, 19.29]
Subtotal (95% CI)	38		36		+	21.7 %	2.46 [-14.37, 19.29]
Heterogeneity: not applic	able						
Test for overall effect: Z =	= 0.29 (P = 0.7	7)					
Total (95% CI)	198		112		•	100.0 %	13.15 [-2.28, 28.59]
Heterogeneity: Tau ² = 21	1.68; $Chi^2 = 4$	1.02, df = 3 (P-	<0.00001); 2 =93%				
Test for overall effect: Z =	= 1.67 (P = 0.0	95)					
Test for subgroup differen	nces: Chi ² = 1.1	8, df = 1 (P =	0.28), I ² = I 6%				
						1	
				-10	0 -50 0 50	100	

-100 -50 0 5 No suppl/placebo Inter

Intermittent iron suppl

Analysis 3.22. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months, Outcome 22 Ferritin (by anaemia status at baseline).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months

Outcome: 22 Ferritin (by anaemia status at baseline)

Study or subgroup	Intermittent iron suppl		No suppl/placebo		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% Cl		IV,Random,95% CI
I by anaemia status at bas	eline: anaemic						
Subtotal (95% CI)	0		0				Not estimable
Heterogeneity: not applica	ble						
Test for overall effect: not	applicable						
2 by anaemia status at bas	eline: non-ana	emic					
Yang 2004 (C)	38	64.14 (33.63)	36	61.68 (39.8)		21.7 %	2.46 [-14.37, 19.29]
Subtotal (95% CI)	38		36		+	21.7 %	2.46 [-14.37, 19.29]
Heterogeneity: not applica	ble						
Test for overall effect: Z =	0.29 (P = 0.7	7)					
3 by anaemia status at bas	eline: mixed/ur	nknown					
Baqui 2003	111	8.9 (6)	37	14.3 (14.3)	-	28.2 %	4.60 [-0.89, 10.09]
Ermis 2002	30	45 (12.7)	23	17.2 (4.6)	•	28.4 %	27.80 [22.88, 32.72]
Yurdakok 2004	19	59.7 (27.7)	16	43.9 (23.7)		21.6 %	5.80 [- .23, 32.83]
Subtotal (95% CI)	160		76		•	78.3 %	16.12 [-1.81, 34.05]
Heterogeneity: $Tau^2 = 224$	4.94; Chi ² = 38	8.13, df = 2 (P<	:0.00001); I ² =95%				
Test for overall effect: Z =	1.76 (P = 0.0	78)					
Total (95% CI)	198		112		•	100.0 %	13.15 [-2.28, 28.59]
Heterogeneity: Tau ² = 21	1.68; Chi ² = 4	1.02, df = 3 (P<	:0.00001); I ² =93%				
Test for overall effect: $Z =$	I.67 (P = 0.09	95)					
Test for subgroup differen	ces: Chi ² = 1.1	8, df = 1 (P = 0	$0.28), ^2 = 6\%$				

-100 -50 0 50 100

No suppl/placebo

Intermittent iron suppl

Analysis 3.23. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months, Outcome 23 Ferritin (by supplementation regimen).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months

Outcome: 23 Ferritin (by supplementation regimen)

Study or subgroup	Intermittent iron suppl		No suppl/placebo		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI		IV,Random,95% CI
l One supplement a wee	ek						
Baqui 2003	111	18.9 (16)	37	14.3 (14.3)	-	28.2 %	4.60 [-0.89, 10.09]
Yang 2004 (C)	38	64.14 (33.63)	36	61.68 (39.8)		21.7 %	2.46 [-14.37, 19.29]
Yurdakok 2004	19	59.7 (27.7)	16	43.9 (23.7)		21.6 %	5.80 [-1.23, 32.83]
Subtotal (95% CI)	168		89		•	71.6 %	5.37 [0.39, 10.36]
Heterogeneity: $Tau^2 = 0.0$	0; Chi ² = 1.63	, df = 2 (P = 0.	44); l ² =0.0%				
Test for overall effect: Z =	= 2.11 (P = 0.0	035)					
2 Other intermittent regin	men						
Ermis 2002	30	45 (12.7)	23	17.2 (4.6)	-	28.4 %	27.80 [22.88, 32.72]
Subtotal (95% CI)	30		23		•	28.4 %	27.80 [22.88, 32.72]
Heterogeneity: not applic	able						
Test for overall effect: Z =	= .08 (P < 0	0.00001)					
Total (95% CI)	198		112		•	100.0 %	13.15 [-2.28, 28.59]
Heterogeneity: $Tau^2 = 21$	1.68; $Chi^2 = -$	41.02, df = 3 (P	<0.00001); I ² =93%				
Test for overall effect: Z =	= 1.67 (P = 0.0	095)					
Test for subgroup differen	nces: $Chi^2 = 3$	9.39, df = 1 (P	= 0.00), l ² =97%				

-100 -50

No suppl/placebo

0

50 100

Intermittent iron suppl

Analysis 3.24. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months, Outcome 24 Ferritin (by sex).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months

Outcome: 24 Ferritin (by sex)

	itermittent iron suppl	No s	uppl/placebo		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI	_	IV,Random,95% CI
l Girls							
Subtotal (95% CI)	0		0				Not estimable
Heterogeneity: not applicable	e						
Test for overall effect: not ap	plicable						
2 Boys							
Subtotal (95% CI)	0		0				Not estimable
Heterogeneity: not applicable	e						
Test for overall effect: not ap	plicable						
3 Mixed/unknown							
Yurdakok 2004	19	59.7 (27.7)	16	43.9 (23.7)		21.6 %	5.80 [-1.23, 32.83]
Yang 2004 (C)	38	64.14 (33.63)	36	61.68 (39.8)		21.7 %	2.46 [-14.37, 19.29]
Baqui 2003	111	18.9 (16)	37	14.3 (14.3)	-	28.2 %	4.60 [-0.89, 10.09]
Ermis 2002	30	45 (12.7)	23	17.2 (4.6)	-	28.4 %	27.80 [22.88, 32.72]
Subtotal (95% CI)	198		112		•	100.0 %	13.15 [-2.28, 28.59]
Heterogeneity: $Tau^2 = 211.6$	8; Chi ² = 4	H.02, df = 3 (P<0.000	01); I ² =93%				
Test for overall effect: $Z = 1.6$	67 (P = 0.0)95)					
Total (95% CI)	198		112		•	100.0 %	13.15 [-2.28, 28.59]
Heterogeneity: Tau ² = 211.6	8; Chi ² = 4	HI.02, df = 3 (P<0.000	01); I ² =93%				
Test for overall effect: $Z = 1.0$	67 (P = 0.0	95)					
Test for subgroup differences	s: Not appli	cable					

-100 -50 0 No suppl/placebo

Intermittent iron suppl

Analysis 3.25. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months, Outcome 25 Ferritin (by nutrient).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months

Outcome: 25 Ferritin (by nutrient)

Study or subgroup	Intermittent iron suppl		No suppl/placebo		Mean Difference	Weight	Mean Difference
, , ,	N	Mean(SD)	N	Mean(SD)	IV,Random,95% CI	-	IV,Random,95% CI
l Iron alone							
Baqui 2003	38	17.6 (14.4)	18	4.6 (4.3)	+	21.6 %	3.00 [-5.04, .04]
Ermis 2002	30	45 (12.7)	23	17.2 (4.6)	-	22.8 %	27.80 [22.88, 32.72]
Yurdakok 2004	19	59.7 (27.7)	16	43.9 (23.7)		16.8 %	5.80 [-1.23, 32.83]
Subtotal (95% CI)	87		57		•	61.2 %	15.70 [-2.68, 34.08]
Heterogeneity: $Tau^2 = 23$	4.18; Chi ² = 2	6.95, df = 2 (P	<0.00001); 12 =93%				
Test for overall effect: Z =	= 1.67 (P = 0.0	94)					
2 Iron + folic acid							
Subtotal (95% CI)	0		0				Not estimable
Heterogeneity: not application	able						
Test for overall effect: not	applicable						
3 Iron + multiple micronu	utrients						
Baqui 2003	73	19.6 (16.8)	19	14.6 (14.3)	-	21.9 %	5.00 [-2.50, 12.50]
Yang 2004 (C)	38	64.14 (33.63)	36	61.68 (39.8)		16.9 %	2.46 [-14.37, 19.29]
Subtotal (95% CI)	111		55		•	38.8 %	4.58 [-2.27, 11.43]
Heterogeneity: $Tau^2 = 0.0$); Chi ² = 0.07,	df = 1 (P = 0.7)	79); l ² =0.0%				
Test for overall effect: Z =	= 1.31 (P = 0.1	9)					
Total (95% CI)	198		112		•	100.0 %	11.15 [-1.92, 24.22]
Heterogeneity: $Tau^2 = 18$	88.86; $Chi^2 = 4$	2.84, df = 4 (P	<0.00001); 2 =91%				
Test for overall effect: Z =	= 1.67 (P = 0.0	95)					
Test for subgroup differen	nces: $Chi^2 = 1.2$	24, df = 1 (P =	0.27), ² = 9%				
0		,				i	
				-100	-50 0 50	100	

No suppl/placebo


Intermittent iron suppl

Analysis 3.26. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months, Outcome 26 All cause morbidity (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months

Outcome: 26 All cause morbidity (ALL)



Analysis 3.27. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months, Outcome 27 Any side effects (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months

Outcome: 27 Any side effects (ALL)

Study or subgroup	Intermittent iron suppl	No suppl/placebo		Risk Ratio M-	Weight	Risk Ratio M-
	n/N	n/N	F	I,Random,95% Cl		H,Random,95% Cl
Ermis 2002	2/30	0/23	-			3.87 [0.19, 76.92]
Total (95% CI)	30	23	-		100.0 %	3.87 [0.19, 76.92]
Total events: 2 (Intermitte	ent iron suppl), 0 (No	suppl/placebo)				
Heterogeneity: not applie	cable					
Test for overall effect: Z	= 0.89 (P = 0.37)					
Test for subgroup differen	nces: Not applicable					
					I	
			0.01 0.1	1 10	100	
		Ir	ntermittent iron supp	No sup	plementation	

Analysis 3.28. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months, Outcome 28 Adherence (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months

Outcome: 28 Adherence (ALL)

Study or subgroup	Intermittent iron suppl	No suppl/placebo	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M- H,Random,95% Cl		M- H,Random,95% Cl
Baqui 2003	43/49	40/45		13.7 %	0.99 [0.85, 1.14]
Ekvall 2000	96/98	91/97		86.3 %	1.04 [0.98, 1.11]
Total (95% CI)	147	142	•	100.0 %	1.04 [0.98, 1.09]
Total events: 139 (Interm Heterogeneity: Tau ² = 0. Test for overall effect: Z : Test for subgroup differen	0; $Chi^2 = 0.60$, $df = 1$ = 1.28 (P = 0.20)				
		Intermi	0.5 0.7 I I.5 ttent iron suppl No supp	2 Ilementation	

Analysis 3.29. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months, Outcome 29 Mental development scale (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months

Outcome: 29 Mental development scale (ALL)

Study or subgroup	Intermittent iron suppl N	Mean(SD)	No suppl/placebo N	Mean(SD)		Mean ference dom,95% Cl	Weight	Mean Difference IV,Random,95% Cl
Baqui 2003	127	104.7 (11.2)	45	102.7 (13.5)		+	100.0 %	2.00 [-2.40, 6.40]
Total (95% CI) Heterogeneity: not ap Test for overall effect: Test for subgroup diffe	Z = 0.89 (P =	/	45			•	100.0 %	2.00 [-2.40, 6.40]
					-100 -50 ttent iron suppl	0 50 10 No supplem	00 entation	

Analysis 3.30. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months, Outcome 30 Orientation engagement (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months

Outcome: 30 Orientation engagement (ALL)


Study or subgroup	Intermittent iron suppl N	Mean(SD)	No suppl/placebo N	Mean(SD)		Mean erence om,95% Cl	Weight	Mean Difference IV,Random,95% Cl
Baqui 2003	127	75.4 (26.8)	45	67 (31)			100.0 %	8.40 [-1.79, 18.59]
Total (95% CI)	127		45			•	100.0 %	8.40 [-1.79, 18.59]
Heterogeneity: not applicable								
Test for overall effect: $Z = 1.62 (P = 0.11)$								
Test for subgroup diffe	erences: Not ap	plicable						
					-100 -50	0 50 I	100	
				Intermi	tent iron suppl	No supplen	nentation	

Analysis 3.31. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months, Outcome 31 Emotional regulation (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months

Outcome: 31 Emotional regulation (ALL)



Analysis 3.32. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months, Outcome 32 Motor quality (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months

Outcome: 32 Motor quality (ALL)


Study or subgroup	Intermittent iron suppl N	Mean(SD)	No suppl/placebo N	Mean(SD)		Mean ference dom,95% Cl	Weight	Mean Difference IV,Random,95% Cl
Baqui 2003	127	37.7 (30.5)	45	22.1 (20.2)			100.0 %	5.60 [7.66, 23.54]
Total (95% CI)	127		45			•	100.0 %	15.60 [7.66, 23.54]
Heterogeneity: not ap	oplicable							
Test for overall effect:	Z = 3.85 (P =	0.00012)						
Test for subgroup diffe	erences: Not ap	oplicable						
					<u> </u>		L	
					-100 -50	0 50 I	00	
				Intermit	tent iron suppl	No supplem	nentation	

Analysis 3.33. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months, Outcome 33 Psychomotor development index (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months

Outcome: 33 Psychomotor development index (ALL)



Analysis 3.34. Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months, Outcome 34 HAZ.

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 3 Intermittent iron supplementation versus placebo or no intervention: children 0 - 59 months

Outcome: 34 HAZ

Study or subgroup	Intermittent iron suppl N	Mean(SD)	No suppl/placebo N	Mean(SD)		Mean erence om,95% Cl	Weight	Mean Difference IV,Random,95% Cl
Palupi 1997	96	0.07 (0.27)	98	0.03 (0.26)			93.9 %	0.04 [-0.03, 0.11]
Thu 1999	54	-1.81 (0.84)	54	-1.82 (0.7)		•	6.1 %	0.01 [-0.28, 0.30]
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: Test for subgroup diff	Z = 1.03 (P =	0.30)	152 5); I ² =0.0%				100.0 %	0.04 [-0.03, 0.11]
					-100 -50 upplementation	0 50 Intermitte	100 ent iron suppl	

Analysis 4.1. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months, Outcome I Anaemia (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months

Outcome: I Anaemia (ALL)

Study or subgroup	Intermittent iron suppl	Daily iron suppl			Risk Ratio M-		Weight	Risk Ratio M-
_	n/N	n/N		H,Rar	ndom,95% Cl			H,Random,95% Cl
Thu 1999	4/54	3/53					1.6 %	1.31 [0.31, 5.57]
Awasthi 2005 (C)	46/185	29/181			-		19.1 %	1.55 [1.02, 2.36]
Engstrom 2008 (C)	89/147	76/150		I	+		79.3 %	1.19 [0.97, 1.47]
Total (95% CI)	386	384			•		100.0 %	1.26 [1.05, 1.51]
Total events: 139 (Intermit	tent iron suppl), 108 (I	Daily iron suppl)						
Heterogeneity: $Tau^2 = 0.0$; Chi ² = 1.32, df = 2 (l	P = 0.52); I ² =0.0%						
Test for overall effect: Z =	2.47 (P = 0.014)							
Test for subgroup differen	ces: Not applicable							
					<u> </u>			
			0.01	0.1	1 10	100		
		I	ntermittent in	on suppl	Daily iror	n suppl		

Analysis 4.2. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months, Outcome 2 Haemoglobin (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months

Outcome: 2 Haemoglobin (ALL)

Study or subgroup	Intermittent iron suppl		Daily iron suppl		Mean Difference	Weight	Mean Difference
,	N	Mean(SD)	N	Mean(SD)	IV,Random,95% CI	Ū.	IV,Random,95% CI
Awasthi 2005 (C)	185	108.5 (12.9)	8	0.9 (.9)		8.3 %	-2.40 [-4.94, 0.14]
Desai 2004 (C)	266	97.2 (13.7)	261	101.4 (13.8)		8.9 %	-4.20 [-6.55, -1.85]
Engstrom 2008 (C)	147	106.16 (13.203)	150	108.72 (14.832)		6.4 %	-2.56 [-5.75, 0.63]
Ermis 2002	30	116 (2.9)	60	116.5 (3)		13.0 %	-0.50 [-1.79, 0.79]
Faqih 2006	42	121.9 (5.5)	21	120.1 (5.04)		7.7 %	1.80 [-0.92, 4.52]
Khademloo 2009	50	23 (0.)	50	123 (8)		5.6 %	0.0 [-3.57, 3.57]
Liu 1995 (C)	55	133.4 (7)	30	34.3 (7.3)		6.4 %	-0.90 [-4.10, 2.30]
Nguyen 2002	65	120.5 (7.2)	67	123.6 (7.8)		8.2 %	-3.10 [-5.66, -0.54]
Schultink 1995	32	117 (8)	33	4 (0)		4.2 %	3.00 [-1.40, 7.40]
Tavil 2003	48	123 (4)	46	124 (4)		11.7 %	-1.00 [-2.62, 0.62]
Thu 1999	54	123.5 (10.3)	53	124.3 (9.3)		5.3 %	-0.80 [-4.52, 2.92]
Yang 2004 (C)	38	134.16 (12.79)	38	132.2 (9.21)		3.4 %	1.96 [-3.05, 6.97]
Young 2001	146	104.5 (15.3)	85	103.2 (15.3)	<u> </u>	4.6 %	1.30 [-2.79, 5.39]
Yurdakok 2004	19	116 (5)	18	114 (5)		6.4 %	2.00 [-1.22, 5.22]
Total (95% CI)	1177		1093		•	100.0 %	-0.75 [-1.80, 0.29]
Heterogeneity: Tau 2 =	1.73; Chi ² = 2	5.70, df = 13 (P =	0.02); I ² =49%				
Test for overall effect: Z	Z = 1.42 (P =	0.16)					

Test for subgroup differences: Not applicable

-5 0

-10

Daily iron suppl

5 Intermittent iron suppl

10

Analysis 4.3. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months, Outcome 3 Haemoglobin (by dose of elemental iron in the intermittent group).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months

Outcome: 3 Haemoglobin (by dose of elemental iron in the intermittent group)

Study or subgroup	Intermittent iron suppl		Daily iron suppl		Mean Difference	Weight	Mea Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI		IV,Random,95% (
1 25 mg or less/week			150	100 70 (14 000)		() 0(
Engstrom 2008 (C)	147	106.16 (13.203)	150	108.72 (14.832)		6.1 %	-2.56 [-5.75, 0.63
Nguyen 2002	65	120.5 (7.2)	67	123.6 (7.8)	• •	7.9 %	-3.10 [-5.66, -0.54
Thu 1999	54	123.5 (10.3)	53	124.3 (9.3)	• •	5.0 %	-0.80 [-4.52, 2.92
Subtotal (95% CI)	266		270		-	19.0 %	-2.42 [-4.18, -0.66
Heterogeneity: $Tau^2 = 0.0$;)); I ² =0.0%				
Test for overall effect: $Z =$	`	0070)					
2 Greater than 25 mg to 7	0					70.04	
Awasthi 2005 (C)	185	108.5 (12.9)	181	0.9 (.9)	•	7.9 %	-2.40 [-4.94, 0.14
Desai 2004 (C)	266	97.2 (13.7)	261	101.4 (13.8)	•	8.6 %	-4.20 [-6.55, -1.85
Ermis 2002	30	116 (2.9)	60	116.5 (3)		12.9 %	-0.50 [-1.79, 0.79
Faqih 2006	42	121.9 (5.5)	21	120.1 (5.04)		→ 7.4 %	I.80 [-0.92, 4.52
Liu 1995 (C)	55	133.4 (7)	30	34.3 (7.3)	• •	6.1 %	-0.90 [-4.10, 2.30
Schultink 1995	32	117 (8)	33	4 (0)		→ 3.9 %	3.00 [-1.40, 7.40
Sungthong 2002	130	126.9 (9.2)	138	127.8 (9.2)		9.1 %	-0.90 [-3.10, 1.30
Tavil 2003	48	123 (4)	46	124 (4)		11.4 %	-1.00 [-2.62, 0.62
Yang 2004 (C)	38	34. 6 (2.79)	38	132.2 (9.21)		→ 3.2 %	1.96 [-3.05, 6.97
Young 2001	146	104.5 (15.3)	85	103.2 (15.3)		→ 4.4 %	1.30 [-2.79, 5.39
Yurdakok 2004	19	116 (5)	18	114 (5)		→ 6.1 %	2.00 [-1.22, 5.22
Subtotal (95% CI)	991		911		-	81.0 %	-0.45 [-1.59, 0.68
Heterogeneity: $Tau^2 = 1.7$	3; Chi ² = 21.	17, df = 10 (P =	0.02); I ² =53%				
Test for overall effect: $Z =$	`	14)					
3 Greater than 75 mg/wee			0				NT 11
Subtotal (95% CI) Heterogeneity: not applica	0		0				Not estimabl
Test for overall effect: not a							
Total (95% CI)	1257		1181		-	100.0 %	-0.82 [-1.82, 0.18
Heterogeneity: $Tau^2 = 1.5$	9; Chi ² = 25.•	46, df = 13 (P =	0.02); I ² =49%				•
Test for overall effect: Z =	1.60 (P = 0.1	1)					
Test for subgroup difference	tes: Chi ² = 3.	40, df = 1 (P = 0	$0.07), ^2 = 7 \%$				
					<u> </u>	1	

Analysis 4.4. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months, Outcome 4 Haemoglobin (by duration of supplementation).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months

Outcome: 4 Haemoglobin (by duration of supplementation)

Study or subgroup	Intermittent iron suppl		Daily iron suppl		Me Differen		Mear Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,	95% CI	IV,Random,95% C
I 0 to three months							
Desai 2004 (C)	266	97.2 (13.7)	261	101.4 (13.8)		8.9 %	-4.20 [-6.55, -1.85
Faqih 2006	42	121.9 (5.5)	21	120.1 (5.04)		−• 7.7 %	1.80 [-0.92, 4.52]
Khademloo 2009	50	23 (0.)	50	123 (8)		5.6 %	0.0 [-3.57, 3.57
Liu 1995 (C)	55	133.4 (7)	30	34.3 (7.3)	• •	6.4 %	-0.90 [-4.10, 2.30
Schultink 1995	32	117 (8)	33	4 (0)		4.2 %	3.00 [-1.40, 7.40
Tavil 2003	48	123 (4)	46	124 (4)		11.7 %	-1.00 [-2.62, 0.62
Thu 1999	54	123.5 (10.3)	53	124.3 (9.3)	• 	5.3 %	-0.80 [-4.52, 2.92]
Young 2001	146	104.5 (15.3)	85	103.2 (15.3)		4.6 %	1.30 [-2.79, 5.39
Yurdakok 2004	19	116 (5)	18	114 (5)		−−− 6.4 %	2.00 [-1.22, 5.22
Subtotal (95% CI)	712		59 7			- 60.7 %	-0.15 [-1.66, 1.36
Heterogeneity: $Tau^2 = 2$.29, df = 8 (P = 0	1.02); I ² =56%				
Test for overall effect: Z	= 0.20 (P = 0.	84)					
2 More than three mont	hs						
Awasthi 2005 (C)	185	108.5 (12.9)	181	0.9 (.9)	← ∎	8.3 %	-2.40 [-4.94, 0.14
Engstrom 2008 (C)	147	106.16 (13.203)	150	108.72 (14.832)	• • • · · · · · · · · · · · · · · · · ·	6.4 %	-2.56 [-5.75, 0.63
Ermis 2002	30	116 (2.9)	60	116.5 (3)		13.0 %	-0.50 [-1.79, 0.79
Nguyen 2002	65	120.5 (7.2)	67	123.6 (7.8)	←∎	8.2 %	-3.10 [-5.66, -0.54
Yang 2004 (C)	38	34. 6 (2.79)	38	32.2 (9.21)		3.4 %	1.96 [-3.05, 6.97
Subtotal (95% CI)	465		496		-	39.3 %	-1.53 [-2.95, -0.11
Heterogeneity: $Tau^2 = 0$	-	82, df = 4 (P = 0.	$ 8\rangle; ^2 = 37\%$				
Test for overall effect: Z	= 2.11 (P = 0.	035)	,				
Total (95% CI)	1177		1093		-	100.0 %	-0.75 [-1.80, 0.29
Heterogeneity: $Tau^2 = I$.73; Chi ² = 25	.70, df = 13 (P =	0.02); I ² =49%				
Test for overall effect: Z	= 1.42 (P = 0.	16)					
Test for subgroup differe	nces: $Chi^2 = I$.68, df = 1 (P = 0). 9), ² =4 %				
						I I	
					4 -2 0	2 4	
				Da	aily iron suppl	Intermittent iron suppl	

Analysis 4.5. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months, Outcome 5 Haemoglobin (by type of compound).


Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months

Outcome: 5 Haemoglobin (by type of compound)

Study or subgroup	Intermittent iron suppl		Daily iron suppl		Mean Difference	Weight	Mean Difference
	N	Mean(SD)	N	Mean(SD)	IV,Random,95%	CI	IV,Random,95% Cl
I Ferrous sulphate							
Awasthi 2005 (C)	185	108.5 (12.9)	181	0.9 (.9)	·	8.3 %	-2.40 [-4.94, 0.14]
Desai 2004 (C)	266	97.2 (13.7)	261	101.4 (13.8)	←	8.9 %	-4.20 [-6.55, -1.85]
Engstrom 2008 (C)	147	106.16 (13.203)	150	108.72 (14.832)	• • • •	6.4 %	-2.56 [-5.75, 0.63]
Ermis 2002	30	116 (2.9)	60	116.5 (3)		13.0 %	-0.50 [-1.79, 0.79]
Faqih 2006	42	121.9 (5.5)	21	120.1 (5.04)		7.7 %	1.80 [-0.92, 4.52]
Khademloo 2009	50	123 (10.1)	50	123 (8)		5.6 %	0.0 [-3.57, 3.57]
Liu 1995 (C)	55	133.4 (7)	30	34.3 (7.3)		6.4 %	-0.90 [-4.10, 2.30]
Nguyen 2002	65	120.5 (7.2)	67	123.6 (7.8)		8.2 %	-3.10 [-5.66, -0.54]
Schultink 1995	32	117 (8)	33	4 (0)		→→ 4.2 %	3.00 [-1.40, 7.40]
Tavil 2003	48	123 (4)	46	124 (4)		11.7 %	-1.00 [-2.62, 0.62]
Thu 1999	54	123.5 (10.3)	53	124.3 (9.3)	<u>ــــــ</u>	- 5.3 %	-0.80 [-4.52, 2.92]
Young 2001	146	104.5 (15.3)	85	103.2 (15.3)		4.6 %	1.30 [-2.79, 5.39]
Yurdakok 2004	19	116 (5)	18	114 (5)		6.4 %	2.00 [-1.22, 5.22]
Subtotal (95% CI)	1139		1055		-	96.6 %	-0.85 [-1.91, 0.21]
Heterogeneity: $Tau^2 = 1.7^2$	ł; Chi ² = 24.	.45, df = 12 (P =	0.02); I ² =51%				[]
Test for overall effect: $Z =$	I.57 (P = 0.	12)					
2 Ferrous fumarate							
Subtotal (95% CI)	0		0				Not estimable
Heterogeneity: not applical							
Test for overall effect: not a	applicable						
3 Other			2.0				
Yang 2004 (C)	38	34. 6 (2.79)	38	132.2 (9.21)		→ 3.4 %	1.96 [-3.05, 6.97]
					-4 -2 0 2		
						4	
				D	aily iron suppl Intern	nittent iron suppl	(Continued

Intermittent iron supplementation for improving nutrition and development in children under 12 years of age (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. 213



Analysis 4.6. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months, Outcome 6 Haemoglobin (by anaemia status at baseline).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months

Outcome: 6 Haemoglobin (by anaemia status at baseline)

Study or subgroup	Intermittent iron suppl N	Mean(SD)	Daily iron suppl N	Mean(SD)	Diffe	Mean rence om,95% Cl	Weight	Mean Difference IV,Random,95% Cl
Desai 2004 (C)	266	97.2 (13.7)	261	101.4 (13.8)	•		8.9 %	-4.20 [-6.55, -1.85]
Faqih 2006	42	121.9 (5.5)	21	120.1 (5.04)			7.7 %	1.80 [-0.92, 4.52]
Liu 1995 (C)	55	133.4 (7)	30	134.3 (7.3)	• 		6.4 %	-0.90 [-4.10, 2.30]
Schultink 1995	32	117 (8)	33	4 (0)			4.2 %	3.00 [-1.40, 7.40]
Tavil 2003	48	123 (4)	46	124 (4)			11.7 %	-1.00 [-2.62, 0.62]
Subtotal (95% CI) Heterogeneity: Tau ² = 4		38, df = 4 (P = 0.0	391 I); I ² =72%				38.8 %	-0.57 [-2.81, 1.68]
Test for overall effect: Z	= 0.49 (P = 0.6	52)						
2 Non-anaemic Yang 2004 (C)	38	34. 6 (2.79)	38	132.2 (9.21)			3.4 %	1.96 [-3.05, 6.97]
					-4 -2 0 aily iron suppl) 2 Intermittent	4 iron suppl	(Continued)

(... Continued)

							(Continued)
Study or subgroup	Intermittent iron suppl	D	aily iron suppl		Mean Difference	Weight	Mean Difference
	N	Mean(SD)	N	Mean(SD)	IV,Random,95% CI	**Cigint	IV,Random,95% CI
Yurdakok 2004	19	116 (5)	18	114 (5)		→ 6.4 %	2.00 [-1.22, 5.22]
Subtotal (95% CI)	57		56			- 9.8 %	1.99 [-0.72, 4.70]
Heterogeneity: $Tau^2 = 0.0$	0; $Chi^2 = 0.00$,	df = 1 (P = 0.99); l ⁴	2 =0.0%				
Test for overall effect: Z =	= 1.44 (P = 0.15	5)					
3 Mixed/unknown Awasthi 2005 (C)	185	108.5 (12.9)	181	0.9 (.9)		8.3 %	-2.40 [-4.94, 0.14]
Engstrom 2008 (C)		06.16 (13.203)		108.72 (14.832)	← B	6.4 %	
• • • • •				. ,			
Ermis 2002	30	116 (2.9)	60	116.5 (3)		13.0 %	
Khademloo 2009	50	123 (10.1)	50	123 (8)		5.6 %	
Nguyen 2002	65	120.5 (7.2)	67	123.6 (7.8)	• • • • • • • • • • • • • • • • • • •	8.2 %	-3.10 [-5.66, -0.54]
Thu 1999	54	123.5 (10.3)	53	24.3 (9.3)	• • •	5.3 %	-0.80 [-4.52, 2.92]
Young 2001	146	104.5 (15.3)	85	103.2 (15.3)		→ 4.6 %	1.30 [-2.79, 5.39]
Subtotal (95% CI)	677		646		•	51.4 %	-1.20 [-2.22, -0.19]
Heterogeneity: $Tau^2 = 0.2$, ,	$ ^2 = 0\% $				
Test for overall effect: Z = Total (95% CI)	= 2.32 (P = 0.0) 1177	20)	1093			100.0.0/	-0.75 [-1.80, 0.29]
Heterogeneity: $Tau^2 = 1$. Test for overall effect: Z =			2); I ² =49%				
Test for subgroup differer	nces: $Chi^2 = 4.7$	1, df = 2 (P = 0.09), I ² =58%				
						1	
					-4 -2 0 2	4	
				D	aily iron suppl Intermitten	it iron suppl	

Analysis 4.7. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months, Outcome 7 Haemoglobin (by supplementation regimen).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months

Outcome: 7 Haemoglobin (by supplementation regimen)

Study or subgroup	Intermittent iron suppl		Daily iron suppl		Me Differer	nce	Weight	Mean Difference
	N	Mean(SD)	N	Mean(SD)	IV,Random,	95% CI		IV,Random,95% CI
I One supplement a wee								
Engstrom 2008 (C)	147	106.16 (13.203)	150	108.72 (14.832)	· •		6.1 %	-2.56 [-5.75, 0.63]
Faqih 2006	21	122.2 (5.49)	10	120.1 (5.04)			4.6 %	2.10 [-1.81, 6.01]
Khademloo 2009	50	23 (0.)	50	123 (8)	+		5.3 %	0.0 [-3.57, 3.57]
Liu 1995 (C)	28	134.4 (7)	15	134.3 (7.3)	•	,	3.7 %	0.10[-4.41, 4.61]
Nguyen 2002	65	120.5 (7.2)	67	123.6 (7.8)	←∎		7.9 %	-3.10 [-5.66, -0.54]
Thu 1999	54	23.5 (0.3)	53	124.3 (9.3)	د		5.0 %	-0.80 [-4.52, 2.92]
Yang 2004 (C)	38	34. 6 (2.79)	38	32.2 (9.2)			3.2 %	1.96 [-3.05, 6.97]
Young 2001	146	104.5 (15.3)	85	103.2 (15.3)		••••	4.3 %	1.30 [-2.79, 5.39]
Yurdakok 2004	19	116 (5)	18	114 (5)		_ ,	6.0 %	2.00 [-1.22, 5.22]
Subtotal (95% CI)	568		486			-	46.2 %	-0.23 [-1.67, 1.21]
Heterogeneity: $Tau^2 = 1.4$	42; Chi ² = 11.	39, df = 8 (P = 0	. 8); ² =30%					
Test for overall effect: Z =	(76)						
2 Other intermittent regi								
Awasthi 2005 (C)	185	108.5 (12.9)	181	0.9 (.9)			8.0 %	-2.40 [-4.94, 0.14]
Desai 2004 (C)	266	97.2 (13.7)	261	101.4 (13.8)	·		8.6 %	-4.20 [-6.55, -1.85]
Ermis 2002	30	116 (2.9)	60	116.5 (3)			3. %	-0.50 [-1.79, 0.79]
Faqih 2006	21	121.6 (5.49)	11	120.1 (5.04)		•	4.8 %	1.50 [-2.29, 5.29]
Liu 1995 (C)	27	32.3 (7)	15	134.3 (7.3)	• • • • • • • • • • • • • • • • • • • •		3.7 %	-2.00 [-6.54, 2.54]
Schultink 1995	32	117 (8)	33	114 (10)		· •	3.9 %	3.00 [-1.40, 7.40]
Tavil 2003	48	123 (4)	46	124 (4)			11.6 %	-1.00 [-2.62, 0.62]
Subtotal (95% CI)	609		607		-		53.8 %	-1.14 [-2.57, 0.29]
Heterogeneity: $Tau^2 = 1.8$	85; Chi ² = 13.	85, df = 6 (P = 0	.03); I ² =57%					
Test for overall effect: Z =	(12)						
Total (95% CI)	1177		1093				100.0 %	-0.72 [-1.71, 0.27]
Heterogeneity: $Tau^2 = 1.5$			0.04); l ² =43%					
Test for overall effect: Z =	`	,	20) 12 0.004					
Test for subgroup differer	$1 \text{ ces: } Chi^2 = 0$./8, df = 1 (P = 0)	.38), I ² =0.0%					
					-4 -2 0	2 4	1	
				D	aily iron suppl	Intermittent i	iron suppl	

Analysis 4.8. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months, Outcome 8 Haemoglobin (by sex).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months

Outcome: 8 Haemoglobin (by sex)


Study or subgroup	Intermittent iron suppl		Daily iron suppl			Mean rence	Weight	Mean Difference
	N	Mean(SD)	, N	Mean(SD)	IV,Rando	m,95% Cl	0	IV,Random,95% CI
l Girls Subtotal (95% CI) Heterogeneity: not applic	0 able		0					Not estimable
Test for overall effect: not 2 Boys Subtotal (95% CI) Heterogeneity: not applic	0		0					Not estimable
Test for overall effect: not 3 Mixed/unknown								
Awasthi 2005 (C)	185	108.5 (12.9)	181	0.9 (.9)			8.3 %	-2.40 [-4.94, 0.14]
Desai 2004 (C)	266	97.2 (13.7)	261	101.4 (13.8)	•		8.9 %	-4.20 [-6.55, -1.85]
Engstrom 2008 (C)	147	106.16 (13.203)	150	108.72 (14.832)	• • •	_	6.4 %	-2.56 [-5.75, 0.63]
Ermis 2002	30	116 (2.9)	60	116.5 (3)		_	13.0 %	-0.50 [-1.79, 0.79]
Faqih 2006	42	121.9 (5.5)	21	20. (5.04)			7.7 %	1.80 [-0.92, 4.52]
Khademloo 2009	50	123 (10.1)	50	123 (8)			5.6 %	0.0 [-3.57, 3.57]
Liu 1995 (C)	55	133.4 (7)	30	134.3 (7.3)	• — •		6.4 %	-0.90 [-4.10, 2.30]
Nguyen 2002	65	120.5 (7.2)	67	123.6 (7.8)	- -		8.2 %	-3.10 [-5.66, -0.54]
Schultink 1995	32	117 (8)	33	4 (0)			4.2 %	3.00 [-1.40, 7.40]
Tavil 2003	48	123 (4)	46	124 (4)		_	11.7 %	-1.00 [-2.62, 0.62]
Thu 1999	54	123.5 (10.3)	53	124.3 (9.3)	• •		5.3 %	-0.80 [-4.52, 2.92]
Yang 2004 (C)	38	34. 6 (2.79)	38	32.2 (9.21)		,	3.4 %	1.96 [-3.05, 6.97]
Young 2001	146	104.5 (15.3)	85	103.2 (15.3)			4.6 %	1.30 [-2.79, 5.39]
Yurdakok 2004	19	116 (5)	18	114 (5)			6.4 %	2.00 [-1.22, 5.22]
Subtotal (95% CI)	1177		1093				100.0 %	-0.75 [-1.80, 0.29]
					-4 -2 0 Daily iron suppl	2 4 Intermittent		(Continued)

(Continued ...)

Intermittent iron supplementation for improving nutrition and development in children under 12 years of age (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

217

(... Continued)



Analysis 4.9. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months, Outcome 9 Haemoglobin (by nutrient).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months

Outcome: 9 Haemoglobin (by nutrient)

Study or subgroup	Intermittent iron suppl N	Mean(SD)	Daily iron suppl N	Mean(SD)	Mean Difference IV,Random,95% CI	Weight	Mean Difference IV,Random,95% CI
l Iron alone							
Desai 2004 (C)	266	97.2 (13.7)	261	101.4 (13.8)	←	8.9 %	-4.20 [-6.55, -1.85]
Engstrom 2008 (C)	147	106.16 (13.203)	150	108.72 (14.832)	• • • • • • • • • • • • • • • • • • •	6.4 %	-2.56 [-5.75, 0.63]
Ermis 2002	30	116 (2.9)	60	116.5 (3)		13.0 %	-0.50 [-1.79, 0.79]
Faqih 2006	42	121.9 (5.5)	21	120.1 (5.04)		→ 7.7 %	I.80 [-0.92, 4.52]
Khademloo 2009	50	123 (10.1)	50	123 (8)		- 5.6 %	0.0 [-3.57, 3.57]
Liu 1995 (C)	55	133.4 (7)	30	134.3 (7.3)		6.4 %	-0.90 [-4.10, 2.30]
Nguyen 2002	65	120.5 (7.2)	67	123.6 (7.8)	- -	8.2 %	-3.10 [-5.66, -0.54]
Schultink 1995	32	117 (8)	33	4 (0)		4.2 %	3.00 [-1.40, 7.40]
Tavil 2003	48	123 (4)	46	124 (4)		11.7 %	-1.00 [-2.62, 0.62]
					4 2 0 2	4	

Daily iron suppl Intermittent iron suppl

(Continued ...)

(... Continued)

Study or subgroup Immunitient irrn suppl Mundako 2004 N Mean(SD) N Mean(SD) Mean(SD) <th< th=""><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th>(Continuec</th></th<>								(Continuec
N Mean(SD) N Mean(SD) V.Random,95% CI IV.Random,95% CI Yurdakok 2004 19 116 (5) 18 114 (5) 64.4% 200 [-1.22, 522] Subtotal (95% CI) 754 736 Heterogeneity: Tau ² = 2.19; Ch ² = 22.00, df = 9 (P = 0.01); l ² = 59% 78.4 % -0.80 [-2.05, 0.46] Test for overall effect: Z = 1.25 (P = 0.21) 110.9 (11.9) 8.3 % -2.40 [-4.94, 0.14] Subtotal (95% CI) 185 181 8.3 % -2.40 [-4.94, 0.14] Heterogeneity: not applicable 110.9 (11.9) 8.3 % -2.40 [-4.94, 0.14] Thu 1999 54 1235 (10.3) 53 124.3 (9.3) Yang 2004 (C) 38 134.16 (12.79) 38 132.2 (9.21) Yang 2004 (C) 38 134.16 (12.79) 38 132.2 (9.21) Yang 2004 (C) 38 134.16 (12.79) 38 132.2 (9.21) Yang 2004 (C) 38 134.16 (12.79) 38 132.2 (9.21) Yang 2004 (C) 38 134.16 (12.79) 38 133.2 (9.3) Young 2001 146 104.5 (15.3) 85 103.2 (15.3) 13.3 % 0.57 [-1.84, 2.98] <	Study or subgroup			Daily iron suppl		Mean	Weight	Mean
Subtotal (95% CI) 754 Heterogeneity: Tau ² = 2.19; Chi ² = 22.00, df = 9 (P = 0.01); l ² = 59% Test for overall effect: Z = 1.25 (P = 0.21) 2 Iron + folic acid Awasthi 2005 (C) 185 108.5 (12.9) 181 110.9 (11.9) 2 Iron + folic acid Awasthi 2005 (C) 185 108.5 (12.9) 181 110.9 (11.9) 3 Iron + multiple micronutrients Thu 1999 54 123.5 (10.3) 53 124.3 (9.3) Yang 2004 (C) 38 134.16 (12.79) 38 132.2 (9.21) Yang 2001 146 104.5 (15.3) 85 103.2 (15.3) Subtotal (95% CI) 238 176 Heterogeneity: Tau ² = 0.0; Chi ² = 0.94, df = 2 (P = 0.63); l ² = 0.0% Test for overall effect: Z = 1.42 (P = 0.16) Test for soverall effect: Z = 1.42 (P = 0.16) Test for subgroup differences: Chi ² = 2.76, df = 2 (P = 0.25), l ² = 28% -4 -2 0 2 4	study of subgroup				Mean(SD)		-	
Heterogeneity: $Tau^2 = 2.19$; $Chi^2 = 22.00$, $df = 9 (P = 0.01$); $l^2 = 59\%$ Test for overall effect: $Z = 1.25 (P = 0.21)$ 2 Iron + folic acid Awasthi 2005 (C) 185 108.5 (12.9) 181 110.9 (11.9) Subtotal (95% CI) 185 181 Heterogeneity: not applicable Test for overall effect: $Z = 1.85 (P = 0.064)$ 3 Iron + multiple micronutrients Thu 1999 54 123.5 (10.3) 53 124.3 (9.3) Yang 2004 (C) 38 134.16 (12.79) 38 132.2 (9.21) Young 2001 146 104.5 (15.3) 85 103.2 (15.3) Subtotal (95% CI) 238 176 Heterogeneity: Tau ² = 0.0; Chi ² = 0.94, df = 2 (P = 0.63); $l^2 = 0.0\%$ Test for overall effect: $Z = 1.42 (P = 0.64)$ Total (95% CI) 1177 1093 Heterogeneity: Tau ² = 1.73; Chi ² = 25.70, df = 13 (P = 0.02); $l^2 = 49\%$ Test for overall effect: $Z = 1.42 (P = 0.16)$ Test for subgroup differences: Chi ² = 2.76, df = 2 (P = 0.25), $l^2 = 28\%$ -4 -2 Q Z 4	Yurdakok 2004	19	116 (5)	18	114 (5)		→ 6.4 %	2.00 [-1.22, 5.22]
Heterogeneity: Tau ² = 2.19; Chi ² = 22.00, df = 9 (P = 0.01); l ² = 59% Test for overall effect: Z = 1.25 (P = 0.21) 2 Iron + folic acid Awasthi 2005 (C) 185 108.5 (12.9) 181 110.9 (11.9) Subtotal (95% CI) 185 181 Heterogeneity: not applicable Test for overall effect: Z = 1.85 (P = 0.064) 3 Iron + multiple micronutrients Thu 1999 54 123.5 (10.3) 53 124.3 (9.3) Yang 2004 (C) 38 134.16 (12.79) 38 132.2 (9.21) Young 2001 146 104.5 (15.3) 85 103.2 (15.3) Subtotal (95% CI) 238 176 Heterogeneity: Tau ² = 0.0; Chi ² = 0.94, df = 2 (P = 0.63); l ² = 0.0% Test for overall effect: Z = 1.42 (P = 0.64) Total (95% CI) 1177 1093 Heterogeneity: Tau ² = 1.73; Chi ² = 25.70, df = 13 (P = 0.02); l ² = 49% Test for overall effect: Z = 1.42 (P = 0.16) Test for subgroup differences: Chi ² = 2.76, df = 2 (P = 0.25), l ² = 28% $-4 -2 \qquad Q \qquad Z \qquad 4$	Subtotal (95% CI)	754		736		-	78.4 %	-0.80 [-2.05, 0.46]
$\begin{array}{c c c c c c c c c c c c c c c c c c c $			00, df = 9 (P = 0.0					
Awasthi 2005 (C) 185 108.5 (12.9) 181 110.9 (11.9) 8.3 % -2.40 [-4.94, 0.14] Subtotal (95% CI) 185 181 8.3 % -2.40 [-4.94, 0.14] Heterogeneity: not applicable 185 181 8.3 % -2.40 [-4.94, 0.14] Subtotal (95% CI) 185 181 8.3 % -2.40 [-4.94, 0.14] Yang 2004 (C) 38 124.3 (9.3) 5.3 % -0.80 [-4.52, 2.92] Yang 2004 (C) 38 134.16 (12.79) 38 132.2 (9.21) 3.4 % 1.96 [-3.05, 6.97] Young 2001 146 104.5 (15.3) 85 103.2 (15.3) 4.6 % 1.30 [-2.79, 5.39] Subtotal (95% CI) 238 176 13.3 % 0.57 [-1.84, 2.98] 100.0 % -0.75 [-1.80, 0.29] Heterogeneity: Tau ² = 0.0; Chi ² = 0.94, df = 2 (P = 0.63); I ² = 0.0% 100.0 % -0.75 [-1.80, 0.29] 100.0 % -0.75 [-1.80, 0.29] 100.0 % -0.75 [-1.80, 0.29] 100.0 % -0.75 [-1.80, 0.29] 100.0 % -0.75 [-1.80, 0.29] 100.0 % -0.75 [-1.80, 0.29] 100.0 % -0.75 [-1.80, 0.29] 100.0 % -0.75 [-1.80, 0.29] 100.0 % -0.75 [-1.80, 0.29] 100.0 %<	Test for overall effect: Z	= 1.25 (P = 0.2	!)					
Subtotal (95% CI) 185 181 Heterogeneity: not applicable 185 (P = 0.064) 3 Iron + multiple micronutrients Thu 1999 Thu 1999 54 123.5 (10.3) Yang 2004 (C) 38 134.16 (12.79) 38 132.2 (9.21) Young 2001 146 104.5 (15.3) 85 103.2 (15.3) Subtotal (95% CI) 238 176 Heterogeneity: Tau ² = 0.0; Chi ² = 0.94, df = 2 (P = 0.63); l ² = 0.0% Test for overall effect: Z = 0.46 (P = 0.64) Total (95% CI) 1177 1093 Heterogeneity: Tau ² = 1.73; Chi ² = 25.70, df = 13 (P = 0.02); l ² = 49% Test for overall effect: Z = 1.42 (P = 0.16) Test for subgroup differences: Chi ² = 2.76, df = 2 (P = 0.25), l ² = 28%						_		
Heterogeneity: not applicable Test for overall effect: $Z = 1.85$ (P = 0.064) 3 Iron + multiple micronutrients Thu 1999 54 123.5 (10.3) 53 124.3 (9.3) Yang 2004 (C) 38 134.16 (12.79) 38 132.2 (9.21) Young 2001 146 104.5 (15.3) 85 103.2 (15.3) Subtotal (95% CI) 238 176 Heterogeneity: Tau ² = 0.0; Chi ² = 0.94, df = 2 (P = 0.63); l ² = 0.0% Test for overall effect: $Z = 0.46$ (P = 0.64) Total (95% CI) 1177 1093 Heterogeneity: Tau ² = 1.73; Chi ² = 25.70, df = 13 (P = 0.02); l ² = 49% Test for overall effect: $Z = 1.42$ (P = 0.16) Test for subgroup differences: Chi ² = 2.76, df = 2 (P = 0.25), l ² = 28% -4 -2 0 2 4			108.5 (12.9)		110.9 (11.9)	-		-
Test for overall effect: $Z = 1.85$ (P = 0.064) 3 Iron + multiple micronutrients Thu 1999 54 123.5 (10.3) 53 124.3 (9.3) Yang 2004 (C) 38 134.16 (12.79) 38 132.2 (9.21) Young 2001 146 104.5 (15.3) 85 103.2 (15.3) Subtotal (95% CI) 238 176 Heterogeneity: Tau ² = 0.0; Chi ² = 0.94, df = 2 (P = 0.63); l ² = 0.0% Test for overall effect: $Z = 0.46$ (P = 0.64) Total (95% CI) 1177 1093 Heterogeneity: Tau ² = 1.73; Chi ² = 25.70, df = 13 (P = 0.02); l ² = 49% Test for overall effect: $Z = 1.42$ (P = 0.16) Test for subgroup differences: Chi ² = 2.76, df = 2 (P = 0.25), l ² = 28% -4 -2 = 2 = 2 = 4				181	-		8.3 %	-2.40 [-4.94, 0.14]
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	• • • • •							
Thu 1999 54 123.5 (10.3) 53 124.3 (9.3) Yang 2004 (C) 38 134.16 (12.79) 38 132.2 (9.21) Young 2001 146 104.5 (15.3) 85 103.2 (15.3) Subtotal (95% CI) 238 176 Heterogeneity: Tau ² = 0.0; Chi ² = 0.94, df = 2 (P = 0.63); l ² = 0.0% Total (95% CI) 1177 1093 Heterogeneity: Tau ² = 1.73; Chi ² = 25.70, df = 13 (P = 0.02); l ² = 49% Test for overall effect: $Z = 1.42$ (P = 0.16) Test for subgroup differences: Chi ² = 2.76, df = 2 (P = 0.25), l ² = 28% -4 -2 0 2 4		`	164)					
Young 2001 146 104.5 (15.3) 85 103.2 (15.3) Subtotal (95% CI) 238 176 Heterogeneity: Tau ² = 0.0; Chi ² = 0.94, df = 2 (P = 0.63); l ² = 0.0% Test for overall effect: $Z = 0.46$ (P = 0.64) Total (95% CI) 1177 1093 Heterogeneity: Tau ² = 1.73; Chi ² = 25.70, df = 13 (P = 0.02); l ² = 49% Test for overall effect: $Z = 1.42$ (P = 0.16) Test for subgroup differences: Chi ² = 2.76, df = 2 (P = 0.25), l ² = 28% -4 -2 0 2 4	•		23.5 (0.3)	53	24.3 (9.3) ←			-0.80 [-4.52, 2.92]
Young 2001 146 104.5 (15.3) 85 103.2 (15.3) Subtotal (95% CI) 238 176 Heterogeneity: Tau ² = 0.0; Chi ² = 0.94, df = 2 (P = 0.63); l ² = 0.0% Test for overall effect: $Z = 0.46$ (P = 0.64) Total (95% CI) 1177 1093 Heterogeneity: Tau ² = 1.73; Chi ² = 25.70, df = 13 (P = 0.02); l ² = 49% Test for overall effect: $Z = 1.42$ (P = 0.16) Test for subgroup differences: Chi ² = 2.76, df = 2 (P = 0.25), l ² = 28% -4 -2 0 2 4	Yang 2004 (C)	38	34, 6 (2,79)	38	32.2 (9.21)		→ 3.4 %	.96 [-3.05. 6.97 ⁻
Subtotal (95% CI) 238 176 Heterogeneity: Tau ² = 0.0; Chi ² = 0.94, df = 2 (P = 0.63); l ² = 0.0% 13.3 % 0.57 [-1.84, 2.98] Test for overall effect: Z = 0.46 (P = 0.64) 100.0 % -0.75 [-1.80, 0.29] Total (95% CI) 1177 1093 Heterogeneity: Tau ² = 1.73; Chi ² = 25.70, df = 13 (P = 0.02); l ² = 49% 100.0 % -0.75 [-1.80, 0.29] Test for overall effect: Z = 1.42 (P = 0.16) 136 Test for subgroup differences: Chi ² = 2.76, df = 2 (P = 0.25), l ² = 28% -4 -2 0 2 4			. ,		. ,			
Heterogeneity: Tau ² = 0.0; Chi ² = 0.94, df = 2 (P = 0.63); l ² = 0.0% Test for overall effect: $Z = 0.46$ (P = 0.64) Total (95% CI) 1177 1093 Heterogeneity: Tau ² = 1.73; Chi ² = 25.70, df = 13 (P = 0.02); l ² = 49% Test for overall effect: $Z = 1.42$ (P = 0.16) Test for subgroup differences: Chi ² = 2.76, df = 2 (P = 0.25), l ² = 28% -4 -2 0 2 4			10 110 (1010)		10312 (1013)			
Test for overall effect: $Z = 0.46$ (P = 0.64) Total (95% CI) 1177 100.0 % -0.75 [-1.80, 0.29] Heterogeneity: Tau ² = 1.73; Chi ² = 25.70, df = 13 (P = 0.02); l ² =49% Test for overall effect: $Z = 1.42$ (P = 0.16) Test for subgroup differences: Chi ² = 2.76, df = 2 (P = 0.25), l ² =28% -4 -2 0 2 4							13.3 %	0.5/ [-1.84, 2.98]
Total (95% CI) 1177 1093 Heterogeneity: Tau ² = 1.73; Chi ² = 25.70, df = 13 (P = 0.02); l ² =49% 100.0 % -0.75 [-1.80, 0.29] Test for overall effect: Z = 1.42 (P = 0.16) Test for subgroup differences: Chi ² = 2.76, df = 2 (P = 0.25), l ² = 28% -4 -2 0 2 4								
Heterogeneity: Tau ² = 1.73; Chi ² = 25.70, df = 13 (P = 0.02); l ² =49% Test for overall effect: Z = 1.42 (P = 0.16) Test for subgroup differences: Chi ² = 2.76, df = 2 (P = 0.25), l ² =28%				1093		-	100.0 %	-0.75 [-1.80, 0.29]
Test for overall effect: $Z = 1.42$ (P = 0.16) Test for subgroup differences: Chi ² = 2.76, df = 2 (P = 0.25), l ² = 28%	(-		70. df = 13 (P = 0.0				10000 /0	00, 9 [1000, 0029]
Test for subgroup differences: $Chi^2 = 2.76$, $df = 2$ (P = 0.25), $l^2 = 28\%$ -4 -2 0 2 4	0 ,							
			,	5), I ² =28%				
Daily iron suppl Intermittent					-4	-2 0 2	2 4	
					Daily	iron suppl Inter	mittent iron suppl	

Analysis 4.10. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months, Outcome 10 Iron deficiency (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age


Comparison: 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months

Outcome: 10 Iron deficiency (ALL)

Study or subgroup	Intermittent iron suppl	Daily iron suppl			Risk Ratio M-		Weight	Risk Ratio M-	
	n/N	n/N		H,Ra	ndom,95% Cl			H,Random,95% Cl	
Yang 2004 (C)	12/38	3/38					100.0 %	4.00 [.23, 3.05]	
Total (95% CI)	38	38			-		100.0 %	4.00 [1.23, 13.05]	
Total events: 12 (Intermit	tent iron suppl), 3 (Da	aily iron suppl)							
Heterogeneity: not applic	able								
Test for overall effect: Z =	= 2.30 (P = 0.022)								
Test for subgroup differen	nces: Not applicable								
			0.01	0.1	1 10	100			

Intermittent iron suppl

Daily iron suppl



Analysis 4.11. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months, Outcome II Ferritin (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months

Outcome: II Ferritin (ALL)

Study or subgroup	Intermittent iron suppl		Daily iron suppl		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% Cl		IV,Random,95% CI
Ermis 2002	30	45 (12.7)	60	45.45 (7.8)		20.6 %	-0.45 [-5.40, 4.50]
Faqih 2006	22	47.1 (14.13)	12	50.17 (14.1)		9.2 %	-3.07 [-13.00, 6.86]
Khademloo 2009	50	21.4 (15.9)	50	24.3 (12.3)		18.6 %	-2.90 [-8.47, 2.67]
Liu 1995 (C)	57	36.9 (6.3)	29	44.8 (7)	-	27.9 %	-7.90 [-10.93, -4.87]
Schultink 1995	32	41.2 (30)	33	34.9 (28.7)		5.1 %	6.30 [-7.98, 20.58]
Tavil 2003	48	41.7 (22.2)	46	41.9 (22.8)		10.4 %	-0.20 [-9.30, 8.90]
Yang 2004 (C)	38	64.14 (33.63)	38	73.17 (32.72)	·	4.7 %	-9.03 [-23.95, 5.89]
Yurdakok 2004	19	59.7 (27.7)	18	55.7 (26.4)		3.6 %	4.00 [-13.43, 21.43]
Total (95% CI)	296		286		•	100.0 %	-3.10 [-6.59, 0.39]
Heterogeneity: Tau ² =	= 8.98; Chi ² =	12.12, df = 7 (P	= 0.10); l ² =42%				
Test for overall effect:	Z = 1.74 (P =	0.082)					
Test for subgroup diffe	erences: Not a	oplicable					

-20 -10 Daily iron suppl

10 Intermittent iron suppl

20

0

Analysis 4.12. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months, Outcome 12 Ferritin (by dose of elemental iron in the intermittent subgroup).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months

Outcome: 12 Ferritin (by dose of elemental iron in the intermittent subgroup)

	iron suppl		Daily iron suppl		Mean Difference	Weight	Mea Differenc
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI		IV,Random,95% C
1 25 mg or less/week Subtotal (95% CI)	0		0				Not estimabl
Heterogeneity: not applicable	e						
Test for overall effect: not ap	plicable						
2 Greater than 25 mg to 75	mg/week						
Yurdakok 2004	19	59.7 (27.7)	18	55.7 (26.4)		4.1 %	4.00 [-13.43, 21.43
Yang 2004 (C)	38	64.14 (33.63)	38	73.17 (32.72)		5.3 %	-9.03 [-23.95, 5.89
Schultink 1995	32	41.2 (30)	33	34.9 (28.7)		5.7 %	6.30 [-7.98, 20.58
Faqih 2006	22	47. (4. 3)	12	50.17 (14.1)	-	9.6 %	-3.07 [-13.00, 6.86
Tavil 2003	48	41.7 (22.2)	46	41.9 (22.8)	+	10.7 %	-0.20 [-9.30, 8.90
Ermis 2002	30	45 (12.7)	60	45.45 (7.8)	+	18.8 %	-0.45 [-5.40, 4.50
Khademloo 2009	50	123 (10.1)	50	123 (8)	+	22.3 %	0.0 [-3.57, 3.57
Liu 1995 (C)	57	36.9 (6.3)	29	44.8 (7)	-	23.5 %	-7.90 [-10.93, -4.87
Subtotal (95% CI)	296		286		•	100.0 %	-2.22 [-6.03, 1.59
3 Greater than 75 mg/week Subtotal (95% CI)	0		0				Not estimab
Subtotal (95% CI)	0		0				Not estimabl
Heterogeneity: not applicable Test for overall effect: not ap							
Total (95% CI)	296		286		•	100.0 %	-2.22 [-6.03, 1.59
Heterogeneity: Tau ² = 13.66		.82. df = 7 (P =				100.0 /0	2.22 [*0.03, 1.9)
Test for overall effect: $Z = 1$.			,,				
Test for subgroup differences		,					
						1	
				-	00 -50 0 50	100	

Analysis 4.13. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months, Outcome 13 Ferritin (by duration of supplementation).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months

Outcome: 13 Ferritin (by duration of supplementation)

Study or subgroup	Intermittent iron suppl		Daily iron suppl		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% Cl	-	IV,Random,95% CI
I 0 to three months							
Yurdakok 2004	19	59.7 (27.7)	18	55.7 (26.4)		3.6 %	4.00 [-13.43, 21.43]
Schultink 1995	32	41.2 (30)	33	34.9 (28.7)		5.1 %	6.30 [-7.98, 20.58]
Tavil 2003	48	41.7 (22.2)	46	41.9 (22.8)	-	10.4 %	-0.20 [-9.30, 8.90]
Khademloo 2009	50	21.4 (15.9)	50	24.3 (12.3)	-	18.6 %	-2.90 [-8.47, 2.67]
Liu 1995 (C)	57	36.9 (6.3)	29	44.8 (7)	-	27.9 %	-7.90 [-10.93, -4.87]
Subtotal (95% CI)	206		176		•	65.5 %	-3.02 [-7.91, 1.87]
Heterogeneity: $Tau^2 = 13$		30, df = 4 (P = 0.	08); I ² =52%				
Test for overall effect: Z =	= 1.21 (P = 0.2	3)					
2 More than three month	าร						
Yang 2004 (C)	38	64.14 (33.63)	38	73.17 (32.72)		4.7 %	-9.03 [-23.95, 5.89]
Faqih 2006	22	47.1 (14.13)	12	50.17 (14.1)		9.2 %	-3.07 [-13.00, 6.86]
Ermis 2002	30	45 (12.7)	60	45.45 (7.8)	-	20.6 %	-0.45 [-5.40, 4.50]
Subtotal (95% CI)	90		110		•	34.5 %	-1.63 [-5.88, 2.62]
Heterogeneity: $Tau^2 = 0.0$); Chi ² = 1.24,	df = 2 (P = 0.54); ² =0.0%				
Test for overall effect: Z =	= 0.75 (P = 0.4	5)					
Total (95% CI)	296		286		•	100.0 %	-3.10 [-6.59, 0.39]
Heterogeneity: $Tau^2 = 8.9$	98; Chi ² = 12.1	2, df = 7 (P = 0.	10); l ² =42%				
Test for overall effect: Z =	= 1.74 (P = 0.0	82)					
Test for subgroup differer	nces: $Chi^2 = 0.$	18, df = 1 (P = 0	67), l ² =0.0%				

Daily iron suppl Intermittent iron suppl

Analysis 4.14. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months, Outcome 14 Ferritin (by type of compound).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months

Outcome: 14 Ferritin (by type of compound)

Study or subgroup	Intermittent iron suppl		Daily iron suppl		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% Cl		IV,Random,95% CI
I Ferrous sulphate							
Yurdakok 2004	19	59.7 (27.7)	18	55.7 (26.4)	_ 	3.6 %	4.00 [-13.43, 21.43]
Schultink 1995	32	41.2 (30)	33	34.9 (28.7)		5.1 %	6.30 [-7.98, 20.58]
Faqih 2006	22	47.1 (14.13)	12	50.17 (14.1)	-	9.2 %	-3.07 [-13.00, 6.86]
Tavil 2003	48	41.7 (22.2)	46	41.9 (22.8)	+	10.4 %	-0.20 [-9.30, 8.90]
Khademloo 2009	50	21.4 (15.9)	50	24.3 (12.3)	-	8.6 %	-2.90 [-8.47, 2.67]
Ermis 2002	30	45 (12.7)	60	45.45 (7.8)	+	20.6 %	-0.45 [-5.40, 4.50]
Liu 1995 (C)	57	36.9 (6.3)	29	44.8 (7)	-	27.9 %	-7.90 [-10.93, -4.87]
Subtotal (95% CI)	258		248		•	95.3 %	-2.69 [-6.42, 1.05]
Heterogeneity: $Tau^2 = 10$	$0.56; Chi^2 = 11$.78, df = 6 (P =	: 0.07); l ² =49%				
Test for overall effect: Z =	= 1.41 (P = 0.1	6)					
2 Ferrous fumarate							
Subtotal (95% CI)	0		0				Not estimable
Heterogeneity: not applic	able						
Test for overall effect: not	applicable						
3 Other							
Yang 2004 (C)	38	64.14 (33.63)	38	73.17 (32.72)		4.7 %	-9.03 [-23.95, 5.89]
Subtotal (95% CI)	38		38		•	4.7 %	-9.03 [-23.95, 5.89]
Heterogeneity: not applic	able						
Test for overall effect: Z =	= 1.19 (P = 0.2	4)					
Total (95% CI)	296		286		•	100.0 %	-3.10 [-6.59, 0.39]
Heterogeneity: $Tau^2 = 8.9$			0.10 ; $l^2 = 42\%$				
Test for overall effect: Z =		,					
Test for subgroup differer	nces: Chi ² = 0.6	65, df = 1 (P =	0.42), I ² =0.0%				
				•		100	
				-10		100	
				Dai	ly iron suppl Intermitte	nt iron suppl	

Analysis 4.15. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months, Outcome 15 Ferritin (by anaemia status at baseline).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months

Outcome: 15 Ferritin (by anaemia status at baseline)

Study or subgroup	Intermittent iron suppl N	Mean(SD)	Daily iron suppl N	Mean(SD)	Mean Difference IV,Random,95% Cl	Weight	Mean Difference IV,Random,95% CI
l Anaemic							
Faqih 2006	22	47. (4. 3)	12	50.17 (14.1)	-	9.9 %	-3.07 [-13.00, 6.86]
Liu 1995 (C)	20	38.1 (6.9)	12	55.2 (8.4)	-	14.6 %	-17.10 [-22.73, -11.47]
Schultink 1995	32	41.2 (30)	33	34.9 (28.7)		6.6 %	6.30 [-7.98, 20.58]
Tavil 2003	48	41.7 (22.2)	46	41.9 (22.8)	+	10.7 %	-0.20 [-9.30, 8.90]
Subtotal (95% CI)	122		103		•	41.8 %	-4.47 [-15.45, 6.52]
Heterogeneity: Tau ² = 101 Test for overall effect: Z = 2 Non-anaemic							
Liu 1995 (C)	34	36.1 (6)	20	38.7 (6.1)	-	17.0 %	-2.60 [-5.95, 0.75]
Yang 2004 (C)	38	64.14 (33.63)	38	73.17 (32.72)		6.2 %	-9.03 [-23.95, 5.89]
Yurdakok 2004	19	59.7 (27.7)	18	55.7 (26.4)		5.0 %	4.00 [-13.43, 21.43]
Subtotal (95% CI)	91		76		•	28.2 %	-2.67 [-5.89, 0.54]
Heterogeneity: Tau ² = 0.0 Test for overall effect: Z = 3 Mixed/unknown			3); I ² =0.0%				
Ermis 2002	30	45 (12.7)	60	45.45 (7.8)	•	15.3 %	-0.45 [-5.40, 4.50]
Khademloo 2009	50	21.4 (15.9)	50	24.3 (12.3)	-	14.6 %	-2.90 [-8.47, 2.67]
Subtotal (95% CI) Heterogeneity: Tau ² = 0.0 Test for overall effect: Z =			110 2); I ² =0.0%		•	30.0 %	-1.53 [-5.23, 2.17]
Total (95% CI)	293	<i>∠)</i>	289		•	100.0 %	-3.70 [-8.25, 0.86]
Heterogeneity: Tau ² = 28. Test for overall effect: Z = Test for subgroup difference	82; $Chi^2 = 27$.	I)	0.00058); I ² =719	6			

Daily iron suppl

Intermittent iron suppl

Analysis 4.16. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months, Outcome 16 Ferritin (by supplementation regimen).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months

Outcome: 16 Ferritin (by supplementation regimen)

iron suppl	, , , , , , , , , , , , , , , , , , , ,		Difference	Weight	Mean Difference	
IN	I*lean(SD)	IN	Mean(SD)	IV,Random,95% CI		IV,Random,95% CI
19	59.7 (27.7)	18	55.7 (26.4)		5.1 %	4.00 [-13.43, 21.43]
38	64.14 (33.63)	38	73.17 (32.72)		6.3 %	-9.03 [-23.95, 5.89]
22	47.1 (14.13)	12	50.17 (14.1)	-	9.9 %	-3.07 [-13.00, 6.86]
50	21.4 (15.9)	50	24.3 (12.3)	-	14.5 %	-2.90 [-8.47, 2.67]
29	31.2 (5)	15	44.8 (7)	-	16.2 %	-13.60 [-17.58, -9.62]
158		133		•	51.9 %	-6.21 [-12.98, 0.55]
9; Chi ² = 13	.23, df = 4 (P =	0.01); l ² =70%				
.80 (P = 0.0	72)					
en						
32	41.2 (30)	33	34.9 (28.7)		6.6 %	6.30 [-7.98, 20.58]
48	41.7 (22.2)	46	41.9 (22.8)	+	10.7 %	-0.20 [-9.30, 8.90]
30	45 (12.7)	60	45.45 (7.8)	-	15.2 %	-0.45 [-5.40, 4.50]
27	42.8 (7.7)	15	44.8 (7)	+	15.6 %	-2.00 [-6.58, 2.58]
137		154		•	48.1 %	-0.81 [-3.89, 2.27]
Chi ² = 1.25,	df = 3 (P = 0.7	4); I ² =0.0%				
0.51 (P = 0.6	1)					
295		287		•	100.0 %	-3.27 [-7.87, 1.33]
4; Chi ² = 28	.27, df = 8 (P =	0.00043); l ² =72%	6			
· ·	/					
es: Chi ² = 2.0	03, df = 1 (P =	0.15), I ² =51%				
	55, di 1 (i	0.13),1 31/0				
	N 19 38 22 50 29 158 $9; Chi^{2} = 13$ $1.80 (P = 0.0)$ 20 32 48 30 27 137 $Chi^{2} = 1.25,$ $0.51 (P = 0.6)$ 295 $4; Chi^{2} = 28$ $1.39 (P = 0.1)$	N Mean(SD) 19 59.7 (27.7) 38 64.14 (33.63) 22 47.1 (14.13) 50 21.4 (15.9) 29 31.2 (5) 158 9; Chi ² = 13.23, df = 4 (P = 1.80 (P = 0.072) en 32 41.2 (30) 48 41.7 (22.2) 30 45 (12.7) 27 42.8 (7.7) 137 Chi ² = 1.25, df = 3 (P = 0.7) 0.51 (P = 0.61) 295 4; Chi ² = 28.27, df = 8 (P = 1.39 (P = 0.16)	N Mean(SD) N 19 59.7 (27.7) 18 38 64.14 (33.63) 38 22 47.1 (14.13) 12 50 21.4 (15.9) 50 29 31.2 (5) 15 158 133 9; Chi ² = 13.23, df = 4 (P = 0.01); l ² =70% 1.80 (P = 0.072) 2n 32 41.2 (30) 33 48 41.7 (22.2) 46 30 45 (12.7) 60 27 42.8 (7.7) 15 137 154 Chi ² = 1.25, df = 3 (P = 0.74); l ² =0.0% 0.51 (P = 0.61) 295 287 4; Chi ² = 28.27, df = 8 (P = 0.00043); l ² =729	N Mean(SD) N Mean(SD) 19 $59.7 (27.7)$ 18 $55.7 (26.4)$ 38 $64.14 (33.63)$ 38 $73.17 (32.72)$ 22 $47.1 (14.13)$ 12 $50.17 (14.1)$ 50 $21.4 (15.9)$ 50 $24.3 (12.3)$ 29 $31.2 (5)$ 15 $44.8 (7)$ 158 133 9: Chi ² = 13.23, df = 4 (P = 0.01); l ² = 70% .80 (P = 0.072) an 32 $41.2 (30)$ 33 $34.9 (28.7)$ 48 $41.7 (22.2)$ 46 $41.9 (22.8)$ 30 $45 (12.7)$ 60 $45.45 (7.8)$ 27 $42.8 (7.7)$ 15 $44.8 (7)$ 137 154 Chi ² = 1.25, df = 3 (P = 0.74); l ² = 0.0% 0.51 (P = 0.61) 295 287 4; Chi ² = 28.27, df = 8 (P = 0.00043); l ² = 72% .39 (P = 0.16) .39 (P = 0.16) es: Chi ² = 2.03, df = 1 (P = 0.15), l ² = 51%	N Mean(SD) N Mean(SD) IV.Random,95% Cl 19 59.7 (27.7) 18 55.7 (26.4) 38 64.14 (33.63) 38 73.17 (32.72) 22 47.1 (14.13) 12 50.17 (14.1) 50 21.4 (15.9) 50 24.3 (12.3) 29 31.2 (5) 15 44.8 (7) 158 133 9; Chi ² = 13.23, df = 4 (P = 0.01); l ² = 70% 180 (P = 0.072) an 32 41.2 (30) 33 34.9 (28.7) 48 41.7 (22.2) 46 41.9 (22.8) 30 45 (12.7) 60 45.45 (7.8) 27 42.8 (7.7) 15 44.8 (7) 137 154 Chi ² = 1.25, df = 3 (P = 0.74); l ² = 0.0% 295 287 4; Chi ² = 28.27, df = 8 (P = 0.00043); l ² = 72% 1.39 (P = 0.16) as: Chi ² = 2.03, df = 1 (P = 0.15), l ² = 51%	N Mean(SD) N Mean(SD) IV.Random,95% CI 19 $59.7 (27.7)$ 18 $55.7 (26.4)$ 5.1% 38 $64.14 (33.63)$ 38 $73.17 (32.72)$ 6.3% 22 $47.1 (14.13)$ 12 $50.17 (14.1)$ 9.9% 50 $21.4 (15.9)$ 50 $24.3 (12.3)$ 14.5% 29 $31.2 (5)$ 15 $44.8 (7)$ 162% 158 133 9.7% 162% 9: Chi ² = 13.23, df = 4 (P = 0.01); l ² = 70\% $180 (P = 0.072)$ 162% an 32 $41.2 (30)$ 33 $34.9 (28.7)$ 66.6% $180 (P = 0.072)$ 15 $44.8 (7)$ 15.2% 10.7% 30 $45 (12.7)$ 60 $45.45 (7.8)$ 15.2% 27 $42.8 (7.7)$ 15 $44.8 (7)$ 15.6% 137 154 48.1% 925 287 100.0% 295 287 100.0% 100.0% 100.0% $39 (P = 0.16)$ $29.5 (16^{2} = 10.5), l2 = 51\%$ 10

Daily iron suppl

Intermittent iron suppl

Analysis 4.17. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months, Outcome 17 Ferritin (by sex).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months

Outcome: 17 Ferritin (by sex)

Study or subgroup	Intermittent iron suppl	C	aily iron suppl		Mean Difference	Weight	Mean Difference
	N	Mean(SD)	N	Mean(SD)	IV,Random,95% CI		IV,Random,95% CI
l Girls Subtotal (95% CI) Heterogeneity: not applic Test for overall effect: not			0				Not estimable
2 Boys Subtotal (95% CI) Heterogeneity: not applica- Test for overall effect: not			0				Not estimable
3 Mixed/unknown Yurdakok 2004	19	59.7 (27.7)	18	55.7 (26.4)		3.6 %	4.00 [-13.43, 21.43]
Yang 2004 (C)	38	64.14 (33.63)	38	73.17 (32.72)		4.7 %	-9.03 [-23.95, 5.89]
Schultink 1995	32	41.2 (30)	33	34.9 (28.7)		5.1 %	6.30 [-7.98, 20.58]
Fagih 2006	22	47.1 (14.1)	12	50.17 (14.1)	-	9.2 %	-3.07 [-12.99, 6.85]
Tavil 2003	48	41.7 (22.2)	46	41.9 (22.8)	+	10.4 %	-0.20 [-9.30, 8.90]
Khademloo 2009	50	21.4 (15.9)	50	24.3 (12.3)	-	18.6 %	-2.90 [-8.47, 2.67]
Ermis 2002	30	45 (12.7)	60	45.45 (7.8)	-	20.6 %	-0.45 [-5.40, 4.50]
Liu 1995 (C)	57	36.9 (6.3)	29	44.8 (7)	-	27.9 %	-7.90 [-10.93, -4.87]
Subtotal (95% CI) Heterogeneity: $Tau^2 = 8.5$ Test for overall effect: Z =		2, df = 7 (P = 0.10	286); ² =42%		•		-3.10 [-6.58, 0.39]
Total (95% CI) Heterogeneity: Tau ² = 8.5 Test for overall effect: Z = Test for subgroup differen	296 98; Chi ² = 12.1 = 1.74 (P = 0.0	2, df = 7 (P = 0.10) 82)	286); I ² =42%			100.0 %	-3.10 [-6.58, 0.39]
				-	100 -50 0 50	100	
				C	Daily iron suppl Intermitt	ent iron suppl	

Analysis 4.18. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months, Outcome 18 Ferritin (by nutrient).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months

Outcome: 18 Ferritin (by nutrient)

Study or subgroup	Intermittent iron suppl N	Mean(SD)	Daily iron suppl N	Mean(SD)	Mean Difference IV.Random,95% CI	Weight	Mean Difference IV.Random,95% Cl
	11	r icali(SD)		1 (GB)			
l Iron alone Yurdakok 2004	19	59.7 (27.7)	18	55.7 (26.4)	_ 	3.6 %	4.00 [-13.43, 21.43]
Schultink 1995	32	41.2 (30)	33	34.9 (28.7)		5.1 %	6.30 [-7.98, 20.58]
Faqih 2006	22	47.1 (14.13)	12	50.17 (14.1)	-	9.2 %	-3.07 [-13.00, 6.86]
Tavil 2003	48	41.7 (22.2)	46	41.9 (22.8)	+	10.4 %	-0.20 [-9.30, 8.90]
Khademloo 2009	50	21.4 (15.9)	50	24.3 (12.3)	-	18.6 %	-2.90 [-8.47, 2.67]
Ermis 2002	30	45 (12.7)	60	45.45 (7.8)	+	20.6 %	-0.45 [-5.40, 4.50]
Liu 1995 (C)	57	36.9 (6.3)	29	44.8 (7)	-	27.9 %	-7.90 [-10.93, -4.87]
Subtotal (95% CI) Heterogeneity: Tau ² = 10 Test for overall effect: Z =			248 0.07); I ² =49%		•	95.3 %	-2.69 [-6.42, 1.05]
2 Iron + folic acid Subtotal (95% CI) Heterogeneity: not applic Test for overall effect: not 3 Iron + multiple micronu	applicable		0				Not estimable
Yang 2004 (C)		64.14 (33.63)	38	73.17 (32.72)		4.7 %	-9.03 [-23.95, 5.89]
Subtotal (95% CI) Heterogeneity: not applic			38		•	4.7 %	-9.03 [-23.95, 5.89]
Test for overall effect: Z = Total (95% CI) Heterogeneity: Tau ² = 8.9 Test for overall effect: Z =	296 98; Chi ² = 12.1 = 1.74 (P = 0.0	2, df = 7 (P = 0 82)			•	100.0 %	-3.10 [-6.59, 0.39]
Test for subgroup differen	ices: Chi ² = 0.6	55, df = (P = (0.42), I ² =0.0%		00 -50 0 50 aily iron suppl Intermitt	100 ent iron suppl	

Analysis 4.19. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months, Outcome 19 All cause morbidity (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months

Outcome: 19 All cause morbidity (ALL)

Study or subgroup	Intermittent bgroup iron suppl Daily iron suppl Risk Ratio M- H,Random,95%			Weight	Risk Ratio M- H,Random,95%				
	n/N	n/N		,	ĊI			Cl	
Desai 2004 (C)	35/27	128/251			-		100.0 %	0.98 [0.82, 1.16]	
Total (95% CI)	271	251			•		100.0 %	0.98 [0.82, 1.16]	
Total events: 135 (Interm	ittent iron suppl), 128	(Daily iron suppl)							
Heterogeneity: not applic	able								
Test for overall effect: Z =	= 0.27 (P = 0.79)								
Test for subgroup differer	nces: Not applicable								
					-	1			
			0.01	0.1	1 10	100			
			Intermittent in	on suppl	Daily irc	on suppl			

Analysis 4.20. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months, Outcome 20 Diarrhoea (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months

Outcome: 20 Diarrhoea (ALL)

Study or subgroup	Intermittent iron suppl	Daily iron suppl			Risk Ratio M-	Weight	Risk Ratio M-
	n/N	n/N		H,Rar	ndom,95% Cl		H,Random,95% Cl
Yurdakok 2004	1/23	0/22				100.0 %	2.88 [0.12, 67.03]
Total (95% CI)	23	22				100.0 %	2.88 [0.12, 67.03]
Total events: I (Intermitte	ent iron suppl), 0 (Dai	y iron suppl)					
Heterogeneity: not applic	able						
Test for overall effect: Z =	= 0.66 (P = 0.51)						
Test for subgroup differen	nces: Not applicable						
			0.01	0.1	1 10 100		
		Ir	ntermittent in	on suppl	Daily iron suppl		

Analysis 4.21. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months, Outcome 21 Any side effects (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months

Outcome: 21 Any side effects (ALL)

Study or subgroup	Intermittent iron suppl	Daily iron suppl			Risk Ratio M-		Weight	Risk Ratio M-
	n/N	n/N		H,R	andom,95% Cl			H,Random,95% Cl
Ermis 2002	1/30	3/60			•		14.4 %	0.67 [0.07, 6.14]
Liu 1995 (C)	9/154	31/84					28.2 %	0.16 [0.08, 0.32]
Yurdakok 2004	12/22	8/23					28.4 %	1.57 [0.80, 3.09]
Desai 2004 (C)	19/271	22/251			•		29.1 %	0.80 [0.44, 1.44]
Total (95% CI)	477	418			-		100.0 %	0.60 [0.19, 1.87]
Total events: 41 (Intermit	tent iron suppl), 64 (D	aily iron suppl)						
Heterogeneity: $Tau^2 = 1$.	07; Chi ² = 23.53, df =	3 (P = 0.00003); I ² =87%						
Test for overall effect: Z =	= 0.89 (P = 0.38)							
Test for subgroup differen	nces: Not applicable							
			0.01	0.1	1 10	100		

Intermittent iron suppl Daily iron suppl

Analysis 4.22. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months, Outcome 22 Adherence (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months

Outcome: 22 Adherence (ALL)


Study or subgroup	Intermittent iron suppl n/N	Daily iron suppl n/N		Risk Ratio M- ndom,95% Cl		Weight	Risk Ratio M- H,Random,95% Cl
Desai 2004 (C)	153/271	110/251		-		27.2 %	1.29 [1.08, 1.53]
Engstrom 2008 (C)	2/ 47	98/150		•		33.1 %	1.17 [1.01, 1.35]
Awasthi 2005 (C)	164/185	4/ 8		-		39.7 %	1.41 [1.24, 1.59]
Total (95% CI)	603	582		•		100.0 %	1.29 [1.15, 1.45]
Total events: 429 (Intermit Heterogeneity: Tau ² = 0.0 Test for overall effect: Z = Test for subgroup difference	0; Chi ² = 3.71 , df = 2 (4.34 (P = 0.000014)	, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,					
					I		
			0.1 0.2 0.5	25	10		
			Daily iron suppl	Intermitter	nt iron suppl		

Analysis 4.23. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months, Outcome 23 HAZ.

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months

Outcome: 23 HAZ



Analysis 4.24. Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months, Outcome 24 WAZ.

Review: Intermittent iron supplementation for improving nutrition and development in children under 2 years of age

Comparison: 4 Intermittent iron supplementation versus daily iron supplementation: children 0 - 59 months

Outcome: 24 WAZ

Study or subgroup	Intermittent iron suppl N	Mean(SD)	Daily iron suppl N	Mean(SD)		Std. Mean ference om,95% Cl	Weight	Std. Mean Difference IV,Random,95% Cl
Thu 1999	54	-1.77 (0.78)	55	-1.42 (0.79)			100.0 %	-0.44 [-0.82, -0.06]
Total (95% CI) Heterogeneity: not ap Test for overall effect: Test for subgroup diffe	Z = 2.28 (P =	,	55		-100 -50 (Daily iron suppl		100.0 %	-0.44 [-0.82, -0.06]

Analysis 5.1. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years, Outcome I Anaemia (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years

Outcome: I Anaemia (ALL)

Study or subgroup	Intermittent iron suppl	No suppl/placebo	Risk Ratio M-	Weight	Risk Ratio M-
	n/N	n/N	H,Random,95% Cl		H,Random,959 Cl
Aguayo 2000	5/33	6/31		10.8 %	0.78 [0.27, 2.31]
Arcanjo 2011 (C)	6/23	17/22	-	15.0 %	0.34 [0.16, 0.70]
Berger 1997	8/59	55/58	-	16.0 %	0.14 [0.07, 0.27]
Roschnik 2003 (C)	19/46	18/46	+	17.9 %	1.06 [0.64, 1.74]
Roschnik 2004 (C)	29/163	47/184	-	19.0 %	0.70 [0.46, 1.05]
Hall 2002 (C)	123/248	160/253	-	21.3 %	0.78 [0.67, 0.92]
Total (95% CI)	572	594	•	100.0 %	0.54 [0.33, 0.90]
Fest for overall effect: Z = Fest for subgroup difference	, ,		0.01 0.1 1 10 100		
		Interm	ittent iron suppl No suppl/placebo		
		Intern	Intent Iron supply into supply placebo		

Analysis 5.2. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years, Outcome 2 Anaemia (by dose).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years

Outcome: 2 Anaemia (by dose)

Study or subgroup	Intermittent iron suppl	No suppl/placebo	D	Risk Ratio M-	Weight	Risk Ratio M-
	n/N	n/N	1	H,Random,95% Cl		H,Random,95 Cl
1 25 mg or less/week						
Subtotal (95% CI)	0	C)			Not estimable
Total events: 0 (Intermittent i	iron suppl), 0 (No su	opl/placebo)				
Heterogeneity: not applicable	e					
Test for overall effect: not ap	plicable					
2 Greater than 25 mg to 75	mg/week					
Arcanjo 2011 (C)	6/23	17/22	2		15.0 %	0.34 [0.16, 0.70]
Berger 1997	8/59	55/58	3		16.0 %	0.14 [0.07, 0.27]
Roschnik 2003 (C)	19/46	18/46	ó	+	17.9 %	1.06 [0.64, 1.74]
Hall 2002 (C)	123/248	160/253	3	-	21.3 %	0.78 [0.67, 0.92]
Subtotal (95% CI)	376	379)	•	70.2 %	0.47 [0.21, 1.02]
Test for overall effect: Z = 1. 3 Greater than 75 mg/week Aguayo 2000	92 (P = 0.055) 5/33	6/31			10.8 %	0.78 [0.27, 2.31]
Roschnik 2004 (C)	29/163	47/184	1	-	19.0 %	0.70 [0.46, 1.05]
	196	215			29.8 %	2 3
Subtotal (95% CI) Total events: 34 (Intermittent)	•	29.8 %	0.71 [0.48, 1.04]
Heterogeneity: $Tau^2 = 0.0$; C	11 / (,				
Test for overall effect: $Z = 1.1$,	- 0.01), 1 -0.070				
Total (95% CI)	572	594	í	•	100.0 %	0.54 [0.33, 0.90]
Total events: 190 (Intermitter	nt iron suppl), 303 (N	lo suppl/placebo)				
Heterogeneity: $Tau^2 = 0.30;$	$Chi^2 = 34.02, df = 5$	(P<0.00001); I ² =85%				
	20 (D - 0.017)					
Test for overall effect: $Z = 2$.	.38 (P - 0.017)					
Test for overall effect: $Z = 2$. Test for subgroup differences	· · · ·	(P = 0.35), I ² =0.0%				
	· · · ·	(P = 0.35), I ² =0.0%			- 1	
	· · · ·	(P = 0.35), I ² =0.0%	0.01	0.1 10	100	

Analysis 5.3. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years, Outcome 3 Anaemia (by duration).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years

Outcome: 3 Anaemia (by duration)

Study or subgroup	Intermittent iron suppl	No suppl/placebo	Risk Ratio M- H,Random,95%	Weight	Risk Ratio M- H,Random,959
	n/N	n/N	H,Random,75% Cl		Cl
0 to three months					
Roschnik 2004 (C)	29/163	47/184	-	19.0 %	0.70 [0.46, 1.05]
Hall 2002 (C)	123/248	160/253	-	21.3 %	0.78 [0.67, 0.92]
Subtotal (95% CI)	411	437	•	40.3 %	0.77 [0.67, 0.89]
Total events: 152 (Intermittent Heterogeneity: Tau ² = 0.0; Ch Test for overall effect: $Z = 3.4$: 2 More than three months	$i^2 = 0.30, df = 1 (P)$				
Aguayo 2000	5/33	6/3		10.8 %	0.78 [0.27, 2.31]
Arcanjo 2011 (C)	6/23	17/22		15.0 %	0.34 [0.16, 0.70]
Berger 1997	8/59	55/58		16.0 %	0.14 [0.07, 0.27]
Roschnik 2003 (C)	19/46	18/46	+	17.9 %	1.06 [0.64, 1.74]
Subtotal (95% CI)	161	157	-	59. 7 %	0.44 [0.16, 1.24]
Fotal events: 38 (Intermittent i Heterogeneity: Tau ² = 0.96; C Fest for overall effect: $Z = 1.5$	$chi^2 = 26.39, df = 3$ 5 (P = 0.12)	(P<0.00001); l ² =89%			
Fotal (95% CI) Fotal events: 190 (Intermittent Heterogeneity: Tau ² = 0.30; C Fest for overall effect: Z = 2.3 Fest for subgroup differences:	$Chi^2 = 34.02, df = 5$ 8 (P = 0.017)	(P<0.00001); l ² =85%		100.0 %	0.54 [0.33, 0.90]
			0.01 0.1 1 10 10		
				00	

Analysis 5.4. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years, Outcome 4 Anaemia (by type of compound).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years

Outcome: 4 Anaemia (by type of compound)

Intermittent

Study or subgroup	Intermittent iron suppl	No suppl/placebo	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M- H,Random,95% Cl		M- H,Random,959 Cl
I Ferrous sulphate					
Aguayo 2000	5/33	6/3		10.8 %	0.78 [0.27, 2.31]
Arcanjo 2011 (C)	6/23	17/22		15.0 %	0.34 [0.16, 0.70]
Berger 1997	8/59	55/58		16.0 %	0.14 [0.07, 0.27]
Roschnik 2003 (C)	19/46	18/46	+	17.9 %	1.06 [0.64, 1.74]
Roschnik 2004 (C)	29/163	47/184	-	19.0 %	0.70 [0.46, 1.05]
Hall 2002 (C)	123/248	160/253	-	21.3 %	0.78 [0.67, 0.92]
Subtotal (95% CI)	572	594	•	100.0 %	0.54 [0.33, 0.90]
Total events: 190 (Intermitten Heterogeneity: Tau ² = 0.30; C Test for overall effect: $Z = 2.3$	$Chi^2 = 34.02, df = 5$				
2 Ferrous fumarate Subtotal (95% CI)	0	0			Not estimable
Total events: 0 (Intermittent in Heterogeneity: not applicable Test for overall effect: not app 3 Other					
Subtotal (95% CI)	0	0			Not estimable
Total events: 0 (Intermittent in Heterogeneity: not applicable Test for overall effect: not app	ron suppl), 0 (No su				
Total (95% CI)	572	594	•	100.0 %	0.54 [0.33, 0.90]
Total events: 190 (Intermitten Heterogeneity: Tau ² = 0.30; C Test for overall effect: $Z = 2.3$ Test for subgroup differences:	$Chi^2 = 34.02, df = 5$ 38 (P = 0.017)				
			0.01 0.1 1 10 10	0	
		Inter	mittent iron suppl No suppl/plac		

Analysis 5.5. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years, Outcome 5 Anaemia (by anaemia status at baseline).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years

Outcome: 5 Anaemia (by anaemia status at baseline)

Study or subgroup	Intermittent iron suppl	No suppl/placebc	D R	isk Ratio \ M-	Weight	Risk Ratio M-
	n/N	n/N		dom,95% Cl		H,Random,95 Cl
I Anaemic						
Berger 1997	8/59	55/58	3		16.0 %	0.14 [0.07, 0.27]
Subtotal (95% CI)	59	58	•	16	.0 %	0.14 [0.07, 0.27]
Total events: 8 (Intermittent ir	ron suppl), 55 (No s	uppl/placebo)				
Heterogeneity: not applicable						
Test for overall effect: $Z = 5.8$	89 (P < 0.00001)					
2 Non-anaemic						
Aguayo 2000	5/33	6/31		_	10.8 %	0.78 [0.27, 2.31]
Subtotal (95% CI)	33	31	-	► 10	.8 %	0.78 [0.27, 2.31]
Total events: 5 (Intermittent ir Heterogeneity: not applicable	,	ppl/placebo)				
Test for overall effect: $Z = 0.4$	14 (P = 0.66)					
3 Mixed/unknown						
Arcanjo 2011 (C)	6/23	17/22			15.0 %	0.34 [0.16, 0.70]
Roschnik 2003 (C)	19/46	18/46	, -	F	17.9 %	1.06 [0.64, 1.74]
Roschnik 2004 (C)	29/163	47/184	• •		19.0 %	0.70 [0.46, 1.05]
Hall 2002 (C)	123/248	160/253	3 🗖	:	21.3 %	0.78 [0.67, 0.92]
Subtotal (95% CI)	480	505	•	73	.2 %	0.73 [0.54, 0.98]
Total events: 177 (Intermitten	t iron suppl), 242 (N	lo suppl/placebo)				
Heterogeneity: Tau ² = 0.05; C	$Chi^2 = 6.84, df = 3$ (1	P = 0.08); I ² =56%				
Test for overall effect: $Z = 2.0$	07 (P = 0.038)					
Total (95% CI)	572	594	•	100	.0 %	0.54 [0.33, 0.90]
Total events: 190 (Intermitten	t iron suppl), 303 (N	lo suppl/placebo)				
Heterogeneity: $Tau^2 = 0.30$; C		(P<0.00001); I ² =85%				
Test for overall effect: $Z = 2.3$	(/					
Test for subgroup differences:	$Chi^2 = 20.36, df = 2$	2 (P = 0.00), $I^2 = 90\%$				
			0.01 0.1 1	10 100		
			Intermittent iron suppl	No suppl/placebo		

Analysis 5.6. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years, Outcome 6 Anaemia (by intermittent regimen).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years

Outcome: 6 Anaemia (by intermittent regimen)

Study or subgroup	Intermittent iron suppl	No suppl/placebo			Ratio M-	Weight	Risk Ratio M-
	n/N	n/N		H,Rando			H,Random,95% Cl
I One supplement a week							
Aguayo 2000	5/33	6/31				10.8 %	0.78 [0.27, 2.31]
Arcanjo 2011 (C)	6/23	17/22				15.0 %	0.34 [0.16, 0.70]
Berger 1997	8/59	55/58				16.0 %	0.14 [0.07, 0.27]
Hall 2002 (C)	123/248	160/253		•		21.3 %	0.78 [0.67, 0.92]
Roschnik 2003 (C)	19/46	18/46		+		17.9 %	1.06 [0.64, 1.74]
Roschnik 2004 (C)	29/163	47/184		-		19.0 %	0.70 [0.46, 1.05]
Subtotal (95% CI)	572	594		•		100.0 %	0.54 [0.33, 0.90]
2 Other intermittent regimes Subtotal (95% CI) Total events: 0 (Intermittent Heterogeneity: not applicable Test for overall effect: not ap	0 iron suppl), 0 (No suj e	O ppl/placebo)					Not estimable
Total (95% CI)	572	594		•		100.0 %	0.54 [0.33, 0.90]
Total events: 190 (Intermitte Heterogeneity: Tau ² = 0.30; Test for overall effect: Z = 2. Test for subgroup differences	$Chi^2 = 34.02, df = 5$ 38 (P = 0.017)	,					
			0.01	0.1	10 100		
			Favours exper		Favours control		

Analysis 5.7. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years, Outcome 7 Anaemia (by sex).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years

Outcome: 7 Anaemia (by sex)

Study or subgroup	Intermittent iron suppl	No suppl/placebo		sk Ratio Weight M-	Risk Ratio M-
	n/N	n/N	H,Rano	dom,95% Cl	H,Random,95 Cl
I Girls					
Hall 2002 (C)	56/122	77/126	-	18.5 %	0.75 [0.59, 0.95]
Subtotal (95% CI)	122	126	•	18.5 %	0.75 [0.59, 0.95]
Total events: 56 (Intermittent	iron suppl), 77 (No	suppl/placebo)			
Heterogeneity: not applicable					
Test for overall effect: $Z = 2.3$	36 (P = 0.018)				
2 Boys					
Hall 2002 (C)	67/126	83/127		18.8 %	0.81 [0.66, 1.00]
Subtotal (95% CI)	126	127	•	18.8 %	0.81 [0.66, 1.00]
Total events: 67 (Intermittent	iron suppl), 83 (No	suppl/placebo)			
Heterogeneity: not applicable					
Test for overall effect: $Z = 1.9$	95 (P = 0.051)				
3 Mixed/unknown	5/22				
Aguayo 2000	5/33	6/31	-	- 7.6 %	0.78 [0.27, 2.31]
Arcanjo 2011 (C)	6/23	17/22		11.5 %	0.34 [0.16, 0.70]
Berger 1997	8/59	55/58		12.6 %	0.14 [0.07, 0.27]
Roschnik 2003 (C)	19/46	18/46	-	- 4.8 %	1.06 [0.64, 1.74]
Roschnik 2004 (C)	29/163	47/184	-	16.1 %	0.70 [0.46, 1.05]
Subtotal (95% CI)	324	341	•	62. 7 %	0.49 [0.24, 1.01]
Total events: 67 (Intermittent	iron suppl), 143 (No	suppl/placebo)			
Heterogeneity: $Tau^2 = 0.56$; ($(P = 0.0000); ^2 = 86\%$			
Test for overall effect: $Z = 1.9$	· · · · ·	(
Total (95% CI)	572	594	•	100.0 %	0.59 [0.40, 0.86]
Total events: 190 (Intermitter	11, (
Heterogeneity: $Tau^2 = 0.19$; (Test for overall effect: $Z = 2.7$		(P<0.00001); I ² =83%			
Test for subgroup differences:	````	$(P - 0.40)$ $l^2 - 0.0\%$			
lest for subgroup differences.	. Chi = 1.85, di = 2	(1 – 0.40), 1 –0.0%			
			0.01 0.1 1	10 100	
		In	termittent iron suppl	No suppl/placebo	

Analysis 5.8. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years, Outcome 8 Anaemia (by nutrient).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years

Outcome: 8 Anaemia (by nutrient)

n/N 6/31 17/22 55/58 47/184 295 50) 7); 1 ² =84%	M- H,Random,95% Cl	10.8 % 15.0 % 16.0 % 19.0 % 60.8 %	M- H,Random,95 0.78 [0.27, 2.31] 0.34 [0.16, 0.70] 0.14 [0.07, 0.27] 0.70 [0.46, 1.05] 0.39 [0.17, 0.90]
17/22 55/58 47/184 295 00) 7); 1 ² =84%		15.0 % 16.0 % 19.0 % 60.8 %	0.34 [0.16, 0.70] 0.14 [0.07, 0.27] 0.70 [0.46, 1.05] 0.39 [0.17, 0.90]
17/22 55/58 47/184 295 00) 7); 1 ² =84%	 	15.0 % 16.0 % 19.0 % 60.8 %	0.34 [0.16, 0.70] 0.14 [0.07, 0.27] 0.70 [0.46, 1.05] 0.39 [0.17, 0.90]
55/58 47/184 295 Do) 7); 1 ² =84%	+ + +	16.0 % 19.0 % 60.8 %	0.14 [0.07, 0.27] 0.70 [0.46, 1.05] 0.39 [0.17, 0.90]
47/184 295 00) 7); 1 ² =84%	•	19.0 % 60.8 %	0.70 [0.46, 1.05] 0.39 [0.17, 0.90]
295 500) 7); 1 ² =84%	-	60.8 %	0.39 [0.17, 0.90]
00) 7); l ² =84%	•		
7); l ² =84%	+	179 %	
		17.770	1.06 [0.64, 1.74]
160/253	-	21.3 %	0.78 [0.67, 0.92]
299		39.2 %	0.83 [0.66, 1.03]
ebo) =20%			
0			Not estimable
594	•	100.0 %	0.54 [0.33, 0.90]
; I ² =85%			
	<u> </u>	1	
		100 opl/placebo	
	594 ebo) ; l ² =85% ² =65%	594 ← ebo) ; l ² =85% 2 ² =65%	594 ← 100.0 % ebo) ; l ² =85% ² =65% 0.01 0.1 10 100

Analysis 5.9. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years, Outcome 9 Haemoglobin (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years

Outcome: 9 Haemoglobin (ALL)

Study or subgroup	Intermittent iron suppl		No suppl/placebo		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% Cl		IV,Random,95% Cl
Aguayo 2000	33	155 (9.2)	31	153 (9)		9.7 %	2.00 [-2.46, 6.46]
Arcanjo 2011 (C)	23	119 (7.6)	22	114 (5.4)		10.1 %	5.00 [1.16, 8.84]
Berger 1997	58	150.5 (6.9)	57	32.2 (8.1)		► 10.6 %	18.30 [15.55, 21.05]
Hall 2002 (C)	248	116.4 (12.7)	253	112.6 (12.7)	-=-	10.8 %	3.80 [1.58, 6.02]
Olsen 2000	108	8.5 (2.4)	92	117.8 (5.98)		10.7 %	0.70 [-1.94, 3.34]
Roschnik 2003 (C)	46	110 (12.3)	46	111.5 (12.5)		9.3 %	-1.50 [-6.57, 3.57]
Roschnik 2004 (C)	163	124.5 (11.6)	184	122.3 (12.8)	-=-	10.7 %	2.20 [-0.37, 4.77]
Sen 2009 (C)	30	120 (4)	8	116 (6.3)		9.6 %	4.00 [-0.59, 8.59]
Sungthong 2002	130	126.9 (9.2)	121	125.3 (9.3)		10.8 %	I.60 [-0.69, 3.89]
Taylor 2001	64	-2.4 (11.65)	61	-5.8 (27.6)		7.8 %	3.40 [-4.09, 10.89]
Total (95% CI) Heterogeneity: Tau ² =	903 32.40; Chi ² = 1	20.88, df = 9 (f	875 P<0.00001); I ² =93%		•	100.0 %	4.04 [0.30, 7.78]
Test for overall effect: Z	Z = 2.12 (P = 0)	.034)					
Test for subgroup differ	rences: Not app	licable					
					-20 -10 0 10 2	20	

-20 -10 0 No suppl/placebo

Intermittent iron suppl

Analysis 5.10. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years, Outcome 10 Haemoglobin (by dose of elemental iron in the intermittent group).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years

Outcome: 10 Haemoglobin (by dose of elemental iron in the intermittent group)

Study or subgroup	Intermittent iron suppl N	Mean(SD)	No suppl/placebo N	Mean(SD)	Mean Difference IV.Random,95% CI	Weight	Mean Difference IV,Random,95% CI
	11	Ticari(SD)		1 (car(5D)			14,14a110011,7576 C
1 25 mg or less/week Subtotal (95% CI)	0		0				Not estimable
Heterogeneity: not applic			v				1 of Cstillable
Test for overall effect: not							
2 Greater than 25 mg to	75 mg/week						
Arcanjo 2011 (C)	23	119 (7.6)	22	114 (5.4)		10.1 %	5.00 [1.16, 8.84
Berger 1997	58	150.5 (6.9)	57	132.2 (8.1)	-	► 10.6 %	18.30 [15.55, 21.05]
Hall 2002 (C)	248	6.4 (2.7)	253	2.6 (2.7)		10.8 %	3.80 [1.58, 6.02]
Roschnik 2003 (C)	46	110 (12.3)	46	.5 (2.5)		9.3 %	-1.50 [-6.57, 3.57
Sungthong 2002	130	126.9 (9.2)	121	125.3 (9.3)		10.8 %	1.60 [-0.69, 3.89]
Taylor 2001	64	-2.4 (11.65)	61	-5.8 (27.6)		7.8 %	3.40 [-4.09, 10.89]
	569		560			50 3 %	5.24 [-0.78, 11.26]
Subtotal (95% CI)		277 df - 5 (D				J7.J ⁷⁰	9.21 [*0.70, 11.20]
Heterogeneity: $Tau^2 = 52$ Test for overall effect: Z = 3 Group: greater than 75	2.07; $Chi^2 = 10$ = 1.70 (P = 0.0 mg/week	88)	<0.00001); 12 =95%				
Heterogeneity: $Tau^2 = 52$ Test for overall effect: Z =	2.07; $Chi^2 = 10$ = 1.70 (P = 0.0			153 (9)	-+	9.7 %	
Heterogeneity: $Tau^2 = 52$ Test for overall effect: Z = 3 Group: greater than 75	2.07; $Chi^2 = 10$ = 1.70 (P = 0.0 mg/week	88)	<0.00001); 12 =95%	53 (9) 7.8 (5.98)			2.00 [-2.46, 6.46
Heterogeneity: Tau ² = 52 Test for overall effect: Z = 3 Group: greater than 75 Aguayo 2000	2.07; Chi ² = 10 = 1.70 (P = 0.0 mg/week 33	88)	<0.00001); 1 ² =95%		-+- + +	9.7 %	2.00 [-2.46, 6.46 0.70 [-1.94, 3.34
Heterogeneity: Tau ² = 52 Test for overall effect: Z = 3 Group: greater than 75 Aguayo 2000 Olsen 2000	2.07; Chi ² = 10 = 1.70 (P = 0.0 mg/week 33 108	88) 155 (9.2) 118.5 (12.4)	<0.00001); I ² =95% 31 92	117.8 (5.98)		9.7 % 10.7 %	2.00 [-2.46, 6.46 0.70 [-1.94, 3.34 2.20 [-0.37, 4.77 4.00 [-0.59, 8.59
Heterogeneity: Tau ² = 52 Test for overall effect: Z = 3 Group: greater than 75 Aguayo 2000 Olsen 2000 Roschnik 2004 (C)	2.07; Chi ² = 10 = 1.70 (P = 0.0 mg/week 33 108 163 30	88) 155 (9.2) 118.5 (12.4) 124.5 (11.6)	<0.00001); I ² =95% 31 92 184	7.8 (5.98) 22.3 (12.8)		9.7 % 10.7 % 10.7 %	2.00 [-2.46, 6.46 0.70 [-1.94, 3.34 2.20 [-0.37, 4.77
Heterogeneity: Tau ² = 52 Test for overall effect: Z = 3 Group: greater than 75 Aguayo 2000 Olsen 2000 Roschnik 2004 (C) Sen 2009 (C)	2.07; Chi ² = 1C = 1.70 (P = 0.0 mg/week 33 108 163 30 334	88) 155 (9.2) 118.5 (12.4) 124.5 (11.6) 120 (4)	<0.00001); I ² =95% 31 92 184 8 315	7.8 (5.98) 22.3 (12.8)		9.7 % 10.7 % 10.7 % 9.6 %	2.00 [-2.46, 6.46 0.70 [-1.94, 3.34 2.20 [-0.37, 4.77 4.00 [-0.59, 8.59
Heterogeneity: Tau ² = 52 Test for overall effect: Z = 3 Group: greater than 75 Aguayo 2000 Olsen 2000 Roschnik 2004 (C) Sen 2009 (C) Subtotal (95% CI)	2.07; Chi ² = 10 = 1.70 (P = 0.0 mg/week 33 108 163 30 334 0; Chi ² = 1.65,	88) 155 (9.2) 118.5 (12.4) 124.5 (11.6) 120 (4) df = 3 (P = 0.6	<0.00001); I ² =95% 31 92 184 8 315	7.8 (5.98) 22.3 (12.8)		9.7 % 10.7 % 10.7 % 9.6 %	2.00 [-2.46, 6.46 0.70 [-1.94, 3.34 2.20 [-0.37, 4.77 4.00 [-0.59, 8.59
Heterogeneity: Tau ² = 52 Test for overall effect: Z = 3 Group: greater than 75 Aguayo 2000 Olsen 2000 Roschnik 2004 (C) Sen 2009 (C) Subtotal (95% CI) Heterogeneity: Tau ² = 0.0 Test for overall effect: Z = Total (95% CI)	2.07; Chi ² = 10 = 1.70 (P = 0.0 mg/week 33 108 163 30 334 0; Chi ² = 1.65, = 2.26 (P = 0.0 903	88) 155 (9.2) 118.5 (12.4) 124.5 (11.6) 120 (4) df = 3 (P = 0.6 24)	<0.00001); l ² =95% 31 92 184 8 315 55); l ² =0.0% 875	7.8 (5.98) 22.3 (12.8)		9.7 % 10.7 % 10.7 % 9.6 %	2.00 [-2.46, 6.46 0.70 [-1.94, 3.34 2.20 [-0.37, 4.77 4.00 [-0.59, 8.59
Heterogeneity: Tau ² = 52 Test for overall effect: Z = 3 Group: greater than 75 Aguayo 2000 Olsen 2000 Roschnik 2004 (C) Sen 2009 (C) Subtotal (95% CI) Heterogeneity: Tau ² = 0.0 Tost for overall effect: Z = Total (95% CI) Heterogeneity: Tau ² = 32	2.07; $Chi^2 = 10$ = 1.70 (P = 0.0 mg/week 33 108 163 30 334 0; $Chi^2 = 1.65$, = 2.26 (P = 0.0 903 2.40; $Chi^2 = 12$	88) 155 (9.2) 118.5 (12.4) 124.5 (11.6) 120 (4) df = 3 (P = 0.6 24) 0.88, df = 9 (P-	<0.00001); l ² =95% 31 92 184 8 315 55); l ² =0.0% 875	7.8 (5.98) 22.3 (12.8)		9.7 % 10.7 % 10.7 % 9.6 % 40.7 %	2.00 [-2.46, 6.46 0.70 [-1.94, 3.34 2.20 [-0.37, 4.77 4.00 [-0.59, 8.59 1.84 [0.25, 3.44
Heterogeneity: Tau ² = 52 Test for overall effect: Z = 3 Group: greater than 75 Aguayo 2000 Olsen 2000 Roschnik 2004 (C) Sen 2009 (C) Subtotal (95% CI) Heterogeneity: Tau ² = 0.0 Test for overall effect: Z = Total (95% CI)	2.07; $Chi^2 = 10$ = 1.70 (P = 0.0 mg/week 33 108 163 30 334 0; $Chi^2 = 1.65$, = 2.26 (P = 0.0 903 2.40; $Chi^2 = 12$ = 2.12 (P = 0.0	88) 155 (9.2) 118.5 (12.4) 124.5 (11.6) 120 (4) df = 3 (P = 0.6 24) 0.88, df = 9 (P- 34)	<0.00001); l ² =95% 31 92 184 8 315 55); l ² =0.0% 875 <0.00001); l ² =93%	7.8 (5.98) 22.3 (12.8)	•	9.7 % 10.7 % 10.7 % 9.6 % 40.7 %	2.00 [-2.46, 6.46 0.70 [-1.94, 3.34 2.20 [-0.37, 4.77 4.00 [-0.59, 8.59 1.84 [0.25, 3.44

No suppl/placebo Intermittent iron suppl

Analysis 5.11. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years, Outcome 11 Haemoglobin (by duration of the supplementation).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years

Outcome: II Haemoglobin (by duration of the supplementation)

Study or subgroup	Intermittent iron suppl	No suppl/placebo			Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI		IV,Random,95% CI
l 0 to three months							
Hall 2002 (C)	248	116.4 (12.7)	253	2.6 (2.7)		10.8 %	3.80 [1.58, 6.02]
Roschnik 2004 (C)	163	24.5 (.6)	184	22.3 (2.8)		10.7 %	2.20 [-0.37, 4.77]
Taylor 2001	64	-2.4 (11.65)	61	-5.8 (27.6)		7.8 %	3.40 [-4.09, 10.89]
Subtotal (95% CI)	475		498		•	29.3 %	3.13 [1.49, 4.77]
Heterogeneity: $Tau^2 = 0.0$); $Chi^2 = 0.86$,	df = 2 (P = 0.6	5); I ² =0.0%				
Test for overall effect: Z =	= 3.74 (P = 0.0	0019)					
2 More than three month	IS						
Aguayo 2000	33	155 (9.2)	31	153 (9)		9.7 %	2.00 [-2.46, 6.46]
Arcanjo 2011 (C)	23	119 (7.6)	22	114 (5.4)		10.1 %	5.00 [1.16, 8.84]
Berger 1997	58	150.5 (6.9)	57	32.2 (8.1)	-=•	10.6 %	18.30 [15.55, 21.05]
Olsen 2000	108	8.5 (2.4)	92	117.8 (5.98)	-	10.7 %	0.70 [-1.94, 3.34]
Roschnik 2003 (C)	46	110 (12.3)	46	.5 (2.5)		9.3 %	-1.50 [-6.57, 3.57]
Sen 2009 (C)	30	120 (4)	8	116 (6.3)		9.6 %	4.00 [-0.59, 8.59]
Sungthong 2002	130	126.9 (9.2)	121	125.3 (9.3)		10.8 %	1.60 [-0.69, 3.89]
Subtotal (95% CI)	428		377			7 0. 7 %	4.38 [-1.20, 9.96]
Heterogeneity: $Tau^2 = 52$	97; Chi ² = 11	6.60, df = 6 (P<	<0.00001); I ² =95%				
Test for overall effect: Z =	= 1.54 (P = 0.12	2)					
Total (95% CI)	903		875		•	100.0 %	4.04 [0.30, 7.78]
Heterogeneity: $Tau^2 = 32$.40; $Chi^2 = 120$	0.88, df = 9 (P<	<0.00001); I ² =93%				
Test for overall effect: Z =	= 2.12 (P = 0.02)	34)					
Test for subgroup differen	ices: $Chi^2 = 0.1$	8, df = 1 (P =	0.67), l ² =0.0%				

-10 0 -20

10 No suppl/placebo Intermittent iron suppl

20

Analysis 5.12. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years, Outcome 12 Haemoglobin (by type of iron compound).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years

Outcome: 12 Haemoglobin (by type of iron compound)

Study or subgroup	Intermittent iron suppl N	Mean(SD)	No suppl/placebo N	Mean(SD)	Mean Difference IV,Random,95% CI	Weight	Mean Difference IV,Random,95% Cl
l Ferrous sulphate							
Roschnik 2003 (C)	46	0 (2.3)	46	.5 (2.5)		9.3 %	-1.50 [-6.57, 3.57]
Aguayo 2000	33	155 (9.2)	31	153 (9)		9.7 %	2.00 [-2.46, 6.46]
Arcanjo 2011 (C)	23	9 (7.6)	22	114 (5.4)		10.1 %	5.00 [1.16, 8.84]
Berger 1997	58	150.5 (6.9)	57	32.2 (8.1)		• 10.6 %	18.30 [15.55, 21.05]
Roschnik 2004 (C)	163	24.5 (.6)	184	22.3 (2.8)		10.7 %	2.20 [-0.37, 4.77]
Sungthong 2002	130	126.9 (9.2)	121	125.3 (9.3)		10.8 %	1.60 [-0.69, 3.89]
Hall 2002 (C)	248	6.4 (2.7)	253	2.6 (2.7)	-	10.8 %	3.80 [1.58, 6.02]
Subtotal (95% CI) Heterogeneity: $Tau^2 = 4C$ Test for overall effect: Z =	0.42; Chi ² = $ $		714 <0.00001); I ² =95%		-	72.0 %	4.59 [-0.30, 9.47]
2 Ferrous fumarate Taylor 2001	64	-2.4 (11.65)	61	-5.8 (27.6)		7.8 %	3.40 [-4.09, 10.89]
Subtotal (95% CI) Heterogeneity: not applic Test for overall effect: Z =		7)	61			7.8 %	3.40 [-4.09, 10.89]
3 Other Sen 2009 (C)	30	120 (4)	8	116 (6.3)		9.6 %	4.00 [-0.59, 8.59]
Olsen 2000	108	120 (1)		117.8 (5.98)	_	10.7 %	0.70 [-1.94, 3.34]
		110.3 (12.4)		117.6 (3.76)			
Subtotal (95% CI) Heterogeneity: $Tau^2 = 1$. Test for overall effect: Z =	79; Chi ² = 1.49	,	100 0.22); I ² =33%			20.3 %	1.79 [-1.25, 4.84]
Total (95% CI)	903	,	875		•	100.0 %	4.04 [0.30, 7.78]
Heterogeneity: Tau ² = 32 Test for overall effect: Z = Test for subgroup differen	= 2.12 (P = 0.0	34)	,				

-20 -10 0

10 No suppl/placebo Intermittent iron suppl

20

Analysis 5.13. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years, Outcome 13 Haemoglobin (by anaemia status at baseline).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years

Outcome: 13 Haemoglobin (by anaemia status at baseline)

Study or subgroup	Intermittent iron suppl N	Mean(SD)	No suppl/placebo N	Mean(SD)	Mean Difference IV,Random,95% CI	Weight	Mean Difference IV,Random,95% CI
I Anaemic							
Berger 1997	58	150.5 (6.9)	57	32.2 (8.1)		• 10.6 %	18.30 [15.55, 21.05]
Subtotal (95% CI) Heterogeneity: not applica	58 able		57			10.6 %	18.30 [15.55, 21.05]
Test for overall effect: Z = 2 Non-anaemic	: 13.03 (P < 0	.00001)					
Aguayo 2000	33	155 (9.2)	31	153 (9)		9.7 %	2.00 [-2.46, 6.46]
Subtotal (95% CI)	33		31		-	9. 7 %	2.00 [-2.46, 6.46]
Heterogeneity: not applica Test for overall effect: Z = 3 Mixed/unknown		88)					
Taylor 2001	64	-2.4 (11.65)	61	-5.8 (27.6)		7.8 %	3.40 [-4.09, 10.89]
Roschnik 2003 (C)	46	0 (2.3)	46	.5 (2.5)		9.3 %	-1.50 [-6.57, 3.57]
Sen 2009 (C)	30	120 (4)	8	116 (6.3)		9.6 %	4.00 [-0.59, 8.59]
Arcanjo 2011 (C)	23	9 (7.6)	22	114 (5.4)		10.1 %	5.00 [1.16, 8.84]
Olsen 2000	108	8.5 (2.4)	92	7.8 (5.98)	-	10.7 %	0.70 [-1.94, 3.34]
Roschnik 2004 (C)	163	24.5 (.6)	184	22.3 (2.8)		10.7 %	2.20 [-0.37, 4.77]
Sungthong 2002	130	126.9 (9.2)	121	125.3 (9.3)		10.8 %	1.60 [-0.69, 3.89]
Hall 2002 (C)	248	6.4 (2.7)	253	2.6 (2.7)	-	10.8 %	3.80 [1.58, 6.02]
Subtotal (95% CI)	812		787		•	7 9. 7 %	2.37 [1.17, 3.57]
Heterogeneity: $Tau^2 = 0.4$ Test for overall effect: Z =		,	0.32); ² = 4%				
Total (95% CI)	903		875		•	100.0 %	4.04 [0.30, 7.78]
Heterogeneity: Tau ² = 32	.40; Chi ² = 12	20.88, df = 9 (F	P<0.0000∣); ² =93%				
Test for overall effect: Z = Test for subgroup differen		,					

-20 -10 0

10 20 No suppl/placebo Intermittent iron suppl

Analysis 5.14. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years, Outcome 14 Haemoglobin (by supplementation regimen).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years

Outcome: 14 Haemoglobin (by supplementation regimen)

Study or subgroup	Intermittent iron suppl N	Mean(SD)	No suppl/placebo N	Mean(SD)	Mean Difference IV,Random,95% Cl	Weight	Mean Difference IV,Random,95% Cl
I One supplement a wee	k						
Taylor 2001	64	-2.4 (11.65)	61	-5.8 (27.6)		7.2 %	3.40 [-4.09, 10.89]
Sen 2009 (C)	13	120 (4)	4	116 (6.3)		7.8 %	4.00 [-2.55, 10.55]
Aguayo 2000	33	155 (9.2)	31	153 (9)		9.0 %	2.00 [-2.46, 6.46]
Roschnik 2003 (C)	91	4.8 (5.4)	91	6. (5.)		9.0 %	-1.30 [-5.73, 3.13]
Arcanjo 2011 (C)	23	119 (7.6)	22	114 (5.4)		9.4 %	5.00 [1.16, 8.84]
Berger 1997	58	150.5 (6.9)	57	32.2 (8.1)	-=-	9.9 %	18.30 [15.55, 21.05]
Roschnik 2004 (C)	163	124.5 (11.6)	184	122.3 (12.8)		9.9 %	2.20 [-0.37, 4.77]
Sungthong 2002	130	126.9 (9.2)	121	125.3 (9.3)		10.0 %	1.60 [-0.69, 3.89]
Hall 2002 (C)	248	6.4 (2.7)	253	2.6 (2.7)		10.1 %	3.80 [1.58, 6.02]
Subtotal (95% CI)	823		824		-	82.3 %	4.43 [0.21, 8.65]
Heterogeneity: $Tau^2 = 37$.04; $Chi^2 = 112$	3.59, df = 8 (P<	<0.00001); I ² =93%				
Test for overall effect: Z =	= 2.06 (P = 0.04	40)					
2 Other intermittent regir	men						
Sen 2009 (C)	17	120 (4)	4	116 (6.3)		7.8 %	4.00 [-2.46, 10.46]
Olsen 2000	108	8.5 (2.4)	92	117.8 (5.98)		9.9 %	0.70 [-1.94, 3.34]
Subtotal (95% CI)	125		96		+	17.7 %	1.17 [-1.27, 3.61]
Heterogeneity: $Tau^2 = 0.0$); Chi ² = 0.86,	df = 1 (P = 0.3	5); I ² =0.0%				
Test for overall effect: Z =	= 0.94 (P = 0.3	5)					
Total (95% CI)	948	,	920		-	100.0 %	4.04 [0.45, 7.62]
Heterogeneity: Tau ² = 31	.95; Chi ² = 12	2.00, df = 10 (F	P<0.0000∣); ² =92%				
Test for overall effect: Z =	= 2.21 (P = 0.0	27)					
Test for subgroup differen	ces: $Chi^2 = 1.7$	'I, df = I (P =	0.19), 1 ² =42%				

-20 -10 0 10 20

No suppl/placebo Intermittent iron suppl

Analysis 5.15. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years, Outcome 15 Haemoglobin (by sex).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years

Outcome: 15 Haemoglobin (by sex)

Study or subgroup	Intermittent iron suppl		No suppl/placebo		Mean Difference	Weight	Mean Difference
,	N	Mean(SD)	N	Mean(SD)	IV,Random,95% CI	-	IV,Random,95% C
Girls							
Hall 2002 (C)	122	7 (2.4)	126	3 (3.)		9.5 %	4.00 [0.83, 7.17]
Subtotal (95% CI)	122		126		•	9.5 %	4.00 [0.83, 7.17]
Heterogeneity: not applica	ble						
Test for overall effect: Z =	2.47 (P = 0.0	14)					
2 Boys Hall 2002 (C)	126	5.9 (2.9)	127	2.2 (2.4)		9.5 %	3.70 [0.58, 6.82]
Subtotal (95% CI)	126		127		•	9.5 %	3.70 [0.58, 6.82]
Heterogeneity: not applica							<i>bii</i> e [ei <i>s</i> e <i>i</i> e] e
Test for overall effect: Z =	2.33 (P = 0.02	20)					
3 Mixed/unknown							
Aguayo 2000	33	155 (9.2)	31	153 (9)		8.8 %	2.00 [-2.46, 6.46]
Arcanjo 2011 (C)	23	9 (7.6)	22	114 (5.4)		9.1 %	5.00 [1.16, 8.84]
Berger 1997	58	150.5 (6.9)	57	32.2 (8.1)	-	► 9.7 %	8.30 [5.55, 2 .05 <u> </u>
Olsen 2000	108	8.5 (2.4)	92	117.8 (5.98)	-	9.7 %	0.70 [-1.94, 3.34]
Roschnik 2003 (C)	46	110 (12.3)	46	.5 (2.5)	=	8.5 %	-1.50 [-6.57, 3.57]
Roschnik 2004 (C)	163	24.5 (.6)	184	122.3 (12.8)		9.7 %	2.20 [-0.37, 4.77]
Sen 2009 (C)	30	120 (4)	8	116 (6.3)		8.7 %	4.00 [-0.59, 8.59]
Sungthong 2002	130	126.9 (9.2)	2	125.3 (9.3)		9.8 %	1.60 [-0.69, 3.89]
Taylor 200 I	64	-2.4 (11.65)	61	-5.8 (27.6)	_	7.0 %	3.40 [-4.09, 10.89]
Subtotal (95% CI)	655		622		-	81.0 %	4.05 [-0.37, 8.46]
Heterogeneity: $Tau^2 = 41$.	22; Chi ² = 120	0.57, df = 8 (P<	<0.00001); 12 =93%				
Test for overall effect: Z =		72)					
Total (95% CI)	903		875		•	100.0 %	4.03 [0.51, 7.55]
Heterogeneity: Tau ² = 31. Test for overall effect: Z =			³ <0.00001); l ² =92%				
lest for overall effect: Z – Test for subgroup difference		,	$0.00)$ $1^{2} - 0.09'$				

-20 -10 0 No suppl/placebo I

Intermittent iron suppl

Analysis 5.16. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years, Outcome 16 Haemoglobin (by nutrient).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years

Outcome: 16 Haemoglobin (by nutrient)


Study or subgroup	Intermittent iron suppl		No suppl/placebo		Mean Difference	Weight	Mear Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% Cl	-	IV,Random,95% C
l Iron alone							
Aguayo 2000	33	155 (9.2)	31	153 (9)		9.7 %	2.00 [-2.46, 6.46]
Arcanjo 2011 (C)	23	119 (7.6)	22	114 (5.4)		10.1 %	5.00 [1.16, 8.84
Berger 1997	58	150.5 (6.9)	57	132.2 (8.1)	-	• 10.6 %	18.30 [15.55, 21.05
Olsen 2000	108	8.5 (2.4)	92	7.8 (5.98)	-	10.7 %	0.70 [-1.94, 3.34
Roschnik 2004 (C)	163	24.5 (.6)	184	22.3 (2.8)		10.7 %	2.20 [-0.37, 4.77
Sungthong 2002	130	126.9 (9.2)	121	125.3 (9.3)		10.8 %	1.60 [-0.69, 3.89
Subtotal (95% CI)	515		507			62.5 %	4.98 [-0.71, 10.68]
Heterogeneity: $Tau^2 = 48$.04; Chi ² = 11	4.64, df = 5 (P·	<0.00001); 1 ² =96%			-	
Test for overall effect: Z =	= 1.72 (P = 0.0	86)	,				
2 Iron + folic acid		,					
Taylor 2001	64	-2.4 (11.65)	61	-5.8 (27.6)		7.8 %	3.40 [-4.09, 10.89
Roschnik 2003 (C)	46	0 (2.3)	46	.5 (2.5)		9.3 %	-1.50 [-6.57, 3.57
Sen 2009 (C)	30	120 (4)	8	116 (6.3)		9.6 %	4.00 [-0.59, 8.59
Hall 2002 (C)	248	6.4 (2.7)	253	2.6 (2.7)		10.8 %	3.80 [1.58, 6.02
Subtotal (95% CI)	388		368		•	37.5 %	2.91 [0.65, 5.16
Heterogeneity: Tau ² = 1.1	4; Chi ² = 3.70), df = 3 (P = 0	.30); l ² = l 9%				
Test for overall effect: Z =	= 2.53 (P = 0.0	12)					
3 Iron + multiple micronu	itrients						
Subtotal (95% CI)	0		0				Not estimable
Heterogeneity: not application	able						
Test for overall effect: not	applicable						
Total (95% CI)	903		875		•	100.0 %	4.04 [0.30, 7.78
Heterogeneity: Tau ² = 32	.40; Chi ² = 12	0.88, df = 9 (P·	<0.00001); 12 =93%				
Test for overall effect: Z =	= 2.12 (P = 0.0	34)					
Test for subgroup differen	ces: $Chi^2 = 0.4$	14, df = 1 (P =	0.5 I), I ² =0.0%				
				-20	0 -10 0 10	20	
				Nosu	ppl/placebo Intermitten	t iron suppl	

Analysis 5.17. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years, Outcome 17 Ferritin (ALL).


Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years

Outcome: 17 Ferritin (ALL)



Analysis 5.18. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years, Outcome 18 All cause morbidity (ALL).



Analysis 5.19. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years, Outcome 19 Any side effects (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years

Outcome: 19 Any side effects (ALL)

Study or subgroup	Intermittent iron suppl	No suppl/placebo			Risk Ratio M-		Weight	Risk Ratio M-
	n/N	n/N		н,ка	ndom,95% Cl			H,Random,95% Cl
Ermis 2002	2/30	0/23			-		100.0 %	3.87 [0.19, 76.92]
Total (95% CI)	30	23					100.0 %	3.87 [0.19, 76.92]
Total events: 2 (Intermitt	ent iron suppl), 0 (No	suppl/placebo)						
Heterogeneity: not applie	cable							
Test for overall effect: Z	= 0.89 (P = 0.37)							
Test for subgroup differe	nces: Not applicable							
						I.		
			0.01	0.1	I I0	100		
		Ir	ntermittent ir	on suppl	No supp	ementation		

Analysis 5.20. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years, Outcome 20 Nausea.

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years

Outcome: 20 Nausea

Study or subgroup	Intermittent iron suppl	No suppl/placebo		Risk Ratio M-	Weight	Risk Ratio M-
	n/N	n/N	H,Rar	ndom,95% Cl		H,Random,95% Cl
Aguayo 2000	1/33	0/31			100.0 %	2.82 [0.12, 66.82]
Total (95% CI)	33	31			100.0 %	2.82 [0.12, 66.82]
Total events: (Intermitt	ent iron suppl), 0 (No	suppl/placebo)				
Heterogeneity: not appli	cable					
Test for overall effect: Z	= 0.64 (P = 0.52)					
Test for subgroup differe	nces: Not applicable					
					ı	
			0.01 0.1	1 10 10	00	
		Intern	nittent iron suppl	No intervent	tion/placebo	

Analysis 5.21. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years, Outcome 21 IQ (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years

Outcome: 21 IQ (ALL)

Study or subgroup	Intermittent iron suppl N	Mean(SD)	No suppl/placebo N	Mean(SD)	t Differ IV,Randor	Mean rence m,95% Cl	Weight	Mean Difference IV,Random,95% Cl
Sungthong 2002	130	83 (12)	122	86 (12)	+		100.0 %	-3.00 [-5.96, -0.04]
Total (95% CI)	130		122		•		100.0 %	-3.00 [-5.96, -0.04]
Heterogeneity: not ap								
Test for overall effect:								
Test for subgroup diffe	erences: Not ap	plicable						
				-10		50 10		
				INO SUPPI	ementation	Intermittent	iron suppl	

Analysis 5.22. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years, Outcome 22 Thai language (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years

Outcome: 22 Thai language (ALL)

Study or subgroup	Intermittent iron suppl		Mean No suppl/placebo Difference			Weight	Mean Difference				
	Ν	Mean(SD)	Ν	Mean(SD)		IV,Ran	(Random,95% Cl				IV,Random,95% CI
Sungthong 2002	105	0.001 (0.8)	103	0.3 (0.7)						100.0 %	-0.30 [-0.50, -0.09]
Total (95% CI)	105		103							100.0 %	-0.30 [-0.50, -0.09]
Heterogeneity: not ap	plicable										
Test for overall effect:	Z = 2.87 (P =	0.0041)									
Test for subgroup diffe	erences: Not ap	plicable									
							_				
				-	100	-50	0	50	100		
				No su	ppleme	entation		Intermitt	tent iro	n suppl	

Analysis 5.23. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years, Outcome 23 Mathematics (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 2 years of age Comparison: 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years Outcome: 23 Mathematics (ALL) Intermittent Mean Difference Weight Study or subgroup No suppl/placebo iron suppl IV,Random,95% CI N Mean(SD) N Mean(SD) Sungthong 2002 130 0.03 (0.7) 103 0.3 (0.65) 100.0 % Total (95% CI) 130 103 100.0 % -0.27 [-0.44, -0.10] Heterogeneity: not applicable Test for overall effect: Z = 3.04 (P = 0.0023) Test for subgroup differences: Not applicable

No supplementation

0

-100 -50

Intermittent iron suppl

50 100

Intermittent iron supplementation for improving nutrition and development in children under 12 years of age (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

252

Mean

Difference

IV,Random,95% Cl

-0.27 [-0.44, -0.10]

Analysis 5.24. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years, Outcome 24 Increase in steps climbed (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years

Outcome: 24 Increase in steps climbed (ALL)

Study or subgroup	Intermittent iron suppl N	Mean(SD)	No suppl/placebo N	Mean(SD)	r	Diffe	Mean erence om,95% Cl	Weight	Mean Difference IV,Random,95% Cl
Sen 2009 (C)	43	21 (13.53)	17	3 (6.26)				100.0 %	8.00 [-0.72, 6.72]
Total (95% CI)	43		17				•	100.0 %	8.00 [-0.72, 16.72]
Heterogeneity: not ap	plicable								
Test for overall effect:	Z = 1.80 (P =	0.072)							
Test for subgroup diffe	erences: Not ap	plicable							
								1	
					-100 -5	i0 (50	100	
				No	suppl/plac	ebo	Intermitt	ent iron suppl	

Analysis 5.25. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years, Outcome 25 WAZ.

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years

Outcome: 25 WAZ


Study or subgroup	Intermittent iron suppl N	Mean(SD)	No suppl/placebo N	Mean(SD)			Std. Mean ifference dom,95% Cl	Weight	Std. Mean Difference IV,Random,95% Cl
Aguayo 2000	33	-0.98 (0.92)	31	-0.79 (0.56)		ļ		100.0 %	-0.24 [-0.74, 0.25]
Total (95% CI)	33		31					100.0 %	-0.24 [-0.74, 0.25]
Heterogeneity: not ap	plicable								
Test for overall effect:	Z = 0.97 (P =	0.33)							
Test for subgroup diffe	rences: Not ap	oplicable							
					100	-50	0 50	100	
				No su	pplemer	ntation	Intermitt	ent iron suppl	

Analysis 5.26. Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years, Outcome 26 HAZ.

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 5 Intermittent iron supplementation versus placebo or no intervention: children 5 - 12 years

Outcome: 26 HAZ



Analysis 6.1. Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years, Outcome I Anaemia (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years

Outcome: I Anaemia (ALL)

Study or subgroup	Intermittent iron suppl n/N	Daily iron suppl			Risk Ratio M- ndom,95% Cl		Weight	Risk Ratio M- H,Random,95% Cl_
Sinisterra 1997 (C)	5/15	3/12		_			33.3 %	1.33 [0.40, 4.49]
Berger 1997	8/59	10/59		4	-		66.7 %	0.80 [0.34, 1.88]
Total (95% CI)	74	71		-	•		100.0 %	0.95 [0.47, 1.91]
Total events: 13 (Intermitte	ent iron suppl), 13 (Da	ily iron suppl)						
Heterogeneity: $Tau^2 = 0.0$;	$Chi^2 = 0.46, df = 1$ (I	P = 0.50); I ² =0.0%						
Test for overall effect: Z =	0.15 (P = 0.88)							
Test for subgroup difference	es: Not applicable							
			1					
			0.01	0.1	I I0	100		
			Intermittent in	on suppl	Daily irc	n suppl		

Analysis 6.2. Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years, Outcome 2 Haemoglobin (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years

Outcome: 2 Haemoglobin (ALL)

Study or subgroup	Intermittent iron suppl		Daily iron suppl		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI		IV,Random,95% CI
Sen 2009 (C)	30	120 (4)	12	122 (5.5)		17.2 %	-2.00 [-5.43, 1.43]
Siddiqui 2004	30	121.2 (6)	30	124.4 (5.4)		19.3 %	-3.20 [-6.09, -0.31]
Soemantri 1997	45	27. (5.)	50	123.3 (8)		20.2 %	3.80 [1.13, 6.47]
Berger 1997	58	150.5 (6.9)	58	150.1 (6.7)		21.1 %	0.40 [-2.08, 2.88]
Sungthong 2002	130	126.9 (9.2)	138	127.8 (9.2)		22.2 %	-0.90 [-3.10, 1.30]
Total (95% CI)	293		288		-	100.0 %	-0.31 [-2.59, 1.97]
					-10 -5 0 5 Daily iron suppl Intermitte	10 ent iron suppl	

Analysis 6.3. Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years, Outcome 3 Haemoglobin (by dose of elemental iron).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years

Outcome: 3 Haemoglobin (by dose of elemental iron)

Study or subgroup	Intermittent iron suppl N	Mean(SD)	Daily iron suppl N	Mean(SD)		Mean erence om,95% Cl	Weight	Mean Difference IV,Random,95% CI
1 25 mg or less/week								
Subtotal (95% CI)	0		0					Not estimable
Heterogeneity: not applica	ble							
Test for overall effect: not	applicable							
2 Greater than 25 mg to 7	′5 mg/week							
Siddiqui 2004	30	121.2 (6)	30	124.4 (5.4)	←∎		19.3 %	-3.20 [-6.09, -0.31]
Berger 1997	58	150.5 (6.9)	58	150.1 (6.7)			21.1 %	0.40 [-2.08, 2.88]
Sungthong 2002	130	126.9 (9.2)	138	127.8 (9.2)			22.2 %	-0.90 [-3.10, 1.30]
Subtotal (95% CI)	218		226				62.6 %	-1.10 [-3.01, 0.80]
Heterogeneity: $Tau^2 = 1.20$	0; Chi ² = 3.46,	df = 2 (P = 0.18); l ² =42%					
Test for overall effect: Z =								
3 Intermittent group: great	er than 75 mg/	week						
Sen 2009 (C)	30	120 (4)	12	122 (5.5)	← ■		17.2 %	-2.00 [-5.43, 1.43]
Soemantri 1997	45	127.1 (5.1)	50	123.3 (8)			20.2 %	3.80 [1.13, 6.47]
Subtotal (95% CI)	75		62				37.4 %	1.00 [-4.68, 6.68]
Heterogeneity: $Tau^2 = 14.2$	36; Chi ² = 6.85	df = 1 (P = 0.0)	I); I ² =85%					
Test for overall effect: Z =	0.35 (P = 0.73)						
Total (95% CI)	293		288				100.0 %	-0.31 [-2.59, 1.97]
Heterogeneity: $Tau^2 = 4.8$	5; Chi ² = 14.43	8, df = 4 (P = 0.0	I); I ² =72%					
Test for overall effect: $Z =$	0.26 (P = 0.79)						
Test for subgroup difference	ces: $Chi^2 = 0.48$	8, df = 1 (P = 0.4	9), l ² =0.0%					
							1	
					-4 -2	0 2	4	
					Daily iron suppl	Intermittent	iron suppl	

Analysis 6.4. Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years, Outcome 4 Haemoglobin (by duration of the supplementation).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years

Outcome: 4 Haemoglobin (by duration of the supplementation)

Study or subgroup	Intermittent iron suppl		Daily iron suppl		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI		IV,Random,95% CI
0 to three months							
Siddiqui 2004	30	121.2 (6)	30	124.4 (5.4)	←■	19.3 %	-3.20 [-6.09, -0.31]
Soemantri 1997	45	127.1 (5.1)	50	123.3 (8)		2 0.2 %	3.80 [1.13, 6.47]
Subtotal (95% CI)	75		80			- 39.6 %	0.32 [-6.54, 7.18]
Heterogeneity: $Tau^2 = 22$.	.49; Chi ² = 12.1	6, df = 1 (P =	0.00049); l ² =92%				
Test for overall effect: Z =	0.09 (P = 0.93)					
2 More than three months	s						
Sen 2009 (C)	30	120 (4)	12	122 (5.5)	•	17.2 %	-2.00 [-5.43, 1.43]
Berger 1997	58	150.5 (6.9)	58	150.1 (6.7)		21.1 %	0.40 [-2.08, 2.88]
Sungthong 2002	130	126.9 (9.2)	138	127.8 (9.2)		22.2 %	-0.90 [-3.10, 1.30]
Subtotal (95% CI)	218		208		-	60.4 %	-0.64 [-2.12, 0.84]
Heterogeneity: $Tau^2 = 0.0$; Chi ² = 1.34, c	If = 2 (P = 0.5	I); I ² =0.0%				
Test for overall effect: Z =	0.84 (P = 0.40)					
Total (95% CI)	293		288			100.0 %	-0.31 [-2.59, 1.97]
Heterogeneity: $Tau^2 = 4.8$	5; Chi ² = 14.43	8, df = 4 (P = 0	0.01); I ² =72%				
Test for overall effect: $Z =$	0.26 (P = 0.79)					
Test for subgroup difference	ces: $Chi^2 = 0.07$	7, df = 1 (P = 0	0.79), l ² =0.0%				

-2 0 2 4

-4

Daily iron suppl Intermittent iron suppl

Analysis 6.5. Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years, Outcome 5 Haemoglobin (by type of compound).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years

Outcome: 5 Haemoglobin (by type of compound)

Study or subgroup	Intermittent iron suppl		Daily iron suppl		Diffen		Weight	Mean Difference
	Ν	Mean(SD)	N	Mean(SD)	IV,Randor	n,95% Cl		IV,Random,95% CI
I Ferrous sulphate								
Siddiqui 2004	30	121.2 (6)	30	124.4 (5.4)	• •		19.3 %	-3.20 [-6.09, -0.31]
Soemantri 1997	45	127.1 (5.1)	50	123.3 (8)			20.2 %	3.80 [1.13, 6.47]
Berger 1997	58	150.5 (6.9)	58	150.1 (6.7)			21.1 %	0.40 [-2.08, 2.88]
Sungthong 2002	130	126.9 (9.2)	138	127.8 (9.2)			22.2 %	-0.90 [-3.10, 1.30]
Subtotal (95% CI)	263		276				82.8 %	0.04 [-2.63, 2.71]
Heterogeneity: $Tau^2 = 5.7$	2; Chi ² = 13.22	2, df = 3 (P = 0).004); l ² =77%					
Test for overall effect: Z =		``	· ·					
2 Ferrous fumarate	,	,						
Subtotal (95% CI)	0		0					Not estimable
Heterogeneity: not applica	ble							
Test for overall effect: not	applicable							
3 Other								
Sen 2009 (C)	30	120 (4)	12	122 (5.5)			17.2 %	-2.00 [-5.43, 1.43]
Subtotal (95% CI)	30		12				17.2 %	-2.00 [-5.43, 1.43]
Heterogeneity: not applica	ble							
Test for overall effect: Z =	1.14 (P = 0.25)						
Total (95% CI)	293		288				100.0 %	-0.31 [-2.59, 1.97]
Heterogeneity: $Tau^2 = 4.8$	5; Chi ² = 14.43	8, df = 4 (P = 0	0.01); I ² =72%					
Test for overall effect: Z =	0.26 (P = 0.79)						
Test for subgroup difference	ces: $Chi^2 = 0.85$	5, df = 1 (P = 0	0.36), I ² =0.0%					
						1	1	
				-	4 -2 0	2 4	4	
				Da	aily iron suppl	Intermittent	iron suppl	

Analysis 6.6. Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years, Outcome 6 Haemoglobin (by baseline prevalence of anaemia).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years

Outcome: 6 Haemoglobin (by baseline prevalence of anaemia)

Study or subgroup	Intermittent iron suppl		Daily iron suppl		M Differe	lean ence	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Randon	n,95% Cl		IV,Random,95% CI
I Anaemic								
Siddiqui 2004	30	121.2 (6)	30	124.4 (5.4)	• •		19.3 %	-3.20 [-6.09, -0.31]
Soemantri 1997	45	127.1 (5.1)	50	123.3 (8)			20.2 %	3.80 [1.13, 6.47]
Berger 1997	58	150.5 (6.9)	58	150.1 (6.7)			21.1 %	0.40 [-2.08, 2.88]
Subtotal (95% CI)	133		138				60.6 %	0.37 [-3.44, 4.17]
Heterogeneity: $Tau^2 = 9.46$	6; Chi ² = 12.17	7, df = 2 (P = 0	0.002); I ² =84%					
Test for overall effect: $Z =$	0.19 (P = 0.85)						
2 Non-anaemic								
Subtotal (95% CI)	0		0					Not estimable
Heterogeneity: not applical Test for overall effect: not a								
3 Mixed/unknown	applicable							
Sen 2009 (C)	30	120 (4)	12	122 (5.5)	•		17.2 %	-2.00 [-5.43, 1.43]
Sungthong 2002	130	126.9 (9.2)	138	127.8 (9.2)			22.2 %	-0.90 [-3.10, 1.30]
Subtotal (95% CI)	160		150				39.4 %	-1.22 [-3.08, 0.63]
Heterogeneity: $Tau^2 = 0.0$;	; Chi ² = 0.28, c	lf = 1 (P = 0.6	0); l ² =0.0%					
Test for overall effect: Z =	I.29 (P = 0.20)						
Total (95% CI)	293		288				100.0 %	-0.31 [-2.59, 1.97]
Heterogeneity: $Tau^2 = 4.85$			0.01); I ² =72%					
Test for overall effect: $Z =$,						
Test for subgroup difference	ces: Chi ² = 0.5^{4}	1, df = 1 (P =	0.46), l ² =0.0%					
				-	-4 -2 0		4	
				L	Daily iron suppl	Intermittent	iron suppl	

Analysis 6.7. Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years, Outcome 7 Haemoglobin (by supplementation regimen).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years

Outcome: 7 Haemoglobin (by supplementation regimen)

Study or subgroup	Intermittent iron suppl		Daily iron suppl		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% Cl		IV,Random,95% CI
l by supplementation reg	imen: one suppl	lement a week					
Sen 2009 (C)	30	120 (4)	12	122 (5.5)	· •	17.2 %	-2.00 [-5.43, 1.43]
Siddiqui 2004	30	121.2 (6)	30	124.4 (5.4)	· •	19.3 %	-3.20 [-6.09, -0.3]
Soemantri 1997	45	127.1 (5.1)	50	123.3 (8)		20.2 %	3.80 [1.13, 6.47]
Berger 1997	58	150.5 (6.9)	58	150.1 (6.7)		21.1 %	0.40 [-2.08, 2.88]
Sungthong 2002	130	126.9 (9.2)	138	127.8 (9.2)		22.2 %	-0.90 [-3.10, 1.30]
Subtotal (95% CI)	293		288			100.0 %	-0.31 [-2.59, 1.97]
Heterogeneity: Tau ² = 4.8	35; Chi ² = 14.43	B, df = 4 (P = 0.	01); I ² =72%				
Test for overall effect: Z =	0.26 (P = 0.79	')					
2 by supplementation regi	imen: other inte	ermittent regime	n				
Subtotal (95% CI)	0		0				Not estimable
Heterogeneity: not applica	able						
Test for overall effect: not	applicable						
Total (95% CI)	293		288			100.0 %	-0.31 [-2.59, 1.97]
Heterogeneity: Tau ² = 4.8	35; Chi ² = 14.43	3, df = 4 (P = 0.	01); I ² =72%				
Test for overall effect: Z =	0.26 (P = 0.79	')					
Test for subgroup differen	ces: Not applica	able					

-4 -2 0 2 4

Daily iron suppl Intermittent iron suppl

Analysis 6.8. Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years, Outcome 8 Haemoglobin (by sex).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years

Outcome: 8 Haemoglobin (by sex)

Study or subgroup	Intermittent iron suppl	1	Daily iron suppl		Mean Difference	Weight	Mear Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% (IV,Random,95% C
Girls							
Sen 2009 (C)	30	120 (4)	12	122 (5.5)	• •	17.2 %	-2.00 [-5.43, 1.43
Subtotal (95% CI)	30		12			17.2 %	-2.00 [-5.43, 1.43
Heterogeneity: not applica	able						
Test for overall effect: Z =	= 1.14 (P = 0.25)					
2 Boys							
Subtotal (95% CI)	0		0				Not estimable
Heterogeneity: not applica							
Test for overall effect: not	applicable						
3 Mixed/unknown Siddiqui 2004	30	121.2 (6)	30	124.4 (5.4)	• • •	19.3 %	-3.20 [-6.09, -0.31
Soemantri 1997	45	127.1 (5.1)	50	123.3 (8)		20.2 %	3.80 [1.13, 6.47
Berger 1997	58	150.5 (6.9)	58	150.1 (6.7)		- 21.1 %	0.40 [-2.08, 2.88
0		× /		· · · ·			
Sungthong 2002	130	126.9 (9.2)	138	127.8 (9.2)		22.2 %	-0.90 [-3.10, 1.30
Subtotal (95% CI)	263		276			82.8 %	0.04 [-2.63, 2.71
Heterogeneity: $Tau^2 = 5.7$	72; Chi ² = 13.22	e, df = 3 (P = 0.00	04); I ² =77%				
Test for overall effect: Z =)					
Total (95% CI)	293		288			100.0 %	-0.31 [-2.59, 1.97
Heterogeneity: $Tau^2 = 4.8$,	I); I ² =72%				
Test for overall effect: Z =							
Test for subgroup differen	ices: Chi ² = 0.85	5, df = 1 (P = 0.3	6), I ² =0.0%				
					4 -2 0 2	4	
						4 hittent iron suppl	
				Da	пу пон заррі пілент	interne ir orr suppr	

Analysis 6.9. Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years, Outcome 9 Haemoglobin (by nutrient).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years

Outcome: 9 Haemoglobin (by nutrient)

Study or subgroup	Intermittent iron suppl		Daily iron suppl		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI		IV,Random,95% CI
l Iron alone							
Siddiqui 2004	30	121.2 (6)	30	124.4 (5.4)	•	19.3 %	-3.20 [-6.09, -0.31]
Soemantri 1997	45	127.1 (5.1)	50	123.3 (8)		20.2 %	3.80 [1.13, 6.47]
Berger 1997	58	150.5 (6.9)	58	150.1 (6.7)		21.1 %	0.40 [-2.08, 2.88]
Sungthong 2002	130	126.9 (9.2)	138	127.8 (9.2)		22.2 %	-0.90 [-3.10, 1.30]
Subtotal (95% CI)	263		276			82.8 %	0.04 [-2.63, 2.71]
Heterogeneity: $Tau^2 = 5.7$	2; Chi ² = 13.22	2, df = 3 (P = 0)	$(0.004); 1^2 = 77\%$				
Test for overall effect: Z =							
2 Iron + folic acid	``	,					
Sen 2009 (C)	30	120 (4)	12	122 (5.5)	• •	17.2 %	-2.00 [-5.43, 1.43]
Subtotal (95% CI)	30		12			17.2 %	-2.00 [-5.43, 1.43]
Heterogeneity: not applica	ble						
Test for overall effect: Z =	I.I4 (P = 0.25)					
3 By nutrient: iron + multi	ple micronutrie	nts					
Subtotal (95% CI)	0		0				Not estimable
Heterogeneity: not applica	ble						
Test for overall effect: not	applicable						
Total (95% CI)	293		288			100.0 %	-0.31 [-2.59, 1.97]
Heterogeneity: $Tau^2 = 4.8$	5; Chi ² = 14.43	8, df = 4 (P = 0	0.01); I ² =72%				
Test for overall effect: Z =			,				
Test for subgroup differend	ces: $Chi^2 = 0.8!$, 5. df = 1 (P =)	0.36), l ² =0.0%				
0							
					4 -2 0 2	4	
						nt iron suppl	
				Da	iy i on suppi intermitter	сползаррі	

Analysis 6.10. Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years, Outcome 10 Ferritin (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years

Outcome: 10 Ferritin (ALL)

Study or subgroup	Intermittent iron suppl		Daily iron suppl				Mean ference	Weight	Mean Difference
	N	Mean(SD)	N	Mean(SD)		IV,Ranc	dom,95% Cl		IV,Random,95% CI
Sungthong 2002	123	54 (24.2)	137	79.7 (36.6)	٠			49.1 %	-25.70 [-33.17, -18.23]
Siddiqui 2004	30	22.78 (0.6)	30	20.74 (0.54)				50.9 %	2.04 [1.75, 2.33]
Total (95% CI)	153		167					100.0 %	-11.57 [-38.75, 15.61]
Heterogeneity: Tau ² =	= 377.47; Chi ²	= 52.85, df = 1	(P<0.00001); I ² =	98%					
Test for overall effect:	Z = 0.83 (P =	0.40)							
Test for subgroup diffe	erences: Not aj	pplicable							
								1	
					-20	-10	0 10	20	

Daily iron suppl Intermittent iron suppl

Analysis 6.11. Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years, Outcome 11 All cause morbidity (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years

Outcome: II All cause morbidity (ALL)

Study or subgroup	Intermittent iron suppl n/N	Daily iron suppl			Risk Ratic M- Idom,959 Cl		Weight	Risk Ratio M- H,Random,95% Cl
Da Silva 2008	25/38	28/39		-	-		100.0 %	0.92 [0.68, 1.24]
Total (95% CI)	38	39		•	•		100.0 %	0.92 [0.68, 1.24]
Total events: 25 (Intermit	ttent iron suppl), 28 (D	aily iron suppl)						
Heterogeneity: not applic	cable							
Test for overall effect: Z =	= 0.57 (P = 0.57)							
Test for subgroup differer	nces: Not applicable							
						1		
			0.01	0.1	I IO	100		
			Intermittent in	on suppl	Daily	iron suppl		

Analysis 6.12. Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years, Outcome 12 Diarrhoea (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years

Outcome: 12 Diarrhoea (ALL)

Study or subgroup	Intermittent iron suppl	Daily iron suppl		Risk Ratio M-	Weight	Risk Ratio M- H Random 959
	n/N	n/N	H,Rar	ndom,95% Cl		H,Random,95 Cl
Da Silva 2008	12/38	11/39		•	100.0 %	1.12 [0.56, 2.22]
Total (95% CI)	38	39		•	100.0 %	1.12 [0.56, 2.22]
Total events: 12 (Intermit Heterogeneity: not applic		aily iron suppl)				
Test for overall effect: Z =						
Test for subgroup differer	nces: Not applicable					
			I			
			0.01 0.1	1 10 100		
			Intermittent iron suppl	Daily iron suppl		

Analysis 6.13. Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years, Outcome 13 Adherence (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years

Intermittent

Outcome: 13 Adherence (ALL)

Study or subgroup	iron suppl	Daily iron suppl	н	Risk Ratio M- Random,95%	Weight	Risk Ratio M- H,Random,95%
	n/N	n/N	,	CI		Cl
Sen 2009 (C)	56/85	17/42			48.3 %	1.63 [1.09, 2.42]
Berger 1997	59/59	57/59		•	51.7 %	1.03 [0.98, 1.10]
Total (95% CI)	144	101	-		100.0 %	1.29 [0.44, 3.75]
Total events: 115 (Interm	ittent iron suppl), 74 (Daily iron suppl)				
Heterogeneity: $Tau^2 = 0$.	58; Chi ² = 28.43, df =	(P<0.0000); ² =96%				
Test for overall effect: Z =	= 0.46 (P = 0.64)					
Test for subgroup differer	nces: Not applicable					
			0.1 0.2 0.5	i 2 5 IC)	

Daily iron suppl Intermittent iron suppl

Analysis 6.14. Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years, Outcome 14 IQ (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years

Outcome: 14 IQ (ALL)

Study or subgroup	Intermittent iron suppl N	Mean(SD)	Daily iron suppl N	Mean(SD)		Mean ference dom,95% Cl	Weight	Mean Difference IV,Random,95% CI
Sungthong 2002	130	83 (12)	122	86 (12)		+	100.0 %	-3.00 [-5.96, -0.04]
Total (95% CI)	130		122			•	100.0 %	-3.00 [-5.96, -0.04]
Heterogeneity: not ap	plicable							
Test for overall effect:	Z = 1.98 (P = 0)).047)						
Test for subgroup diffe	erences: Not ap	olicable						
				-10	-50	0 50	100	
				Dail	iron suppl	Intermitte	ent iron suppl	

Analysis 6.15. Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years, Outcome 15 Thai language (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years

Outcome: 15 Thai language (ALL)

Me Differer IV,Random,95%	Weight	Mean Difference /,Random,95% Cl)	Mean(SD)	Daily iron suppl N	Mean(SD)	Intermittent iron suppl N	Study or subgroup
-0.30 [-0.50, -0.0	100.0 %)	0.3 (0.7)	103	0.001 (0.8)	105	Sungthong 2002
-0.30 [-0.50, -0.09	100.0 %				103		105	Total (95% CI)
						200412		Heterogeneity: not ap
								Test for overall effect: Test for subgroup diffe
	1					рпсавіс	crences. Not app	lest for subgroup and
	00	0 0 50 1	-100 -5					
			Daily iron s					

Analysis 6.16. Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years, Outcome 16 Mathematics (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years

Outcome: 16 Mathematics (ALL)

Study or subgroup	Intermittent iron suppl N	Mean(SD)	Daily iron suppl N	Mean(SD)		Mean erence om,95% Cl	Weight	Mean Difference IV,Random,95% Cl
Sungthong 2002	130	0.03 (0.7)	103	0.3 (0.65)			100.0 %	-0.27 [-0.44, -0.10]
Total (95% CI) Heterogeneity: not ap Test for overall effect: Test for subgroup diffe	Z = 3.04 (P = 0)	<i>'</i>	103				100.0 %	-0.27 [-0.44, -0.10]
					-100 -50 Daily iron suppl	0 50 Intermittent	00 : iron suppl	

Analysis 6.17. Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years, Outcome 17 Increase in steps climbed (ALL).

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years

Outcome: 17 Increase in steps climbed (ALL)

Study or subgroup	Intermittent iron suppl N	Mean(SD)	Daily iron suppl N	Mean(SD)	Diffe	Mean erence om,95% Cl	Weight	Mean Difference IV,Random,95% Cl
Sen 2009 (C)	43	24 (17.4)	22	29 (15.6)	-		100.0 %	-5.00 [-13.34, 3.34]
Total (95% CI) Heterogeneity: not ap Test for overall effect: Test for subgroup diff	Z = 1.18 (P = 0	,	22		•		100.0 %	-5.00 [-13.34, 3.34]
					-100 -50 C Daily iron suppl) 50 l Intermittent	00 iron suppl	

Analysis 6.18. Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years, Outcome 18 HAZ.

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years

Outcome: 18 HAZ

Study or subgroup	Intermittent iron suppl	M(CD)	Daily iron suppl	M(CD)			Std. Mean Difference	CI	Weight	Std. Mean Difference
	Ν	Mean(SD)	N	Mean(SD)		iv,Ran	dom,95%	CI		IV,Random,95% Cl
Da Silva 2008	39	0.283 (1.308)	36	0.08 (0.983)					49.6 %	0.17 [-0.28, 0.62]
Soemantri 1997	45	0 (0.1)	50	0.08 (0.1)					50.4 %	-0.79 [-1.21, -0.37]
Total (95% CI)	84		86						100.0 %	-0.32 [-1.26, 0.63]
Heterogeneity: Tau ² =	$= 0.41; Chi^2 = 9$	9.35, df = 1 (P =	0.002); l ² =89%							
Test for overall effect:	Z = 0.66 (P =	0.51)								
Test for subgroup diff	erences: Not ap	oplicable								
					-100	-50	0 50	100		

Daily iron suppl

Intermittent iron suppl

Analysis 6.19. Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years, Outcome 19 WAZ.

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years

Outcome: 19 WAZ

Study or subgroup	Intermittent iron suppl N	Mean(SD)	Daily iron suppl N	Mean(SD)	Iv	Std. Mean Difference (Random,95% Cl	Weight	Std. Mean Difference IV,Random,95% Cl
Da Silva 2008	39	0.29 (1.358)	36	0.03 (1.097)			44.0 %	0.21 [-0.24, 0.66]
Soemantri 1997	45	0.09 (0.1)	50	0.09 (0.01)			56.0 %	0.0 [-0.40, 0.40]
Total (95% CI)	84		86				100.0 %	0.09 [-0.21, 0.39]
Heterogeneity: Tau ² =	$= 0.0; Chi^2 = 0.4$	16, df = 1 (P = 0.	.50); l ² =0.0%					
Test for overall effect:	Z = 0.60 (P =	0.55)						
Test for subgroup diff	erences: Not ap	plicable						
					-100 -50	0 50	100	
					Daily iron su	ppl Intermit	tent iron suppl	

Analysis 6.20. Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years, Outcome 20 WAZ.

Review: Intermittent iron supplementation for improving nutrition and development in children under 12 years of age

Comparison: 6 Intermittent iron supplementation versus daily iron supplementation: children 5 - 12 years

Outcome: 20 WAZ

Study or subgroup	Intermittent iron suppl	Nc	suppl/placebo		D	Std. Mean ifference	Weight	Std. Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Ranc	lom,95% Cl		IV,Random,95% CI
Palupi 1997	96	0.14 (0.36)	98	0.06 (0.41)	l		55.6 %	0.21 [-0.08, 0.49]
Thu 1999	54	-1.77 (0.78)	54	-1.64 (0.67)			44.4 %	-0.18 [-0.56, 0.20]
Total (95% CI)	150		152				100.0 %	0.04 [-0.34, 0.41]
Heterogeneity: Tau ² =	= 0.04; Chi ² = 2	2.54, df = 1 (P = 0.11); I ² =61%					
Test for overall effect:	Z = 0.19 (P =	0.85)						
Test for subgroup diffe	erences: Not ap	plicable						
				-	00 -50	0 50	00	
				No sup	plementation	Intermittent	iron suppl	

ADDITIONAL TABLES

Table 1. Intermittent iron supplementation versus placebo or no intervention by age group

Outcome	Comparison 3 Children 0 to 59 months Relative effect (95% CI) Number of trials and effective sample size	Comparison 5 Children 60 months and older Relative effect (95% CI Number of trials and effective sample size
Anaemia	RR 0.43 (0.23 to 0.80) 4 trials, 658 children	RR 0.54, (0.33 to 0.90) 6 trials, 1166 children

 Table 1. Intermittent iron supplementation versus placebo or no intervention by age group (Continued)

Haemoglobin (g/L)	MD 6.45 (2.36 to 10.55) 9 trials, 1254 children	MD 4.04 (0.30 to 7.78) 10 trials, 1778 children 4.04 [0.30, 7.78]
Iron deficiency (using ferritin concentra- tions)	RR 0.24 (0.06 to 0.91) 3 trials, 431 children	None of the trials reported on this outcome
Ferritin (µg/L)	MD 13.15 (-2.28 to 28.59) 4 trials, 310 children	MD 16.60 (11.12 to 22.08) 1 trial, 240 children
Adherence	RR 1.04 (0.98 to 1.09) 2 trials, 289 children	None of the trials reported on this outcome

Table 2. Intermittent versus daily iron supplementation by age group

Outcome	Comparison 4 Children 0 to 59 months Relative effect (95% CI) Number of trials and effective sample size	Comparison 6 Children 60 months and older Relative effect (95% CI) Number of trials and effective sample size
Anaemia	RR 1.26 (1.05 to 1.51) 3 trials, 770 children	RR 0.95 (0.47 to 1.91) 2 trials, 145 children
Haemoglobin (g/L)	MD -0.75 (-1.80 to 0.29) 14 trials, 2270 children	MD -0.31 (-2.59 to 1.97) 5 trials, 581 children
Iron deficiency	RR 4.00 (1.23 to 13.05) 1 trial, 76 children	None of the trials reported on this outcome
Ferritin (µg/L)	MD -3.10 (-6.59 to 0.39) 8 trials, 582 children	MD -11.57 (-38.75 to 15.61) 2 trials, 320 children
Adherence	RR 1.29 (1.15 to 1.45) 3 trials, 1185 children	RR 1.29 (0.44 to 3.75) 2 trials, 245 children

APPENDICES

Appendix I. Search strategies

CENTRAL

#1MeSH descriptor Iron, this term only #2MeSH descriptor Iron, Dietary, this term only #3MeSH descriptor Anemia, Iron-Deficiency, this term only #4MeSH descriptor Folic Acid, this term only #5MeSH descriptor Dietary Supplements, this term only #6MeSH descriptor Trace Elements, this term only #7iron* #8folic* or folate* or folvite* or folacin* or pteroylglutamic* #9diet* NEAR/3 supplement* #10micro-nutrient* or micronutrient* or multi-nutrient* or multinutrient* #11MeSH descriptor Ferric Compounds, this term only #12MeSH descriptor Ferrous Compounds, this term only #13ferrous* or ferric* or fe #14MeSH descriptor Micronutrients, this term only #15(#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14) #16MeSH descriptor Drug Administration Schedule, this term only #17MeSH descriptor Dose-Response Relationship, Drug explode all trees #18MeSH descriptor Time Factors, this term only #19week* or biweek* or bi NEXT week* or intermittent* or alternat* #20(#16 OR #17 OR #18 OR #19) #21(#15 AND #20) #22(iron NEAR/3 (dose* or dosage or administer* or administration or frequency)) #23(#21 OR #22) #24 (baby or babies or newborn* or neonat* or toddler* or child* or preschool* or schoolchild* or boy* or girl* or pre-school* or teen* or adolescen* or preteen* or youth* or young person* or young people) #25(#23 AND #24)

MEDLINE

1 Iron/ or Anemia, Iron-Deficiency/ or Iron, Dietary/ 2 Folic Acid/ 3 micronutrients/ 4 Dietary Supplements/ 5 iron\$.tw. 6 (folic\$ or folate\$ or folvite\$ or folacin\$ or pteroylglutamic\$).tw. 7 Trace Elements/ 8 (diet\$ adj3 supplement\$).tw. 9 (micro-nutrient\$ or micronutrient\$ or multi-nutrient\$ or multinutrient\$).tw. 10 Ferric Compounds/ 11 Ferrous Compounds/ 12 (ferrous\$ or ferric\$ or fe).tw. 13 or/1-12 14 Drug Administration Schedule/ 15 Dose-Response Relationship, Drug/ 16 Time Factors/ 17 (week\$ or biweek\$ or bi-week\$ or intermittent\$ or alternat\$).tw. 18 or/14-17

19 13 and 18 20 (iron adj3 (dose\$ or dosage or administer\$ or administration or frequency)).tw. 21 19 or 20 22 exp Infant/ 23 exp Child/ 24 Adolescent/ 25 (baby or babies or newborn\$ or neonat\$ or toddler\$ or child\$ or preschool\$ or schoolchild\$ or boy\$ or girl\$ or pre-school\$ or teen\$ or adolescen\$ or preteen\$ or youth\$ or young person\$ or young people).tw. 26 or/22-25 27 randomized controlled trial.pt. 28 controlled clinical trial.pt. 29 randomi#ed.ab. 30 placebo\$.ab. 31 drug therapy.fs. 32 randomly.ab. 33 trial.ab. 34 groups.ab. 35 or/27-34 36 exp animals/ not humans.sh. 37 35 not 36 38 21 and 26 and 37

EMBASE

1 iron/ 2 iron intake/ 3 iron deficiency anemia/ 4 folic acid/ 5 exp trace element/ 6 diet supplementation/ 7 iron\$.tw. 8 (folic\$ or folate\$ or folvite\$ or folacin\$ or pteroylglutamic\$).tw. 9 (diet\$ adj3 supplement\$).tw. 10 (micro-nutrient\$ or micronutrient\$ or multi-nutrient\$ or multinutrient\$).tw. 11 ferric ion/ 12 ferrous ion/ 13 or/1-12 14 drug administration/ 15 drug dose regimen/ 16 time/ 17 (week\$ or biweek\$ or bi-week\$ or intermittent\$ or alternat\$).tw. 18 or/14-17 19 13 and 18 20 (iron adj3 (dose\$ or dosage or administer\$ or administration or frequency)).tw. 21 19 or 20 22 exp infant/ 23 exp child/ 24 adolescent/ 25 (baby or babies or newborn\$ or neonat\$ or toddler\$ or child\$ or preschool\$ or schoolchild\$ or boy\$ or girl\$ or pre-school\$ or teen\$ or adolescen\$ or preteen\$ or youth\$ or young person\$ or young people).tw. 26 or/22-25 27 21 and 26 28 exp Clinical trial/

29 Randomization/ 30 Single blind procedure/ 31 Double blind procedure/ 32 Crossover procedure/ 33 Placebo/ 34 Randomi#ed.tw. 35 RCT.tw. 36 (random\$ adj3 (allocat\$ or assign\$)).tw. 37 randomly.ab. 38 groups.ab. 39 trial.ab. 40 ((singl\$ or doubl\$ or trebl\$ or tripl\$) adj3 (blind\$ or mask\$)).tw. 41 Placebo\$.tw. 42 prospective study/ 43 (crossover or cross-over).tw. 44 prospective.tw. 45 or/28-44 46 27 and 45 **CINAHL** S43 S24 and S42 S42 S25 or S26 or S27 or S28 or S29 or S30 or S31 or S32 or S33 or S34 or \$35 or \$36 or \$37 or \$38 or \$39 or \$40 or \$41 S41 (MH "Evaluation Research") OR (MH "Summative Evaluation Research") OR (MH "Program Evaluation") S40 (MH "Treatment Outcomes") S39 (MH "Comparative Studies") S38 TI (evaluat* study or evaluat* research) or AB (evaluat* study or evaluat* research) or TI (effectiv* study or effectiv* research) or AB (effectiv* study or effectiv* research) OR TI (prospectiv* study or prospectiv* research) or AB(prospectiv* study or prospectiv* research) or TI (follow-up study or follow-up research) or AB (follow-up study or follow-up research) S37 placebo* S36 crossover* or "cross over*" S35 (MH "Crossover Design") S34 (tripl* N3 mask*) or (tripl* N3 blind*) S33 (trebl* N3 mask*) or (trebl* N3 blind*) S32 (doubl* N3 mask*) or (doubl* N3 blind*) S31 (singl* N3 mask*) or (singl* N3 blind*) S30 (clinic* N3 trial*) or (control* N3 trial*) S29 (random* N3 allocat*) or (random* N3 assign*) S28 randomis* or randomiz* S27 (MH "Meta Analysis") S26 (MH "Clinical Trials+") S25 MH random assignment S24 S19 and S23 S23 S20 or S21 or S22 S22 baby or babies or newborn* or neonat* or toddler* or child or preschool* or schoolchild* or boy* or girl* or pre-school* or teen* or adolescen* or preteen* or youth* or young person* or young people S21 AG adolescent S20 AG infant or child S19 S17 or S18 S18 (iron N3 dose*) or (iron N3 dosage) or (iron N3 administer*) or (iron N3 administration) or (iron N3 frequency) S17 S11 and S16

S16 S12 or S13 or S14 or S15 S15 (week* or biweek* or bi-week* or bi week* or intermittent* or alternat*) S14 (MH "Time Factors") S13 (MH "Dose-Response Relationship, Drug") S12 (MH "Drug Administration Schedule") S11 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 S10 micro-nutrient* or micronutrient* or micro nutrient* multi-nutrient* or multinutrient* or multi nutrient* S9 ferrous* or ferric* or "fe" S8 diet* N3 supplement* S7 folic* or folate* or folvite* or folacin* or pteroylglutamic* S6 iron* S5 (MH "Micronutrients") S4 (MH "Trace Elements") S3 (MH "Dietary Supplements") S2 (MH "Folic Acid") S1 (MH "Iron") OR (MH "Anemia, Iron Deficiency") OR (MH "Iron Compounds") OR (MH "Ferric Compounds") OR (MH "Ferrous Compounds")

POPLINE

(iron*/folic*/folate*/supplement*/micro-nutrient*) & (week*/bi-week*

ICTRP

Intervention: iron or folic or folate or micronutrient* limited to Clinical trials in children IMBIOMED

Intervention: suplementacion hierro LILACS

Intervention: suplementacion hierro IBECS

Intervention: suplementacion hierro Scielo

Intervention: suplementacion hierro

CONTRIBUTIONS OF AUTHORS

All four review authors contributed to drafting the text of the review, commented on the drafts and approved the final version.

DECLARATIONS OF INTEREST

Luz Maria De-Regil - none known. Maria Elena D Jefferds - none known. Allison C Sylvetsky - none known. Therese Dowswell - none known.

Disclaimer: Luz Maria De-Regil is a full-time staff member of the World Health Organization (WHO), Allison C Sylvetsky did a 6week internship at WHO (summer 2010), and Therese Dowswell has received financial support from the WHO for her work on this review. Maria Elena Jefferds is a full-time staff member of the US Centers for Disease Control and Prevention. The authors alone are responsible for the views expressed in this publication and they do not necessarily represent the official position, decisions, policy or views of these Organisations.

SOURCES OF SUPPORT

Internal sources

- Centers for Disease Control and Prevention (CDC), Division of Nutrition, Physical Activity, and Obesity, USA.
- Micronutrients Unit, Department of Nutrition for Health and Development, World Health Organization, Switzerland.

External sources

• Micronutrients Unit, Department of Nutrition for Health and Development, World Health Organization, Switzerland. Dr Therese Dowswell received partial financial support for her work on this review.

• Government of Luxembourg, Luxembourg.

WHO acknowledges the Government of Luxembourg for their financial support to the Micronutrients Unit for conducting systematic reviews on micronutrient interventions

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

We added a description of the methodology followed to produce the 'Summary of findings' tables in the 'Assessment of risk of bias in included studies' section.

We made the following changes to the outcomes section:

• we modified the order of the primary outcomes so that the effects of the same indicator, presented either as a continuous or as a dichotomous variable, could be assessed together (for example, anaemia and haemoglobin concentrations);

• since there are no official cut-offs for children younger than 6 months, we changed the definition of anaemia from "haemoglobin < 110 g/L or < 115 g/L for children 6 to 59 months or 5 to 11 years old, respectively, adjusted by altitude where appropriate" to "haemoglobin below a cut-off defined by trialists, taking into account the age group and altitude";

• for our secondary outcome 'all-cause morbidity', we replaced 'at least one event' with 'at least one reported illness' to make it clearer;

• we renamed our secondary outcome 'folic acid status' as 'folate status' and replaced the units with 'as measured by trialists'. Folate may be measured in serum, plasma or red blood cells and the most frequently used units may vary.

• as the duration of the trials was mostly short, we changed the definition of our secondary outcome 'growth impairment (stunting and wasting)' to 'height-for-age and weight-for-age Z-scores' and moved this to the end of our list of outcomes.

INDEX TERMS

Medical Subject Headings (MeSH)

*Dietary Supplements; Anemia, Iron-Deficiency [blood; complications; *drug therapy]; Child Development [*drug effects]; Child Nutritional Physiological Phenomena [drug effects]; Drug Administration Schedule; Glycated Hemoglobin A [metabolism]; Iron, Dietary [*administration & dosage]; Randomized Controlled Trials as Topic; Trace Elements [administration & dosage]; Vitamins [administration & dosage]

MeSH check words

Child; Child, Preschool; Female; Humans; Male